{
  "filename": "ehac262.pdf",
  "title": "2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death",
  "type": "ventricular_arrhythmias",
  "year": 2022,
  "total_pages": 130,
  "extracted_at": "2026-01-15T00:20:23.116672",
  "chapters": [
    {
      "number": "1",
      "title": "2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death",
      "start_page": 1,
      "end_page": 6,
      "content": "2022 ESC Guidelines for the management of\npatients with ventricular arrhythmias and the\nprevention of sudden cardiac death\nDeveloped by the task force for the management of patients with\nventricular arrhythmias and the prevention of sudden cardiac\ndeath of the European Society of Cardiology (ESC)\nEndorsed by the Association for European Paediatric and\nCongenital Cardiology (AEPC)\nAuthors/Task Force Members: Katja Zeppenfeld*† (Chairperson) (Netherlands),\nJacob Tfelt-Hansen\n*† (Chairperson) (Denmark), Marta de Riva** (Task Force\nCoordinator) (Netherlands), Bo Gregers Winkel** (Task Force Coordinator)\n(Denmark), Elijah R. Behr (United Kingdom), Nico A. Blom1 (Netherlands),\nPhilippe Charron (France), Domenico Corrado (Italy), Nikolaos Dagres\n(Germany), Christian de Chillou (France), Lars Eckardt (Germany), Tim Friede\n(Germany), Kristina H. Haugaa (Norway), Mélèze Hocini (France), Pier\nD. Lambiase (United Kingdom), Eloi Marijon (France), Jose L. Merino (Spain),\nPetr Peichl (Czech Republic), Silvia G. Priori (Italy), Tobias Reichlin (Switzerland),\nJeanette Schulz-Menger (Germany), Christian Sticherling (Switzerland),\nStylianos Tzeis (Greece), Axel Verstrael (Belgium), Maurizio Volterrani (Italy),\nand ESC Scientiﬁc Document Group\n*Corresponding authors: Katja Zeppenfeld, Department of Cardiology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, Netherlands. Tel +31 715262020, E-mail:\nK.Zeppenfeld@LUMC.nl\nJacob Tfelt-Hansen, The Department of Cardiology, The Heart Centre, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark. Tel +45 61360399,\nE-mail: jacob.tfelt@regionh.dk\n†The two chairpersons contributed equally to the document and are joint corresponding authors.\n**The two task force Coordinators contributed equally to the document.\nAuthor/task force Member afﬁliations are listed in Author information.\n1Representing the Association for European Paediatric and Congenital Cardiology (AEPC).\nESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.\nESC subspecialty communities having participated in the development of this document:\nAssociations: Association for Acute CardioVascular Care (ACVC), Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Cardiovascular\nImaging (EACVI), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).\nWorking Groups: Cardiac Cellular Electrophysiology, Myocardial and Pericardial Diseases.\nPatient Forum\nThe content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC\nGuidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University\nPress, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (Journals.Permissions@oup.com).\nEuropean Heart Journal (2022) 43, 3997–4126\nhttps://doi.org/10.1093/eurheartj/ehac262\nESC GUIDELINES\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nDocument-Reviewers: Maja Cikes (CPG Review Coordinator) (Croatia), Paulus Kirchhof (CPG Review\nCoordinator) (Germany), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Elena Arbelo (Spain),\nFernando Arribas (Spain), Riccardo Asteggiano (Italy), Cristina Basso (Italy), Axel Bauer (Austria),\nEmanuele Bertaglia (Italy), Tor Biering-Sørensen (Denmark), Carina Blomström-Lundqvist (Sweden),\nMichael A. Borger (Germany), Jelena Čelutkienė (Lithuania), Bernard Cosyns (Belgium), Volkmar Falk\n(Germany), Laurent Fauchier (France), Bulent Gorenek (Turkey), Sigrun Halvorsen (Norway), Robert Hatala\n(Slovakia), Hein Heidbuchel (Belgium), Stefan Kaab (Germany), Aleksandra Konradi (Russian Federation),\nKonstantinos C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf Landmesser (Germany),\nBasil S. Lewis (Israel), Ales Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Lars H. Lund (Sweden),\nAndreas Metzner (Germany), Richard Mindham (United Kingdom), Jens Cosedis Nielsen (Denmark),\nTone M. Norekvål (Norway), Monica Patten (Germany), Eva Prescott (Denmark), Amina Rakisheva\n(Kazakhstan), Carol Ann Remme (Netherlands), Ivo Roca-Luque (Spain), Andrea Sarkozy (Belgium),\nDaniel Scherr (Austria), Marta Sitges (Spain), Rhian M. Touyz (Canada/United Kingdom), Nicolas Van Mieghem\n(Netherlands), Vedran Velagic (Croatia), Sami Viskin (Israel), and Paul G. A. Volders (Netherlands)\nAll experts involved in the development of these guidelines have submitted declarations of interest. These have\nbeen compiled in a report and published in a supplementary document simultaneously to the guidelines. The\nreport is also available on the ESC website www.escardio.org/Guidelines\nSee the European Heart Journal online for supplementary data that includes background information and\ndetailed discussion of the data that have provided the basis of the guidelines.\nClick here to access the corresponding ESC CardioMed chapters.\nKeywords\nGuidelines • Anti-arrhythmic drugs • Cardiac magnetic resonance • Cardiomyopathies • Catheter ablation •\nChronic coronary artery disease • Genetic testing • Implantable cardioverter deﬁbrillator • Premature ventricular\ncomplex • Primary electrical disease • Recommendations • Risk calculator • Risk stratiﬁcation • Sudden cardiac\ndeath • Sudden death • Ventricular arrhythmia • Ventricular ﬁbrillation • Ventricular tachycardia\nTable of contents\n1. Preamble ........................................................................................................\n4003\n2. Introduction .................................................................................................\n4005\n2.1. What is new ........................................................................................ 4005\n3. Deﬁnitions .....................................................................................................\n4011\n3.1. Ventricular arrhythmia subtypes ................................................ 4011\n3.2. Sudden cardiac death ....................................................................... 4011\n3.3. Syncope ................................................................................................. 4011\n3.4. Specialized centres ............................................................................ 4011\n3.5. Genetics ................................................................................................. 4011\n4. Epidemiology of sudden cardiac death, public awareness, and\nrisk stratiﬁcation ..............................................................................................\n4011\n4.1. Incidence of sudden cardiac death ............................................. 4011\n4.2. Causes of sudden cardiac death in different age groups . 4012\n4.3. Population vs. individual risk prediction .................................. 4012\n4.4. Risk calculators for sudden cardiac death and review of the\nmethodology ................................................................................................ 4012\n4.5. Awareness and intervention: public basic life support, and\naccess to automated external deﬁbrillators ................................... 4012\n5. Evaluation and treatment. General aspects ....................................\n4014\n5.1. Diagnostic tools ................................................................................. 4014\n5.1.1. History and physical examination ......................................\n4014\n5.1.2. Laboratory testing ....................................................................\n4014\n5.1.3. Non-invasive and invasive tests ..........................................\n4014\n5.1.3.1. Electrocardiogram and ambulatory\nelectrocardiographic monitoring ................................................ 4014\n5.1.3.2. Signal-averaged electrocardiogram ............................ 4014\n5.1.3.3. Exercise testing .................................................................. 4014\n5.1.3.4. Imaging ................................................................................... 4014\n5.1.3.5. Provocative diagnostic tests ......................................... 4015\n5.1.3.6. Electrophysiological study ............................................. 4015\nDisclaimer: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientiﬁc and medical knowledge and the evidence available at the\ntime of their publication. The ESC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC Guidelines and any other ofﬁcial recommendations\nor guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the\nESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strat-\negies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consid-\neration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health\nprofessionals from taking into full and careful consideration the relevant ofﬁcial updated recommendations or guidelines issued by the competent public health authorities, in order to\nmanage each patient’s case in light of the scientiﬁcally accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to\nverify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.\n© The European Society of Cardiology 2022. All rights reserved. For permissions please e-mail: Journals.Permissions@oup.com\n3998\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n5.1.4. Genetic testing ...........................................................................\n4015\n5.2. Diagnostic evaluation at ﬁrst presentation with\nventricular arrhythmia in patients without known cardiac\ndisease .................................................................................................... 4018\n5.2.1. Scenario 1: Incidental ﬁnding of a non-sustained\nventricular tachycardia ........................................................................\n4018\n5.2.2. Scenario 2: First presentation of sustained\nmonomorphic ventricular tachycardia .........................................\n4018\n5.2.3. Scenario 3: Sudden cardiac arrest survivor ...................\n4020\n5.2.4. Scenario 4: Sudden death victim ........................................\n4023\n5.2.5. Scenario 5: Relatives of sudden arrhythmic death\nsyndrome decedents ...........................................................................\n4024\n6. Therapies for ventricular arrhythmias. General aspects ...........\n4027\n6.1. Acute management .......................................................................... 4027\n6.1.1. Treatment of reversible causes ..........................................\n4027\n6.1.2. Acute management of sustained monomorphic\nventricular tachycardia ........................................................................\n4029\n6.1.3. Management of electrical storm and incessant\nventricular tachycardia ........................................................................\n4030\n6.2. Long-term management ................................................................. 4034\n6.2.1. Pharmacotherapy ......................................................................\n4034\n6.2.2. Device therapy ...........................................................................\n4038\n6.2.2.1. Implantable cardioverter deﬁbrillator ....................... 4038\n6.2.2.2. Adding cardiac resynchronization therapy ............. 4040\n6.2.2.3. Wearable cardioverter deﬁbrillator .......................... 4040\n6.2.3. Special aspects of device therapy ......................................\n4041\n6.2.3.1. Optimization of device programming ...................... 4041\n6.2.3.2. Concomitant treatment to avoid inappropriate\nimplantable cardioverter deﬁbrillator therapy ..................... 4041\n6.2.3.3. Psychosocial impact of implantable cardioverter\ndeﬁbrillator treatment .................................................................... 4042\n6.2.3.4. Patients with left ventricular assist devices ............ 4042\n6.2.3.5. Complications of devices ............................................... 4042\n6.2.3.6. End-of-life issues ................................................................ 4043\n6.2.4. Interventional therapy ............................................................\n4043\n6.2.4.1. Catheter ablation .............................................................. 4043\n6.2.4.1.1. Patients with structural heart disease ............. 4043\n6.2.4.1.2. Patients without apparent structural heart\ndisease ............................................................................................... 4044\n6.2.4.2. Autonomic modulation .................................................. 4044\n7. Diagnostic evaluation, management, and risk\nstratiﬁcation according to clinical presentation and known (likely)\ndisease ..................................................................................................................\n4044\n7.1. Speciﬁc structural heart diseases ................................................ 4044\n7.1.1. Coronary artery disease ........................................................\n4044\n7.1.1.1. Acute coronary syndromes and vasospasm .......... 4044\n7.1.1.1.1. Acute coronary syndromes ................................. 4044\n7.1.1.1.2. Vasospasm ................................................................... 4045\n7.1.1.2. Early after myocardial infarction ................................. 4046\n7.1.1.3. Chronic coronary artery disease ................................ 4046\n7.1.1.3.1. Primary prevention of sudden cardiac death in\npatients with reduced ejection fraction ............................. 4046\n7.1.1.3.2. Primary prevention of sudden cardiac death in\npatients with preserved or mildly reduced ejection\nfraction ............................................................................................. 4047\n7.1.1.3.3. Secondary prevention of sudden cardiac\ndeath .................................................................................................. 4047\n7.1.1.3.4. Management of patients with\nhaemodynamically tolerated ventricular tachycardia and\npreserved and mildly reduced ejection fraction ............. 4048\n7.1.1.3.5. Management of recurrent ventricular\ntachycardia in implantable cardioverter deﬁbrillator\ncarriers .............................................................................................. 4049\n7.1.1.4. Coronary anomalies ......................................................... 4049\n7.1.2. Idiopathic premature ventricular complexes/\nventricular tachycardia and premature ventricular complex-\ninduced cardiomyopathy ...................................................................\n4050\n7.1.2.1. Idiopathic premature ventricular complexes/\nventricular tachycardia .................................................................... 4050\n7.1.2.2. Premature ventricular complex-induced/-\naggravated cardiomyopathy .......................................................... 4052\n7.1.3. Cardiomyopathies ....................................................................\n4054\n7.1.3.1. Dilated cardiomyopathy and hypokinetic non-\ndilated cardiomyopathy .................................................................. 4054\n7.1.3.1.1. Diagnostic evaluation and risk stratiﬁcation .. 4054\n7.1.3.1.2. Primary prevention of sudden cardiac death\n4055\n7.1.3.1.3. Secondary prevention of sudden cardiac death\nand management of ventricular arrhythmias ................... 4057\n7.1.3.2. Arrhythmogenic right ventricular\ncardiomyopathy ................................................................................. 4058\n7.1.3.2.1. Risk stratiﬁcation ....................................................... 4058\n7.1.3.2.2. Treatment .................................................................... 4060\n7.1.3.3. Hypertrophic cardiomyopathy .................................... 4060\n7.1.3.3.1. Risk stratiﬁcation and primary prevention of\nsudden cardiac death .................................................................. 4061\n7.1.3.3.2. Treatment to prevent ventricular arrhythmia\nrecurrence ....................................................................................... 4062\n7.1.3.4. Left ventricular non-compaction ................................ 4063\n7.1.3.5. Restrictive cardiomyopathy .......................................... 4063\n7.1.3.6. Neuromuscular disorders ............................................. 4063\n7.1.4. Inﬂammatory cardiac diseases .............................................\n4066\n7.1.4.1. Myocarditis ........................................................................... 4066\n7.1.4.2. Cardiac sarcoidosis ........................................................... 4067\n7.1.4.3. Chagas’ cardiomyopathy ................................................ 4068\n7.1.5. Valvular heart disease .............................................................\n4070\n7.1.6. Congenital heart disease ........................................................\n4071\n7.2. Primary electrical disease ............................................................... 4073\n7.2.1. Idiopathic ventricular ﬁbrillation .........................................\n4073\n7.2.2. Long QT syndrome (including acquired long QT\nsyndrome) ................................................................................................\n4074\n7.2.3. Andersen–Tawil syndrome Type 1 ..................................\n4079\n7.2.4. Brugada syndrome ...................................................................\n4079\n7.2.5. Early repolarization syndromes ..........................................\n4081\n7.2.6. Catecholaminergic polymorphic ventricular\ntachycardia ...............................................................................................\n4084\n7.2.7. Short QT syndrome ................................................................\n4086\n8. Special aspects in selected populations ............................................\n4088\n8.1. Pregnant patients and peri-partum cardiomyopathy ......... 4088\n8.1.1. Electrocardioversion and implantable cardioverter\ndeﬁbrillator therapy in pregnancy ..................................................\n4088\n8.1.2. Pharmacological treatment ...................................................\n4088\n8.1.3. Catheter ablation ......................................................................\n4088\n8.2. Heart transplantation ...................................................................... 4089\n8.3. Sudden cardiac death in athletes ................................................ 4089\nESC Guidelines\n3999\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n8.4. Wolff–Parkinson–White syndrome .......................................... 4090\n8.5. Prevention of sudden cardiac death in the elderly ............. 4090\n9. Key messages ...............................................................................................\n4090\n9.1. General aspects .................................................................................. 4090\n9.2. Structural heart disease .................................................................. 4090\n9.3. Primary electrical disease ............................................................... 4091\n10. Gaps in evidence ......................................................................................\n4091\n10.1. General aspects ............................................................................... 4091\n10.2. Structural heart disease—general ........................................... 4091\n10.3. Idiopathic premature ventricular complexes/ventricular\ntachycardia .................................................................................................... 4091\n10.4. Coronary artery disease .............................................................. 4091\n10.5. Cardiomyopathies .......................................................................... 4091\n10.6. Valvular heart disease ................................................................... 4091\n10.7. Congenital heart disease .............................................................. 4091\n10.8. Primary electrical disease ............................................................ 4091\n11. ‘What to do’ and ‘what not to do’ messages from the\nGuidelines ...........................................................................................................\n4092\n12. Quality indicators ....................................................................................\n4099\n13. Supplementary data ................................................................................\n4099\n14. Data availability statement ...................................................................\n4099\n15. Author information ................................................................................\n4099\n16. Appendix .....................................................................................................\n4100\n17. References ..................................................................................................\n4101\nTables of Recommendations\nRecommendation Table 1 — Recommendations for public\nbasic life support and access to automated external\ndeﬁbrillators ............................................................................................ 4014\nRecommendation Table 2 — Recommendations for genetic\ntesting ...................................................................................................................\n4018\nRecommendation Table 3 — Recommendations for evaluation\nof patients presenting with newly documented ventricular\narrhythmia ..........................................................................................................\n4018\nRecommendation Table 4 — Recommendations for evaluation of\npatients presenting with a ﬁrst episode of sustained\nmonomorphic ventricular tachycardia ...................................................\n4020\nRecommendation Table 5 — Recommendations for evaluation of\nsudden cardiac arrest survivors ................................................................\n4022\nRecommendation Table 6 — Recommendations for evaluation of\nsudden death victims .....................................................................................\n4023\nRecommendation Table 7 — Recommendations for evaluation of\nrelatives of sudden arrhythmic death syndrome decedents ........\n4027\nRecommendation Table 8 — Recommendations for treatment of\nreversible conditions ......................................................................................\n4029\nRecommendation Table 9 — Recommendations for the acute\nmanagement of sustained ventricular tachycardia and electrical\nstorm ....................................................................................................................\n4033\nRecommendation Table 10 — Recommendations for treatment\nwith heart failure medication .....................................................................\n4034\nRecommendation Table 11 — Recommendations for implantable\ncardioverter deﬁbrillator implantation (general aspects) ..............\n4040\nRecommendation Table 12 — Recommendations for secondary\nprevention of sudden cardiac death .......................................................\n4040\nRecommendation Table 13 — Recommendations for\nsubcutaneous implantable cardioverter deﬁbrillator .......................\n4040\nRecommendation Table 14 — Recommendations for adding\ncardiac resynchronization therapy to implantable cardioverter\ndeﬁbrillator ........................................................................................................\n4040\nRecommendation Table 15 — Recommendations for wearable\ncardioverter deﬁbrillator ..............................................................................\n4040\nRecommendation Table 16 — Recommendations for\noptimization of device programming .....................................................\n4041\nRecommendation Table 17 — Recommendations for\nconcomitant treatment to avoid inappropriate implantable\ncardioverter deﬁbrillator therapy ............................................................\n4042\nRecommendation Table 18 — Recommendations for\npsychosocial management after implantable cardioverter\ndeﬁbrillator implantation .............................................................................\n4042\nRecommendation Table 19 — Recommendations for implantable\ncardioverter deﬁbrillator implantation in left ventricular assist\ndevice recipients ..............................................................................................\n4042\nRecommendation Table 20 — Recommendations for prevention\nof implantable cardioverter deﬁbrillator complications .................\n4043\nRecommendation Table 21 — Recommendations for end-of-life\nissues in implantable cardioverter deﬁbrillator carriers .................\n4043\nRecommendation Table 22 — Recommendations for treatment\nof ventricular arrhythmias in acute coronary syndrome and\nvasospasm ..........................................................................................................\n4046\nRecommendation Table 23 — Recommendations for risk\nstratiﬁcation and treatment of ventricular arrhythmias early after\nmyocardial infarction .....................................................................................\n4046\nRecommendation Table 24 — Recommendations for risk\nstratiﬁcation, sudden cardiac death prevention, and treatment of\nventricular arrhythmias in chronic coronary artery disease .........\n4047\nRecommendation Table 25 — Recommendations for sudden\ncardiac death prevention in patients with coronary anomalies .......\n4050\nRecommendation Table 26 — Recommendations for the\nmanagement of patients with idiopathic premature ventricular\ncomplexes/ventricular tachycardia ..........................................................\n4052\nRecommendation Table 27 — Recommendations for the\nmanagement of patients with premature ventricular\ncomplex-induced or premature ventricular complex-aggravated\ncardiomyopathy ............................................................................................................. 4053\nRecommendation Table 28 — Recommendations for risk\nstratiﬁcation, sudden cardiac death prevention, and treatment\nof ventricular arrhythmias in dilated cardiomyopathy/\nhypokinetic non-dilated cardiomyopathy ......................................\n4057\nRecommendation Table 29 — Recommendations for diagnostic,\nrisk stratiﬁcation, sudden cardiac death prevention, and\ntreatment of ventricular arrhythmias in arrhythmogenic right\nventricular cardiomyopathy ........................................................................\n4060\nRecommendation Table 30 — Recommendations for risk\nstratiﬁcation, sudden cardiac death prevention, and treatment of\nventricular arrhythmias in hypertropic cardiomyopathy ...............\n4062\nRecommendation Table 31 — Recommendations for implantable\ncardioverter deﬁbrillator implantation in left ventricular\nnon-compaction ..............................................................................................\n4063\nRecommendation Table 32 — Recommendations for implantable\ncardioverter deﬁbrillator implantation in patients with cardiac\namyloidosis .........................................................................................................\n4063\nRecommendation Table 33 — Recommendations for risk\nstratiﬁcation, sudden cardiac death prevention, and treatment of\nventricular arrhythmias in neuromuscular diseases .........................\n4065\n4000\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nRecommendation Table 34 — Recommendations for sudden\ncardiac death prevention and treatment of ventricular\narrhythmias in myocarditis ..........................................................................\n4066\nRecommendation Table 35 — Recommendations for risk\nstratiﬁcation, sudden cardiac death prevention, and treatment of\nventricular arrhythmias in cardiac sarcoidosis ....................................\n4067\nRecommendation Table 36 — Recommendations for the\ntreatment of ventricular arrhythmias in Chagas’\ncardiomyopathy ....................................................................................... 4070\nRecommendation Table 37 — Recommendations for sudden\ncardiac death prevention and treatment of ventricular\narrhythmias in valvular heart disease ......................................................\n4070\nRecommendation Table 38 — Recommendations for risk\nstratiﬁcation and primary prevention of sudden cardiac death in\ncongenital heart disease ...............................................................................\n4072\nRecommendation Table 39 — Recommendations for secondary\nprevention of sudden cardiac death and treatment of ventricular\narrhythmia in congenital heart disease ..................................................\n4072\nRecommendation Table 40 — Recommendations for the\nmanagement of patients with idiopathic ventricular ﬁbrillation ..\n4073\nRecommendation Table 41 — Recommendations for the\nmanagement of patients with long QT syndrome ...........................\n4077\nRecommendation Table 42 — Recommendations for\nmanagement of patients with Andersen–Tawil syndrome ...........\n4079\nRecommendation Table 43 — Recommendations for\nmanagement of patients with Brugada syndrome ............................\n4080\nRecommendation Table 44 — Recommendations for the\nmanagement of patients with early repolarization pattern/\nsyndrome ............................................................................................................\n4083\nRecommendation Table 45 — Recommendations for the\nmanagement of patients with catecholaminergic polymorphic\nventricular tachycardia ..................................................................................\n4086\nRecommendation Table 46 — Recommendations for the\nmanagement of patients with short QT syndrome .........................\n4087\nRecommendation Table 47 — Recommendations for the\nprevention of sudden cardiac death and management of\nventricular arrhythmia during pregnancy ..............................................\n4088\nRecommendation Table 48 — Recommendations for the\nprevention of sudden cardiac death before and after heart\ntransplantation .................................................................................................\n4089\nRecommendation Table 49 — Recommendations for risk\nstratiﬁcation and prevention of sudden cardiac death in athletes\n4089\nRecommendation Table 50 — Recommendations for implantable\ncardioverter deﬁbrillator implantation in the elderly ......................\n4090\nList of tables\nTable 1 Classes of recommendations ....................................................\n4003\nTable 2 Levels of evidence ..........................................................................\n4004\nTable 3 New sections and concepts ......................................................\n4005\nTable 4 New recommendations in 2022 .............................................\n4005\nTable 5 Changes in recommendations since 2015 ...........................\n4010\nTable 6 Intravenous provocative diagnostic tests .............................\n4016\nTable 7 Genetic tests and suggested work-up of probands and\nrelatives with primary electrical diseases ..............................................\n4017\nTable 8 Anti-arrhythmic drugs (acute and chronic treatment) ..\n4035\nTable 9 Summary of the recommendations for the treatment of\npatients with frequent idiopathic premature ventricular\ncomplexes/ventricular tachycardia or premature ventricular\ncomplex-induced cardiomyopathy ..........................................................\n4051\nTable 10 Modiﬁed long QT syndrome diagnostic score ...................... 4076\nList of ﬁgures\nFigure 1 Central ﬁgure ..................................................................................\n4013\nFigure 2 Algorithm for the evaluation of patients presenting with\nan incidental ﬁnding of non-sustained ventricular tachycardia ....\n4019\nFigure 4 Algorithm for the evaluation of patients presenting with a\nﬁrst sustained monomorphic ventricular tachycardia episode ....\n4021\nFigure 3 Typical idiopathic ventricular tachycardia morphologies\n4020\nFigure 5 Bundle branch re-entrant ventricular tachycardia ..........\n4022\nFigure 6 Part One. Algorithm for the evaluation of sudden cardiac\narrest survivors ................................................................................................\n4024\nFigure 6 Part Two. Algorithm for the evaluation of sudden cardiac\narrest survivors ................................................................................................\n4025\nFigure 7 Algorithm for the evaluation of sudden death victims .\n4026\nFigure 8 Algorithm for the evaluation of relatives of unexplained\nsudden death decedents ..............................................................................\n4028\nFigure 9 Algorithm for the acute management of regular wide\nQRS complex tachycardia ...........................................................................\n4029\nFigure 10 Repetitive runs of ventricular tachycardia interrupted\nby occasional sinus beats .............................................................................\n4030\nFigure 11 Part One. Management of patients with electrical\nstorm or repeated implantable cardioverter deﬁbrillator\ndischarges ......................................................................................................... 4031\nFigure 11 Part Two.Management of patients with electrical\nstorm or repeated implantable cardioverter deﬁbrillator\ndischarges ................................................................................................... 4032\nFigure 11 Part Three. Management of patients with electrical\nstorm or repeated implantable cardioverter deﬁbrillator\ndischarges ...........................................................................................................\n4033\nFigure 12 Algorithm for evaluation before initiation and follow-up\nof patients requiring sodium channel blocking agents ....................\n4038\nFigure 13 Algorithm for evaluation before initiation and follow-up\nof patients requiring drugs associated with QT prolongation ....\n4039\nFigure 14 Algorithm for the prevention and management of\nventricular arrhythmias in ST-elevation myocardial infarction .........\n4045\nFigure 15 Algorithm for risk stratiﬁcation and primary prevention\nof sudden cardiac death in patients with chronic coronary artery\ndisease and reduced ejection fraction ....................................................\n4048\nFigure 16 Algorithm for the management of sustained\nmonomorphic ventricular tachycardia in patients with chronic\ncoronary artery disease ................................................................................\n4049\nFigure 17 Algorithm for the management of patients with\nidiopathic premature ventricular complexes/ventricular\ntachycardia and non-apparent structural heart disease .................\n4051\nFigure 18 Algorithm for the management of patients with\npremature ventricular complex-induced/-aggravated\ncardiomyopathy ...............................................................................................\n4053\nFigure 19 Algorithm for risk stratiﬁcation and primary prevention\nof sudden cardiac death in patients with dilated cardiomyopathy/\nhypokinetic non-dilated cardiomyopathy .............................................\n4055\nESC Guidelines\n4001\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nFigure 20 Typical features of dilated cardiomyopathy associated\nwith lamin A/C gene mutation with ventricular arrhythmias ......\n4056\nFigure 21 Typical features of arrhythmogenic right\nventricular cardiomyopathy associated with ventricular\narrhythmias ................................................................................................ 4059\nFigure 22 Typical features of hypertrophic cardiomyopathy\nassociated with sustained monomorphic ventricular\ntachycardia ................................................................................................. 4061\nFigure 23 Algorithm for risk stratiﬁcation, sudden cardiac death\nprevention, and treatment of ventricular arrhythmia in myotonic\ndystrophy .......................................................................................................................... 4064\nFigure 24 Algorithm for sudden cardiac death prevention and\ntreatment of ventricular arrhythmia in patients with cardiac\nsarcoidosis ..........................................................................................................\n4068\nFigure 25 Typical features of cardiac sarcoidosis associated with\nsustained monomorphic ventricular tachycardia ..............................\n4069\nFigure 26 Algorithm for the management of sustained ventricular\narrhythmia in patients with congenital heart disease ......................\n4071\nFigure 27 Algorithm for the management of patients with\nidiopathic ventricular ﬁbrillation ...............................................................\n4074\nFigure 28 Idiopathic ventricular ﬁbrillation triggered by\nshort-coupled premature ventricular complexes .............................\n4075\nFigure 29 Long QT syndrome electrocardiograms and\ntorsade-de-pointes ventricular tachycardia .........................................\n4076\nFigure 30 Brisk standing electrocardiogram changes and T wave\nalternans in Long QT syndrome patients .............................................\n4077\nFigure 31 Algorithm for the management of patients with long\nQT syndrome ...................................................................................................\n4078\nFigure 32 Typical examples of (A) Brugada type 1\nelectrocardiogram, and (B) early repolarization pattern\nelectrocardiogram ...........................................................................................\n4080\nFigure 33 Part One. Algorithm for the management of patients\nwith Brugada pattern electrocardiogram .............................................\n4082\nFigure 33 Part Two. Algorithm for the management of patients\nwith Brugada pattern electrocardiogram .............................................\n4083\nFigure 34 Management of patients with early repolarization\npattern/syndrome ...........................................................................................\n4084\nFigure 35 Management of patients with catecholaminergic\npolymorphic ventricular tachycardia ......................................................\n4085\nFigure 36 Exercise test of a patient with catecholaminergic\npolymorphic ventricular tachycardia ......................................................\n4086\nFigure 37 Short QT syndrome .................................................................\n4087\nAbbreviations and acronyms\nAAD\nAnti-arrhythmic drug\nACE-I\nAngiotensin-converting enzyme inhibitor\nACS\nAcute coronary syndrome\nAED\nAutomated external deﬁbrillator\nAF\nAtrial ﬁbrillation\nAH\nAtrial–His interval\nALS\nAdvanced life support\nARB\nAngiotensin receptor blocker\nARNI\nAngiotensin receptor neprilysin inhibitor\nARVC\nArrhythmogenic right ventricular cardiomyopathy\nATP\nAnti-tachycardia pacing\nAV\nAtrioventricular\nAVRT\nAV re-entry tachycardia\nBBR-VT\nBundle branch re-entrant ventricular tachycardia\nBrS\nBrugada syndrome\nCA\nCardiac arrest\ncAMP\nCyclic adenosine monophosphate\nCAD\nCoronary artery disease\nCAG\nCoronary angiogram\nCCB\nCalcium channel blocker\nCHD\nCongenital heart disease\nCIED\nCardiac implantable electronic devices\nCMR\nCardiac magnetic resonance\nCPR\nCardiopulmonary resuscitation\nCPVT\nCatecholaminergic polymorphic ventricular tachycardia\nCRT\nCardiac resynchronization therapy\nCT/CTA\nComputed tomography/Computed tomography\nangiography\nDCM\nDilated cardiomyopathy\nDNA\nDeoxyribonucleic acid\nECG\nElectrocardiogram\nEF\nEjection fraction\nERP\nEarly repolarization pattern\nERS\nEarly repolarization syndrome\nFBI\nFast, broad, irregular\nHCM\nHypertrophic cardiomyopathy\nHFrEF\nHeart failure with reduced ejection fraction\nHNDCM\nHypokinetic non-dilated cardiomyopathy\nHTX\nHeart transplantation\nHV\nHis–ventricular interval\nICD\nImplantable cardioverter deﬁbrillator\nILR\nImplantable loop recorder\nIVF\nIdiopathic ventricular ﬁbrillation\nLBBB\nLeft bundle branch block\nLCSD\nLeft cardiac sympathetic denervation\nLGE\nLate gadolinium enhancement\nLMNA\nLamin A/C\nLQTS\nLong QT syndrome\nLV\nLeft ventricular\nLVAD\nLeft ventricular assist device\nLVEF\nLeft ventricular ejection fraction\nLVH\nLeft ventricular hypertrophy\nLVNC\nLeft ventricular non-compaction\nLVOT\nLeft ventricle outﬂow tract\nMI\nMyocardial infarction\nMRA\nMineralocorticoid receptor antagonist\nMVP\nMitral valve prolapse\nMVT\nMonomorphic ventricular tachycardia\nNSVT\nNon-sustained ventricular tachycardia\nNYHA\nNew York Heart Association\nOHCA\nOut-of-hospital cardiac arrest\nOMT\nOptimal medical treatment\nPCI\nPercutaneous coronary intervention\nPCR\nPolymerase chain reaction\nPES\nProgrammed electrical stimulation\nPET-CT\nPositron emission tomography computed\ntomography\nPPCM\nPeri-partum cardiomyopathy\nPVC\nPremature ventricular complex\nPVT\nPolymorphic ventricular tachycardia\nQI\nQuality indicators\nRBBB\nRight bundle branch block\n4002\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 2",
          "page": 2,
          "content": " |  | urheartj/article/43/40/399\n | Keywords Guidelines • Anti-arrhythmic drugs • Cardiac magnetic resonance • Cardiomyopathies • Catheter ablation •\nChronic coronary artery disease • Genetic testing • Implantable cardioverter defibrillator • Premature ventricular\ncomplex • Primary electrical disease • Recommendations • Risk calculator • Risk stratification • Sudden cardiac\ndeath • Sudden death • Ventricular arrhythmia • Ventricular fibrillation • Ventricular tachycardia | \n |  | ",
          "rows": 3,
          "cols": 3
        }
      ],
      "keywords": [
        "ct",
        "intervention",
        "cardiac",
        "heart failure",
        "management",
        "prevention",
        "patients",
        "guidelines",
        "death",
        "pci",
        "sudden",
        "imaging",
        "ventricular",
        "arrhythmias"
      ]
    },
    {
      "number": "2",
      "title": "Abbreviations and acronyms",
      "start_page": 6,
      "end_page": 7,
      "content": "Figure 20 Typical features of dilated cardiomyopathy associated\nwith lamin A/C gene mutation with ventricular arrhythmias ......\n4056\nFigure 21 Typical features of arrhythmogenic right\nventricular cardiomyopathy associated with ventricular\narrhythmias ................................................................................................ 4059\nFigure 22 Typical features of hypertrophic cardiomyopathy\nassociated with sustained monomorphic ventricular\ntachycardia ................................................................................................. 4061\nFigure 23 Algorithm for risk stratiﬁcation, sudden cardiac death\nprevention, and treatment of ventricular arrhythmia in myotonic\ndystrophy .......................................................................................................................... 4064\nFigure 24 Algorithm for sudden cardiac death prevention and\ntreatment of ventricular arrhythmia in patients with cardiac\nsarcoidosis ..........................................................................................................\n4068\nFigure 25 Typical features of cardiac sarcoidosis associated with\nsustained monomorphic ventricular tachycardia ..............................\n4069\nFigure 26 Algorithm for the management of sustained ventricular\narrhythmia in patients with congenital heart disease ......................\n4071\nFigure 27 Algorithm for the management of patients with\nidiopathic ventricular ﬁbrillation ...............................................................\n4074\nFigure 28 Idiopathic ventricular ﬁbrillation triggered by\nshort-coupled premature ventricular complexes .............................\n4075\nFigure 29 Long QT syndrome electrocardiograms and\ntorsade-de-pointes ventricular tachycardia .........................................\n4076\nFigure 30 Brisk standing electrocardiogram changes and T wave\nalternans in Long QT syndrome patients .............................................\n4077\nFigure 31 Algorithm for the management of patients with long\nQT syndrome ...................................................................................................\n4078\nFigure 32 Typical examples of (A) Brugada type 1\nelectrocardiogram, and (B) early repolarization pattern\nelectrocardiogram ...........................................................................................\n4080\nFigure 33 Part One. Algorithm for the management of patients\nwith Brugada pattern electrocardiogram .............................................\n4082\nFigure 33 Part Two. Algorithm for the management of patients\nwith Brugada pattern electrocardiogram .............................................\n4083\nFigure 34 Management of patients with early repolarization\npattern/syndrome ...........................................................................................\n4084\nFigure 35 Management of patients with catecholaminergic\npolymorphic ventricular tachycardia ......................................................\n4085\nFigure 36 Exercise test of a patient with catecholaminergic\npolymorphic ventricular tachycardia ......................................................\n4086\nFigure 37 Short QT syndrome .................................................................\n4087\nAbbreviations and acronyms\nAAD\nAnti-arrhythmic drug\nACE-I\nAngiotensin-converting enzyme inhibitor\nACS\nAcute coronary syndrome\nAED\nAutomated external deﬁbrillator\nAF\nAtrial ﬁbrillation\nAH\nAtrial–His interval\nALS\nAdvanced life support\nARB\nAngiotensin receptor blocker\nARNI\nAngiotensin receptor neprilysin inhibitor\nARVC\nArrhythmogenic right ventricular cardiomyopathy\nATP\nAnti-tachycardia pacing\nAV\nAtrioventricular\nAVRT\nAV re-entry tachycardia\nBBR-VT\nBundle branch re-entrant ventricular tachycardia\nBrS\nBrugada syndrome\nCA\nCardiac arrest\ncAMP\nCyclic adenosine monophosphate\nCAD\nCoronary artery disease\nCAG\nCoronary angiogram\nCCB\nCalcium channel blocker\nCHD\nCongenital heart disease\nCIED\nCardiac implantable electronic devices\nCMR\nCardiac magnetic resonance\nCPR\nCardiopulmonary resuscitation\nCPVT\nCatecholaminergic polymorphic ventricular tachycardia\nCRT\nCardiac resynchronization therapy\nCT/CTA\nComputed tomography/Computed tomography\nangiography\nDCM\nDilated cardiomyopathy\nDNA\nDeoxyribonucleic acid\nECG\nElectrocardiogram\nEF\nEjection fraction\nERP\nEarly repolarization pattern\nERS\nEarly repolarization syndrome\nFBI\nFast, broad, irregular\nHCM\nHypertrophic cardiomyopathy\nHFrEF\nHeart failure with reduced ejection fraction\nHNDCM\nHypokinetic non-dilated cardiomyopathy\nHTX\nHeart transplantation\nHV\nHis–ventricular interval\nICD\nImplantable cardioverter deﬁbrillator\nILR\nImplantable loop recorder\nIVF\nIdiopathic ventricular ﬁbrillation\nLBBB\nLeft bundle branch block\nLCSD\nLeft cardiac sympathetic denervation\nLGE\nLate gadolinium enhancement\nLMNA\nLamin A/C\nLQTS\nLong QT syndrome\nLV\nLeft ventricular\nLVAD\nLeft ventricular assist device\nLVEF\nLeft ventricular ejection fraction\nLVH\nLeft ventricular hypertrophy\nLVNC\nLeft ventricular non-compaction\nLVOT\nLeft ventricle outﬂow tract\nMI\nMyocardial infarction\nMRA\nMineralocorticoid receptor antagonist\nMVP\nMitral valve prolapse\nMVT\nMonomorphic ventricular tachycardia\nNSVT\nNon-sustained ventricular tachycardia\nNYHA\nNew York Heart Association\nOHCA\nOut-of-hospital cardiac arrest\nOMT\nOptimal medical treatment\nPCI\nPercutaneous coronary intervention\nPCR\nPolymerase chain reaction\nPES\nProgrammed electrical stimulation\nPET-CT\nPositron emission tomography computed\ntomography\nPPCM\nPeri-partum cardiomyopathy\nPVC\nPremature ventricular complex\nPVT\nPolymorphic ventricular tachycardia\nQI\nQuality indicators\nRBBB\nRight bundle branch block\n4002\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nRCM\nRestrictive cardiomyopathy\nRCT\nRandomized control trial\nRV\nRight ventricular\nRVOT\nRight ventricle outﬂow tract\nSADS\nSudden arrhythmic death syndrome\nSaECG\nSignal-averaged ECG\nSCA\nSudden cardiac arrest\nSCD\nSudden cardiac death\nSD\nSudden death\nSGLT2\nSodium–glucose co-transporter 2\nSHD\nStructural heart disease\nS-ICD\nSubcutaneous implantable cardioverter\ndeﬁbrillator\nSMVT\nSustained monomorphic ventricular tachycardia\nSPTV\nSustained polymorphic ventricular tachycardia\nSQTS\nShort QT syndrome\nSTEMI\nST elevation myocardial infarction\nSVT\nSupraventricular tachycardia\nTAVI\nTranscatheter aortic valve implantation\nTdP\nTorsades de pointes\nTOF\nTetralogy of Fallot\nVA\nVentricular arrhythmia\nVF\nVentricular ﬁbrillation\nVT\nVentricular tachycardia\nWCD\nWearable cardioverter deﬁbrillator\nWPW\nWolff–Parkinson–White\n1. Preamble\nGuidelines summarize and evaluate available evidence with the aim of\nassisting health professionals in proposing the best management\nstrategies for an individual patient with\na given\ncondition.\nGuidelines and their recommendations should facilitate decision\nmaking of health professionals in their daily practice. However, guide-\nlines are not a substitute for the patient’s relationship with their prac-\ntitioner. The ﬁnal decisions concerning an individual patient must be\nmade by the responsible health professional(s), based on what they\nconsider to be the most appropriate in the circumstances. These de-\ncisions are made in consultation with the patient and caregiver as\nappropriate.\nGuidelines are intended for use by health professionals. To ensure\nthat all users have access to the most recent recommendations, the\nESC makes its guidelines freely available. The ESC warns readers that\nthe technical language may be misinterpreted and declines any re-\nsponsibility in this respect.\nA great number of guidelines have been issued in recent years by\nthe ESC. Because of their impact on clinical practice, quality criteria\nfor the development of guidelines have been established to make all\ndecisions transparent to the user. The recommendations for formu-\nlating and issuing ESC Guidelines can be found on the ESC website\n(https://www.escardio.org/Guidelines). The ESC Guidelines re-\npresent the ofﬁcial position of the ESC on a given topic and are regu-\nlarly updated.\nIn addition to the publication of Clinical Practice Guidelines, the\nESC carries out the EURObservational Research Programme of\ninternational registries of cardiovascular diseases and interventions\nthat are essential to assess diagnostic/therapeutic processes, use of\nresources, and adherence to guidelines. These registries aim at pro-\nviding a better understanding of medical practice in Europe and\naround the world, based on high-quality data collected during rou-\ntine clinical practice.\nFurthermore, the ESC develops sets of quality indicators (QIs),\nwhich are tools to evaluate the level of implementation of the guide-\nlines and may be used by the ESC, hospitals, healthcare providers,\nand professionals to measure clinical practice, and in educational\nTable 1\nClasses of recommendations\n©ESC 2022\nClasses of recommendations\nClass I \nEvide\nbeneficial, useful, effective.\neffcacy of the given treatment or procedure.\nnce and/or general agreement\nthat a given treatment or procedure is\nConﬂicting evidence and/or a divergence of opinion about the usefulness/ \nIs recommended or is indicated\nWording to use\nDeﬁnition\nClass III \nEvidence or general agreement that the\ngiven tr\nuseful/effective, and in some cases\neatment or procedure is not\nmay be harmful. \nIs not recommended\nClass IIb\nestablished by evidence/opinion.\nMay be considered\nClass IIa\nW\nfavour of usefulness/effcacy.\neight of \nUsefulness/efficacy is less well\nevidence/opinion is in\nShould be considered\nClass II \n© ESC 2022\nESC Guidelines\n4003\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 7",
          "page": 7,
          "content": "Class II | Conflicting evidence and/or a divergence of opinion about the usefulness/\neffcacy of the given treatment or procedure. |  |  | \n |  |  |  | \nClass IIa |  | Weight of evidence/opinion is in\nfavour of usefulness/effcacy. | Should be considered | \n |  |  |  | \nClass IIb |  | Usefulness/efficacy is less well\nestablished by evidence/opinion. | May be considered | ",
          "rows": 5,
          "cols": 5
        }
      ],
      "keywords": [
        "cardiomyopathy",
        "ct",
        "echo",
        "acronyms",
        "risk",
        "treatment",
        "abbreviations"
      ]
    },
    {
      "number": "3",
      "title": "1. Preamble",
      "start_page": 7,
      "end_page": 9,
      "content": "RCM\nRestrictive cardiomyopathy\nRCT\nRandomized control trial\nRV\nRight ventricular\nRVOT\nRight ventricle outﬂow tract\nSADS\nSudden arrhythmic death syndrome\nSaECG\nSignal-averaged ECG\nSCA\nSudden cardiac arrest\nSCD\nSudden cardiac death\nSD\nSudden death\nSGLT2\nSodium–glucose co-transporter 2\nSHD\nStructural heart disease\nS-ICD\nSubcutaneous implantable cardioverter\ndeﬁbrillator\nSMVT\nSustained monomorphic ventricular tachycardia\nSPTV\nSustained polymorphic ventricular tachycardia\nSQTS\nShort QT syndrome\nSTEMI\nST elevation myocardial infarction\nSVT\nSupraventricular tachycardia\nTAVI\nTranscatheter aortic valve implantation\nTdP\nTorsades de pointes\nTOF\nTetralogy of Fallot\nVA\nVentricular arrhythmia\nVF\nVentricular ﬁbrillation\nVT\nVentricular tachycardia\nWCD\nWearable cardioverter deﬁbrillator\nWPW\nWolff–Parkinson–White\n1. Preamble\nGuidelines summarize and evaluate available evidence with the aim of\nassisting health professionals in proposing the best management\nstrategies for an individual patient with\na given\ncondition.\nGuidelines and their recommendations should facilitate decision\nmaking of health professionals in their daily practice. However, guide-\nlines are not a substitute for the patient’s relationship with their prac-\ntitioner. The ﬁnal decisions concerning an individual patient must be\nmade by the responsible health professional(s), based on what they\nconsider to be the most appropriate in the circumstances. These de-\ncisions are made in consultation with the patient and caregiver as\nappropriate.\nGuidelines are intended for use by health professionals. To ensure\nthat all users have access to the most recent recommendations, the\nESC makes its guidelines freely available. The ESC warns readers that\nthe technical language may be misinterpreted and declines any re-\nsponsibility in this respect.\nA great number of guidelines have been issued in recent years by\nthe ESC. Because of their impact on clinical practice, quality criteria\nfor the development of guidelines have been established to make all\ndecisions transparent to the user. The recommendations for formu-\nlating and issuing ESC Guidelines can be found on the ESC website\n(https://www.escardio.org/Guidelines). The ESC Guidelines re-\npresent the ofﬁcial position of the ESC on a given topic and are regu-\nlarly updated.\nIn addition to the publication of Clinical Practice Guidelines, the\nESC carries out the EURObservational Research Programme of\ninternational registries of cardiovascular diseases and interventions\nthat are essential to assess diagnostic/therapeutic processes, use of\nresources, and adherence to guidelines. These registries aim at pro-\nviding a better understanding of medical practice in Europe and\naround the world, based on high-quality data collected during rou-\ntine clinical practice.\nFurthermore, the ESC develops sets of quality indicators (QIs),\nwhich are tools to evaluate the level of implementation of the guide-\nlines and may be used by the ESC, hospitals, healthcare providers,\nand professionals to measure clinical practice, and in educational\nTable 1\nClasses of recommendations\n©ESC 2022\nClasses of recommendations\nClass I \nEvide\nbeneficial, useful, effective.\neffcacy of the given treatment or procedure.\nnce and/or general agreement\nthat a given treatment or procedure is\nConﬂicting evidence and/or a divergence of opinion about the usefulness/ \nIs recommended or is indicated\nWording to use\nDeﬁnition\nClass III \nEvidence or general agreement that the\ngiven tr\nuseful/effective, and in some cases\neatment or procedure is not\nmay be harmful. \nIs not recommended\nClass IIb\nestablished by evidence/opinion.\nMay be considered\nClass IIa\nW\nfavour of usefulness/effcacy.\neight of \nUsefulness/efficacy is less well\nevidence/opinion is in\nShould be considered\nClass II \n© ESC 2022\nESC Guidelines\n4003\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nprogrammes, alongside the key messages from the guidelines, to im-\nprove quality of care and clinical outcomes.\nThe Members of this task force were selected by the ESC to re-\npresent professionals involved with the medical care of patients\nwith this pathology. The selection procedure aimed to ensure that\nthere is a representative mix of members predominantly from across\nthe whole of the ESC region and from relevant ESC Subspecialty\nCommunities. Consideration was given to diversity and inclusion,\nnotably with respect to gender and country of origin. A critical evalu-\nation of diagnostic and therapeutic procedures was performed, in-\ncluding assessment of the risk–beneﬁt ratio. The level of evidence\nand the strength of the recommendation of particular management\noptions were weighed and scored according to predeﬁned scales, as\noutlined below. The task force followed the ESC voting procedures.\nAll recommendations subject to a vote achieved at least 75% among\nvoting members.\nThe experts of the writing and reviewing panels provided declar-\nation of interest forms for all relationships that might be perceived as\nreal or potential sources of conﬂicts of interest. Their declarations of\ninterest were reviewed according to the ESC declaration of interest\nrules and can be found on the ESC website (http://www.escardio.org/\nGuidelines) and have been compiled in a report and published in a\nsupplementary document simultaneously to the guidelines.\nThis process ensures transparency and prevents potential biases in\nthe development and review processes. Any changes in declarations of\ninterest that arise during the writing period were notiﬁed to the ESC\nand updated. The task force received its entire ﬁnancial support from\nthe ESC without any involvement from the healthcare industry.\nThe ESC CPG Committee supervises and coordinates the prepar-\nation of new guidelines. The Committee is also responsible for the\napproval process of these guidelines. The ESC Guidelines undergo\nextensive review by the CPG Committee and external experts, in-\ncluding a mix of members from across the whole of the ESC region\nand from relevant ESC Subspecialty Communities and National\nCardiac Societies. After appropriate revisions, the guidelines are\nsigned off by all the experts involved in the task force. The ﬁnalized\ndocument is signed off by the CPG Committee for publication in the\nEuropean Heart Journal. The guidelines were developed after careful\nconsideration of the scientiﬁc and medical knowledge and the evi-\ndence available at the time of their writing.\nThe task of developing ESC Guidelines also includes the creation\nof educational tools and implementation programmes for the re-\ncommendations, including condensed pocket guideline versions,\nsummary slides, summary cards for non-specialists, and an electronic\nversion for digital applications (smartphones, etc.). These versions\nare abridged and thus, for more detailed information, the user\nshould always access the full-text version of the guidelines, which\nis freely available via the ESC website and the European Heart\nJournal. The National Cardiac Societies of the ESC are encouraged\nto endorse, adopt, translate, and implement all ESC Guidelines.\nImplementation programmes are needed because it has been shown\nthat the outcome of disease may be favourably inﬂuenced by the\nthorough application of clinical recommendations.\nHealth professionals are encouraged to take the ESC Guidelines\nfully into account when exercising their clinical judgement, as well\nas in the determination and the implementation of preventive,\ndiagnostic, or therapeutic medical strategies. However, the ESC\nGuidelines do not override in any way whatsoever the individual re-\nsponsibility of health professionals to make appropriate and accurate\ndecisions in consideration of each patient‘s health condition and in\nconsultation with that patient or the patient’s caregiver where ap-\npropriate and/or necessary. It is also the health professional’s re-\nsponsibility to verify the rules and regulations applicable in each\ncountry to drugs and devices at the time of prescription and, where\nappropriate, to respect the ethical rules of their profession.\nOff-label use of medication may be presented in this guideline if\nsufﬁcient level of evidence shows that it can be considered medically\nappropriate to a given condition and if patients could beneﬁt from\nthe recommended therapy. However, the ﬁnal decisions concerning\nan individual patient must be made by the responsible health profes-\nsional giving special consideration to:\n(1) the speciﬁc situation of the patient. In this respect, it is speciﬁed\nthat, unless otherwise provided for by national regulations, off-\nTable 2\nLevels of evidence\nLevel of\nevidence A\nLevel of\nevidence B\nLevel of\nevidence C\nData derived from multiple randomized clinical trials\nor meta-analyses.\nData derived from a single randomized clinical trial\nor large non-randomized studies.\nConsensus of opinion of the experts and/or small studies,\nretrospective studies, registries.\n©ESC 2022\n4004\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nlabel use of medication should be limited to situations where it is\nin the patient’s interest to do so, with regard to the quality,\nsafety, and efﬁcacy of care, and only after the patient has been\ninformed and has provided consent;\n(2) country-speciﬁc health regulations, indications by governmental\ndrug regulatory agencies, and the ethical rules to which health\nprofessionals are subject, where applicable.\n2. Introduction\nThis document presents an update of the 2015 ESC Guidelines\nfor the management of patients with ventricular arrhythmias (VA)\nand the prevention of sudden cardiac death (SCD). New insights\ninto the epidemiology of SCD, new evidence on genetics, imaging,\nand clinical ﬁndings for risk stratiﬁcation for VA and SCD, and ad-\nvances in diagnostic evaluation and therapeutic strategies made this\nrevision necessary. The committee was composed of 25 members\nincluding 23 expert physicians, one methodologist, and one patient\nrepresentative. Experts were selected to cover all areas of VA and\nSCD as well as subspecialties of cardiology with the assistance of re-\nlated ESC working groups.\nAll 25 members of the task force committee approved the guide-\nline\nrecommendations\nafter\nan\nanonymous\nvoting\nprocess.\nNinety-nine peer reviewers reviewed the document. A systematic\nliterature survey was conducted, after instructions by the method-\nologist in the group, that led to the incorporation of 1155 references,\nof which 485 were selected to support the recommendations and\nfurther speciﬁed in the table of evidence (Supplementary data).\n2.1. What is new\nThe diagnostic and management parts of the guidelines have been\nadapted to facilitate their use in everyday clinical decision-making.\nThe ﬁrst general part has new sections on diagnostic evaluation,\nincluding pharmacologic provocative tests, genetic testing, and a sys-\ntematic work-up of probands and relatives with primary electrical\ndiseases. Comprehensive ﬂowcharts and recommendations for the\ndiagnostic evaluation at ﬁrst presentation with a VA of patients with-\nout a previously known cardiac disease are provided for ﬁve fre-\nquently encountered clinical scenarios. Practical recommendations\nfor optimization of implantable cardioverter deﬁbrillator (ICD) pro-\ngramming and algorithms for management of patients experiencing\nregular wide complex tachycardia and electrical storm are presented\n(Table 3).\nTable 3\nNew sections and concepts\nNew sections and concepts\nSection\nProvocative diagnostic tests\n5.1.3.5\nGenetic testing\n5.1.4\nDiagnostic evaluation at ﬁrst presentation with VA in\npatients without known cardiac disease\n5.2\nManagement of patients with electrical storm\n6.1.3\nSpecial aspects of device therapy\n6.2.3\n© ESC 2022\nTable 4\nNew recommendations in 2022\nRecommendations\nClass\nPublic basic life support and access to AEDs\nIt is recommended that public-access deﬁbrillation be available\nat sites where cardiac arrest is more likely to occur.a\nI\nPrompt CPR by bystanders is recommended at OHCA.\nI\nIt is recommended to promote community training in basic life\nsupport to increase bystander CPR rate and AED use.\nI\nMobile phone-based alerting of basic life support-trained\nbystander volunteers to assist nearby OHCA victims should be\nconsidered.\nIIa\nTreatment of VA. General aspects\nDC cardioversion is recommended as the ﬁrst-line treatment\nfor patients presenting with tolerated SMVT provided that the\nanaesthetic/sedation risk is low.\nI\nOptimal medical treatment including ACE-I/ARB/ARNIs,\nMRAs, beta-blockers, and SGLT2 inhibitors is indicated in all\nheart failure patients with reduced EF.\nI\nImplantation of a cardioverter deﬁbrillator is only\nrecommended in patients who have an expectation of\ngood-quality survival .1 year.\nI\nIn patients presenting with a haemodynamically tolerated\nSMVT and known or suspected SHD, intravenous\nprocainamide should be considered.\nIIa\nIn patients presenting with a haemodynamically tolerated\nSMVT in the absence of an established diagnosis, intravenous\namiodarone may be considered.\nIIb\nIn patients with SMVT or SPVT/VF triggered by a PVC with\nsimilar morphology and an indication for ICD, catheter ablation\nmay be considered when an ICD is not available,\ncontraindicated for concurrent medical reasons, or declined by\nthe patient.\nIIb\nThe WCD may be considered in the early phase after MI in\nselected patients.\nIIb\nCoronary artery disease\nIn patients with CAD and recurrent, symptomatic SMVT, or\nICD shocks for SMVT despite chronic amiodarone therapy,\ncatheter ablation is recommended in preference to escalating\nAAD therapy.\nI\nCardiac stress imaging during physical exercise is\nrecommended in addition to cardiopulmonary exercise test\nafter surgery in patients with anomalous aortic origin of a\ncoronary artery with a history of aborted CA.\nI\nIn SCA survivors with coronary artery spasm, implantation of\nan ICD should be considered.\nIIa\nICD therapy should be considered in patients with CAD,\nNYHA class I, and LVEF ≤30% despite ≥3 months of OMT.\nIIa\nICD implantation should be considered in patients with CAD,\nLVEF ≤40% despite ≥3 months of OMT and NSVT, if they are\ninducible for SMVT by PES.\nIIa\nContinued\nESC Guidelines\n4005\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 7",
          "page": 7,
          "content": "Class II | Conflicting evidence and/or a divergence of opinion about the usefulness/\neffcacy of the given treatment or procedure. |  |  | \n |  |  |  | \nClass IIa |  | Weight of evidence/opinion is in\nfavour of usefulness/effcacy. | Should be considered | \n |  |  |  | \nClass IIb |  | Usefulness/efficacy is less well\nestablished by evidence/opinion. | May be considered | ",
          "rows": 5,
          "cols": 5
        },
        {
          "title": "Table on page 9",
          "page": 9,
          "content": "Recommendations |  | Class | \n | Public basic life support and access to AEDs |  | \nIt is recommended that public-access defibrillation be available\nat sites where cardiac arrest is more likely to occur.a |  | I | \nPrompt CPR by bystanders is recommended at OHCA. |  | I | \nIt is recommended to promote community training in basic life\nsupport to increase bystander CPR rate and AED use. |  | I | \nMobile phone-based alerting of basic life support-trained\nbystander volunteers to assist nearby OHCA victims should be\nconsidered. |  | IIa | \n | Treatment of VA. General aspects |  | \nDC cardioversion is recommended as the first-line treatment\nfor patients presenting with tolerated SMVT provided that the\nanaesthetic/sedation risk is low. |  | I | \nOptimal medical treatment including ACE-I/ARB/ARNIs,\nMRAs, beta-blockers, and SGLT2 inhibitors is indicated in all\nheart failure patients with reduced EF. |  | I | \nImplantation of a cardioverter defibrillator is only\nrecommended in patients who have an expectation of\ngood-quality survival .1 year. |  | I | \nIn patients presenting with a haemodynamically tolerated\nSMVT and known or suspected SHD, intravenous\nprocainamide should be considered. |  | IIa | \nIn patients presenting with a haemodynamically tolerated\nSMVT in the absence of an established diagnosis, intravenous\namiodarone may be considered. |  | IIb | \nIn patients with SMVT or SPVT/VF triggered by a PVC with\nsimilar morphology and an indication for ICD, catheter ablation\nmay be considered when an ICD is not available,\ncontraindicated for concurrent medical reasons, or declined by\nthe patient. |  | IIb | \nThe WCD may be considered in the early phase after MI in\nselected patients. |  | IIb | \n | Coronary artery disease |  | \nIn patients with CAD and recurrent, symptomatic SMVT, or\nICD shocks for SMVT despite chronic amiodarone therapy,\ncatheter ablation is recommended in preference to escalating\nAAD therapy. |  | I | \nCardiac stress imaging during physical exercise is\nrecommended in addition to cardiopulmonary exercise test\nafter surgery in patients with anomalous aortic origin of a\ncoronary artery with a history of aborted CA. |  | I | \nIn SCA survivors with coronary artery spasm, implantation of\nan ICD should be considered. |  | IIa | \nICD therapy should be considered in patients with CAD,\nNYHA class I, and LVEF ≤30% despite ≥3 months of OMT. |  | IIa | \nICD implantation should be considered in patients with CAD,\nLVEF ≤40% despite ≥3 months of OMT and NSVT, if they are\ninducible for SMVT by PES. |  | IIa | ",
          "rows": 20,
          "cols": 4
        },
        {
          "title": "Table on page 9",
          "page": 9,
          "content": "New sections and concepts | Section\nProvocative diagnostic tests | 5.1.3.5\nGenetic testing | 5.1.4\nDiagnostic evaluation at first presentation with VA in\npatients without known cardiac disease | 5.2\nManagement of patients with electrical storm | 6.1.3\nSpecial aspects of device therapy | 6.2.3",
          "rows": 6,
          "cols": 2
        }
      ],
      "keywords": [
        "cardiomyopathy",
        "myocardial infarction",
        "intervention",
        "ct",
        "preamble",
        "tavi",
        "sglt2",
        "icd",
        "recommendation"
      ]
    },
    {
      "number": "4",
      "title": "2. Introduction",
      "start_page": 9,
      "end_page": 15,
      "content": "label use of medication should be limited to situations where it is\nin the patient’s interest to do so, with regard to the quality,\nsafety, and efﬁcacy of care, and only after the patient has been\ninformed and has provided consent;\n(2) country-speciﬁc health regulations, indications by governmental\ndrug regulatory agencies, and the ethical rules to which health\nprofessionals are subject, where applicable.\n2. Introduction\nThis document presents an update of the 2015 ESC Guidelines\nfor the management of patients with ventricular arrhythmias (VA)\nand the prevention of sudden cardiac death (SCD). New insights\ninto the epidemiology of SCD, new evidence on genetics, imaging,\nand clinical ﬁndings for risk stratiﬁcation for VA and SCD, and ad-\nvances in diagnostic evaluation and therapeutic strategies made this\nrevision necessary. The committee was composed of 25 members\nincluding 23 expert physicians, one methodologist, and one patient\nrepresentative. Experts were selected to cover all areas of VA and\nSCD as well as subspecialties of cardiology with the assistance of re-\nlated ESC working groups.\nAll 25 members of the task force committee approved the guide-\nline\nrecommendations\nafter\nan\nanonymous\nvoting\nprocess.\nNinety-nine peer reviewers reviewed the document. A systematic\nliterature survey was conducted, after instructions by the method-\nologist in the group, that led to the incorporation of 1155 references,\nof which 485 were selected to support the recommendations and\nfurther speciﬁed in the table of evidence (Supplementary data).\n2.1. What is new\nThe diagnostic and management parts of the guidelines have been\nadapted to facilitate their use in everyday clinical decision-making.\nThe ﬁrst general part has new sections on diagnostic evaluation,\nincluding pharmacologic provocative tests, genetic testing, and a sys-\ntematic work-up of probands and relatives with primary electrical\ndiseases. Comprehensive ﬂowcharts and recommendations for the\ndiagnostic evaluation at ﬁrst presentation with a VA of patients with-\nout a previously known cardiac disease are provided for ﬁve fre-\nquently encountered clinical scenarios. Practical recommendations\nfor optimization of implantable cardioverter deﬁbrillator (ICD) pro-\ngramming and algorithms for management of patients experiencing\nregular wide complex tachycardia and electrical storm are presented\n(Table 3).\nTable 3\nNew sections and concepts\nNew sections and concepts\nSection\nProvocative diagnostic tests\n5.1.3.5\nGenetic testing\n5.1.4\nDiagnostic evaluation at ﬁrst presentation with VA in\npatients without known cardiac disease\n5.2\nManagement of patients with electrical storm\n6.1.3\nSpecial aspects of device therapy\n6.2.3\n© ESC 2022\nTable 4\nNew recommendations in 2022\nRecommendations\nClass\nPublic basic life support and access to AEDs\nIt is recommended that public-access deﬁbrillation be available\nat sites where cardiac arrest is more likely to occur.a\nI\nPrompt CPR by bystanders is recommended at OHCA.\nI\nIt is recommended to promote community training in basic life\nsupport to increase bystander CPR rate and AED use.\nI\nMobile phone-based alerting of basic life support-trained\nbystander volunteers to assist nearby OHCA victims should be\nconsidered.\nIIa\nTreatment of VA. General aspects\nDC cardioversion is recommended as the ﬁrst-line treatment\nfor patients presenting with tolerated SMVT provided that the\nanaesthetic/sedation risk is low.\nI\nOptimal medical treatment including ACE-I/ARB/ARNIs,\nMRAs, beta-blockers, and SGLT2 inhibitors is indicated in all\nheart failure patients with reduced EF.\nI\nImplantation of a cardioverter deﬁbrillator is only\nrecommended in patients who have an expectation of\ngood-quality survival .1 year.\nI\nIn patients presenting with a haemodynamically tolerated\nSMVT and known or suspected SHD, intravenous\nprocainamide should be considered.\nIIa\nIn patients presenting with a haemodynamically tolerated\nSMVT in the absence of an established diagnosis, intravenous\namiodarone may be considered.\nIIb\nIn patients with SMVT or SPVT/VF triggered by a PVC with\nsimilar morphology and an indication for ICD, catheter ablation\nmay be considered when an ICD is not available,\ncontraindicated for concurrent medical reasons, or declined by\nthe patient.\nIIb\nThe WCD may be considered in the early phase after MI in\nselected patients.\nIIb\nCoronary artery disease\nIn patients with CAD and recurrent, symptomatic SMVT, or\nICD shocks for SMVT despite chronic amiodarone therapy,\ncatheter ablation is recommended in preference to escalating\nAAD therapy.\nI\nCardiac stress imaging during physical exercise is\nrecommended in addition to cardiopulmonary exercise test\nafter surgery in patients with anomalous aortic origin of a\ncoronary artery with a history of aborted CA.\nI\nIn SCA survivors with coronary artery spasm, implantation of\nan ICD should be considered.\nIIa\nICD therapy should be considered in patients with CAD,\nNYHA class I, and LVEF ≤30% despite ≥3 months of OMT.\nIIa\nICD implantation should be considered in patients with CAD,\nLVEF ≤40% despite ≥3 months of OMT and NSVT, if they are\ninducible for SMVT by PES.\nIIa\nContinued\nESC Guidelines\n4005\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nIn patients with CAD and haemodynamically well-tolerated\nSMVT and LVEF ≥40%, catheter ablation in experienced\ncentres should be considered as an alternative to ICD therapy,\nprovided that established endpoints have been reached.b\nIIa\nCatheter ablation should be considered in patients with CAD\nand recurrent, symptomatic SMVT, or ICD shocks for SMVT\ndespite beta-blocker or sotalol treatment.\nIIa\nIdiopathic PVC/VT and PVC-induced cardiomyopathy\nCatheter ablation as ﬁrst-line treatment is recommended for\nsymptomatic idiopathic VT/PVCs from the RVOT or the left\nfascicles.\nI\nBeta-blockers or non-dihydropyridine CCBs are indicated in\nsymptomatic patients with idiopathic VT/PVCs from an origin\nother than the RVOT or the left fascicles.\nI\nIn patients with PVCs/VT and a presentation not typical for an\nidiopathic origin,c CMR should be considered, despite a normal\nechocardiogram.\nIIa\nBeta-blockers, non-dihydropyridine CCBs or ﬂecainide should\nbe considered when catheter ablation is not available, not\ndesired, or is particularly risky in symptomatic patients with\nidiopathic VT/PVCs from the RVOT or the left fascicles.\nIIa\nCatheter ablation or ﬂecainide should be considered in\nsymptomatic patients with idiopathic VT/PVCs from an origin\nother than the RVOT or the left fascicles.\nIIa\nIn patients with an unexplained reduced EF and a PVC burden\nof at least 10%, PVC-induced cardiomyopathy should be\nconsidered.\nIIa\nIn patients with suspected PVC-induced cardiomyopathy, CMR\nshould be considered.\nIIa\nIn non-responders to CRT with frequent, predominately\nmonomorphic PVCs limiting optimal biventricular pacing\ndespite pharmacological therapy, catheter ablation or AADs\nshould be considered.\nIIa\nCatheter ablation may be considered for idiopathic VT/PVCs in\nasymptomatic patients with repeatedly more than 20% of\nPVCs per day at follow-up.\nIIb\nAmiodarone as a ﬁrst-line treatment is not recommended in\npatients with idiopathic VTs/PVCs.\nIII\nDCM/HNDCM\nGenetic testing (including at least LMNA, PLN, RBM20, and\nFLNC genes) is recommended in patients with DCM/HNDCM\nand AV conduction delay at ,50 years, or who have a family\nhistory of DCM/HNDCM or SCD in a ﬁrst-degree relative (at\nage ,50 years).\nI\nIn a ﬁrst-degree relative of a DCM/HNDCM patient, an ECG,\nand an echocardiogram are recommended if:\n• the index patient was diagnosed ,50 years of age or has\nclinical features suggestive of an inherited cause, or\n• there is a family history of DCM/HNDCM, or premature\nunexpected SD.\nI\nCMR with LGE should be considered in DCM/HNDCM\npatients for assessing the aetiology and the risk of VA/SCD.\nIIa\nContinued\nGenetic testing (including at least LMNA, PLN, RBM20, and\nFLNC genes) should be considered for risk stratiﬁcation in\npatients with apparently sporadic DCM/HNDCM, who\npresent at young age or with signs suspicious for an inherited\naetiology.\nIIa\nICD implantation should be considered in DCM/HNDCM\npatients with an LVEF ,50% and ≥2 risk factors (syncope, LGE\non CMR, inducible SMVT at PES, pathogenic mutations in\nLMNA, PLN, FLNC, and RBM20 genes).\nIIa\nICD implantation should be considered in patients with DCM/\nHNDCM and haemodynamically tolerated SMVT.\nIIa\nIn a ﬁrst-degree relative of a patient with apparently sporadic\nDCM/HNDCM, an ECG, and an echocardiogram may be\nconsidered.\nIIb\nParticipation in high-intensity exercise including competitive\nsports is not recommended for individuals with DCM/\nHNDCM and a LMNA mutation.\nIII\nARVC\nIn patients with suspected ARVC, CMR is recommended.\nI\nIn patients with a suspected or deﬁnite diagnosis of ARVC,\ngenetic counselling and testing are recommended.\nI\nICD implantation should be considered in symptomaticd\npatients with deﬁnite ARVC, moderate right or left ventricular\ndysfunction, and either NSVT or inducibility of SMVT at PES.\nIIa\nIn ARVC patients with indication for ICDs, a device with the\ncapability of ATP programming for SMVT up to high rates\nshould be considered.\nIIa\nAvoidance of high-intensitye exercise may be considered in\ncarriers of ARVC-related pathogenic mutations and no\nphenotype.\nIIb\nBeta-blocker therapy may be considered in all patients with a\ndeﬁnite diagnosis of ARVC.\nIIb\nIn patients with ARVC and symptoms highly suspicious for VA,\nPES may be considered for risk stratiﬁcation.\nIIb\nHCM\nCMR with LGE is recommended in HCM patients for\ndiagnostic work-up.\nI\nGenetic counselling and testing are recommended in HCM\npatients.\nI\nIn a ﬁrst-degree relative of a patient with HCM, ECG, and\nechocardiogram are recommended.\nI\nICD implantation should be considered in HCM patients aged\n16 years or more with an intermediate 5-year risk of SCD (≥4\nto ,6%)f, and with (a) signiﬁcant LGE at CMR (usually ≥15% of\nLV mass); or (b) LVEF ,50%; or (c) abnormal blood pressure\nresponse during exercise testg; or (d) LV apical aneurysm; or\n(e) presence of sarcomeric pathogenic mutation.\nIIa\nIn children ,16 years of age with HCM and an estimated\n5-year risk of SD ≥6% (based on HCM Risk-Kids scoreh), ICD\nimplantation should be considered.\nIIa\nIn patients with HCM presenting with haemodynamically\ntolerated SMVT, ICD implantation should be considered.\nIIa\nContinued\n4006\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nIn patients with HCM and recurrent, symptomatic VA, or\nrecurrent symptomatic ICD therapy, AAD treatment should\nbe considered.\nIIa\nParticipation in high-intensity exercise may be considered for\nasymptomatic adult HCM patients without risk markers.\nIIb\nICD implantation may be considered in HCM patients aged 16\nyears or more with a low estimated 5-year risk of SCD (,4%),f\nand with (a) signiﬁcant LGE at CMR (usually ≥15% of LV mass);\nor (b) LVEF , 50%; or (c) LV apical aneurysm.\nIIb\nCatheter ablation in specialized centres may be considered in\nselected patients with HCM and recurrent, symptomatic\nSMVT, or ICD shocks for SMVT, in whom AADs are\nineffective, contraindicated, or not tolerated.\nIIb\nLVNC and RCM\nIn patients with an LVNC cardiomyopathy phenotype based on\nCMR or echocardiography, implantation of an ICD for primary\nprevention of SCD should be considered to follow DCM/\nHNDCM recommendations.\nIIa\nAn ICD should be considered in patients with light-chain\namyloidosis or transthyretin-associated cardiac amyloidosis\nand haemodynamically not-tolerated VT.\nIIa\nNeuromuscular diseases\nInvasive electrophysiological evaluation is recommended in\npatients with myotonic dystrophy and palpitations or syncope\nsuggestive of VA or surviving a CA.\nI\nICD implantation is recommended in patients with myotonic\ndystrophy and SMVT or aborted CA not caused by BBR-VT.\nI\nInvasive electrophysiological evaluation should be considered\nin patients with myotonic dystrophy and a sudden increase in\nthe PR interval or QRS duration.\nIIa\nInvasive electrophysiological evaluation should be considered\nin patients with myotonic dystrophy and a PR interval ≥240 ms\nor QRS duration ≥120 ms or who are older than 40 years and\nhave supraventricular arrhythmias, or who are older than 40\nyears and have signiﬁcant LGE on CMR\nIIa\nIn myotonic dystrophy patients without AV conduction delay\nand a syncope highly suspicious for VA, ICD implantation\nshould be considered.\nIIa\nIn myotonic dystrophy patients with palpitations highly\nsuspicious for VA and induction of a non-BBR-VT, ICD\nimplantation should be considered.\nIIa\nIn patients with limb-girdle type 1B or Emery–Dreifuss\nmuscular dystrophies and indication for pacing, ICD\nimplantation should be considered.\nIIa\nImplantation of an ICD may be considered in patients with\nDuchenne/Becker muscular dystrophy and signiﬁcant LGE at\nCMR.\nIIb\nImplantation of an ICD over a permanent pacemaker may be\nconsidered in myotonic dystrophy patients with additional risk\nfactorsi for VA and SCD.\nIIb\nIn patients with myotonic dystrophy, serial electrophysiological\nevaluation of AV conduction and arrhythmia induction is not\nrecommended without arrhythmia suspicion or progression of\nECG conduction disorders.\nIII\nContinued\nInﬂammatory diseases\nIn patients with haemodynamically not-tolerated sustained VT\nor VF during the acute phase of myocarditis, ICD implantation\nbefore hospital discharge should be considered.\nIIa\nIn post-myocarditis patients with recurrent, symptomatic VT,\nAAD treatment should be considered.\nIIa\nCatheter ablation, performed in specialized centres, should be\nconsidered in post-myocarditis patients with recurrent,\nsymptomatic SMVT, or ICD shocks for SMVT in whom AADs\nare ineffective, not tolerated, or not desired.\nIIa\nIn patients with haemodynamically tolerated SMVT occurring\nin the chronic phase of myocarditis, ICD implantation should\nbe considered.\nIIa\nIn patients with cardiac sarcoidosis who have an LVEF .35%\nbut signiﬁcant LGE at CMR after resolution of acute\ninﬂammation, ICD implantation should be considered.\nIIa\nIn patients with cardiac sarcoidosis who have an LVEF 35–50%\nand minor LGE at CMR, after resolution of acute inﬂammation,\nPES for risk stratiﬁcation should be considered.\nIIa\nIn patients with cardiac sarcoidosis, LVEF 35–50%, and\ninducible SMVT at PES, ICD implantation should be considered.\nIIa\nIn patients with cardiac sarcoidosis and recurrent, symptomatic\nVA, AAD treatment should be considered.\nIIa\nAmiodarone should be considered to reduce arrhythmia\nburden in patients with Chagas’ cardiomyopathy who present\nwith symptomatic PVCs or VT.\nIIa\nIn patients with Chagas’ cardiomyopathy and recurrent,\nsymptomatic SMVT, or ICD shocks for SMVT in whom AADs\nare ineffective, contraindicated, or not tolerated, catheter\nablation in specialized centres should be considered.\nIIa\nIn patients with haemodynamically well-tolerated SMVT\noccurring in the chronic phase of myocarditis, preserved LV\nfunction and a limited scar amenable to ablation, catheter\nablation may be considered as an alternative to ICD therapy,\nafter discussion with the patient and provided that established\nendpoints have been reached.b\nIIb\nCatheter ablation, in specialized centres, may be considered in\ncardiac sarcoidosis ICD recipients with recurrent, symptomatic\nSMVT, or ICD shocks for SMVT, in whom AADs are\nineffective, contraindicated, or not tolerated.\nIIb\nCongenital heart disease\nIn patients with CHD presenting with sustained VAs,\nevaluation for residual lesions or new structural abnormalities\nis recommended.\nI\nIn selected patients with CHD (including atrial bafﬂe repair for\ntransposition of the great arteries, Fontan operation, and\nEbstein anomaly) presenting with CA, evaluation and\ntreatment of SVT with rapid ventricular conduction should be\nconsidered.\nIIa\nIn patients with repaired TOF undergoing surgical or\ntranscutaneous pulmonary valve replacement, pre-operative\ncatheter mapping and transection of VT-related anatomical\nisthmuses before or during the intervention may be\nconsidered.\nIIb\nContinued\nESC Guidelines\n4007\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nIn patients with repaired TOF with a preserved biventricular\nfunction and symptomatic SMVT, catheter ablation or\nconcomitant surgical ablation performed in specialized centres\nmay be considered as an alternative to ICD therapy.\nIIb\nIdiopathic VF\nIt is recommended that idiopathic VF is diagnosed in a SCA\nsurvivor, preferably with documentation of VF, after exclusion\nof an underlying structural, channelopathic, metabolic, or\ntoxicological aetiology.\nI\nIsoproterenol infusion, verapamil, or quinidine for acute\ntreatment of an electrical storm or recurrent ICD discharges\nshould be considered in idiopathic VF.\nIIa\nQuinidine should be considered for chronic therapy to\nsuppress an electrical storm or recurrent ICD discharges in\nidiopathic VF.\nIIa\nClinical testing (history, ECG, and high precordial lead ECG,\nexercise test, echocardiogram) of ﬁrst-degree family members\nof idiopathic VF patients may be considered.\nIIb\nIn idiopathic VF patients, genetic testing of genes related to\nchannelopathy and cardiomyopathy may be considered.\nIIb\nLong QT syndrome\nIn patients with clinically diagnosed LQTS, genetic testing, and\ngenetic counselling are recommended.\nI\nBeta-blockers, ideally non-selective beta-blockers (nadolol or\npropranolol), are recommended in LQTS patients with\ndocumented QT interval prolongation, to reduce risk of\narrhythmic events.\nI\nMexiletine is indicated in LQT3 patients with a prolonged QT\ninterval.\nI\nIn LQTS, it should be considered to calculate the arrhythmic\nrisk before initiation of therapy based on the genotype and the\nduration of QTc interval.\nIIa\nICD implantation may be considered in asymptomatic LQTS\npatients with high-risk proﬁle (according to the 1-2-3 LQTS\nRisk calculator) in addition to genotype-speciﬁc medical\ntherapies (mexiletine in LQT3 patients).\nIIb\nRoutine diagnostic testing with epinephrine challenge is not\nrecommended in LQTS.\nIII\nAndersen–Tawil syndrome\nGenetic testing is recommended in patients with suspected\nAndersen–Tawil syndrome.\nI\nICD implantation is recommended in patients with Andersen–\nTawil syndrome after aborted CA or not-tolerated sustained\nVT.\nI\nAndersen–Tawil syndrome should be considered in patients\nwithout SHD who present with at least two of the following:\n• Prominent U waves with or without prolongation of the QT\ninterval\n• Bidirectional and/or polymorphic PVCs/VT\n• Dysmorphic features\n• Periodic paralysis\n• KCNJ2 pathogenic loss of function mutation.\nIIa\nContinued\nBeta-blockers and/or ﬂecainide with or without acetazolamide\nshould be considered in patients with Andersen–Tawil\nsyndrome to treat VA.\nIIa\nAn ILR should be considered in patients with Andersen–Tawil\nsyndrome and unexplained syncope.\nIIa\nICD implantation may be considered in patients with\nAndersen–Tawil syndrome who have a history of unexplained\nsyncope or suffer from tolerated sustained VT.\nIIb\nBrugada syndrome\nGenetic testing for SCN5A gene is recommended for probands\nwith BrS.\nI\nBrS should be considered in patients with no other heart\ndisease and induced type 1 Brugada pattern who have at least\none of the following:\n• Arrhythmic syncope or nocturnal agonal respiration\n• A family history of BrS\n• A family history of SD (,45 years old) with a negative\nautopsy and circumstance suspicious for BrS.\nIIa\nImplantation of a loop recorder should be considered in BrS\npatients with an unexplained syncope.\nIIa\nBrS may be considered as a diagnosis in patients with no other\nheart disease who exhibit an induced type 1 Brugada ECG.\nIIb\nPES may be considered in asymptomatic patients with a\nspontaneous type I BrS ECG.\nIIb\nSodium channel blocker test is not recommended in patients\nwith a prior type I Brugada pattern.\nIII\nCatheter ablation in asymptomatic BrS patients is not\nrecommended.\nIII\nEarly repolarization syndrome\nIt is recommended that the ERP is diagnosed as J-point elevation\nof ≥1 mm in two adjacent inferior and/or lateral ECG leads.\nI\nIt is recommended that the ERS is diagnosed in a patient\nresuscitated from unexplained VF/PVT in the presence of ERP.\nI\nICD implantation is recommended in patients with a diagnosis\nof ERS who have survived a CA.\nI\nIn a SCD victim with a negative autopsy and medical chart\nreview, and an ante-mortem ECG demonstrating the ERP, the\ndiagnosis of ERS should be considered.\nIIa\nFirst-degree relatives of ERS patients should be considered for\nclinical evaluation for ERP with additional high-risk features.j\nIIa\nILR should be considered in individuals with ERP and at least\none risk featurek or arrhythmic syncope.\nIIa\nIsoproterenol infusion should be considered for ERS patients\nwith electrical storm.\nIIa\nQuinidine in addition to an ICD should be considered for\nrecurrent VF in ERS patients.\nIIa\nPVC ablation should be considered in ERS patients with\nrecurrent VF episodes triggered by a similar PVC\nnon-responsive to medical treatment.\nIIa\nGenetic testing in ERS patients may be considered.\nIIb\nICD implantation or quinidine may be considered in individuals\nwith ERP and arrhythmic syncope and additional risk features.k\nIIb\nContinued\n4008\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nThe second part of the guidelines is structured according to\ndisease-speciﬁc management, providing a link to the updated\nESC CardioMed chapter for additional content. Risk stratiﬁ-\ncation, SCD prevention, treatment of VA, and management of\nfamily members are addressed in a systematic fashion. Indications\nfor cardiac magnetic resonance (CMR) imaging, genetic testing,\nand updated indications for catheter ablation of ventricular ar-\nrhythmias are presented. Flowcharts summarizing the workﬂow\nfor diagnostic and treatment are provided for the disease entities.\nThe colour-coding of the ﬂowcharts reﬂects the class of recommen-\ndation according to this guideline and other ESC Guidelines.1–3\nICD implantation or quinidine may be considered in\nasymptomatic individuals who demonstrate a high-risk ERPj in\nthe presence of a family history of unexplained juvenile SD.\nIIb\nClinical evaluation is not recommended routinely in\nasymptomatic subjects with ERP.\nIII\nICD implantation is not recommended in asymptomatic\npatients with an isolated ERP.\nIII\nCPVT\nGenetic testing and genetic counselling are indicated in patients\nwith clinical suspicion or clinical diagnosis of CPVT.\nI\nBeta-blockers, ideally non-selective (nadolol or propranolol)\nare recommended in all patients with a clinical diagnosis\nof CPVT.\nI\nEpinephrine or isoproterenol challenge may be considered\nfor the diagnosis of CPVT when an exercise test is not\npossible.\nIIb\nShort QT syndrome\nGenetic testing is indicated in patients diagnosed with SQTS.\nI\nSQTS should be considered in the presence of a QTc\n≤320 ms.\nIIa\nSQTS should be considered in the presence of a QTc ≥320 ms\nand ≤360 ms and arrhythmic syncope.\nIIa\nILR should be considered in young SQTS patients.\nIIa\nICD implantation should be considered in SQTS patients with\narrhythmic syncope.\nIIa\nSQTS may be considered in the presence of a\nQTc ≥320 ms and ≤360 ms and a family history of SD\nat age ,40 years.\nIIb\nQuinidine may be considered in (a) SQTS patients who qualify\nfor an ICD but present a contraindication to the ICD or refuse\nit, and (b) asymptomatic SQTS patients and a family history of\nSCD.\nIIb\nIsoproterenol may be considered in SQTS patients with an\nelectrical storm.\nIIb\nSelected populations\nIt is recommended that athletes diagnosed with a\ncardiovascular disease associated with SCD are managed\naccording to current guidelines for sports eligibility.\nI\nContinuation of beta-blockers should be considered during\npregnancy in women with ARVC.\nIIa\nOral metoprolol, propranolol, or verapamil should be\nconsidered for long-term management of idiopathic sustained\nVT during pregnancy.\nIIa\nCatheter ablation using non-ﬂuoroscopic mapping systems\nshould be considered, preferably after the ﬁrst trimester, in\nwomen with highly symptomatic recurrent SMVT refractory or\nwho are intolerant to AADs.\nIIa\nContinued\nIn selected transplanted patients with cardiac allograft\nvasculopathy or treated rejection, ICD implantation may be\nconsidered.\nIIb\nIn elderly patients in whom a beneﬁt from the deﬁbrillator is\nnot expected due to the patient’s age and comorbidities,\nomission of ICD implantation for primary prevention may be\nconsidered.\nIIb\n© ESC 2022\nAAD, anti-arrhythmic drug; ACE-Is, angiotensin-converting enzyme inhibitors; AED,\nautomated external deﬁbrillator; ARBs, angiotensin receptor blockers; ARNIs,\nangiotensin receptor neprilysin inhibitors; ARVC, arrhythmogenic right ventricular\ncardiomyopathy; ATP, anti-tachycardia pacing; AV, atrioventricular; BBR-VT, bundle\nbranch re-entry; BrS, Brugada syndrome; CA, cardiac arrest; CAD, coronary artery\ndisease; CCB, calcium channel blocker; CHD, congenital heart disease; CMR, cardiac\nmagnetic resonance; CPR, cardiopulmonary resuscitation; CPVT, catecholaminergic\npolymorphic ventricular tachycardia; CRT, cardiac resynchronization therapy; DC,\ndirect current; DCM, dilated cardiomyopathy; ECG, electrocardiogram; EF, ejection\nfraction; ERP, early repolarization pattern; ERS, early repolarization syndrome; HCM,\nhypertrophic cardiomyopathy; HNDCM, hypokinetic non-dilated cardiomyopathy;\nICD, implantable cardioverter deﬁbrillator; ILR, implantable loop recorder; LGE, late\ngadolinium enhancement; LMNA, lamin A/C; LQTS, long QT syndrome; LV, left\nventricular;\nLVEF,\nleft\nventricular\nejection\nfraction;\nLVNC,\nleft\nventricular\nnon-compaction;\nMI,\nmyocardial\ninfarction;\nMRAs, mineralocorticoid\nreceptor\nantagonists; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart\nAssociation; OHCA, out-of-hospital cardiac arrest; OMT, optimal medical therapy;\nPES, programmed electrical stimulation; PVC, premature ventricular complex; RCM,\nrestrictive cardiomyopathy; RVOT, right ventricular outﬂow tract; SCA, sudden\ncardiac\narrest;\nSCD,\nsudden\ncardiac\ndeath;\nSD,\nsudden\ndeath;\nSGLT2,\nsodium–glucose co-transporter 2; SHD, structural heart disease; SMVT, sustained\nmonomorphic ventricular tachycardia; SPVT, sustained polymorphic ventricular\ntachycardia; SQTS, short QT syndrome; SVT, supraventricular tachycardia; TOF,\ntetralogy of Fallot; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation; VT,\nventricular tachycardia; WCD, wearable cardioverter deﬁbrillator.\naShopping malls, stadiums, public transport stations, casinos.\nbVT non-inducibility and elimination of electrograms consistent with conduction delay.\ncIncluding but not limited to older age, right bundle branch block (RBBB) morphology,\nSMVT consistent with re-entry.\ndPresyncope or palpitations suggestive of VA.\neThe 2020 ESC Guidelines on sports cardiology and exercise in patients with\ncardiovascular disease.4\nfBased on the HCM Risk SCD: https://doc2do.com/hcm/webHCM.html\ngDeﬁned as a failure to increase systolic pressure by at least 20 mmHg from rest to peak\nexercise, or a fall of .20 mmHg from peak pressure.\nhBased on the HCM Kid Risk score: https://hcmriskkids.org\niFactors favouring ICD implantation: Age,5,6,11 CTG expansion,6–9,13,16 SD or family history\nof SD,5 ECG conduction abnormalities,16 PR prolongation,13 LBBB,5 atrial arrhythmias,6,16\nnon-sustained VT,5 LV dysfunction,17 structural abnormalities in CMR.14,15,18\njERP high risk features: J waves . 2 mm, dynamic changes in J point and ST morphology.\nkHigh-risk ERP: family history of unexplained SD ,40 years, family history of ERS.\nESC Guidelines\n4009\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nAnother novel concept of this document is the table of evidence\n(see Supplementary data). The trials and studies that have been\nselected to support a recommendation are systematically de-\nscribed in the table of evidence after careful review of the available\ndata and the applied methodology, prioritizing papers published\nafter 2015. Recommendations with level of evidence C that are\nnot accompanied by a reference are supported by this panel of ex-\nperts. To assist physicians in their daily clinical practice, diagnostic\nand therapeutic procedures with promising usefulness, typically\nclassiﬁed as class IIb, but for which evidence is limited and difﬁcult\nto collect in the near future, the related recommendations are\nnot only described in the narratives but are listed in the table of\nrecommendation.\nTable 5\nChanges in recommendations since 2015\nClass\n2015\n2022\nCoronary artery disease\nIn patients with syncope and previous STEMI, PES is\nindicated when syncope remains unexplained after\nnon-invasive evaluation.\nIIa\nI\nIntravenous amiodarone treatment should be\nconsidered for patients with recurrent PVT/VF\nduring the acute phase of ACS.\nI\nIIa\nIn patients with CAD eligible for ICD implantation,\ncatheter ablation may be considered just before (or\nimmediately after) ICD implantation to decrease\nsubsequent VT burden and ICD shocks.\nIIa\nIIb\nPVC-induced cardiomyopathy\nIn patients with a cardiomyopathy suspected to be\ncaused by frequent and predominately monomorphic\nPVCs, catheter ablation is recommended.\nIIa\nI\nDCM/HNDCM\nICD implantation should be considered in patients\nwith DCM/HNDCM, symptomatic heart failure\n(NYHA class II–III) and LVEF ≤35% after ≥3 months\nof OMT.\nI\nIIa\nCatheter ablation in specialized centres should be\nconsidered in patients with DCM/HNDCM and\nrecurrent, symptomatic SMVT, or ICD shocks for\nSMVT, in whom AADs are ineffective,\ncontraindicated, or not tolerated.\nIIb\nIIa\nARVC\nICD implantation should be considered in patients\nwith deﬁnite ARVC and an arrhythmic syncope.\nIIb\nIIa\nICD implantation should be considered in patients\nwith deﬁnite ARVC and severe RV or LV systolic\ndysfunction.\nIIb\nIIa\nInﬂammatory diseases\nIn patients with haemodynamically not-tolerated\nSMVT occurring in the chronic phase of myocarditis,\nICD implantation is recommended.\nIIa\nI\nICD implantation is recommended in patients with\ncardiac sarcoidosis who have an LVEF ≤35%.\nIIb\nI\nICD implantation is recommended in patients with\ncardiac sarcoidosis who (1) have documented\nsustained VT, or (2) aborted CA.\nIIb\nI\nIn patients with cardiac sarcoidosis who have an\nindication for permanent cardiac pacing related to\nhigh-degree AV block, ICD implantation should be\nconsidered, regardless of LVEF.\nIIb\nIIa\nIn patients with Chagas’ cardiomyopathy and\nsymptomatic VT in whom AADs (amiodarone and\nbeta-blockers) are ineffective or not tolerated, ICD\nimplantation may be considered.\nIIa\nIIb\nContinued\nCHD\nIn patients after repair of TOF without arrhythmia\nsymptoms, but with a combination of other risk\nfactors,a electrophysiologic evaluation, including PES,\nmay be considered.\nIIa\nIIb\nIn patients with CHD and recurrent, symptomatic\nSMVT, or ICD shocks for SMVT not manageable by\nmedical therapy or ICD reprogramming, catheter\nablation performed in specialized centres should be\nconsidered.\nI\nIIa\nPrimary electrical disease and selected populations\nICD implantation is recommended in patients with\nLQTS who are symptomaticb while receiving\nbeta-blockers and genotype-speciﬁc therapies.\nIIa\nI\nICD implantation should be considered in patients\nwith CPVT who experience arrhythmic syncope and/\nor documented bidirectional/PVT while on the\nhighest tolerated beta-blocker dose and on ﬂecainide.\nI\nIIa\nPre-participation cardiovascular evaluation of\ncompetitive athletes should be considered.\nI\nIIa\nCatheter ablation of triggering PVCs and/or RVOT\nepicardial substrate should be considered in BrS\npatients with recurrent appropriate ICD shocks\nrefractory to drug therapy.\nIIb\nIIa\nLCSD should be considered in patients with diagnosis\nof CPVT when the combination of beta-blockers and\nﬂecainide at therapeutic dosage are either not\neffective, not tolerated, or contraindicated.\nIIb\nIIa\n© ESC 2022\nAAD, anti-arrhythmic drug; ACS, acute coronary syndrome; ARVC, arrhythmogenic\nright ventricular cardiomyopathy; AV, atrioventricular; BrS, Brugada syndrome; CA,\ncardiac arrest; CAD, coronary artery disease; CHD, congenital heart disease; CPVT,\ncatecholaminergic\npolymorphic\nventricular\ntachycardia;\nDCM,\ndilated\ncardiomyopathy;\nHNDCM,\nhypokinetic\nnon-dilated\ncardiomyopathy;\nICD,\nimplantable cardioverter deﬁbrillator; LCSD, left cardiac sympathetic denervation;\nLQTS, long QT syndrome; LV, left ventricle; LVEF, left ventricular ejection fraction;\nNYHA, New York Heart Association; OMT, optimal medical treatment; PES,\nprogrammed electrical stimulation; PVC, premature ventricular complex; PVT,\npolymorphic ventricular tachycardia; RV, right ventricle; RVOT, right ventricular\noutﬂow tract; SMVT, sustained monomorphic ventricular tachycardia; STEMI, ST\nelevation myocardial infarction; TdP, torsade de pointes; TOF, tetralogy of Fallot; VF,\nventricular ﬁbrillation; VT, ventricular tachycardia.\naOther risk factors include moderate RV or LV dysfunction, extensive RV scarring on\nCMR, QRS duration ≥180 ms, and severe QRS fragmentation.\nbArrhythmic syncope or haemodynamically not-tolerated VA.\n4010\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n3. Deﬁnitions\n3.1. Ventricular arrhythmia subtypes\nPremature ventricular complex (PVC): Premature occurrence of an ab-\nnormal QRS complex (duration typically ≥120 ms, corresponding\nT-wave typically broad and in the opposite direction of the major\nQRS deﬂection, no preceding P-wave).\nUnifocal or monomorphic PVCs: PVCs with a single QRS morphology.\nMultifocal, multiform, or polymorphic PVCs: PVCs with different QRS\nmorphologies.\nShort-coupled PVC: A PVC that interrupts the T-wave of the pre-\nceding conducted beat.\nVentricular tachycardia (VT): ≥3 consecutive beats with a rate\n.100 b.p.m. originating from the ventricles, independent from atrial\nand atrioventricular (AV) nodal conduction.\nNon-sustained ventricular tachycardia (NSVT): Run of consecutive\nventricular beats persisting for 3 beats to 30 s.\nMonomorphic ventricular tachycardia (MVT): Same QRS morph-\nology from beat to beat.\nPolymorphic ventricular tachycardia (PVT): Continually changing QRS\nmorphology.\nSustained monomorphic/polymorphic ventricular tachycardia (SMVT/\nSPVT): Continuous VT for at least 30 s, or which requires an interven-\ntion for termination.\nBidirectional ventricular tachycardia: Beat to beat alternation of the\nfrontal QRS axis (e.g. in catecholaminergic polymorphic ventricular\ntachycardia\n[CPVT],\nAndersen–Tawil,\ndigoxin\ntoxicity,\nacute\nmyocarditis).\nTorsades de pointes ventricular tachycardia (TdP): Subtype of a poly-\nmorphic VT in the context of QT prolongation with continually\nchanging QRS complexes that appear to spiral around the baseline\nof the electrocardiogram (ECG) lead in a sinusoidal pattern.\nVentricular ﬁbrillation (VF): A chaotic rhythm with undulations that\nare irregular in timing and morphology, without discrete QRS com-\nplexes on the surface ECG.\nElectrical storm: VA that occurs 3 or more times within 24 h (sepa-\nrated by at least 5 min), each requiring termination by an\nintervention.\nIncessant VT: Continuous sustained VT that recurs promptly des-\npite repeated intervention for termination over several hours.\n3.2. Sudden cardiac death\nSudden cardiac arrest (SCA): Sudden cessation of normal cardiac activ-\nity with haemodynamic collapse.\nSudden cardiac death (SCD): Sudden natural death presumed to be\nof cardiac cause that occurs within 1 h of onset of symptoms in wit-\nnessed cases, and within 24 h of last being seen alive when it is unwit-\nnessed. SCD in autopsied cases is deﬁned as the natural unexpected\ndeath of unknown or cardiac cause.\nSudden unexplained death: Unexplained sudden death occurring in\nan individual older than 1 year.\nSudden infant death syndrome (SIDS): Unexplained sudden death\noccurring in an individual younger than 1 year with negative patho-\nlogical and toxicological assessment and negative forensic examin-\nation of the circumstances of death.\nSudden arrhythmic death syndrome (SADS): Unexplained sudden\ndeath occurring in an individual older than 1 year with negative\npathological and toxicological assessment. Note: Synonymous with\n‘autopsy-negative sudden unexplained death’.\n3.3. Syncope\nUnexplained syncope: Transient loss of consciousness due to cerebral\nhypoperfusion, characterized by a rapid onset, short duration, and\nspontaneous complete recovery, but unexplained after conventional\nworkup. Work-up and differential diagnosis are provided in the 2018\nESC Guidelines for the diagnosis and management of syncope.1\nArrhythmic syncope: as above, but highly suspicious for intermittent\nbradycardia, rapid supraventricular tachycardia (SVT), or VA.\n3.4. Specialized centres\nMultidisciplinary teams: A multidisciplinary team across specialties is\ncharacterized by open communication, positive management and\nleadership,\nappropriate\nresources,\nand\na\nmix\nof\nskills.\nDecision-making should be shared in the team.\nSpecialized centre for catheter ablation of VA: Patient and procedural\ncomplexity vary widely. Some patients require a more experienced\noperator and a centre with more capabilities, which is more likely\nin patients with a non-ischaemic aetiology. A specialized centre has\nat least one operator with appropriate experience in interventions\nthat may be required for a successful procedure (e.g. percutaneous\nepicardial access). The centre performs catheter ablation of VT in\nstructural heart disease (SHD) on a regular basis. In addition, the cen-\ntre has the required resources to manage medical conditions, co-\nmorbidities, and potential complications in patients undergoing\ncomplex VA ablation; this includes interventional cardiology expert-\nise, acute placement of mechanical circulatory assist devices, and car-\ndiothoracic surgical back-up. Considering the variable availability\nacross European countries, it is preferable to treat complex patients\nin the most experienced centre within reasonable distance.\n3.5. Genetics\nPathogenic variant and likely pathogenic variant: The American College\nof Medical Genetics has provided a framework for the interpretation\nof disease causation by genetic variants standardized into classes. The\ngenetic variants most likely to cause an associated disease are termed\nV, ‘pathogenic’, and IV, ‘likely pathogenic’.\nMutation: This term is used in this document to mean a Class IV or\nV variant.\nVariant of uncertain signiﬁcance: A change in a gene’s deoxyribo-\nnucleic acid (DNA) sequence that has an unknown effect on a per-\nson’s health.\n4. Epidemiology of sudden cardiac\ndeath, public awareness, and risk\nstratiﬁcation\n4.1. Incidence of sudden cardiac death\nSCD accounts for approximately 50% of all cardiovascular deaths,\nwith up to 50% being the ﬁrst manifestation of cardiac disease.19–24\nIdeally, cases suspicious of SCD should be identiﬁed from multiple\nESC Guidelines\n4011\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 9",
          "page": 9,
          "content": "Recommendations |  | Class | \n | Public basic life support and access to AEDs |  | \nIt is recommended that public-access defibrillation be available\nat sites where cardiac arrest is more likely to occur.a |  | I | \nPrompt CPR by bystanders is recommended at OHCA. |  | I | \nIt is recommended to promote community training in basic life\nsupport to increase bystander CPR rate and AED use. |  | I | \nMobile phone-based alerting of basic life support-trained\nbystander volunteers to assist nearby OHCA victims should be\nconsidered. |  | IIa | \n | Treatment of VA. General aspects |  | \nDC cardioversion is recommended as the first-line treatment\nfor patients presenting with tolerated SMVT provided that the\nanaesthetic/sedation risk is low. |  | I | \nOptimal medical treatment including ACE-I/ARB/ARNIs,\nMRAs, beta-blockers, and SGLT2 inhibitors is indicated in all\nheart failure patients with reduced EF. |  | I | \nImplantation of a cardioverter defibrillator is only\nrecommended in patients who have an expectation of\ngood-quality survival .1 year. |  | I | \nIn patients presenting with a haemodynamically tolerated\nSMVT and known or suspected SHD, intravenous\nprocainamide should be considered. |  | IIa | \nIn patients presenting with a haemodynamically tolerated\nSMVT in the absence of an established diagnosis, intravenous\namiodarone may be considered. |  | IIb | \nIn patients with SMVT or SPVT/VF triggered by a PVC with\nsimilar morphology and an indication for ICD, catheter ablation\nmay be considered when an ICD is not available,\ncontraindicated for concurrent medical reasons, or declined by\nthe patient. |  | IIb | \nThe WCD may be considered in the early phase after MI in\nselected patients. |  | IIb | \n | Coronary artery disease |  | \nIn patients with CAD and recurrent, symptomatic SMVT, or\nICD shocks for SMVT despite chronic amiodarone therapy,\ncatheter ablation is recommended in preference to escalating\nAAD therapy. |  | I | \nCardiac stress imaging during physical exercise is\nrecommended in addition to cardiopulmonary exercise test\nafter surgery in patients with anomalous aortic origin of a\ncoronary artery with a history of aborted CA. |  | I | \nIn SCA survivors with coronary artery spasm, implantation of\nan ICD should be considered. |  | IIa | \nICD therapy should be considered in patients with CAD,\nNYHA class I, and LVEF ≤30% despite ≥3 months of OMT. |  | IIa | \nICD implantation should be considered in patients with CAD,\nLVEF ≤40% despite ≥3 months of OMT and NSVT, if they are\ninducible for SMVT by PES. |  | IIa | ",
          "rows": 20,
          "cols": 4
        },
        {
          "title": "Table on page 9",
          "page": 9,
          "content": "New sections and concepts | Section\nProvocative diagnostic tests | 5.1.3.5\nGenetic testing | 5.1.4\nDiagnostic evaluation at first presentation with VA in\npatients without known cardiac disease | 5.2\nManagement of patients with electrical storm | 6.1.3\nSpecial aspects of device therapy | 6.2.3",
          "rows": 6,
          "cols": 2
        },
        {
          "title": "Table on page 10",
          "page": 10,
          "content": "In patients with CAD and haemodynamically well-tolerated\nSMVT and LVEF ≥40%, catheter ablation in experienced\ncentres should be considered as an alternative to ICD therapy,\nprovided that established endpoints have been reached.b |  | IIa | \nCatheter ablation should be considered in patients with CAD\nand recurrent, symptomatic SMVT, or ICD shocks for SMVT\ndespite beta-blocker or sotalol treatment. |  | IIa | \n | Idiopathic PVC/VT and PVC-induced cardiomyopathy |  | \nCatheter ablation as first-line treatment is recommended for\nsymptomatic idiopathic VT/PVCs from the RVOT or the left\nfascicles. |  | I | \nBeta-blockers or non-dihydropyridine CCBs are indicated in\nsymptomatic patients with idiopathic VT/PVCs from an origin\nother than the RVOT or the left fascicles. |  | I | \nIn patients with PVCs/VT and a presentation not typical for an\nidiopathic origin,c CMR should be considered, despite a normal\nechocardiogram. |  | IIa | \nBeta-blockers, non-dihydropyridine CCBs or flecainide should\nbe considered when catheter ablation is not available, not\ndesired, or is particularly risky in symptomatic patients with\nidiopathic VT/PVCs from the RVOT or the left fascicles. |  | IIa | \nCatheter ablation or flecainide should be considered in\nsymptomatic patients with idiopathic VT/PVCs from an origin\nother than the RVOT or the left fascicles. |  | IIa | \nIn patients with an unexplained reduced EF and a PVC burden\nof at least 10%, PVC-induced cardiomyopathy should be\nconsidered. |  | IIa | \nIn patients with suspected PVC-induced cardiomyopathy, CMR\nshould be considered. |  | IIa | \nIn non-responders to CRT with frequent, predominately\nmonomorphic PVCs limiting optimal biventricular pacing\ndespite pharmacological therapy, catheter ablation or AADs\nshould be considered. |  | IIa | \nCatheter ablation may be considered for idiopathic VT/PVCs in\nasymptomatic patients with repeatedly more than 20% of\nPVCs per day at follow-up. |  | IIb | \nAmiodarone as a first-line treatment is not recommended in\npatients with idiopathic VTs/PVCs. |  | III | \nDCM/HNDCM |  |  | \nGenetic testing (including at least LMNA, PLN, RBM20, and\nFLNC genes) is recommended in patients with DCM/HNDCM\nand AV conduction delay at ,50 years, or who have a family\nhistory of DCM/HNDCM or SCD in a first-degree relative (at\nage ,50 years). |  | I | \nIn a first-degree relative of a DCM/HNDCM patient, an ECG,\nand an echocardiogram are recommended if:\n• the index patient was diagnosed ,50 years of age or has\nclinical features suggestive of an inherited cause, or\n• there is a family history of DCM/HNDCM, or premature\nunexpected SD. |  | I | \nCMR with LGE should be considered in DCM/HNDCM\npatients for assessing the aetiology and the risk of VA/SCD. |  | IIa | ",
          "rows": 17,
          "cols": 4
        },
        {
          "title": "Table on page 10",
          "page": 10,
          "content": "Genetic testing (including at least LMNA, PLN, RBM20, and\nFLNC genes) should be considered for risk stratification in\npatients with apparently sporadic DCM/HNDCM, who\npresent at young age or with signs suspicious for an inherited\naetiology. |  | IIa | \nICD implantation should be considered in DCM/HNDCM\npatients with an LVEF ,50% and ≥2 risk factors (syncope, LGE\non CMR, inducible SMVT at PES, pathogenic mutations in\nLMNA, PLN, FLNC, and RBM20 genes). |  | IIa | \nICD implantation should be considered in patients with DCM/\nHNDCM and haemodynamically tolerated SMVT. |  | IIa | \nIn a first-degree relative of a patient with apparently sporadic\nDCM/HNDCM, an ECG, and an echocardiogram may be\nconsidered. |  | IIb | \nParticipation in high-intensity exercise including competitive\nsports is not recommended for individuals with DCM/\nHNDCM and a LMNA mutation. |  | III | \n | ARVC |  | \nIn patients with suspected ARVC, CMR is recommended. |  | I | \nIn patients with a suspected or definite diagnosis of ARVC,\ngenetic counselling and testing are recommended. |  | I | \nICD implantation should be considered in symptomaticd\npatients with definite ARVC, moderate right or left ventricular\ndysfunction, and either NSVT or inducibility of SMVT at PES. |  | IIa | \nIn ARVC patients with indication for ICDs, a device with the\ncapability of ATP programming for SMVT up to high rates\nshould be considered. |  | IIa | \nAvoidance of high-intensitye exercise may be considered in\ncarriers of ARVC-related pathogenic mutations and no\nphenotype. |  | IIb | \nBeta-blocker therapy may be considered in all patients with a\ndefinite diagnosis of ARVC. |  | IIb | \nIn patients with ARVC and symptoms highly suspicious for VA,\nPES may be considered for risk stratification. |  | IIb | \n | HCM |  | \nCMR with LGE is recommended in HCM patients for\ndiagnostic work-up. |  | I | \nGenetic counselling and testing are recommended in HCM\npatients. |  | I | \nIn a first-degree relative of a patient with HCM, ECG, and\nechocardiogram are recommended. |  | I | \nICD implantation should be considered in HCM patients aged\n16 years or more with an intermediate 5-year risk of SCD (≥4\nto ,6%)f, and with (a) significant LGE at CMR (usually ≥15% of\nLV mass); or (b) LVEF ,50%; or (c) abnormal blood pressure\nresponse during exercise testg; or (d) LV apical aneurysm; or\n(e) presence of sarcomeric pathogenic mutation. |  | IIa | \nIn children ,16 years of age with HCM and an estimated\n5-year risk of SD ≥6% (based on HCM Risk-Kids scoreh), ICD\nimplantation should be considered. |  | IIa | \nIn patients with HCM presenting with haemodynamically\ntolerated SMVT, ICD implantation should be considered. |  | IIa | ",
          "rows": 20,
          "cols": 4
        },
        {
          "title": "Table on page 11",
          "page": 11,
          "content": "In patients with HCM and recurrent, symptomatic VA, or\nrecurrent symptomatic ICD therapy, AAD treatment should\nbe considered. |  | IIa | \nParticipation in high-intensity exercise may be considered for\nasymptomatic adult HCM patients without risk markers. |  | IIb | \nICD implantation may be considered in HCM patients aged 16\nyears or more with a low estimated 5-year risk of SCD (,4%),f\nand with (a) significant LGE at CMR (usually ≥15% of LV mass);\nor (b) LVEF , 50%; or (c) LV apical aneurysm. |  | IIb | \nCatheter ablation in specialized centres may be considered in\nselected patients with HCM and recurrent, symptomatic\nSMVT, or ICD shocks for SMVT, in whom AADs are\nineffective, contraindicated, or not tolerated. |  | IIb | \n | LVNC and RCM |  | \nIn patients with an LVNC cardiomyopathy phenotype based on\nCMR or echocardiography, implantation of an ICD for primary\nprevention of SCD should be considered to follow DCM/\nHNDCM recommendations. |  | IIa | \nAn ICD should be considered in patients with light-chain\namyloidosis or transthyretin-associated cardiac amyloidosis\nand haemodynamically not-tolerated VT. |  | IIa | \n | Neuromuscular diseases |  | \nInvasive electrophysiological evaluation is recommended in\npatients with myotonic dystrophy and palpitations or syncope\nsuggestive of VA or surviving a CA. |  | I | \nICD implantation is recommended in patients with myotonic\ndystrophy and SMVT or aborted CA not caused by BBR-VT. |  | I | \nInvasive electrophysiological evaluation should be considered\nin patients with myotonic dystrophy and a sudden increase in\nthe PR interval or QRS duration. |  | IIa | \nInvasive electrophysiological evaluation should be considered\nin patients with myotonic dystrophy and a PR interval ≥240 ms\nor QRS duration ≥120 ms or who are older than 40 years and\nhave supraventricular arrhythmias, or who are older than 40\nyears and have significant LGE on CMR |  | IIa | \nIn myotonic dystrophy patients without AV conduction delay\nand a syncope highly suspicious for VA, ICD implantation\nshould be considered. |  | IIa | \nIn myotonic dystrophy patients with palpitations highly\nsuspicious for VA and induction of a non-BBR-VT, ICD\nimplantation should be considered. |  | IIa | \nIn patients with limb-girdle type 1B or Emery–Dreifuss\nmuscular dystrophies and indication for pacing, ICD\nimplantation should be considered. |  | IIa | \nImplantation of an ICD may be considered in patients with\nDuchenne/Becker muscular dystrophy and significant LGE at\nCMR. |  | IIb | \nImplantation of an ICD over a permanent pacemaker may be\nconsidered in myotonic dystrophy patients with additional risk\nfactorsi for VA and SCD. |  | IIb | \nIn patients with myotonic dystrophy, serial electrophysiological\nevaluation of AV conduction and arrhythmia induction is not\nrecommended without arrhythmia suspicion or progression of\nECG conduction disorders. |  | III | ",
          "rows": 18,
          "cols": 4
        },
        {
          "title": "Table on page 11",
          "page": 11,
          "content": " | Inflammatory diseases |  | \nIn patients with haemodynamically not-tolerated sustained VT\nor VF during the acute phase of myocarditis, ICD implantation\nbefore hospital discharge should be considered. |  | IIa | \nIn post-myocarditis patients with recurrent, symptomatic VT,\nAAD treatment should be considered. |  | IIa | \nCatheter ablation, performed in specialized centres, should be\nconsidered in post-myocarditis patients with recurrent,\nsymptomatic SMVT, or ICD shocks for SMVT in whom AADs\nare ineffective, not tolerated, or not desired. |  | IIa | \nIn patients with haemodynamically tolerated SMVT occurring\nin the chronic phase of myocarditis, ICD implantation should\nbe considered. |  | IIa | \nIn patients with cardiac sarcoidosis who have an LVEF .35%\nbut significant LGE at CMR after resolution of acute\ninflammation, ICD implantation should be considered. |  | IIa | \nIn patients with cardiac sarcoidosis who have an LVEF 35–50%\nand minor LGE at CMR, after resolution of acute inflammation,\nPES for risk stratification should be considered. |  | IIa | \nIn patients with cardiac sarcoidosis, LVEF 35–50%, and\ninducible SMVT at PES, ICD implantation should be considered. |  | IIa | \nIn patients with cardiac sarcoidosis and recurrent, symptomatic\nVA, AAD treatment should be considered. |  | IIa | \nAmiodarone should be considered to reduce arrhythmia\nburden in patients with Chagas’ cardiomyopathy who present\nwith symptomatic PVCs or VT. |  | IIa | \nIn patients with Chagas’ cardiomyopathy and recurrent,\nsymptomatic SMVT, or ICD shocks for SMVT in whom AADs\nare ineffective, contraindicated, or not tolerated, catheter\nablation in specialized centres should be considered. |  | IIa | \nIn patients with haemodynamically well-tolerated SMVT\noccurring in the chronic phase of myocarditis, preserved LV\nfunction and a limited scar amenable to ablation, catheter\nablation may be considered as an alternative to ICD therapy,\nafter discussion with the patient and provided that established\nendpoints have been reached.b |  | IIb | \nCatheter ablation, in specialized centres, may be considered in\ncardiac sarcoidosis ICD recipients with recurrent, symptomatic\nSMVT, or ICD shocks for SMVT, in whom AADs are\nineffective, contraindicated, or not tolerated. |  | IIb | \nCongenital heart disease |  |  | \nIn patients with CHD presenting with sustained VAs,\nevaluation for residual lesions or new structural abnormalities\nis recommended. |  | I | \nIn selected patients with CHD (including atrial baffle repair for\ntransposition of the great arteries, Fontan operation, and\nEbstein anomaly) presenting with CA, evaluation and\ntreatment of SVT with rapid ventricular conduction should be\nconsidered. |  | IIa | \nIn patients with repaired TOF undergoing surgical or\ntranscutaneous pulmonary valve replacement, pre-operative\ncatheter mapping and transection of VT-related anatomical\nisthmuses before or during the intervention may be\nconsidered. |  | IIb | ",
          "rows": 17,
          "cols": 4
        },
        {
          "title": "Table on page 12",
          "page": 12,
          "content": "In patients with repaired TOF with a preserved biventricular\nfunction and symptomatic SMVT, catheter ablation or\nconcomitant surgical ablation performed in specialized centres\nmay be considered as an alternative to ICD therapy. |  | IIb | \n | Idiopathic VF |  | \nIt is recommended that idiopathic VF is diagnosed in a SCA\nsurvivor, preferably with documentation of VF, after exclusion\nof an underlying structural, channelopathic, metabolic, or\ntoxicological aetiology. |  | I | \nIsoproterenol infusion, verapamil, or quinidine for acute\ntreatment of an electrical storm or recurrent ICD discharges\nshould be considered in idiopathic VF. |  | IIa | \nQuinidine should be considered for chronic therapy to\nsuppress an electrical storm or recurrent ICD discharges in\nidiopathic VF. |  | IIa | \nClinical testing (history, ECG, and high precordial lead ECG,\nexercise test, echocardiogram) of first-degree family members\nof idiopathic VF patients may be considered. |  | IIb | \nIn idiopathic VF patients, genetic testing of genes related to\nchannelopathy and cardiomyopathy may be considered. |  | IIb | \n | Long QT syndrome |  | \nIn patients with clinically diagnosed LQTS, genetic testing, and\ngenetic counselling are recommended. |  | I | \nBeta-blockers, ideally non-selective beta-blockers (nadolol or\npropranolol), are recommended in LQTS patients with\ndocumented QT interval prolongation, to reduce risk of\narrhythmic events. |  | I | \nMexiletine is indicated in LQT3 patients with a prolonged QT\ninterval. |  | I | \nIn LQTS, it should be considered to calculate the arrhythmic\nrisk before initiation of therapy based on the genotype and the\nduration of QTc interval. |  | IIa | \nICD implantation may be considered in asymptomatic LQTS\npatients with high-risk profile (according to the 1-2-3 LQTS\nRisk calculator) in addition to genotype-specific medical\ntherapies (mexiletine in LQT3 patients). |  | IIb | \nRoutine diagnostic testing with epinephrine challenge is not\nrecommended in LQTS. |  | III | \n | Andersen–Tawil syndrome |  | \nGenetic testing is recommended in patients with suspected\nAndersen–Tawil syndrome. |  | I | \nICD implantation is recommended in patients with Andersen–\nTawil syndrome after aborted CA or not-tolerated sustained\nVT. |  | I | \nAndersen–Tawil syndrome should be considered in patients\nwithout SHD who present with at least two of the following:\n• Prominent U waves with or without prolongation of the QT\ninterval\n• Bidirectional and/or polymorphic PVCs/VT\n• Dysmorphic features\n• Periodic paralysis\n• KCNJ2 pathogenic loss of function mutation. |  | IIa | ",
          "rows": 18,
          "cols": 4
        },
        {
          "title": "Table on page 12",
          "page": 12,
          "content": "Beta-blockers and/or flecainide with or without acetazolamide\nshould be considered in patients with Andersen–Tawil\nsyndrome to treat VA. |  | IIa | \nAn ILR should be considered in patients with Andersen–Tawil\nsyndrome and unexplained syncope. |  | IIa | \nICD implantation may be considered in patients with\nAndersen–Tawil syndrome who have a history of unexplained\nsyncope or suffer from tolerated sustained VT. |  | IIb | \n | Brugada syndrome |  | \nGenetic testing for SCN5A gene is recommended for probands\nwith BrS. |  | I | \nBrS should be considered in patients with no other heart\ndisease and induced type 1 Brugada pattern who have at least\none of the following:\n• Arrhythmic syncope or nocturnal agonal respiration\n• A family history of BrS\n• A family history of SD (,45 years old) with a negative\nautopsy and circumstance suspicious for BrS. |  | IIa | \nImplantation of a loop recorder should be considered in BrS\npatients with an unexplained syncope. |  | IIa | \nBrS may be considered as a diagnosis in patients with no other\nheart disease who exhibit an induced type 1 Brugada ECG. |  | IIb | \nPES may be considered in asymptomatic patients with a\nspontaneous type I BrS ECG. |  | IIb | \nSodium channel blocker test is not recommended in patients\nwith a prior type I Brugada pattern. |  | III | \nCatheter ablation in asymptomatic BrS patients is not\nrecommended. |  | III | \n | Early repolarization syndrome |  | \nIt is recommended that the ERP is diagnosed as J-point elevation\nof ≥1 mm in two adjacent inferior and/or lateral ECG leads. |  | I | \nIt is recommended that the ERS is diagnosed in a patient\nresuscitated from unexplained VF/PVT in the presence of ERP. |  | I | \nICD implantation is recommended in patients with a diagnosis\nof ERS who have survived a CA. |  | I | \nIn a SCD victim with a negative autopsy and medical chart\nreview, and an ante-mortem ECG demonstrating the ERP, the\ndiagnosis of ERS should be considered. |  | IIa | \nFirst-degree relatives of ERS patients should be considered for\nclinical evaluation for ERP with additional high-risk features.j |  | IIa | \nILR should be considered in individuals with ERP and at least\none risk featurek or arrhythmic syncope. |  | IIa | \nIsoproterenol infusion should be considered for ERS patients\nwith electrical storm. |  | IIa | \nQuinidine in addition to an ICD should be considered for\nrecurrent VF in ERS patients. |  | IIa | \nPVC ablation should be considered in ERS patients with\nrecurrent VF episodes triggered by a similar PVC\nnon-responsive to medical treatment. |  | IIa | \nGenetic testing in ERS patients may be considered. |  | IIb | \nICD implantation or quinidine may be considered in individuals\nwith ERP and arrhythmic syncope and additional risk features.k |  | IIb | ",
          "rows": 23,
          "cols": 4
        },
        {
          "title": "Table on page 13",
          "page": 13,
          "content": "ICD implantation or quinidine may be considered in\nasymptomatic individuals who demonstrate a high-risk ERPj in\nthe presence of a family history of unexplained juvenile SD. |  | IIb | \nClinical evaluation is not recommended routinely in\nasymptomatic subjects with ERP. |  | III | \nICD implantation is not recommended in asymptomatic\npatients with an isolated ERP. |  | III | \n | CPVT |  | \nGenetic testing and genetic counselling are indicated in patients\nwith clinical suspicion or clinical diagnosis of CPVT. |  | I | \nBeta-blockers, ideally non-selective (nadolol or propranolol)\nare recommended in all patients with a clinical diagnosis\nof CPVT. |  | I | \nEpinephrine or isoproterenol challenge may be considered\nfor the diagnosis of CPVT when an exercise test is not\npossible. |  | IIb | \n | Short QT syndrome |  | \nGenetic testing is indicated in patients diagnosed with SQTS. |  | I | \nSQTS should be considered in the presence of a QTc\n≤320 ms. |  | IIa | \nSQTS should be considered in the presence of a QTc ≥320 ms\nand ≤360 ms and arrhythmic syncope. |  | IIa | \nILR should be considered in young SQTS patients. |  | IIa | \nICD implantation should be considered in SQTS patients with\narrhythmic syncope. |  | IIa | \nSQTS may be considered in the presence of a\nQTc ≥320 ms and ≤360 ms and a family history of SD\nat age ,40 years. |  | IIb | \nQuinidine may be considered in (a) SQTS patients who qualify\nfor an ICD but present a contraindication to the ICD or refuse\nit, and (b) asymptomatic SQTS patients and a family history of\nSCD. |  | IIb | \nIsoproterenol may be considered in SQTS patients with an\nelectrical storm. |  | IIb | \n | Selected populations |  | \nIt is recommended that athletes diagnosed with a\ncardiovascular disease associated with SCD are managed\naccording to current guidelines for sports eligibility. |  | I | \nContinuation of beta-blockers should be considered during\npregnancy in women with ARVC. |  | IIa | \nOral metoprolol, propranolol, or verapamil should be\nconsidered for long-term management of idiopathic sustained\nVT during pregnancy. |  | IIa | \nCatheter ablation using non-fluoroscopic mapping systems\nshould be considered, preferably after the first trimester, in\nwomen with highly symptomatic recurrent SMVT refractory or\nwho are intolerant to AADs. |  | IIa | ",
          "rows": 21,
          "cols": 4
        },
        {
          "title": "Table on page 13",
          "page": 13,
          "content": "In selected transplanted patients with cardiac allograft\nvasculopathy or treated rejection, ICD implantation may be\nconsidered. | IIb\nIn elderly patients in whom a benefit from the defibrillator is\nnot expected due to the patient’s age and comorbidities,\nomission of ICD implantation for primary prevention may be\nconsidered. | IIb",
          "rows": 2,
          "cols": 2
        },
        {
          "title": "Table on page 14",
          "page": 14,
          "content": " | CHD |  |  | \nIn patients after repair of TOF without arrhythmia\nsymptoms, but with a combination of other risk\nfactors,a electrophysiologic evaluation, including PES,\nmay be considered. |  | IIa | IIb | \nIn patients with CHD and recurrent, symptomatic\nSMVT, or ICD shocks for SMVT not manageable by\nmedical therapy or ICD reprogramming, catheter\nablation performed in specialized centres should be\nconsidered. |  | I | IIa | \n | Primary electrical disease and selected populations |  |  | \nICD implantation is recommended in patients with\nLQTS who are symptomaticb while receiving\nbeta-blockers and genotype-specific therapies. |  | IIa | I | \nICD implantation should be considered in patients\nwith CPVT who experience arrhythmic syncope and/\nor documented bidirectional/PVT while on the\nhighest tolerated beta-blocker dose and on flecainide. |  | I | IIa | \nPre-participation cardiovascular evaluation of\ncompetitive athletes should be considered. |  | I | IIa | \nCatheter ablation of triggering PVCs and/or RVOT\nepicardial substrate should be considered in BrS\npatients with recurrent appropriate ICD shocks\nrefractory to drug therapy. |  | IIb | IIa | \nLCSD should be considered in patients with diagnosis\nof CPVT when the combination of beta-blockers and\nflecainide at therapeutic dosage are either not\neffective, not tolerated, or contraindicated. |  | IIb | IIa | ",
          "rows": 9,
          "cols": 5
        },
        {
          "title": "Table on page 14",
          "page": 14,
          "content": " |  | Class |  | \n |  | 2015 | 2022 | \n | Coronary artery disease |  |  | \nIn patients with syncope and previous STEMI, PES is\nindicated when syncope remains unexplained after\nnon-invasive evaluation. |  | IIa | I | \nIntravenous amiodarone treatment should be\nconsidered for patients with recurrent PVT/VF\nduring the acute phase of ACS. |  | I | IIa | \nIn patients with CAD eligible for ICD implantation,\ncatheter ablation may be considered just before (or\nimmediately after) ICD implantation to decrease\nsubsequent VT burden and ICD shocks. |  | IIa | IIb | \n | PVC-induced cardiomyopathy |  |  | \nIn patients with a cardiomyopathy suspected to be\ncaused by frequent and predominately monomorphic\nPVCs, catheter ablation is recommended. |  | IIa | I | \n | DCM/HNDCM |  |  | \nICD implantation should be considered in patients\nwith DCM/HNDCM, symptomatic heart failure\n(NYHA class II–III) and LVEF ≤35% after ≥3 months\nof OMT. |  | I | IIa | \nCatheter ablation in specialized centres should be\nconsidered in patients with DCM/HNDCM and\nrecurrent, symptomatic SMVT, or ICD shocks for\nSMVT, in whom AADs are ineffective,\ncontraindicated, or not tolerated. |  | IIb | IIa | \n | ARVC |  |  | \nICD implantation should be considered in patients\nwith definite ARVC and an arrhythmic syncope. |  | IIb | IIa | \nICD implantation should be considered in patients\nwith definite ARVC and severe RV or LV systolic\ndysfunction. |  | IIb | IIa | \n | Inflammatory diseases |  |  | \nIn patients with haemodynamically not-tolerated\nSMVT occurring in the chronic phase of myocarditis,\nICD implantation is recommended. |  | IIa | I | \nICD implantation is recommended in patients with\ncardiac sarcoidosis who have an LVEF ≤35%. |  | IIb | I | \nICD implantation is recommended in patients with\ncardiac sarcoidosis who (1) have documented\nsustained VT, or (2) aborted CA. |  | IIb | I | \nIn patients with cardiac sarcoidosis who have an\nindication for permanent cardiac pacing related to\nhigh-degree AV block, ICD implantation should be\nconsidered, regardless of LVEF. |  | IIb | IIa | \nIn patients with Chagas’ cardiomyopathy and\nsymptomatic VT in whom AADs (amiodarone and\nbeta-blockers) are ineffective or not tolerated, ICD\nimplantation may be considered. |  | IIa | IIb | ",
          "rows": 20,
          "cols": 5
        }
      ],
      "keywords": [
        "introduction",
        "ct",
        "risk",
        "indication",
        "imaging",
        "icd",
        "recommendation"
      ]
    },
    {
      "number": "5",
      "title": "3. Definitions",
      "start_page": 15,
      "end_page": 15,
      "content": "3. Deﬁnitions\n3.1. Ventricular arrhythmia subtypes\nPremature ventricular complex (PVC): Premature occurrence of an ab-\nnormal QRS complex (duration typically ≥120 ms, corresponding\nT-wave typically broad and in the opposite direction of the major\nQRS deﬂection, no preceding P-wave).\nUnifocal or monomorphic PVCs: PVCs with a single QRS morphology.\nMultifocal, multiform, or polymorphic PVCs: PVCs with different QRS\nmorphologies.\nShort-coupled PVC: A PVC that interrupts the T-wave of the pre-\nceding conducted beat.\nVentricular tachycardia (VT): ≥3 consecutive beats with a rate\n.100 b.p.m. originating from the ventricles, independent from atrial\nand atrioventricular (AV) nodal conduction.\nNon-sustained ventricular tachycardia (NSVT): Run of consecutive\nventricular beats persisting for 3 beats to 30 s.\nMonomorphic ventricular tachycardia (MVT): Same QRS morph-\nology from beat to beat.\nPolymorphic ventricular tachycardia (PVT): Continually changing QRS\nmorphology.\nSustained monomorphic/polymorphic ventricular tachycardia (SMVT/\nSPVT): Continuous VT for at least 30 s, or which requires an interven-\ntion for termination.\nBidirectional ventricular tachycardia: Beat to beat alternation of the\nfrontal QRS axis (e.g. in catecholaminergic polymorphic ventricular\ntachycardia\n[CPVT],\nAndersen–Tawil,\ndigoxin\ntoxicity,\nacute\nmyocarditis).\nTorsades de pointes ventricular tachycardia (TdP): Subtype of a poly-\nmorphic VT in the context of QT prolongation with continually\nchanging QRS complexes that appear to spiral around the baseline\nof the electrocardiogram (ECG) lead in a sinusoidal pattern.\nVentricular ﬁbrillation (VF): A chaotic rhythm with undulations that\nare irregular in timing and morphology, without discrete QRS com-\nplexes on the surface ECG.\nElectrical storm: VA that occurs 3 or more times within 24 h (sepa-\nrated by at least 5 min), each requiring termination by an\nintervention.\nIncessant VT: Continuous sustained VT that recurs promptly des-\npite repeated intervention for termination over several hours.\n3.2. Sudden cardiac death\nSudden cardiac arrest (SCA): Sudden cessation of normal cardiac activ-\nity with haemodynamic collapse.\nSudden cardiac death (SCD): Sudden natural death presumed to be\nof cardiac cause that occurs within 1 h of onset of symptoms in wit-\nnessed cases, and within 24 h of last being seen alive when it is unwit-\nnessed. SCD in autopsied cases is deﬁned as the natural unexpected\ndeath of unknown or cardiac cause.\nSudden unexplained death: Unexplained sudden death occurring in\nan individual older than 1 year.\nSudden infant death syndrome (SIDS): Unexplained sudden death\noccurring in an individual younger than 1 year with negative patho-\nlogical and toxicological assessment and negative forensic examin-\nation of the circumstances of death.\nSudden arrhythmic death syndrome (SADS): Unexplained sudden\ndeath occurring in an individual older than 1 year with negative\npathological and toxicological assessment. Note: Synonymous with\n‘autopsy-negative sudden unexplained death’.\n3.3. Syncope\nUnexplained syncope: Transient loss of consciousness due to cerebral\nhypoperfusion, characterized by a rapid onset, short duration, and\nspontaneous complete recovery, but unexplained after conventional\nworkup. Work-up and differential diagnosis are provided in the 2018\nESC Guidelines for the diagnosis and management of syncope.1\nArrhythmic syncope: as above, but highly suspicious for intermittent\nbradycardia, rapid supraventricular tachycardia (SVT), or VA.\n3.4. Specialized centres\nMultidisciplinary teams: A multidisciplinary team across specialties is\ncharacterized by open communication, positive management and\nleadership,\nappropriate\nresources,\nand\na\nmix\nof\nskills.\nDecision-making should be shared in the team.\nSpecialized centre for catheter ablation of VA: Patient and procedural\ncomplexity vary widely. Some patients require a more experienced\noperator and a centre with more capabilities, which is more likely\nin patients with a non-ischaemic aetiology. A specialized centre has\nat least one operator with appropriate experience in interventions\nthat may be required for a successful procedure (e.g. percutaneous\nepicardial access). The centre performs catheter ablation of VT in\nstructural heart disease (SHD) on a regular basis. In addition, the cen-\ntre has the required resources to manage medical conditions, co-\nmorbidities, and potential complications in patients undergoing\ncomplex VA ablation; this includes interventional cardiology expert-\nise, acute placement of mechanical circulatory assist devices, and car-\ndiothoracic surgical back-up. Considering the variable availability\nacross European countries, it is preferable to treat complex patients\nin the most experienced centre within reasonable distance.\n3.5. Genetics\nPathogenic variant and likely pathogenic variant: The American College\nof Medical Genetics has provided a framework for the interpretation\nof disease causation by genetic variants standardized into classes. The\ngenetic variants most likely to cause an associated disease are termed\nV, ‘pathogenic’, and IV, ‘likely pathogenic’.\nMutation: This term is used in this document to mean a Class IV or\nV variant.\nVariant of uncertain signiﬁcance: A change in a gene’s deoxyribo-\nnucleic acid (DNA) sequence that has an unknown effect on a per-\nson’s health.\n4. Epidemiology of sudden cardiac\ndeath, public awareness, and risk\nstratiﬁcation\n4.1. Incidence of sudden cardiac death\nSCD accounts for approximately 50% of all cardiovascular deaths,\nwith up to 50% being the ﬁrst manifestation of cardiac disease.19–24\nIdeally, cases suspicious of SCD should be identiﬁed from multiple\nESC Guidelines\n4011\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "ct",
        "intervention",
        "echo",
        "definitions"
      ]
    },
    {
      "number": "6",
      "title": "4. Epidemiology of sudden cardiac death, public awareness, and risk stratification",
      "start_page": 15,
      "end_page": 18,
      "content": "3. Deﬁnitions\n3.1. Ventricular arrhythmia subtypes\nPremature ventricular complex (PVC): Premature occurrence of an ab-\nnormal QRS complex (duration typically ≥120 ms, corresponding\nT-wave typically broad and in the opposite direction of the major\nQRS deﬂection, no preceding P-wave).\nUnifocal or monomorphic PVCs: PVCs with a single QRS morphology.\nMultifocal, multiform, or polymorphic PVCs: PVCs with different QRS\nmorphologies.\nShort-coupled PVC: A PVC that interrupts the T-wave of the pre-\nceding conducted beat.\nVentricular tachycardia (VT): ≥3 consecutive beats with a rate\n.100 b.p.m. originating from the ventricles, independent from atrial\nand atrioventricular (AV) nodal conduction.\nNon-sustained ventricular tachycardia (NSVT): Run of consecutive\nventricular beats persisting for 3 beats to 30 s.\nMonomorphic ventricular tachycardia (MVT): Same QRS morph-\nology from beat to beat.\nPolymorphic ventricular tachycardia (PVT): Continually changing QRS\nmorphology.\nSustained monomorphic/polymorphic ventricular tachycardia (SMVT/\nSPVT): Continuous VT for at least 30 s, or which requires an interven-\ntion for termination.\nBidirectional ventricular tachycardia: Beat to beat alternation of the\nfrontal QRS axis (e.g. in catecholaminergic polymorphic ventricular\ntachycardia\n[CPVT],\nAndersen–Tawil,\ndigoxin\ntoxicity,\nacute\nmyocarditis).\nTorsades de pointes ventricular tachycardia (TdP): Subtype of a poly-\nmorphic VT in the context of QT prolongation with continually\nchanging QRS complexes that appear to spiral around the baseline\nof the electrocardiogram (ECG) lead in a sinusoidal pattern.\nVentricular ﬁbrillation (VF): A chaotic rhythm with undulations that\nare irregular in timing and morphology, without discrete QRS com-\nplexes on the surface ECG.\nElectrical storm: VA that occurs 3 or more times within 24 h (sepa-\nrated by at least 5 min), each requiring termination by an\nintervention.\nIncessant VT: Continuous sustained VT that recurs promptly des-\npite repeated intervention for termination over several hours.\n3.2. Sudden cardiac death\nSudden cardiac arrest (SCA): Sudden cessation of normal cardiac activ-\nity with haemodynamic collapse.\nSudden cardiac death (SCD): Sudden natural death presumed to be\nof cardiac cause that occurs within 1 h of onset of symptoms in wit-\nnessed cases, and within 24 h of last being seen alive when it is unwit-\nnessed. SCD in autopsied cases is deﬁned as the natural unexpected\ndeath of unknown or cardiac cause.\nSudden unexplained death: Unexplained sudden death occurring in\nan individual older than 1 year.\nSudden infant death syndrome (SIDS): Unexplained sudden death\noccurring in an individual younger than 1 year with negative patho-\nlogical and toxicological assessment and negative forensic examin-\nation of the circumstances of death.\nSudden arrhythmic death syndrome (SADS): Unexplained sudden\ndeath occurring in an individual older than 1 year with negative\npathological and toxicological assessment. Note: Synonymous with\n‘autopsy-negative sudden unexplained death’.\n3.3. Syncope\nUnexplained syncope: Transient loss of consciousness due to cerebral\nhypoperfusion, characterized by a rapid onset, short duration, and\nspontaneous complete recovery, but unexplained after conventional\nworkup. Work-up and differential diagnosis are provided in the 2018\nESC Guidelines for the diagnosis and management of syncope.1\nArrhythmic syncope: as above, but highly suspicious for intermittent\nbradycardia, rapid supraventricular tachycardia (SVT), or VA.\n3.4. Specialized centres\nMultidisciplinary teams: A multidisciplinary team across specialties is\ncharacterized by open communication, positive management and\nleadership,\nappropriate\nresources,\nand\na\nmix\nof\nskills.\nDecision-making should be shared in the team.\nSpecialized centre for catheter ablation of VA: Patient and procedural\ncomplexity vary widely. Some patients require a more experienced\noperator and a centre with more capabilities, which is more likely\nin patients with a non-ischaemic aetiology. A specialized centre has\nat least one operator with appropriate experience in interventions\nthat may be required for a successful procedure (e.g. percutaneous\nepicardial access). The centre performs catheter ablation of VT in\nstructural heart disease (SHD) on a regular basis. In addition, the cen-\ntre has the required resources to manage medical conditions, co-\nmorbidities, and potential complications in patients undergoing\ncomplex VA ablation; this includes interventional cardiology expert-\nise, acute placement of mechanical circulatory assist devices, and car-\ndiothoracic surgical back-up. Considering the variable availability\nacross European countries, it is preferable to treat complex patients\nin the most experienced centre within reasonable distance.\n3.5. Genetics\nPathogenic variant and likely pathogenic variant: The American College\nof Medical Genetics has provided a framework for the interpretation\nof disease causation by genetic variants standardized into classes. The\ngenetic variants most likely to cause an associated disease are termed\nV, ‘pathogenic’, and IV, ‘likely pathogenic’.\nMutation: This term is used in this document to mean a Class IV or\nV variant.\nVariant of uncertain signiﬁcance: A change in a gene’s deoxyribo-\nnucleic acid (DNA) sequence that has an unknown effect on a per-\nson’s health.\n4. Epidemiology of sudden cardiac\ndeath, public awareness, and risk\nstratiﬁcation\n4.1. Incidence of sudden cardiac death\nSCD accounts for approximately 50% of all cardiovascular deaths,\nwith up to 50% being the ﬁrst manifestation of cardiac disease.19–24\nIdeally, cases suspicious of SCD should be identiﬁed from multiple\nESC Guidelines\n4011\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nsources and undergo autopsy, which is required to reliably exclude\nnon-cardiac causes of sudden death (SD).\nThe incidence of SCD increases markedly with age. With a very\nlow incidence during infancy and childhood (1 per 100 000 person-\nyears),25–27 the incidence is approximately 50 per 100 000 person-\nyears in middle-aged individuals (in the ﬁfth to sixth decades of\nlife).28–30 In the eighth decade of life, it reaches an annual incidence\nof at least 200 per 100 000 person-years.20 At any age, males have\nhigher SCD rates compared with females, even after adjustment\nfor risk factors of coronary artery disease (CAD).24,31–33 Ethnic\nbackground also seems to have large effects.34,35 It is estimated\nthat 10–20% of all deaths in Europe are SCD.36,37 Approximately\n300 000 people in Europe have out-of-hospital cardiac arrest\n(OHCA) treated by emergency medical systems every year.38,39\nIn the Western world, the epidemiology of SCD is closely related\nto CAD, which is responsible for up to 75–80% of SCD cases.40\nWhile the prevalence of CAD has not decreased, there has been a\nsigniﬁcant decline in mortality due to CAD. Reports show that the\nincidence of SCD is declining,40–42 but the risk of SCD as a propor-\ntion of the overall cardiovascular deaths may have increased.43,44\nAlthough regular physical activity beneﬁts cardiovascular health,\nsport, particularly when practiced vigorously, has been shown to\nbe associated with SCD during or shortly after exercise in selected\npopulations.45–51 Reports have suggested that the majority of sports-\nrelated SCD occurs in a recreational52,53 rather than competitive\nsetting, especially among middle-aged male participants, suggesting\nthat CAD is the most common underlying cause.46,54,55\n4.2. Causes of sudden cardiac death in\ndifferent age groups\nCardiac diseases associated with SCD vary depending on the indivi-\ndual’s age. In the young there is a predominance of primary electric\ndiseases and cardiomyopathies, as well as myocarditis, and coronary\nanomalies.25,27,56–61 However, half of SCD cases during the fourth\ndecade are related to CAD, especially acute coronary syndrome\n(ACS).62,63\nIn older populations, chronic structural diseases predominate\n(CAD either through acute coronary events or chronic coronary\nstenoses, valvular heart diseases, and heart failure), while potentially\ninherited electrical diseases or structural non-ischaemic diseases may\ncause more than 50% of SCD in individuals under the age of 50\nyears.27\nAge distribution at presentation with ventricular arrhythmias and\nsudden cardiac death, dominant arrhythmia subtypes, triggers, genet-\nic factors, and gender associated with increased risk for ventricular\narrhythmias in selected primary electrical and structural heart dis-\neases are presented in Figure 1.\n4.3. Population vs. individual risk\nprediction\nIn the general population (individuals without known heart disease),\nthe most effective approach for preventing SCD resides in quantiﬁ-\ncation of the individual risk of developing CAD based on risk score\ncharts.64,65 Several studies have provided evidence that there is a\ngenetic predisposition to die suddenly during acute ischaemia.66–70\nThe goal would be to identify the relatively small, high-risk subgroups\nfrom the general population at risk of SCD as their ﬁrst cardiac event.\nModels for novel SCD risk stratiﬁcation in the general population\nhave recently been proposed.71–73 There are no clear data support-\ning the beneﬁt of mass screening programs in the general population\nfor preventing SCD.74–76\nFor decades, investigators have envisioned a broad range of ‘indi-\ncators’ for SCD, especially occurring in the setting of CAD. Several\nnon-invasive markers of risk have been proposed (including late po-\ntentials, heart rate variability, periodic repolarization dynamics, and\nbaroreﬂex sensitivity).77 Despite the promising outcomes of initial\nstudies, however, these ‘predictors’ have not yet inﬂuenced clinical\npractice. Left ventricular ejection fraction (LVEF) is only used, often\nin combination with New York Heart Association (NYHA) class, for\nprimary prevention indication of an ICD in the setting of chronic\nCAD and dilated cardiomyopathy (DCM). Risk stratiﬁcation schemes\nand calculators have been developed for inheritable arrhythmogenic\ndiseases, such as hypertrophic cardiomyopathy (HCM), arrhythmo-\ngenic right ventricular cardiomyopathy (ARVC), and lamin A/C\n(LMNA) cardiomyopathy.78–82\nWhat is considered low, intermediate, or high risk will depend on\nthe type of event (e.g. fatal or not) and the risk of an event in the\nbackground population. For instance, mortality depends on age,\nsex, and other risk factors including comorbidities. The situation is\nfurther complicated when considering a speciﬁc type of death, e.g.\nSCD. Then non-SCD deaths are competing events (or competing\nrisks) to SCD in the sense that their occurrence prevents the obser-\nvation of SCD, and may make interventions to prevent SCD, such as\nan ICD, of limited beneﬁt.\n4.4. Risk calculators for sudden cardiac\ndeath and review of the methodology\nA number of risk calculators for SCD have been proposed for adult\nand paediatric populations.80,81,83–85 The ﬁeld of prediction modelling\nhas evolved over the past decades, establishing standards for the de-\nvelopment, validation (internal and external), and reporting of pre-\ndiction models in SCD.86,87 In addition to discrimination measures\nsuch as the c-index, measures of calibration such as the calibration\nslope have recently received more attention because it is not only\nimportant to distinguish patients with higher risks from those with\nlower risks but also to obtain a robust quantiﬁcation of the risk itself\nfrom the risk calculators.88 Typical shortcomings in the development\nand validation of risk calculators include, but are not limited to, the\nuse of historic samples not representative of contemporary patient\ncohorts, missing values, composite outcomes with composite events\nof different clinical importance, lack of external validation, and miss-\ning calibration. In this document different cut-off for 5 years risk of\nSCD/VA is used for indication of ICD. Each cut-off was chosen by\nthe original authors and the task force group considering the com-\npeting risk, the outcome measured (SCD vs VA) and the robustness\nof each risk calculator.\n4.5. Awareness and intervention: public\nbasic life support, and access to\nautomated external deﬁbrillators\nSurvival rate remains strikingly low after OHCA,89–95 although major\nregional disparities have been described.96 Early implementation of\n4012\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nresuscitative interventions, especially prior to emergency medical\nsystem arrival, has been identiﬁed as key elements to improve sur-\nvival.95,97 Bystander cardiopulmonary resuscitation (CPR) and use\nof public automated external deﬁbrillators (AEDs) have demon-\nstrated improvement of neurological and functional outcome as\nwell as survival of OHCA patients. Data support the need for\nincreased availability of public access deﬁbrillators and community\ntraining in basic life support,89–95 preferably initiated in childhood\nand repetitive.98–100 Finally, dispatch of basic life support-trained vo-\nlunteers, through speciﬁc mobile apps networks, has been shown to\nincrease the rate of bystander-initiated CPR, and as a result, greatly\nreduces the resuscitation-free interval and improves the outcome of\nGenetic risks and triggers\nfor VA/SCD\nCPVT\nLQT\nBrS\nACS\nSarcoid\nHCM\nDCM\nARVC\nrTOF\nchronic\nCAD\nAge at \nVA/SCD\nDominant subtype\nof VA (%)\n10\n20\n30\n40\n50\n60\n70\n80\nPVT\nMVT\nP\nM\nPVT\nMVT\nP\nM\nPVT\nMVT\nP\nM\nPVT\nMVT\nP\nM\nPVT\nMVT\nP\nM\nPVT\nMVT\nP\nM\nPVT\nMVT\nP\nM\nPVT\nMVT\nP\nM\nPVT\nMVT\nP\nM\nPVT\nMVT\nP\nM\n0\n50\n100\nFigure 1 Central ﬁgure. Genetic risk for VA/SCD, typical triggers for VA/SCD, age at presentation with VA/SCD, sex predominance, and typical VA\n(PVT/VF vs. MVT) in different diseases associated with VA/SCD. ACS, acute coronary syndrome; ARVC, arrhythmogenic right ventricular cardiomyop-\nathy; BrS, Brugada syndrome; CAD, coronary artery disease; CPVT, catecholaminergic polymorphic ventricular tachycardia; DCM, dilated cardiomyop-\nathy; HCM, hypertrophic cardiomyopathy; LQT, long QT syndrome; MVT, monomorphic ventricular tachycardia; PVT, polymorphic ventricular\ntachycardia; rTOF, repaired tetralogy of Fallot; SCD, sudden cardiac death; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation.\nESC Guidelines\n4013\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nOHCA victims.101–103 Education of public ofﬁcials and community\nmembers regarding the importance of increasing rates of bystander\nCPR and promoting the use of early deﬁbrillation by lay and profes-\nsional rescuers is critical to increasing survival rates.\n5. Evaluation and treatment.\nGeneral aspects\n5.1. Diagnostic tools\n5.1.1. History and physical examination\nHistory should focus on ‘red ﬂags’, including features of arrhythmic\nsyncope, e.g. absence of vagal prodrome, and family history of pre-\nmature or SCD including, e.g. drowning or car accident in long QT\nsyndrome (LQTS), and CPVT.1,106 Subtle features to suggest inher-\nited causes include a family history of epilepsy, sudden infant death\nsyndrome, deafness (LQTS), heart failure, or pacemaker implantation\nat ,50 years old. Features of diseases related to pro-arrhythmic con-\nditions include mid-systolic click in mitral valve prolapse (MVP) and\noutﬂow tract murmurs with Valsalva in HCM. Speciﬁc skin features\nmay be relevant, e.g. Lupus pernio, erythema nodosum in sarcoidosis,\nangiokeratoma in Fabry’s disease, xanthelasma/xanthoma, and palmo-\nplantar keratosis in ARVC.\n5.1.2. Laboratory testing\nNatriuretic peptides (b-type-natriuretic peptide, or N-terminal\npro-b-type-natriuretic peptide) may have a role in the identiﬁcation\nof individuals at increased risk of SCD in the general population107,108\nor in patients with CAD.109 There is not sufﬁcient evidence to use\nb-type-natriuretic peptide as a method to select the need for an\nICD.110,111\n5.1.3. Non-invasive and invasive tests\n5.1.3.1. Electrocardiogram and ambulatory electrocardiographic\nmonitoring2\nThe 12-lead ECG is an important tool for the diagnosis of underlying\ndisease, for risk stratiﬁcation in selected populations, and for the\ndiagnosis of the VA subtype, if captured. Documentation of arrhyth-\nmias related to symptoms is clinically pivotal but may be challenging\nwith sporadic events. The type of ECG-monitoring device and the re-\ncording time should therefore match the frequency of clinical events.\nMonitoring over a period of 24–48 h (typically ‘Holter recording’) is\nappropriate for daily arrhythmias,112 while intermittent monitoring\nover a longer period, with patient-activated ECG recorders (or\nmobile-health/smartphones), should be preferred for infrequent\nevents.113 Implantable loop recorders (ILR) can be useful in diagnos-\ning arrhythmias in patients with potentially life-threatening symp-\ntoms, such as unexplained syncope.114\n5.1.3.2. Signal-averaged electrocardiogram\nSignal-averaged electrocardiogram (SaECG) can detect very low\namplitude signals (‘late potentials’) in the terminal QRS segment115\nusing three time-domain measurements: QRS duration, low-amplitude\n(,40 µV) signal duration and root mean square voltage of terminal\n40 ms QRS.112 Abnormalities in the SaECG can also be assessed by\nfrequency-domain analysis.112 SaECG can contribute to the diagno-\nsis of ARVC.116\n5.1.3.3. Exercise testing\nExercise testing is useful for the diagnosis and for evaluating response\nto therapy in patients with suspected/proven adrenergic-dependent\nrhythm disturbances, such as exercise-induced idiopathic MVT, PVT,\nor bidirectional VT in CPVT.117,118 The 4-minute recovery QTc after\nexercise testing can contribute to the diagnosis LQTS.119\n5.1.3.4. Imaging\nImaging is crucial to assess cardiac function and detect cardiomy-\nopathies (\nESC CardioMed chapter 10).120 A negative imaging\nstudy supports primary electrical disease in a patient with VA.\nEchocardiography is a readily available and ﬁrst-line diagnostic and risk\nstratiﬁcation tool for valve diseases, CAD and DCM, HCM, ARVC,121\nand left ventricular non-compaction (LVNC). Echocardiographic strain-\nrate imaging allows differentiation between active and passive move-\nment of myocardial segments and early detection of myocardial dys-\nfunction. Wall motion abnormalities can indicate previous infarcts,\ncardiomyopathies, or inﬂammatory disease. Global longitudinal strain\nis a robust measure of left ventricular (LV) function and can detect sub-\ntle changes in LV function while LVEF is still preserved.122 Strain imaging\ncan assess mechanical dispersion reﬂecting inhomogeneous contraction\nthat could be associated with increased risk of VA.122–125\nCMR currently provides the most accurate and reproducible meas-\nurement of atrial, biventricular global and regional systolic function,\nand can detect myocardial oedema, ﬁbrosis, inﬁltration, and\nRecommendation Table 1 — Recommendations for\npublic basic life support and access to automated ex-\nternal deﬁbrillators\nRecommendations\nClassa\nLevelb\nIt is recommended that public access deﬁbrillation\nbe available at sites where cardiac arrest is more\nlikely to occur.c,90–92\nI\nB\nPrompt CPR by bystanders is recommended at\nOHCA.93–95\nI\nB\nIt is recommended to promote community\ntraining in basic life support to increase bystander\nCPR rate and AED use.93,97,104\nI\nB\nMobile phone-based alerting of basic life\nsupport-trained bystander volunteers to\nassist nearby OHCA victims should be\nconsidered.101–103,105\nIIa\nB\n© ESC 2022\nAED, automated external deﬁbrillator; CPR, cardiopulmonary resuscitation; OHCA,\nout-of-hospital cardiac arrest.\naClass of recommendation.\nbLevel of evidence.\ncShopping centres, stadiums, public transport stations, casinos.\n4014\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 18",
          "page": 18,
          "content": "Recommendations | Classa | Levelb\nIt is recommended that public access defibrillation\nbe available at sites where cardiac arrest is more\nlikely to occur.c,90–92 | I | B\nPrompt CPR by bystanders is recommended at\nOHCA.93–95 | I | B\nIt is recommended to promote community\ntraining in basic life support to increase bystander\nCPR rate and AED use.93,97,104 | I | B\nMobile phone-based alerting of basic life\nsupport-trained bystander volunteers to\nassist nearby OHCA victims should be\nconsidered.101–103,105 | IIa | B",
          "rows": 5,
          "cols": 3
        }
      ],
      "keywords": [
        "intervention",
        "ct",
        "echo",
        "cardiac",
        "epidemiology",
        "awareness",
        "stratification",
        "risk",
        "public",
        "sudden",
        "death"
      ]
    },
    {
      "number": "7",
      "title": "5. Evaluation and treatment. General aspects",
      "start_page": 18,
      "end_page": 31,
      "content": "OHCA victims.101–103 Education of public ofﬁcials and community\nmembers regarding the importance of increasing rates of bystander\nCPR and promoting the use of early deﬁbrillation by lay and profes-\nsional rescuers is critical to increasing survival rates.\n5. Evaluation and treatment.\nGeneral aspects\n5.1. Diagnostic tools\n5.1.1. History and physical examination\nHistory should focus on ‘red ﬂags’, including features of arrhythmic\nsyncope, e.g. absence of vagal prodrome, and family history of pre-\nmature or SCD including, e.g. drowning or car accident in long QT\nsyndrome (LQTS), and CPVT.1,106 Subtle features to suggest inher-\nited causes include a family history of epilepsy, sudden infant death\nsyndrome, deafness (LQTS), heart failure, or pacemaker implantation\nat ,50 years old. Features of diseases related to pro-arrhythmic con-\nditions include mid-systolic click in mitral valve prolapse (MVP) and\noutﬂow tract murmurs with Valsalva in HCM. Speciﬁc skin features\nmay be relevant, e.g. Lupus pernio, erythema nodosum in sarcoidosis,\nangiokeratoma in Fabry’s disease, xanthelasma/xanthoma, and palmo-\nplantar keratosis in ARVC.\n5.1.2. Laboratory testing\nNatriuretic peptides (b-type-natriuretic peptide, or N-terminal\npro-b-type-natriuretic peptide) may have a role in the identiﬁcation\nof individuals at increased risk of SCD in the general population107,108\nor in patients with CAD.109 There is not sufﬁcient evidence to use\nb-type-natriuretic peptide as a method to select the need for an\nICD.110,111\n5.1.3. Non-invasive and invasive tests\n5.1.3.1. Electrocardiogram and ambulatory electrocardiographic\nmonitoring2\nThe 12-lead ECG is an important tool for the diagnosis of underlying\ndisease, for risk stratiﬁcation in selected populations, and for the\ndiagnosis of the VA subtype, if captured. Documentation of arrhyth-\nmias related to symptoms is clinically pivotal but may be challenging\nwith sporadic events. The type of ECG-monitoring device and the re-\ncording time should therefore match the frequency of clinical events.\nMonitoring over a period of 24–48 h (typically ‘Holter recording’) is\nappropriate for daily arrhythmias,112 while intermittent monitoring\nover a longer period, with patient-activated ECG recorders (or\nmobile-health/smartphones), should be preferred for infrequent\nevents.113 Implantable loop recorders (ILR) can be useful in diagnos-\ning arrhythmias in patients with potentially life-threatening symp-\ntoms, such as unexplained syncope.114\n5.1.3.2. Signal-averaged electrocardiogram\nSignal-averaged electrocardiogram (SaECG) can detect very low\namplitude signals (‘late potentials’) in the terminal QRS segment115\nusing three time-domain measurements: QRS duration, low-amplitude\n(,40 µV) signal duration and root mean square voltage of terminal\n40 ms QRS.112 Abnormalities in the SaECG can also be assessed by\nfrequency-domain analysis.112 SaECG can contribute to the diagno-\nsis of ARVC.116\n5.1.3.3. Exercise testing\nExercise testing is useful for the diagnosis and for evaluating response\nto therapy in patients with suspected/proven adrenergic-dependent\nrhythm disturbances, such as exercise-induced idiopathic MVT, PVT,\nor bidirectional VT in CPVT.117,118 The 4-minute recovery QTc after\nexercise testing can contribute to the diagnosis LQTS.119\n5.1.3.4. Imaging\nImaging is crucial to assess cardiac function and detect cardiomy-\nopathies (\nESC CardioMed chapter 10).120 A negative imaging\nstudy supports primary electrical disease in a patient with VA.\nEchocardiography is a readily available and ﬁrst-line diagnostic and risk\nstratiﬁcation tool for valve diseases, CAD and DCM, HCM, ARVC,121\nand left ventricular non-compaction (LVNC). Echocardiographic strain-\nrate imaging allows differentiation between active and passive move-\nment of myocardial segments and early detection of myocardial dys-\nfunction. Wall motion abnormalities can indicate previous infarcts,\ncardiomyopathies, or inﬂammatory disease. Global longitudinal strain\nis a robust measure of left ventricular (LV) function and can detect sub-\ntle changes in LV function while LVEF is still preserved.122 Strain imaging\ncan assess mechanical dispersion reﬂecting inhomogeneous contraction\nthat could be associated with increased risk of VA.122–125\nCMR currently provides the most accurate and reproducible meas-\nurement of atrial, biventricular global and regional systolic function,\nand can detect myocardial oedema, ﬁbrosis, inﬁltration, and\nRecommendation Table 1 — Recommendations for\npublic basic life support and access to automated ex-\nternal deﬁbrillators\nRecommendations\nClassa\nLevelb\nIt is recommended that public access deﬁbrillation\nbe available at sites where cardiac arrest is more\nlikely to occur.c,90–92\nI\nB\nPrompt CPR by bystanders is recommended at\nOHCA.93–95\nI\nB\nIt is recommended to promote community\ntraining in basic life support to increase bystander\nCPR rate and AED use.93,97,104\nI\nB\nMobile phone-based alerting of basic life\nsupport-trained bystander volunteers to\nassist nearby OHCA victims should be\nconsidered.101–103,105\nIIa\nB\n© ESC 2022\nAED, automated external deﬁbrillator; CPR, cardiopulmonary resuscitation; OHCA,\nout-of-hospital cardiac arrest.\naClass of recommendation.\nbLevel of evidence.\ncShopping centres, stadiums, public transport stations, casinos.\n4014\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nperfusion defects (\nESC CardioMed chapter 11.4).126 CMR is\nmore sensitive than echocardiography to diagnose ARVC,127 is diag-\nnostic in LVNC, and can detect apical aneurysms in HCM. Fibrosis\ndetection by late gadolinium enhancement (LGE) contributes to\nVA risk stratiﬁcation in HCM,128 DCM,129 and potentially in mitral\nvalve prolapse arrhythmic syndrome.130,131 Novel myocardial map-\nping techniques can detect diffuse ﬁbrosis and can suggest the aeti-\nology of left ventricular hypertrophy (LVH) for speciﬁc therapy\nguiding, e.g. Fabry disease and amyloidosis. The prognostic value re-\nmains to be evaluated.\nCardiac imaging by computed tomography (CT) has the advantage\nof a high spatial resolution (\nESC CardioMed chapter 12.1).132\nECG synchronization, additional breath-hold sequences, and beta-\nblocker to lower the heart rate improve the quality. Radiation\nexposure is in the range of an invasive coronary angiogram\n(CAG). Coronary computed tomography angiography (CTA) is\nthe preferred method to rule out coronary artery stenosis\nin patients with low probability of CAD.133,134 The quality of\nalmost all image modalities is inﬂuenced by the presence of frequent\nPVCs.\n5.1.3.5. Provocative diagnostic tests\nThese are summarized in Table 6. Common tests performed are so-\ndium channel blocker testing for Brugada syndrome (BrS) and adeno-\nsine test to exclude latent pre-excitation.135,136 Epinephrine\nchallenge may be useful in CPVT when exercise cannot be per-\nformed. Epinephrine test is not recommended for LQTS due to\nthe high false positive rate and utility of exercise testing.137\nCoronary vasospasm as a cause of VF in the absence of obstructive\ncoronary diseases/cardiomyopathy can be tested with incremental\nintracoronary doses of acetylcholine/ergonovine.\n5.1.3.6. Electrophysiological study\nElectrophysiological studies including measurement of baseline inter-\nvals (e.g. atrial–His interval [AH] and His–ventricular interval [HV]),\nprogrammed electrical stimulation (PES), and electroanatomical\nmapping can be used for diagnostic purposes and to guide ther-\napy.145–150 The yield of PES varies with the underlying cardiac condi-\ntion and its severity, the presence or absence of spontaneous VT,\nconcomitant drug therapy, stimulation protocol, and site(s) of stimu-\nlation. Typical protocols include stimulation from 2 right ventricular\n(RV) sites with 2–3 basic drive cycle lengths, introduction of 3 extra-\nstimuli, and isoprenaline administration.148,151,152\nIn the current era, PES is mainly employed to conﬁrm the diagnosis\nof VT and induce mappable VAs with non-inducibility being an abla-\ntion endpoint. Patients with heart failure and LVEF ≤35% generally\nwill have an indication for an ICD; therefore, VT/VF induction before\nimplantation is not necessary. In patients with SHD and mildly re-\nduced or preserved LVEF who present with unexplained syncope, in-\nduction of SMVT with PES can be helpful to identify the underlying\ncause and to predict subsequent events.146,153 PVT/VF induction in\nSHD is in general considered as a non-speciﬁc ﬁnding.154–156\nIn primary electrical diseases, PES is not of prognostic value, al-\nthough there is some evidence to consider its use in BrS.127\nInvasive electrophysiological evaluation can have important clinical\nimplications in patients with myotonic dystrophy.157\nWith advances in high-density mapping, voltage mapping, conduc-\ntion/repolarisation metrics, and electrogram fractionation can\nbe\nemployed\nto\nidentify\nablation\ntargets,\nor\nto\ndiagnose\ncardiomyopathic disease. Endocardial mapping may be helpful in\nthe differentiation of ARVC from benign outﬂow tract VT and for\ntargeting biopsy in suspected myocarditis, ARVC, and sarcoidosis\ncases.158–162\n5.1.4. Genetic testing\nMassive parallel or next-generation sequencing has led to increasing\navailability of genetic testing at reduced cost. Most diagnostic cardiac\ngenetic testing employs large gene panels determined by associations\nwith disease generated by prior research, i.e. candidate genes.163\nMany previous gene associations have, however, been challenged\nfor their diagnostic utility. Therefore, it is not recommended to in-\nclude questionable genes in routine diagnostic panels.164–168\nGenome-wide association studies have identiﬁed that common gen-\netic variation single nucleotide polymorphisms can cause or modify\nphenotypes in BrS, LQTS, HCM, and DCM. Polygenic risk scores,\nmeasures derived from the cumulative effects of these single nucleo-\ntide polymorphisms, may therefore play a role in diagnosis and prog-\nnostication in these conditions in the future.168–173\nSequencing produces digital data that require subsequent bio-\ninformatic analysis, permitting accurate ascertainment of most\nDNA alterations affecting the coding frame of each gene.174 The\nmost common ﬁndings are single nucleotide variants causing simple\namino acid substitutions (missense), premature terminations, or spli-\ncing abnormalities. Insertions and/or deletions are rarer. The clinical\nimportance\nof\nmost\nnon-coding\nvariants\nis\nstill\nto\nbe\ndetermined.174,175\nA framework for the interpretation of disease causation by genetic\nvariants has standardized adjudication into ﬁve classes: V ‘pathogen-\nic’; IV ‘likely pathogenic’; III ‘variant of uncertain signiﬁcance’; II ‘likely\nbenign’; and I ‘benign’. A combination of evidence is employed: gene–\ndisease association; presence of a variant in healthy and/or diseased\npopulations; in silico data; in vitro and in vivo functional data; and family\nsegregation data.176\nA mutation (Class IV or V variant) can be used immediately either\nfor conﬁrmation of diagnosis in probands (the ﬁrst affected family\nmember), or for initial diagnosis of relatives and may help to guide\ntherapy and/or prognosis. Periodic reassessment of all class IV and\nIII variants is indicated.176\nPre-implantation genetic testing is an early form of pre-natal gen-\netic diagnosis. Genetic diagnoses of in vitro fertilized embryos are\nidentiﬁed by biopsies, thereby allowing transfer of genetically normal\nembryos into the uterus. If the technique is available, it is important\nto provide information to patients with monogenic heart diseases in\nchild-bearing age. The legislation for pre-implantation genetic testing\nvaries in different countries and strategies differ.\nGenetic and clinical testing should be undertaken only by multidis-\nciplinary teams including professionals with skills to counsel on the\nimplications and the uncertainty of results and experienced cardiol-\nogists able to direct testing to the correct phenotype.135,177–179 A\nnegative result does not exclude a diagnosis and should not be\nused for this purpose. A framework for genetic and other clinical\ndiagnostic tests for primary electrical diseases based on evidence\nwhere available has been provided in Table 7.\nESC Guidelines\n4015\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nTable 6\nIntravenous provocative diagnostic tests\nDiagnostic\ntest\nIndication\nProtocols\nDose/infusion\nrate/duration\nPositive test\nContraindications\nCriteria to stop test,\ncounselling and\nmanagement\nObservation\ntimes\nLocation\nRef\nAjmaline\nFamily history of BrS\nor SADS.\nResuscitated CA\nwithout SHD.\n1 mg/kg over 5–10 min\n(maximum dose\n100 mg) or 1 mg/kg\nat 10 mg/min.\nRecord in standard\nand high precordial\nleads over 30 min.\nBrS type 1 ECG.\nType I BrS ECG, HF.\nPrecaution if evidence of\nconduction disease (consider\ntemporary pacing wire).\nVT/VF, Type 1 BrS ECG,\nPVCs, QRS widening\n.150%.\nIf VT/VF, administer iv\nisoprenaline, iv sodium\nbicarbonate.\n30 min if negative\ntest; 4 h if positive\ntest.\nCath lab or\noutpatient testing\nlocation with full\nresuscitation\nequipment.\n136,138,139\nFlecainide\nSame as ajmaline.\n2 mg/kg over 10 min\n(maximum dose\n150 mg).\nRecord in standard\nand high precordial\nleads over 30 min.\nSame as ajmaline.\nSame as ajmaline.\nSame as ajmaline.\n4 h if negative test;\n24 h if positive test.\nSame as ajmaline.\n140\nEpinephrine\nCPVT and\nresuscitated CA\nwith or without\nSHD when exercise\ntest not feasible.\nFamily history of\nSADS.\nRest 10 min.\nStart at 0.025 µg/ kg/\nmin for 10 min\nincrease sequentially\nto 0.05, 0.1 and 0.2 µg/\nkg/min in 5 min steps.\n≥3 beats of PVT\nor bidirectional\nVT.\nQTc prolongation ≥480 ms.\nSystolic blood pressure ≥\n200 mmHg,\nnon-sustained VT or PVT,\n.10 PVCs /min, T-wave\nalternans, or patient\nintolerance.\nIf symptoms persist after\ndiscontinuation, iv\nmetoprolol 2.5–5 mg\nover 1 min.\n30 min.\nSame as ajmaline.\n141\nAcetylcholine\nSuspicion of\ncoronary\nvasospasm.\nIntracoronary\ninjection: RCA: 20 and\n50 µg. LCA: 20, 50,\nand 100 µg over 20 s.\n.3-min intervals\nbetween injections.\nMaximal dose of 50 µg\nin the RCA and 100 µg\nin the LCA.\nCoronary artery\nspasm visualized\nduring\nprocedure.\nLeft main stenosis .50%,\n3-vessel disease, 2-vessel\ndisease with total occlusion,\nNYHA III/IV HF, renal failure,\nsevere bronchial asthma.\nTemporary wire for\nback-up pacing.\nRisk of cardiogenic shock.\nNormal\npost-procedure\nobservational time.\nCath lab.\n142\nContinued\n4016\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nTable 7\nGenetic tests and suggested work-up of probands and relatives with primary electrical diseases\nLQTS\nBrS\nCPVT\nIdiopathic VF\nERS\nGenetic test\nClass Ia\nClass I\nClass Ia\nClass IIb\nClass IIb\nProband\nInitial clinical\ntest\nCornerstone for diagnosis\nECG\nExercise test\nECG and high precordial lead ECG\nSodium channel blockers provocative testc\nExercise test\nSee Section 5.2.3, scenario 3\nECG\nOther tests/processes\nExclude acquired\nLQTS\nExclude phenocopyb\nExclude\nphenocopyb/SHD\nHolter\nEchocardiography\nFollow-up\n1–3 years dependent on level of risk\nRelatives\nClinical\nscreening\nECG\nExercise test\n(when feasible)\nFrom birth\nECG and high precordial lead ECGs: start at 10 years\nSodium channel blockers provocative testc: start .16\nyears unless clinically indicated180,181\nECG\nExercise test\nFrom birth\nECG and high precordial\nlead ECGs\nExercise test\nEchocardiogram182\nECG\nEchocardiogram\nFollow-up\nPositive phenotype and/or\nClass IV/V variant\n1–3 years dependent on level of risk\nNegative phenotype and no\nClass IV/V variant\nDischarge\n© ESC 2022\nBrS, Brugada syndrome; CPVT, catecholaminergic polymorphic ventricular tachycardia; ECG, electrocardiogram; ERS, early repolarization syndrome; LQTS, long QT syndrome; VF, ventricular ﬁbrillation.\naIncluding neonatal genetic testing.\nbA phenocopy has characteristics of a genetic disease but is produced environmentally.\ncNot in case of a documented type 1 Brugada pattern.\nErgonovine\nSame as\nacetylcholine.\nIntracoronary\nstepwise injection:\nRCA (20–60 mg)\nLCA (20–60 mg) over\na period of 2–5 min.\nSame as\nacetylcholine\nLeft main stenosis .50%,\n3-vessel disease, 2-vessel\ndisease with total occlusion,\nNYHA III/V HF, renal failure.\nTemporary wire should\nbe placed for back-up\npacing.\nRisk of cardiogenic shock.\nSame as\nacetylcholine.\nCath lab.\n143\nAdenosine\nExclude latent\npre-excitation.\n6, 12, 18 mg boluses\nup to maximum dose\n24 mg or until AV\nblock or\npre-excitation occurs.\nIdentiﬁcation of\naccessory\npathway.\nAsthma, sinus node disease,\nallergy to adenosine.\nSide effects:\nBronchospasm,\nbradycardia, asystole, AF,\nseizure. Antagonist:\ntheophylline.\n5 min.\nSame as ajmaline.\n144\n© ESC 2022\nAF, atrial ﬁbrillation; AV, atrioventricular; BrS, Brugada syndrome; CA, cardiac arrest; CPVT, catecholaminergic polymorphic ventricular tachycardia; ECG, electrocardiogram; HF, heart failure; LCA, left coronary artery; NYHA, New York Heart\nAssociation; PVCs, premature ventricular complexes; PVT, polymorphic ventricular tachycardia; RCA, right coronary artery; SADS, sudden arrhythmic death syndrome; SHD, structural heart disease; VF, ventricular ﬁbrillation; VT, ventricular\ntachycardia.\nESC Guidelines\n4017\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n5.2. Diagnostic evaluation at ﬁrst\npresentation with ventricular\narrhythmia in patients without known\ncardiac disease\nVA and (aborted) SCD are common ﬁrst manifestations of a previ-\nously not known cardiac condition. A comprehensive diagnostic\nevaluation is provided for ﬁve frequently encountered scenarios.\n5.2.1. Scenario 1: Incidental ﬁnding of a\nnon-sustained ventricular tachycardia\nAn algorithm for the evaluation of patients presenting with an inci-\ndental ﬁnding of NSVT is presented in Figure 2.\nIncidental NSVT is a common ﬁnding during routine cardiological\nevaluation (e.g. for non-cardiac diseases, pre-initiation of oncological\ntreatments, pre-participation in sports) and monitoring before in-\nduction of anaesthesia/sedation for non-cardiac procedures.184\nPatients with incidentally found NSVT require further evaluation.\nA recent syncope suspicious for cardiac origin is a high-risk symptom\nand may prompt admission to hospital.1,185 The morphology of\nNSVT (polymorphic or monomorphic) is important to assess.\nTypical MVT morphologies (Figure 3) can suggest an idiopathic origin\nwith favourable prognosis. In contrast, short-coupled PVC initiating\nnon-sustained PVT or monomorphic NSVT with short cycle length\n(usually ,300 ms, average 245 + 28, in one series) may identify pa-\ntients at higher risk of SCD.186,187 Resting 12-lead ECG is a ﬁrst-line\nevaluation and may show signs of SHD or primary electrical diseases\n(\nESC CardioMed chapter 8.6).188 Echocardiography is the ﬁrst-\nline imaging modality that provides important information about car-\ndiac function and potential SHD (\nESC CardioMed 10.3, 10.10,\n10.12).120,189,190 Holter monitoring is useful to assess the frequency\nof NSVT and related PVCs (\nESC CardioMed chapter 8.9).191 In\naddition, an at least 3-lead Holter (V1, two inferior leads) may give a\nﬁrst estimate if NSVT/PVC are unifocal or multifocal and of the\nNSVT site(s) of origin. The latter is important if the NSVT has not\nbeen previously documented on a 12-lead ECG.192\nAn exercise test can be helpful to capture the 12-lead ECG of\nNSVT and to identify exercise-induced arrhythmias. Increasing ar-\nrhythmias with exercise, not suggestive of idiopathic origin, should\nraise suspicion of SHD and may necessitate advice to refrain from\nphysical exercise until diagnosis and initiation of appropriate treat-\nment. Underlying signiﬁcant CAD should be ruled out according to\nthe patient’s pre-test probability.\nCMR should be considered when cardiomyopathies or inﬂamma-\ntory diseases are suspected on initial evaluation (\nESC\nCardioMed chapter 10.4).193 In addition, CMR can identify areas of\nﬁbrosis as substrates of NSVT.129\n5.2.2. Scenario 2: First presentation of sustained\nmonomorphic ventricular tachycardia\nAn algorithm for the evaluation of patients presenting with a ﬁrst\nSMVT episode is presented in Figure 4.\nThe majority of patients presenting with SMVT have\nunderlying SHD. SMVT in SHD is mainly due to scar-related\nre-entry and only occasionally due to re-entry involving a\ndiseased\nconduction\nsystem\nor\ndue\nto\nfocal\nsources.\nRecommendation Table 3 — Recommendations for\nevaluation of patients presenting with newly docu-\nmented ventricular arrhythmia\nRecommendations\nClassa\nLevelb\nIn patients with newly documented VA (frequent\nPVCs, NSVT, SMVT), a baseline 12-lead ECG,\nrecording of the VA on 12-lead ECG, whenever\npossible, and an echocardiogram are\nrecommended as ﬁrst-line evaluation.\nI\nC\nIn patients with newly documented VA (frequent\nPVCs, NSVT, SMVT) and suspicion of SHD other\nthan CAD after initial evaluation, a CMR should be\nconsidered.194,195\nIIa\nB\nIn patients with an incidental ﬁnding of a NSVT,\na ≥24 h Holter ECG should be considered.\nIIa\nC\n© ESC 2022\nCAD,\ncoronary\nartery\ndisease;\nCMR,\ncardiac\nmagnetic\nresonance;\nECG,\nelectrocardiogram; NSVT, non-sustained ventricular tachycardia, PVCs, premature\nventricular\ncontractions;\nSHD,\nstructural\nheart\ndisease;\nSMVT,\nsustained\nmonomorphic ventricular tachycardia; VA, ventricular arrhythmia.\naClass of recommendation.\nbLevel of evidence.\nRecommendation Table 2 — Recommendations for\ngenetic testing\nRecommendations\nClassa\nLevelb\nGenetic testing is recommended when a condition\nis diagnosed in a living or deceased individual with\na likely genetic basis and a risk of VA and\nSCD.56,183\nI\nB\nWhen a putative causative variant is ﬁrst identiﬁed,\nevaluation for pathogenicity is recommended\nusing an internationally accepted framework.176\nI\nC\nWhen a Class IV or Class V variant has been\nidentiﬁed in a living or deceased individual with a\ncondition that carries a risk of VA and SCD,\ngenetic testing of ﬁrst-degree and symptomatic\nrelatives and obligate carriers is recommended.\nI\nC\nIt is recommended that genetic testing and\ncounselling on its potential consequences should\nbe undertaken by an expert multidisciplinary\nteam.179\nI\nC\nIt is recommended that Class III (variants of\nuncertain signiﬁcance) and Class IV variants should\nbe evaluated for segregation in families where\npossible, and the variant re-evaluated periodically.\nI\nC\nIt is not recommended to undertake genetic\ntesting in index patients with insufﬁcient evidence\nof a genetic disease.\nIII\nC\n© ESC 2022\nSCD, sudden cardiac death; VA, ventricular arrhythmia.\naClass of recommendation.\nbLevel of evidence.\n4018\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nThe diagnosis of the underlying aetiology and identiﬁcation of\npatients with idiopathic VT is important. Initial evaluation in-\ncludes a comprehensive clinical and family history, 12-lead\nECG, and echocardiography. Recording of the 12-lead VT ECG\nis indicated as it provides important information on the VT\nsite of origin. Speciﬁc VT morphologies (e.g. right ventricular\noutﬂow tract [RVOT] or fascicular origin) (Figure 3) in the ab-\nsence of a family history for cardiomyopathies and without evi-\ndence for SHD are suggestive for idiopathic VTs.196 Atypical\nECG morphologies and uncommon clinical presentations should\nraise suspicions for underlying SHD even if baseline ECG and\nechocardiogram are normal. In this scenario, additional evalu-\nation with CMR should be considered.194 Bundle branch re-\nentrant ventricular tachycardia (BBR-VT), resembling bundle\nbranch block conﬁguration on the ECG, is a feature of\nconduction impairment, e.g. in DCM, myotonic dystrophy, and\npost-cardiac valve surgery (Figure 5).\nIf initial evaluation raises suspicion of underlying CAD, a CAG can\nexclude signiﬁcant CAD. If ECG and echocardiography are suggestive\nfor a cardiomyopathy, CMR provides important diagnostic informa-\ntion on scar distribution and tissue characteristics (Section 5.1.3.4).\nWhen non-invasive evaluation is inconclusive, electroanatomical\nmapping and PES may be considered for the differential diagnosis be-\ntween idiopathic VT and early ARVC.197 Electroanatomical mapping-\nguided biopsy can be of value to provide a tissue diagnosis for ARVC\nand inﬂammatory diseases with a focal distribution (e.g. cardiac sar-\ncoidosis).198,199 In cases of suspected inﬂammatory diseases, posi-\ntron emission tomography CT (PET-CT), autoimmune serology,\nand biopsies of affected tissue are part of the diagnostic\nevaluation.200,201\nN\nN\nPatient with incidental finding of NSVT\nArrhythmic syncope or fast monomorphic NSVT\nor short coupled PVC foll\nf\nowed by polymorphic NSVT\nDischargee\nGo to section\nIdiopathic PVC/VT\nSuggestive of\nidiopathic origina\nNSVT/PVC burden >10%\n12-lead ECG\n(Class I)\nAmbulatory\nevaluation\nConsider\nadmission\nEchocardiogram\n(Class I)\n≥24 h Holter\n(Class IIa)\nSuggestive of SHDb\nSuggestive/Diagnostic of\nprimary electrical diseasec\nFurther evaluati\na on according\nto most like\nk ly diagnosis\nGo to section\nPrimary electrical disease\nY\nY\nNSVT evaluation\n(Cycle length, morpholo\n,\ngy,y\nexercise induced)\n(Class I)\nPersonal history\n(Cardiovascular r\nr isk factors,\nsymptoms, co\n,\n-morbidities,\nmedicati\na on)\nFamily history\n (SCD, prima\n,\nry electrical\ndisease, ca\n,\nrdiomyopathy)\nLaboratory\n(Electrolytes,\n(NT-)p\nT\nroBNP,P TSH/T4)\nCMR\n(Class IIa)\nExclude\nCADd\nFigure 2 Algorithm for the evaluation of patients presenting with an incidental ﬁnding of non-sustained ventricular tachycardia. CAD, coronary artery\ndisease; CMR, cardiac magnetic resonance; ECG, electrocardiogram; N, No; NSVT, non-sustained ventricular tachycardia; PVC, premature ventricular com-\nplex; SCD, sudden cardiac death; SHD, structural heart disease; Y, Yes. aECG morphology suggestive of RVOT or fascicular origin, negative family history,\nnormal 12-lead ECG, and echocardiogram. be.g. atrioventricular conduction abnormalities, Q waves, broad QRS complex, ST/T waves deviations, abnormally\nhigh or low voltages. Ventricular dysfunction/dilatation/hypertrophy/wall thinning, wall motion abnormalities, multitopic PVCs/NSVTs/increasing ventricular\narrhythmia (VA) burden with exercise. ce.g. Brugada pattern, long/short QT, polymorphic/bidirectional VA with exercise. dDiagnostic test to exclude CAD\naccording to patient proﬁle and symptoms. eConsider re-evaluation in case of new symptoms or changes in patient clinical condition.\nESC Guidelines\n4019\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n5.2.3. Scenario 3: Sudden cardiac arrest survivor\nAn algorithm for the evaluation of sudden cardiac arrest survivors is\npresented in Figure 6.\nUrgent CAG is recommended for patients presenting with ST ele-\nvation myocardial infarction (STEMI).203–206 Despite disparate ﬁndings\nof pooled data analyses,207–211 three randomized controlled trials\n(RCTs) have found no signiﬁcant beneﬁt for early CAG in cardiac ar-\nrest (CA) without ST-elevation. In case of electrical instability after\nCA, suspicious for ongoing ischaemia, this panel found a CAG indi-\ncated. Brain and chest CT scan may acutely identify non-cardiac causes\nof aborted SD,212 as well as blood test results for pertinent toxico-\nlogical analysis.213–215 Retention and storage of suitable blood samples\nwill allow subsequent diagnostic evaluation, including DNA analysis.213\nLV fascicular VT (RBBB- like, superior axis, QRS 130 ms)\nRVOT VT (LBBB-like, inferior axis, V4 transition)\nFigure 3 Typical idiopathic ventricular tachycardia morphologies. LBBB, left bundle branch block; LV, left ventricle; RBBB, right bundle branch block;\nRVOT, right ventricular outﬂow tract; VT, ventricular tachycardia.\nRecommendation Table 4 — Recommendations for\nevaluation of patients presenting with a ﬁrst episode\nof sustained monomorphic ventricular tachycardia\nRecommendations\nClassa\nLevelb\nIn patients presenting with a ﬁrst SMVT episode,\nelectrophysiological study, electroanatomical\nmapping, and mapping-guided biopsies may be\nconsidered for aetiological evaluation.197–199,202\nIIb\nC\n© ESC 2022\nSMVT, sustained monomorphic ventricular tachycardia.\naClass of recommendation.\nbLevel of evidence.\n4020\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nExclude\nCADd\nCMR\n(Class IIa)\nAutoimmune serology\nCardiac/tissue biopsy\nPET-CT\nT\nMapping-guided biopsy\n(if regional ventricular\ninvolvement)\n(Class IIb)\nGo to section\nInflammatory\ncardiac diseases\nr\nFurther evaluation\naccording to most like\nk ly\ndiagnosis\nGo to section\nARVC\nEP study and RV\nR\nelectro-anatomical mapping\n(± mapping-guided biopsy)\n(Class IIb)\nSuggestive of SHD other than CADc\nSuggestive of CADb\nSuggestive of idiopathic origina\nSuggestive of inflammatory diseaseg\nSuggestive of other cardiomyopathyf\nSuggestive of ARVC\nR\ne\nGo to section Idiopathic PVC/VT\nCAG\nCAD\npositive\nnegative\nNo CAD\nGo to section CAD\nC\nN\nY\nPatient with first SMVT episode\n12-lead ECG\n(Class I)\nEchocardiogram\n(Class I)\nVT 12-lead ECG\n(Cycle length, morpholo\n,\ngy,y\nexercise induced)\n(Class I)\nPersonal history\n(Cardiovascular risk factors,\nsymptoms, co\n,\n-morbidities,\nmedicati\na on)\nFamily history\n (SCD, prima\n,\nry electrical\ndisease, ca\n,\nrdiomyopathy)\nLaboratory\n(Electrolytes,\n(NT-)p\nT\nroBNP,P TSH/T4)\nFigure 4 Algorithm for the evaluation of patients presenting with a ﬁrst sustained monomorphic ventricular tachycardia episode. ARVC, arrhythmo-\ngenic RV cardiomyopathy; CAD, coronary artery disease; CAG, coronary angiography; CMR, cardiac magnetic resonance; ECG, electrocardiogram; EP,\nelectrophysiological; LV, left ventricular; N, No; PET-CT, positron emission tomography and computed tomography; PVC, premature ventricular com-\nplex; RV, right ventricular; SCD, sudden cardiac death; SHD, structural heart disease; SMVT, sustained monomorphic ventricular tachycardia; VT, ven-\ntricular tachycardia; Y, Yes. aECG morphology suggestive of RV outﬂow tract or fascicular origin, negative family history, normal 12-lead ECG, and\nechocardiogram. be.g. Q waves, QRS fragmentation, ST/T abnormalities, wall motion abnormalities in coronary territories. ce.g. atrioventricular (AV)\nconduction abnormalities, Q waves, broad QRS complex, T-wave inversion, abnormally high or low voltages. Ventricular dysfunction/dilatation/hyper-\ntrophy/wall thinning/wall motion abnormalities/diffuse hypokinesia. dDiagnostic test to exclude CAD according to patient proﬁle and symptoms.\neAccording to revised task force criteria.116 fe.g. AV conduction abnormalities, abnormally high or low voltages, broad QRS, ST/T wave deviations, LV\ndilatation and dysfunction, late gadolinium enhancement with non-ischaemic distribution. ge.g. AV conduction abnormalities, broad QRS, ST/T deviations,\nmultifocal PVCs, inﬂammatory hyperaemia and oedema, ﬁbrosis, LV and RV systolic dysfunction, pericardial effusion.\nESC Guidelines\n4021\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nAny ECG tracing from emergency services, as well as recordings\nfrom interrogation of cardiovascular implantable electronic devices\n(CIEDs) can also contribute to diagnosis.216–219 The resting 12-lead\nECG (including high precordial lead)220 is fundamental and should\nbe repeated regularly during recovery. Continuous heart rhythm\nmonitoring\nis\nrecommended\nuntil\ndeﬁnite\ntreatment.221,222\nEchocardiography may allow early diagnosis to identify any structural\nabnormality.222,223 Coronary imaging will be important to exclude\nCAD, dissection, or anomalies.62,224 Coronary optical coherence\ntomography and/or intravascular ultrasound may be helpful to\ncharacterize stenosis/plaque stability and underlying mechanism of\nstenosis.225 CMR has repeatedly been shown to provide signiﬁcant in-\ncremental diagnostic value, in particular for concealed cardiomyop-\nathy.131,226–228 Primary electrical diseases may be uncovered by\nprovocative manoeuvres such as sodium channel blocker chal-\nlenge,136,229–231 lying to standing ECGs,232,233 adenosine chal-\nlenge,144,234\nepinephrine\nchallenge,141,152,235–239\nergonovine/\nacetylcholine,222,240\nmental\nstress,241,242\nand\nexercise\ntesting.116,117,119,232,243 Electrophysiological study and electroa-\nnatomic mapping may be useful to provide patient-speciﬁc insights\ninto the mechanism of CA and to offer therapeutic options in\nsome patients.244–248 Genetic testing may identify a molecular\ncause of SCA by identifying pathogenic mutations in genes asso-\nciated with speciﬁc phenotypes.213,249,250\nRecommendation Table 5 — Recommendations for\nevaluation of sudden cardiac arrest survivors\nRecommendations\nClassa\nLevelb\nDiagnostic evaluation\nThe investigation of a SCA survivor without\nobvious extra-cardiac cause is recommended to\nbe overseen by a multidisciplinary team.177,251–256\nI\nB\nIn electrically unstable patients after SCA, with\nsuspicion of ongoing myocardial ischaemia, a\ncoronary angiogram is indicated.\nI\nC\nContinued\nECG during BBR-VT\nECG during sinus rhythm\nI\nII\nIII\naVR\naVL\naVF\nV1\nV4\nV5\nV6\nV2\nV3\nI\nII\nIII\naVR\naVL\naVF\nV1\nV4\nV5\nV6\nV2\nV3\nFigure 5 Bundle branch re-entrant ventricular tachycardia. BBR-VT, bundle branch re-entrant ventricular tachycardia; ECG, electrocardiogram.\n4022\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n5.2.4. Scenario 4: Sudden death victim\nAn algorithm for the evaluation of SD victims is presented in Figure 7.\nPotential genetic cardiac disease can be identiﬁed in 25–49% of\ncases of SCD in the young (,50 years of age). This may also affect\nrelatives of the deceased.25,56,59 To ﬁnd the cause of death, it is im-\nportant to collect all available data on prior symptoms, comorbid-\nities, and family history.25,56,215,262,263\nThe main role of autopsy in SD is to establish the cause of death.\nAn expert cardiac pathologist alters the initial diagnosis in 41% of\ncases, highlighting the need for expert evaluation.263–265 Inherited\ncardiac diseases identiﬁed at autopsy include cardiomyopathies\n(HCM, DCM, ARVC) and premature CAD.25,27,56,266 A toxicology\nscreen can reveal drug overdose or polypharmacy in 31–56% of\nyoung SD cases.267,268 In autopsy-negative cases with negative toxi-\ncology, the term sudden arrhythmic death syndrome (SADS) may be\napplied\nand\nprimary\nelectrical\ndiseases\nare\npotential\ncauses.56,183,223,253 Retaining tissue for DNA extraction is important\nfor post-mortem genetic analysis, where the yield can be as high as\none out of three.183,269,270\nClinical evaluation of ﬁrst-degree relatives is important if the cause\nof death after autopsy is unknown (Section 5.2.5, scenario 5) or\nsuspected to be inherited, with a reported combined diagnostic yield\nof genetic and clinical evaluation of 18–53%.252,266,271 Post-mortem\ngenetic testing on the deceased, targeted to the cause of death, iden-\ntiﬁed mutations in around one-third of cases.56,266,269\nIn SCA survivors, brain/chest CT scan should be\nconsidered when patient characteristics, ECG, and\nechocardiography are not consistent with a cardiac\ncause.212,257\nIIa\nC\nIn SCA survivors, collection of blood samples at\npresentation is recommended for potential\ntoxicology and genetic testing.56,214\nI\nB\nRetrieval of recordings from CIEDs and wearable\nmonitors is recommended for all SCA\nsurvivors.217,218\nI\nB\nIn SCA survivors, repeated 12-lead ECGs during\nstable rhythm (including high precordial lead\nECG), as well as continuous cardiac monitoring,\nare recommended.220,222\nI\nB\nEchocardiography is recommended for evaluation of\ncardiac structure and function in all SCA survivors.\nI\nC\nCoronary imaging and CMR with LGE are\nrecommended for evaluation of cardiac structure\nand function in all SCA survivors without a clear\nunderlying cause.62,222,223,226\nI\nB\nSodium channel blocker test and exercise testing\nis recommended in SCA survivors without a clear\nunderlying cause.117,222,258–260\nI\nB\nIn SCA survivors, ergonovine, acetylcholine, or\nhyperventilation testing may be considered for the\ndiagnosis of coronary vasospasm.240,261\nIIb\nB\n© ESC 2022\nCIEDs, cardiac insertable electronic devices; CMR, cardiac magnetic resonance; CT,\ncomputed tomography; ECG, electrocardiogram; LGE, late gadolinium enhancement;\nSCA, sudden cardiac arrest.\naClass of recommendation.\nbLevel of evidence.\nRecommendation Table 6 — Recommendations for\nevaluation of sudden death victims\nRecommendations\nClassa\nLevelb\nInvestigation of unexpected SD, especially in case\nof suspicion of inherited disease, should be made a\npublic health priority.20,25,56\nI\nB\nIn cases of SD, it is recommended to collect a\ndetailed description of circumstances of death,\nsymptoms prior to death, the family history, and\nto review prior medical ﬁles.25,56\nI\nB\nA comprehensive autopsy is recommended,\nideally, in all cases of unexpected SD, and always in\nthose ,50 years of age.183,264,265,267,269,270\nI\nB\nIn cases of SCD, it is recommended to retain\nsamples suitable for DNA extraction and consult a\ncardiac pathologist when an inherited cause is\nsuspected or the cause of death\nunexplained.264,265\nI\nB\nToxicology screens are recommended in SD cases\nwith uncertain cause of death.267,268\nI\nB\nFor SCD where the cause is known or suspected\nto be heritable, genetic testing targeted to the\ncause is recommended.56,266,269\nI\nB\nFollowing SADS, post-mortem genetic testing\ntargeted to primary electrical disease is\nrecommended when the decedent is young (,50)\nand/or the circumstances and/or family history\nsupport a primary electrical disease.56,183,223\nI\nB\nWhen an autopsy diagnoses possible heritable\ncardiac disease, it is recommended to refer\nﬁrst-degree relatives for cardiac assessment in a\nspecialized clinic.271,272\nI\nB\nIn non-autopsied cases of SD where inherited\ncardiac disease is suspected, it is recommended to\nrefer ﬁrst-degree relatives for cardiac assessment\nin a specialized clinic.223,253,273\nI\nB\nFollowing SADS, post-mortem genetic testing in\nthe decedent for additional genes may be\nconsidered.\nIIb\nC\nFollowing SADS, hypothesis-free post-mortem\ngenetic testing using exome or genome\nsequencing is not recommended.274,275\nIII\nB\n© ESC 2022\nDNA, deoxyribonucleic acid; SADS, sudden arrhythmic death syndrome; SCD, sudden\ncardiac death; SD, sudden death.\naClass of recommendation.\nbLevel of evidence.\nESC Guidelines\n4023\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n5.2.5. Scenario 5: Relatives of sudden arrhythmic\ndeath syndrome decedents\nAn algorithm for the evaluation of relatives of SADS decedents is\npresented in Figure 8.\nStudies evaluating families of SADS decedents have identi-\nﬁed underlying genetic heart disease in relatives that is pre-\nsumed to be the cause of death in the absence of other\nﬁndings. The overall diagnostic yield ranged from 18 to 53%,\ndepending on population and clinical investigative proto-\ncols.276 Aetiologies included LQTS, BrS, CPVT, and other dis-\norders, such as cardiomyopathy.276 All study protocols relied\nupon a similar initial approach of evaluating the decedent’s\npathological reports, medical history, and circumstances of\ndeath, and then offering clinical evaluation to relatives with a min-\nimum of personal history, family history, physical examination,\nECG and exercise test, and echocardiography.223,252,253,277–282\n12-lead ECG (Class I)\nSTEMI\nSuspicious for extraca\nf\nrdiac cause\nExtracardiac cause identified\nPreexcitation or suggestive of\nprimary electrical disease\nNon-cardiac\nBrain and chest CT scan (Class IIa)\nAcute culprit lesion\nFurther evaluation according\nto STEMI guidelines\nElectrical instability\nsuspicious for on\nf\ngoing\nmyocardial ischaemia\nUrgent CAGa (Class I)\nN\nN\nN\nN\nN\nN\nSCA survivor\nY\nY\nY\nY\nY\nPreexcited AF\nor probable primary\nelectrical diseaseb, c\n,\nY\nEvaluation of patient\ncharacteristics and\ncircumstances of SCA\n(Class I)\nEchocardiogram\n(Class I)\nCollect blood sample for t\nf\noxicology\nand genetic testing (Class I)\nReview/Repeat ECG (Class I)\nFigure 6 Part One. Algorithm for the evaluation of sudden cardiac arrest survivors.\n4024\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nCAD/coronary anomaly\nLGE on CMR\nPrimary electrical disease\nEchocardiogram suggestive of CAD/\ncardiomyopathy/valvular heart disease/other SHD\nN\nCardiac CT/CAG (if previously not performed)\nf\n(Class I)\nN\nHigh lead and repeated 12-lead ECGs\n(Class I)\nN\nCMR\n(Class I)\nN\nVasospasm\nV\nY\nFurther evaluation\naccording to most\nlike\nk ly diagnosis.\nIf SMVT,T go to\nscenario 2:\nPatient with\nP\nfif rst\nSMVT episoded\nCAD/Coronary\nanomaly\nY\nPrimary\nelectrical disease\nY\nY\nY\nY\nY\nN\nPositive\nIdiopathicVF\nTest\nT\nfor co\nf\nronary vasospam\n(Class IIb)\nN\nN\nPrimary electrical disease\nN\nSuspicion of vasospasme\nExercise test (Class I)\nSodium channel blocker test (Class I)\nk\nFigure 6 Part Two. Algorithm for the evaluation of sudden cardiac arrest survivors. AF, atrial ﬁbrillation; CAD, coronary artery disease; CAG, cor-\nonary angiogram; CMR, cardiac magnetic resonance; CT, computed tomography; ECG, electrocardiogram; LGE, late gadolinium enhancement; N, No;\nSCA, sudden cardiac arrest; SHD, structural heart disease; SMVT, sustained monomorphic ventricular tachycardia; STEMI, ST elevation myocardial in-\nfarction; VF, ventricular ﬁbrillation; Y, Yes. aThe 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with\nST-segment elevation.3 bRule out SHD according to patient age and characteristics; QT duration needs to be reassessed several days after arrest.\ncConsider cardiac CT/CAG depending on patient characteristics and clinical context. dLeft ventricular function on echocardiogram needs to be reassessed\nseveral days after arrest to exclude stunning as cause of systolic dysfunction. eIn case of high clinical suspicion (typical symptoms and transient ST elevation\nduring monitoring), it can be considered to test for coronary vasospasm earlier.\nESC Guidelines\n4025\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nSudden death victim\nSav\na e tissue for potential genetic testing\nf\n(Class I)\nComprehensive autopsya\n(Class I)\nRefer first-deg\nf\nree relatives\nfor ca\nf\nrdiac assessment\n(Class I)\nPost-mortem genetic testing\nwith genetic counsellingc \n(Class I)\nSav\na e blood for potential t\nf\noxicology testing\n(Class I)\nTargeted genetic testing\nT\n(Class I)\nRefer first-deg\nf\nree relatives\nfor ca\nf\nrdiac assessment\n(Class I)\nTo\nT xicology testing\n(Class I)\nCollect detailed description about:\nNon-cardiac cause of SD\nSCD of non-inherited cause\nCause diagnosed\nNegative autopsy\nGo to Scenario 5:\nRelatives of unexplained SD decedent\nSADS decedent\nage <50 years or circumstances or\nfamily history suggestive\nof heritable disease\nSCD of suspected inherited causeb\nCause of death not due\nto drug overdose\nSudden arrhythmic death syndrome\n(SADS)\nDrug overdose\n(Class I)\nCircumstances of death\nSymptoms and prior history of deceased\nFamily history\nFigure 7 Algorithm for the evaluation of sudden death victims. SADS, sudden arrhythmic death syndrome; SCD, sudden cardiac death; SD, sudden\ndeath. aAutopsy is recommended, ideally in all cases of unexpected SD and always in those under 50 years. Autopsy should include full macroscopic\nexamination and histopathology of all organs. The heart should ideally be examined by an expert cardiac pathologist. Samples suitable for DNA extraction\nshould be retained when inherited causes or unexplained death are suspected. bBased on all circumstances, this includes negative autopsies, autopsies with\nuncertain ﬁndings, non-ischaemic cardiomyopathies, coronary artery disease where familial hypercholesterolaemia is suspected and thoracic aortic dis-\nsections. cAfter informed consent of relatives.\n4026\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nWhere they diverged was the frequency of usage of additional\ntests such as high-lead ECGs, Holter monitoring, signal-averaged\nECG, CMR, and provocative testing.135 Sodium channel blocker\ndrug challenge and high-lead ECGs systematically performed in\nSADS relatives provided a yield of 28% BrS diagnoses in one\nstudy281; however, there are concerns about false positives.139\nFurthermore, epinephrine challenge has not been studied sys-\ntematically in SADS families but, in the opinion of this panel,\nmay be of utility in CPVT-suspected patients who are unable\nto exercise.137\nRecent data indicated at least a 13% genetic yield in SADS\ncases.135,178,183,276,283 Routine follow-up of families without a diag-\nnosis yields little in new diagnoses,284 although children of decedents\nmay be followed for age-penetrant disease until adulthood.181\nIf an autopsy is ambiguous, or if an autopsy was not undertaken in\na young SCD case with family or personal history suspicious for in-\nherited heart disease, then the yield of familial evaluation was similar\nto that in clear SADS cases.223,253,271\n6. Therapies for ventricular\narrhythmias. General aspects\n6.1. Acute management\n6.1.1. Treatment of reversible causes\nReversible causes may account for up to 50% of SCA.285,286 However,\nmost of the time it is difﬁcult to determine the exact underlying cause of\nSCA and whether it is reversible. A comprehensive evaluation of pa-\ntients with SCA is mandatory if the underlying cardiac disease is un-\nknown or disease progression is suspected (Section 5.2.3, scenario 3).\nElectrolyte imbalances, such as hypokalaemia, may trigger VA, and a ra-\npid rise in extracellular potassium may lead to asystole.287–289 Other fac-\ntors such as bradycardia, ischaemia, coronary spasm, thrombosis, fever,\nacute starvation, and dieting may contribute to the occurrence of VA.\n290–292 Acute correction of these reversible factors is recommended.\nDrug-induced arrhythmias should be suspected in patients being\ntreated with agents known to alter the electrical properties of the heart\n(e.g. inducing QRS and/or QT prolongation) or causing electrolyte ab-\nnormalities (e.g. thiazide and loop diuretics). When drug-induced ar-\nrhythmias are presumed, any offending drug needs to be withdrawn\nand substances that are known to prolong QT (e.g. sotalol) should\nbe avoided.293,294 Hypomagnesaemia and/or hypokalaemia may be as-\nsociated with Torsades de pointes (TdP). Intravenous magnesium is an\neffective therapy for TdP even in the absence of hypomagnesaemia.295\nIn refractory cases of recurrent TdP in the setting of acquired long QT,\nthe arrhythmia can be suppressed by increasing the underlying heart\nrate using isoproterenol (isoprenaline) or transvenous pacing.\nPatients who survive SCA in the context of a presumed reversible\ncause may have a high mortality rate.286 In a recent large observational\nstudy296 on survivors of SCA attributed to a reversible and correctable\ncause, subsequent ICD implantation was associated with lower all-cause\nmortality except for aborted CA occurring in the presence of acute\nmyocardial infarction (MI). Thus, the need for prophylactic ICD implant-\nation should be considered based on the underlying cardiac disease and\nan individual evaluation of the future risk of life-threatening VA.\nRecommendation Table 7 — Recommendations for\nevaluation of relatives of sudden arrhythmic death\nsyndrome decedents\nRecommendations\nClassa\nLevelb\nFamilial evaluation of SADS decedents is\nrecommended:\n• for ﬁrst-degree relatives\n• for relatives who must carry a mutation based\non analysis of the family history\n• for relatives with suspicious symptoms\n• when the decedent’s age is ,50 years, or if\nthere is other circumstantial data or family\nhistory to suggest heritable\ndisease.223,252,253,277,281\nI\nB\nFamilial evaluation of SADS decedents is\nrecommended to include genetic testing when\npost-mortem genetic testing in a SADS decedent\ndetects a pathogenic mutation.183,253,277,281\nI\nB\nBaseline familial evaluation of SADS decedents is\nrecommended to include taking a medical history\nand performing physical examination, standard and\nhigh precordial lead ECG, echocardiography, and\nexercise testing.223,252,253,277,281\nI\nB\nIn SADS families without a diagnosis after clinical\nevaluation, follow-up is recommended for\nchildren of decedents until they reach\nadulthood.181,284\nI\nC\nPharmacological testing with a sodium channel\nblocker should be considered in relatives of SADS\ndecedents who are 16 years or older when\nbaseline testing and/or proband ﬁndings increase\nthe suspicion of BrS.277,281\nIIa\nB\nContinued\nAmbulatory cardiac rhythm monitoring and CMR\nmay be considered in relatives of SADS\ndecedents.223,253,277,281\nIIb\nC\nPharmacological testing including epinephrine\nchallenge (if exercise testing is impractical) and\nsodium channel blocker challenge may be\nconsidered in ﬁrst-degree relatives of SADS\ndecedents with normal baseline testing.223,281\nIIb\nB\nIn SADS families without a diagnosis after clinical\nevaluation, follow-up is not recommended for\nasymptomatic adults who can be discharged with\nadvice to return if they develop symptoms or if\nthe family history changes.181,284\nIII\nC\n© ESC 2022\nBrS, Brugada syndrome; CMR, cardiac magnetic resonance; ECG, electrocardiogram;\nSADS, sudden arrhythmic death syndrome.\naClass of recommendation.\nbLevel of evidence.\nESC Guidelines\n4027\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 18",
          "page": 18,
          "content": "Recommendations | Classa | Levelb\nIt is recommended that public access defibrillation\nbe available at sites where cardiac arrest is more\nlikely to occur.c,90–92 | I | B\nPrompt CPR by bystanders is recommended at\nOHCA.93–95 | I | B\nIt is recommended to promote community\ntraining in basic life support to increase bystander\nCPR rate and AED use.93,97,104 | I | B\nMobile phone-based alerting of basic life\nsupport-trained bystander volunteers to\nassist nearby OHCA victims should be\nconsidered.101–103,105 | IIa | B",
          "rows": 5,
          "cols": 3
        },
        {
          "title": "Table on page 20",
          "page": 20,
          "content": "Ref | 136,138,139 | 140 | 141 | 142\nLocation | Cath lab or outpatient testing location with full resuscitation equipment. | Same as ajmaline. | Same as ajmaline. | Cath lab.\nObservation times | 30 min if negative test; 4 h if positive test. | 4 h if negative test; 24 h if positive test. | 30 min. | Normal post-procedure observational time.\nCriteria to stop test, counselling and management | VT/VF, Type 1 BrS ECG, PVCs, QRS widening .150%. If VT/VF, administer iv isoprenaline, iv sodium bicarbonate. | Same as ajmaline. | ≥ Systolic blood pressure 200 mmHg, non-sustained VT or PVT, .10 PVCs /min, T-wave alternans, or patient intolerance. If symptoms persist after discontinuation, iv metoprolol 2.5–5 mg over 1 min. | Temporary wire for back-up pacing. Risk of cardiogenic shock.\nContraindications | Type I BrS ECG, HF. Precaution if evidence of conduction disease (consider temporary pacing wire). | Same as ajmaline. | QTc prolongation ≥480 ms. | Left main stenosis .50%, 3-vessel disease, 2-vessel disease with total occlusion, NYHA III/IV HF, renal failure, severe bronchial asthma.\nPositive test | BrS type 1 ECG. | Same as ajmaline. | ≥3 beats of PVT or bidirectional VT. | Coronary artery spasm visualized during procedure.\nProtocols Dose/infusion rate/duration | 1 mg/kg over 5–10 min (maximum dose 100 mg) or 1 mg/kg at 10 mg/min. Record in standard and high precordial leads over 30 min. | 2 mg/kg over 10 min (maximum dose 150 mg). Record in standard and high precordial leads over 30 min. | Rest 10 min. Start at 0.025 µg/ kg/ min for 10 min increase sequentially to 0.05, 0.1 and 0.2 µg/ kg/min in 5 min steps. | Intracoronary injection: RCA: 20 and 50 µg. LCA: 20, 50, and 100 µg over 20 s. .3-min intervals between injections. Maximal dose of 50 µg in the RCA and 100 µg in the LCA.\nIndication | Family history of BrS or SADS. Resuscitated CA without SHD. | Same as ajmaline. | CPVT and resuscitated CA with or without SHD when exercise test not feasible. Family history of SADS. | Suspicion of coronary vasospasm.\nDiagnostic test | Ajmaline | Flecainide | Epinephrine | Acetylcholine",
          "rows": 9,
          "cols": 5
        },
        {
          "title": "Table on page 21",
          "page": 21,
          "content": "143 | 144\nCath lab. | Same as ajmaline.\nSame as acetylcholine. | 5 min.\nTemporary wire should be placed for back-up pacing. Risk of cardiogenic shock. | Side effects: Bronchospasm, bradycardia, asystole, AF, seizure. Antagonist: theophylline.\nLeft main stenosis .50%, 3-vessel disease, 2-vessel disease with total occlusion, NYHA III/V HF, renal failure. | Asthma, sinus node disease, allergy to adenosine.\nSame as acetylcholine | Identification of accessory pathway.\nIntracoronary stepwise injection: RCA (20–60 mg) LCA (20–60 mg) over a period of 2–5 min. | 6, 12, 18 mg boluses up to maximum dose 24 mg or until AV block or pre-excitation occurs.\nSame as acetylcholine. | Exclude latent pre-excitation.\nErgonovine | Adenosine",
          "rows": 9,
          "cols": 2
        },
        {
          "title": "Table on page 21",
          "page": 21,
          "content": "ERS | Class IIb | ECG | Holter Echocardiography | 1–3 years dependent on level of risk | ECG Echocardiogram | 1–3 years dependent on level of risk | Discharge\nIdiopathic VF | Class IIb | See Section 5.2.3, scenario 3 |  |  | ECG and high precordial lead ECGs Exercise test Echocardiogram182 |  | \nCPVT | Class Ia | Exercise test | Exclude phenocopyb/SHD |  | ECG Exercise test From birth |  | \nBrS | Class I | ECG and high precordial lead ECG Sodium channel blockers provocative testc | Exclude phenocopyb |  | ECG and high precordial lead ECGs: start at 10 years Sodium channel blockers provocative testc: start .16 years unless clinically indicated180,181 |  | \nLQTS | Class Ia | ECG Exercise test | Exclude acquired LQTS |  | ECG Exercise test (when feasible) From birth |  | \n | Genetic test | Cornerstone for diagnosis | Other tests/processes |  |  | Positive phenotype and/or Class IV/V variant | Negative phenotype and no Class IV/V variant\n |  | Initial clinical test |  | Follow-up | Clinical screening | Follow-up | \n |  | Proband |  |  | Relatives |  | ",
          "rows": 8,
          "cols": 8
        },
        {
          "title": "Table on page 22",
          "page": 22,
          "content": "Recommendations | Classa | Levelb\nGenetic testing is recommended when a condition\nis diagnosed in a living or deceased individual with\na likely genetic basis and a risk of VA and\nSCD.56,183 | I | B\nWhen a putative causative variant is first identified,\nevaluation for pathogenicity is recommended\nusing an internationally accepted framework.176 | I | C\nWhen a Class IV or Class V variant has been\nidentified in a living or deceased individual with a\ncondition that carries a risk of VA and SCD,\ngenetic testing of first-degree and symptomatic\nrelatives and obligate carriers is recommended. | I | C\nIt is recommended that genetic testing and\ncounselling on its potential consequences should\nbe undertaken by an expert multidisciplinary\nteam.179 | I | C\nIt is recommended that Class III (variants of\nuncertain significance) and Class IV variants should\nbe evaluated for segregation in families where\npossible, and the variant re-evaluated periodically. | I | C\nIt is not recommended to undertake genetic\ntesting in index patients with insufficient evidence\nof a genetic disease. | III | C",
          "rows": 7,
          "cols": 3
        },
        {
          "title": "Table on page 22",
          "page": 22,
          "content": "Recommendations | Classa | Levelb\nIn patients with newly documented VA (frequent\nPVCs, NSVT, SMVT), a baseline 12-lead ECG,\nrecording of the VA on 12-lead ECG, whenever\npossible, and an echocardiogram are\nrecommended as first-line evaluation. | I | C\nIn patients with newly documented VA (frequent\nPVCs, NSVT, SMVT) and suspicion of SHD other\nthan CAD after initial evaluation, a CMR should be\nconsidered.194,195 | IIa | B\nIn patients with an incidental finding of a NSVT,\na ≥24 h Holter ECG should be considered. | IIa | C",
          "rows": 4,
          "cols": 3
        },
        {
          "title": "Table on page 24",
          "page": 24,
          "content": "Recommendations | Classa | Levelb\nIn patients presenting with a first SMVT episode,\nelectrophysiological study, electroanatomical\nmapping, and mapping-guided biopsies may be\nconsidered for aetiological evaluation.197–199,202 | IIb | C",
          "rows": 2,
          "cols": 3
        },
        {
          "title": "Table on page 26",
          "page": 26,
          "content": "Recommendations |  | Classa | Levelb | \n | Diagnostic evaluation |  |  | \nThe investigation of a SCA survivor without\nobvious extra-cardiac cause is recommended to\nbe overseen by a multidisciplinary team.177,251–256 |  | I | B | \nIn electrically unstable patients after SCA, with\nsuspicion of ongoing myocardial ischaemia, a\ncoronary angiogram is indicated. |  | I | C | ",
          "rows": 4,
          "cols": 5
        },
        {
          "title": "Table on page 27",
          "page": 27,
          "content": "In SCA survivors, brain/chest CT scan should be\nconsidered when patient characteristics, ECG, and\nechocardiography are not consistent with a cardiac\ncause.212,257 | IIa | C\nIn SCA survivors, collection of blood samples at\npresentation is recommended for potential\ntoxicology and genetic testing.56,214 | I | B\nRetrieval of recordings from CIEDs and wearable\nmonitors is recommended for all SCA\nsurvivors.217,218 | I | B\nIn SCA survivors, repeated 12-lead ECGs during\nstable rhythm (including high precordial lead\nECG), as well as continuous cardiac monitoring,\nare recommended.220,222 | I | B\nEchocardiography is recommended for evaluation of\ncardiac structure and function in all SCA survivors. | I | C\nCoronary imaging and CMR with LGE are\nrecommended for evaluation of cardiac structure\nand function in all SCA survivors without a clear\nunderlying cause.62,222,223,226 | I | B\nSodium channel blocker test and exercise testing\nis recommended in SCA survivors without a clear\nunderlying cause.117,222,258–260 | I | B\nIn SCA survivors, ergonovine, acetylcholine, or\nhyperventilation testing may be considered for the\ndiagnosis of coronary vasospasm.240,261 | IIb | B",
          "rows": 8,
          "cols": 3
        },
        {
          "title": "Table on page 27",
          "page": 27,
          "content": "Recommendations | Classa | Levelb\nInvestigation of unexpected SD, especially in case\nof suspicion of inherited disease, should be made a\npublic health priority.20,25,56 | I | B\nIn cases of SD, it is recommended to collect a\ndetailed description of circumstances of death,\nsymptoms prior to death, the family history, and\nto review prior medical files.25,56 | I | B\nA comprehensive autopsy is recommended,\nideally, in all cases of unexpected SD, and always in\nthose ,50 years of age.183,264,265,267,269,270 | I | B\nIn cases of SCD, it is recommended to retain\nsamples suitable for DNA extraction and consult a\ncardiac pathologist when an inherited cause is\nsuspected or the cause of death\nunexplained.264,265 | I | B\nToxicology screens are recommended in SD cases\nwith uncertain cause of death.267,268 | I | B\nFor SCD where the cause is known or suspected\nto be heritable, genetic testing targeted to the\ncause is recommended.56,266,269 | I | B\nFollowing SADS, post-mortem genetic testing\ntargeted to primary electrical disease is\nrecommended when the decedent is young (,50)\nand/or the circumstances and/or family history\nsupport a primary electrical disease.56,183,223 | I | B\nWhen an autopsy diagnoses possible heritable\ncardiac disease, it is recommended to refer\nfirst-degree relatives for cardiac assessment in a\nspecialized clinic.271,272 | I | B\nIn non-autopsied cases of SD where inherited\ncardiac disease is suspected, it is recommended to\nrefer first-degree relatives for cardiac assessment\nin a specialized clinic.223,253,273 | I | B\nFollowing SADS, post-mortem genetic testing in\nthe decedent for additional genes may be\nconsidered. | IIb | C\nFollowing SADS, hypothesis-free post-mortem\ngenetic testing using exome or genome\nsequencing is not recommended.274,275 | III | B",
          "rows": 12,
          "cols": 3
        },
        {
          "title": "Table on page 31",
          "page": 31,
          "content": "Ambulatory cardiac rhythm monitoring and CMR\nmay be considered in relatives of SADS\ndecedents.223,253,277,281 | IIb | C\nPharmacological testing including epinephrine\nchallenge (if exercise testing is impractical) and\nsodium channel blocker challenge may be\nconsidered in first-degree relatives of SADS\ndecedents with normal baseline testing.223,281 | IIb | B\nIn SADS families without a diagnosis after clinical\nevaluation, follow-up is not recommended for\nasymptomatic adults who can be discharged with\nadvice to return if they develop symptoms or if\nthe family history changes.181,284 | III | C",
          "rows": 3,
          "cols": 3
        },
        {
          "title": "Table on page 31",
          "page": 31,
          "content": "Recommendations | Classa | Levelb\nFamilial evaluation of SADS decedents is\nrecommended:\n• for first-degree relatives\n• for relatives who must carry a mutation based\non analysis of the family history\n• for relatives with suspicious symptoms\n• when the decedent’s age is ,50 years, or if\nthere is other circumstantial data or family\nhistory to suggest heritable\ndisease.223,252,253,277,281 | I | B\nFamilial evaluation of SADS decedents is\nrecommended to include genetic testing when\npost-mortem genetic testing in a SADS decedent\ndetects a pathogenic mutation.183,253,277,281 | I | B\nBaseline familial evaluation of SADS decedents is\nrecommended to include taking a medical history\nand performing physical examination, standard and\nhigh precordial lead ECG, echocardiography, and\nexercise testing.223,252,253,277,281 | I | B\nIn SADS families without a diagnosis after clinical\nevaluation, follow-up is recommended for\nchildren of decedents until they reach\nadulthood.181,284 | I | C\nPharmacological testing with a sodium channel\nblocker should be considered in relatives of SADS\ndecedents who are 16 years or older when\nbaseline testing and/or proband findings increase\nthe suspicion of BrS.277,281 | IIa | B",
          "rows": 6,
          "cols": 3
        }
      ],
      "keywords": [
        "evaluation",
        "ct",
        "general",
        "monitoring",
        "heart failure",
        "pacemaker",
        "risk",
        "aspects",
        "treatment",
        "icd",
        "diagnosis"
      ]
    },
    {
      "number": "8",
      "title": "6. Therapies for ventricular arrhythmias. General aspects",
      "start_page": 31,
      "end_page": 45,
      "content": "Where they diverged was the frequency of usage of additional\ntests such as high-lead ECGs, Holter monitoring, signal-averaged\nECG, CMR, and provocative testing.135 Sodium channel blocker\ndrug challenge and high-lead ECGs systematically performed in\nSADS relatives provided a yield of 28% BrS diagnoses in one\nstudy281; however, there are concerns about false positives.139\nFurthermore, epinephrine challenge has not been studied sys-\ntematically in SADS families but, in the opinion of this panel,\nmay be of utility in CPVT-suspected patients who are unable\nto exercise.137\nRecent data indicated at least a 13% genetic yield in SADS\ncases.135,178,183,276,283 Routine follow-up of families without a diag-\nnosis yields little in new diagnoses,284 although children of decedents\nmay be followed for age-penetrant disease until adulthood.181\nIf an autopsy is ambiguous, or if an autopsy was not undertaken in\na young SCD case with family or personal history suspicious for in-\nherited heart disease, then the yield of familial evaluation was similar\nto that in clear SADS cases.223,253,271\n6. Therapies for ventricular\narrhythmias. General aspects\n6.1. Acute management\n6.1.1. Treatment of reversible causes\nReversible causes may account for up to 50% of SCA.285,286 However,\nmost of the time it is difﬁcult to determine the exact underlying cause of\nSCA and whether it is reversible. A comprehensive evaluation of pa-\ntients with SCA is mandatory if the underlying cardiac disease is un-\nknown or disease progression is suspected (Section 5.2.3, scenario 3).\nElectrolyte imbalances, such as hypokalaemia, may trigger VA, and a ra-\npid rise in extracellular potassium may lead to asystole.287–289 Other fac-\ntors such as bradycardia, ischaemia, coronary spasm, thrombosis, fever,\nacute starvation, and dieting may contribute to the occurrence of VA.\n290–292 Acute correction of these reversible factors is recommended.\nDrug-induced arrhythmias should be suspected in patients being\ntreated with agents known to alter the electrical properties of the heart\n(e.g. inducing QRS and/or QT prolongation) or causing electrolyte ab-\nnormalities (e.g. thiazide and loop diuretics). When drug-induced ar-\nrhythmias are presumed, any offending drug needs to be withdrawn\nand substances that are known to prolong QT (e.g. sotalol) should\nbe avoided.293,294 Hypomagnesaemia and/or hypokalaemia may be as-\nsociated with Torsades de pointes (TdP). Intravenous magnesium is an\neffective therapy for TdP even in the absence of hypomagnesaemia.295\nIn refractory cases of recurrent TdP in the setting of acquired long QT,\nthe arrhythmia can be suppressed by increasing the underlying heart\nrate using isoproterenol (isoprenaline) or transvenous pacing.\nPatients who survive SCA in the context of a presumed reversible\ncause may have a high mortality rate.286 In a recent large observational\nstudy296 on survivors of SCA attributed to a reversible and correctable\ncause, subsequent ICD implantation was associated with lower all-cause\nmortality except for aborted CA occurring in the presence of acute\nmyocardial infarction (MI). Thus, the need for prophylactic ICD implant-\nation should be considered based on the underlying cardiac disease and\nan individual evaluation of the future risk of life-threatening VA.\nRecommendation Table 7 — Recommendations for\nevaluation of relatives of sudden arrhythmic death\nsyndrome decedents\nRecommendations\nClassa\nLevelb\nFamilial evaluation of SADS decedents is\nrecommended:\n• for ﬁrst-degree relatives\n• for relatives who must carry a mutation based\non analysis of the family history\n• for relatives with suspicious symptoms\n• when the decedent’s age is ,50 years, or if\nthere is other circumstantial data or family\nhistory to suggest heritable\ndisease.223,252,253,277,281\nI\nB\nFamilial evaluation of SADS decedents is\nrecommended to include genetic testing when\npost-mortem genetic testing in a SADS decedent\ndetects a pathogenic mutation.183,253,277,281\nI\nB\nBaseline familial evaluation of SADS decedents is\nrecommended to include taking a medical history\nand performing physical examination, standard and\nhigh precordial lead ECG, echocardiography, and\nexercise testing.223,252,253,277,281\nI\nB\nIn SADS families without a diagnosis after clinical\nevaluation, follow-up is recommended for\nchildren of decedents until they reach\nadulthood.181,284\nI\nC\nPharmacological testing with a sodium channel\nblocker should be considered in relatives of SADS\ndecedents who are 16 years or older when\nbaseline testing and/or proband ﬁndings increase\nthe suspicion of BrS.277,281\nIIa\nB\nContinued\nAmbulatory cardiac rhythm monitoring and CMR\nmay be considered in relatives of SADS\ndecedents.223,253,277,281\nIIb\nC\nPharmacological testing including epinephrine\nchallenge (if exercise testing is impractical) and\nsodium channel blocker challenge may be\nconsidered in ﬁrst-degree relatives of SADS\ndecedents with normal baseline testing.223,281\nIIb\nB\nIn SADS families without a diagnosis after clinical\nevaluation, follow-up is not recommended for\nasymptomatic adults who can be discharged with\nadvice to return if they develop symptoms or if\nthe family history changes.181,284\nIII\nC\n© ESC 2022\nBrS, Brugada syndrome; CMR, cardiac magnetic resonance; ECG, electrocardiogram;\nSADS, sudden arrhythmic death syndrome.\naClass of recommendation.\nbLevel of evidence.\nESC Guidelines\n4027\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nDiagnosis\nN\nDiagnosis\nN\nDiagnosis\nN\nRelatives of unexplained sudden death decedent\nMedical history\nPhysical examination\nStandard and high\nprecordial lead ECG\nEchocardiography\nExercise testing\nClinical and/or\ngenetic diagnosis\nManage relatives\naccording to condition\nAmbulatory cardiac rhythm\nmonitoring and CMR\n(Class IIb)\nFollow-up for child\nf\nren\nof decedent\nDischarge asymptomatic adultsc\n(Class I)\nNon-autopsied\nsudden death decedent\nwith young age, fami\n,\nly history of\nSCD or circumstances\nsuggestive of heritable heart disease\nSADS decedent\nGenetic testing negative\nor not performed\nf\n(age <50 years or circumstances or\nfamily history suggestive\nof heritable disease)\nSADS decedent\nPathogenic mutation identified\nFamilial evaluation in\nfirst-degree relatives,\nor relatives with suspicious\nsymptoms\n(Class I)\n(Class I)\nY\nY\nY\nFamilial evaluation in\nfirst-degree relatives,\nobligate carriers or relatives\nwith suspicious symptoms\naccording to condition\n(Class I)\nGenetic counselling and\ncascade testing for \nf\nrelatives\n(Class I)\nSodium channel\nblocker test\nk\na\n(Class IIa)\nEpinephrine testb\n(Class IIb)\nFigure 8 Algorithm for the evaluation of relatives of unexplained sudden death decedents. CMR, cardiac magnetic resonance; ECG, electrocardiogram;\nN, No; SADS, sudden arrhythmic death syndrome; SCD, sudden cardiac death; Y, Yes. aOver 16 years old + any suspicions for Brugada syndrome on\ntests or decedent circumstances of death. bIf exercise is not feasible. cRe-evaluate if change in family history or new symptoms.\n4028\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n6.1.2. Acute management of sustained\nmonomorphic ventricular tachycardia\nPatients presenting with SMVT should be treated according to symp-\ntoms and aetiology (Figure 9). Patients presenting with haemodynam-\nic instability require immediate synchronized cardioversion. If\nsynchronization is not possible, an unsynchronized shock should\nbe used. Cardioversion is not indicated in patients with repetitive\nNSVTs (Figure 10). Documentation of any haemodynamically toler-\nated wide QRS tachycardia on 12-lead ECG is important.\nAdministration of adenosine300 or vagal manoeuvres with continuous\nrecording of 12-lead ECG should be considered if supraventricular\ntachycardia (SVT) is likely. Intravenous adenosine may also terminate\nspeciﬁc VT subtypes. Such a response supports cyclic adenosine\nmonophosphate (cAMP)-mediated triggered activity as an underlying\nVT mechanism.301 Pre-excited atrial ﬁbrillation (AF) can be recog-\nnized by the ‘FBI’ (fast, broad, irregular) ECG pattern. It may mimic\nVT, and intravenous administration of drugs that slow AV conduction,\nsuch as adenosine, beta-blockers, and amiodarone, should be\navoided.302 Prompt termination of SMVT is recommended even for\ntolerated SMVT, as rapid haemodynamical deterioration may occur.\nRecommendation Table 8 — Recommendations for\ntreatment of reversible conditions\nRecommendations\nClassa\nLevelb\nWithdrawal of offending agents is recommended\nwhenever drug-induced VAs are\nsuspected.293,294,297\nI\nB\nInvestigation for reversible causes (e.g. electrolyte\nimbalances, ischaemia, hypoxaemia, fever)c is\nrecommended in patients with VA.292,298\nI\nC\nDespite a possible correctable cause for the\npresenting VA, the need for ICD implantation\nshould be considered based on an individual\nevaluation of the risk of subsequent VA/\nSCD.286,296,299\nIIa\nC\n© ESC 2022\nICD, implantable cardioverter deﬁbrillator; SCD, sudden cardiac death; VA, ventricular\narrhythmia.\naClass of recommendation.\nbLevel of evidence.\ncList not exhaustive.\nN\nN\nN\nAcute management of a patient with regular wide QRS complex tachycardia\nCardioversion (Class I)\nProcainamide\n(Class IIa)\nFlecainide\nAjmaline\nSotalol\nAmiodaronec\n(Class IIb)\nProcainamide\n(Class IIa)\nAmiodarone\n(Class IIb)\nVerapamil\n(Class I)\nCardioversion/defibrillation/ALS\n(Class I)\nHistory, physical examination,\n12-lead ECG\nKnown or suspicion\nof structural\nheart disease\nAdenosine or vagal\nmanoeuvres if SVT likelya\n(Class IIa)\nBeta-blockers\n(Class I)\nAnaesthetic risk\nfor cardioversionb\nHaemodynamically\ntolerated\nOther type \nor uncertain\nKnown\noutflow tractVT\nKnown \nfascicularVT\nY\nN\nAnaesthetic risk\nfor cardioversionb\nY\nY\nY\nIdiopathicVT\nFigure 9 Algorithm for the acute management of regular wide QRS complex tachycardia. ALS, advanced life support; ECG, electrocardiogram; N, No;\nSVT, supraventricular tachycardia; VT, ventricular tachycardia; Y, Yes. aBesides SVT, adenosine may also terminate idiopathic VT, which then indicates\ntriggered activity as the mechanism underlying the arrhythmia. bBeneﬁt of cardioversion should be weighed against risks related to anaesthesia/sedation.\ncConsidering limited availability of the other anti-arrhythmic drugs.\nESC Guidelines\n4029\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nTermination can be achieved with electrical cardioversion, anti-\narrhythmic medications, or pacing techniques. All anti-arrhythmic\ndrugs (AADs) may lead to hypotension, but the individual risk of\nanaesthesia/sedation required for cardioversion also needs to be\nconsidered. For pharmacological termination of a haemodynamic-\nally tolerated VT of unknown aetiology, intravenous procainamide\nor amiodarone can be used. In the PROCAMIO trial,303 procaina-\nmide therapy was associated with a higher proportion of tachycar-\ndia termination and fewer major cardiac adverse events than\namiodarone. Intravenous procainamide should not be used in pa-\ntients with severe heart failure, acute MI, and end-stage renal disease.\nAdministration of other AADs (ajmaline, sotalol, and ﬂecainide)304,305\nmay be considered in patients without signiﬁcant heart disease, but\nthe risk of adverse events should be carefully weighed. Availability\nof AADs has to be taken into account, e.g. procainamide is not avail-\nable in many European countries. In patients with an ICD, manual\noverdrive pacing may terminate those VTs with a cycle length under\nthe programmed ICD detection rate. In case of a known idiopathic VT\n(Figure 4), treatment with beta-blockers (for RVOT VT)306 or verap-\namil (for fascicular VT)307 is recommended for acute conversion.\nAlthough verapamil may terminate other types of idiopathic VT,307\nimportant adverse effects such as severe hypotension may occur.\nIf the VT aetiology is uncertain, intravenous administration of ver-\napamil is not recommended.308,309 A comprehensive evaluation of\npatients presenting with SMVT is mandatory if the underlying\ncardiac disease is unknown or disease progression is suspected\n(Section 5.2.2, scenario 2).\n6.1.3. Management of electrical storm and incessant\nventricular tachycardia\nAn electrical storm is common in ICD patients and has been deﬁned\nas three or more episodes of sustained VA occurring within 24 h,\n00:00\nmm:ss\n00:30\n01:00\n01:30\n02:00\n02:30\n03:00\n03:30\n04:00\n04:30\n05:00\n05:30\n06:00\n06:30\n07:00\n07:30\n08:00\n08:30\n09:00\nRepetitive runs of VT\nFigure 10 Repetitive runs of ventricular tachycardia interrupted by occasional sinus beats. VT, ventricular tachycardia.\n4030\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nrequiring either anti-tachycardia pacing (ATP) or cardioversion/\ndeﬁbrillation, with each event separated by at least 5 min.310–312\nPatients who experience an electrical storm are prone to psycho-\nlogical disorders, heart failure decompensation, and increased mor-\ntality.313,314 The severity of an electrical storm can range from\nrecurrent asymptomatic VT episodes terminated by ATP to a life-\nthreatening electrical instability with VA that recurs frequently after\nmultiple shocks. Frequent ICD shocks can also be inappropriately de-\nlivered (Figure 11).\nIn cases of inappropriate ICD shocks (e.g. due to SVTs or lead de-\nfects) or unnecessary ICD therapy (e.g. for NSVT or for repetitive VTs\nthat terminate and restart spontaneously), disabling of ICD therapies is\nrecommended. If an electrophysiology specialist or programmer is not\navailable, the ICD can be disabled by placing a magnet over the device.\nPatient with electrical storm or repeated ICD discharges\nALS including external\ncardioversion/defibrillation\n(Class I)\nRhythm\nassessment/ICD\ninterrogation\nInappropriate therapy due\nto AF/SVT/lead oversensing\nRecurrent non-sustained\nVA episodes\nInappropriate\nor unnecessary\ntherapies\nElectrical\nstorm\nSedation (for comfort)\n(Class I)\nAssessment of\nhaemodynamic\nstatus\nN\nN\nY\nY\nHaemodynamically\nstable\nVA type\nAssessment of VA type\nSTEP 1\nSTEP 2\nSTEP 3\nICD\nprogramming\noptimizationa\n(Class I)\nTreatment\nof AF/SVTa\n(Class I)\nDisable ICD by\nmagnet placement\nif programmer\nnot available\n(Class I)\nICD\nprogramming\noptimizationa\n(Class I)\nDisable ICD by\nmagnet placement\nif programmer\nnot available\n(Class I)\nPolymorphicVA\nMonomorphicVA\nFigure 11 Part One. Management of patients with electrical storm or repeated implantable cardioverter deﬁbrillator discharges.\nESC Guidelines\n4031\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nIn case of haemodynamic instability at initial evaluation, institution\nof advanced life support (ALS) is recommended.315 Reversible con-\nditions contributing to initiation and perpetuation of VA need to be\ncorrected (see Section 6.1.1). Further management depends on the\ntype of VA and the underlying aetiology.312,316 A multifaceted ap-\nproach is often required for management, consisting of ICD repro-\ngramming when appropriate, AAD therapy, sedation, catheter\nablation, autonomic modulation, and mechanical circulatory support.\nElevated sympathetic tone needs to be addressed. For patients\nwith recurrent ICD shocks, sedation is indicated to alleviate psycho-\nlogical distress and decrease pro-arrhythmogenic sympathetic tone.\nInitial treatment with beta-blockers, preferably non-selective beta-\nblockers like propranolol, which was superior to metoprolol in\none study,317 combined with amiodarone318 is most commonly\nused. In patients with recurrent haemodynamically not-tolerated\nVTs\nresistant\nto\namiodarone,\nlandiolol\n(ultra-short-acting\nβ1-selective blocker) was found to be effective for arrhythmia\nsuppression in two smaller studies.319,320 Administration of other\nAADs such as procainamide,321 lidocaine,322 or quinidine296,297 de-\npends on the speciﬁc situation, type of VA, and underlying aetiology.\nWhen electrical storm remains intractable, with multiple shocks in a\nfew hours, despite available anti-arrhythmic therapies, deep sed-\nation/intubation should be considered, along with mechanical venti-\nlation.325 If beta-blocker treatment is insufﬁcient or not tolerated to\ndecrease sympathetic tone, selected patients may beneﬁt from auto-\nnomic modulation, i.e. percutaneous ganglionic stellate blockade,326\nthoracic\nepidural\nanaesthesia,327\nor\nleft\ncardiac\nsympathetic\ndenervation.328\nThe most common arrhythmia underlying electrical storm is\nSMVT associated with SHD that is amenable to catheter abla-\ntion.313,329 Successful ablation was associated with a signiﬁcant re-\nduction in VT and electrical storm recurrence and improved\nlong-term survival in retrospective analyses.330,331 In patients with in-\ncessant slow MVT, catheter ablation is preferred over AAD therapy,\nUnderlying aetiology\nGo to\nﬂowchart\nSTEMI\n(Figure 14)\nTreatment\naccording to\nunderlying\ncondition\n(Class I)\nPolymorphic VA\nAcute\nischaemia\nExternal\nprecipitating\nfactors\nPolymorphic\nVA triggered\nby unifocal\nPVC\nAcquired\nlong QT\nPrimary\nelectrical\ndisease\nCatheter\nablation\n(Class IIa)\nCatheter\nablation\n(Class IIa)\nRemove\nprecipitating\nfactors\n(Class I)\nMg++/K + i.v. \n(Class I)\nMg++/K + i.v. \n(Class I)\nIsoproterenol\n(Class I)\nIsoproterenol\n(Class IIa)\nBrugada, ERS\nRecurrent VA\nIdiopathic VF\nLong QT, CPVT\nQuinidine \n(Class IIa)\nCatheter\nablation of\nPVC triggers\n(Class IIa)\nAutonomic\nmodulation\n(Class IIa)\nAAD\naccording\nto underlying\ndisease\n(Class IIa)\nIsoproterenol\n(Class IIa)\nBeta-blocker\n(Class I)\nQuinidine \n(Class IIa)\nVerapamil\n(Class IIa)\nPacing\n(Class I)\nPacingd\n(Class I)\nQuinidineb\n(Class IIb)\nDeep sedation/ intubation\n(Class IIa)\nMechanical circulatory support\n(Class IIb)\nFigure 11 Part Two.Management of patients with electrical storm or repeated implantable cardioverter deﬁbrillator discharges.\n4032\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nwhich may only further slow VT. Catheter ablation should also\nbe considered in patients with recurrent symptomatic episodes\nof PVT or VF triggered by a similar PVC.221,332–334 Institution\nof mechanical circulatory support may be considered for\nhaemodynamic stabilization, when conventional therapy fails,\nand to provide circulatory support during ablation.335 In a recent\nmeta-analysis336 including 2465 patients, a substantially lower\nmortality was observed with prophylactic mechanical circulatory\nsupport treatment among patients suffering from electrical storm\nor high-risk PAINESD score.337 In contrast, rescue use of mech-\nanical circulatory support during ablation was associated with a\nhigh mortality rate.338 In patients with electrical storm due to re-\ncurrent PVT/VF, the underlying aetiology determines further\nmanagement (Figure 11).\nN\nY\nVA burdenc\nMonomorphicVA\nHigh\nLow\nICD programming optimizationa\n(Class I)\nICD programming optimizationa\n(Class I)\nOn amiodarone or\namiodarone not desirable\nCatheter ablation\n(Class I)\nAAD according to\nunderlying disease\nand cardiac function\nBeta-blocker/sedation\n(Class I)\nCatheter ablation\n(Class I)\nDeep sedation/intubation\n(Class IIa)\nAutonomic modulation\n(Class IIb)\nMechanical circulatory support\n(Class IIb)\nOverdrive pacinge\nAmiodarone i.v.\n(Class I)\nRecurrent VA\nRecurrent VA\nFigure 11 Part Three. Management of patients with electrical storm or repeated implantable cardioverter deﬁbrillator discharges. AAD, anti-\narrhythmic drug; AF, atrial ﬁbrillation, ALS, Advanced life support; CPVT, catecholaminergic polymorphic ventricular tachycardia; ERS, early repolarization\nsyndrome; ICD, implantable cardioverter deﬁbrillator; N, No; PVC, premature ventricular complex; STEMI, ST-elevation myocardial infarction; SVT, su-\npraventricular tachycardia; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation; Y, Yes. aSpecial aspects of device therapy section. bNo data on effect of\nquinidine on PVC-triggered polymorphic VAs in patients with cardiomyopathies. cHigh VA burden refers to a clinical scenario of very frequent VA epi-\nsodes requiring ICD shocks, when only short periods of stable rhythm can be achieved. Low VA burden refers to a clinical scenario of repeated ATPs/ICD\nshocks followed by stable rhythm. dIf bradycardia or post-extrasystolic pauses facilitate initiation of PVT/VF. eOverdrive pacing (by pacing with a slightly\nhigher rate than the baseline rhythm) can be useful to temporarily suppress slow recurrent/incessant VT.\nRecommendation Table 9 — Recommendations for\nthe acute management of sustained ventricular tachy-\ncardia and electrical storm\nRecommendations\nClassa\nLevelb\nAcute management of sustained VT\nDC cardioversion is recommended as the\nﬁrst-line treatment for patients with\nhaemodynamically not-tolerated SMVT.303,339\nI\nB\nDC cardioversion is recommended as the\nﬁrst-line treatment for patients presenting with\ntolerated SMVT provided that the anaesthetic/\nsedation risk is low.\nI\nC\nContinued\nESC Guidelines\n4033\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n6.2. Long-term management\n6.2.1. Pharmacotherapy\nOptimal medical treatment of the underlying cardiac disease, including\nthe maximal tolerated doses of heart failure medication, is mandatory.341\nIn patients with heart failure with reduced ejection fraction\n(HfrEF), the 2021 ESC Guidelines for the diagnosis and treatment\nof acute and chronic heart failure recommend angiotensin-\nconverting enzyme inhibitor (ACE-I)/angiotensin receptor blocker\n(ARB)/angiotensin receptor neprilysin inhibitors (ARNIs), mineralo-\ncorticoid receptor antagonists (MRAs), beta-blockers, and sodium–\nglucose co-transporter 2 (SGLT2) inhibitors to reduce mortality\ndue to heart failure and SCD.342\nAADs have an important role as adjunctive therapy in the manage-\nment of VA, especially in symptomatic patients (Table 8). Until now,\nno AAD except for beta-blockers has demonstrated reduction in all-\ncause mortality. Each drug has a signiﬁcant potential for causing adverse\nevents, including pro-arrhythmia. For example, numerous AADs, as\nwell as a large number of drugs with other therapeutic indications,\ncan prolong the QT interval (http://www.crediblemeds.org) and\nprovoke TdP, have negative chronotropic effects, may deteriorate\nheart failure, and cause bradycardia. Several drugs increase the\nrisk of VA in patients with BrS (http://www.brugadadrugs.org).\nIn patients presenting with a haemodynamically\ntolerated idiopathic VT, treatment with\nintravenous beta-blocker (RVOT VT) or\nverapamil (fascicular VT) is recommended.306,307\nI\nC\nIn patients presenting with a regular\nhaemodynamically tolerated wide QRS complex\ntachycardia suspected for SVT, administration of\nadenosine or vagal manoeuvres should be\nconsidered.300\nIIa\nC\nIn patients presenting with a haemodynamically\ntolerated SMVT and known or suspected SHD,\nintravenous procainamide should be\nconsidered.303\nIIa\nB\nIn patients presenting with a haemodynamically\ntolerated SMVT in the absence of an established\ndiagnosis, intravenous amiodarone may be\nconsidered.303\nIIb\nB\nIn patients presenting with a haemodynamically\ntolerated SMVT in the absence of signiﬁcant SHD,\nﬂecainide, ajmaline, or sotalol may be\nconsidered.304,305\nIIb\nC\nIntravenous verapamil is not recommended in\nbroad QRS complex tachycardia of unknown\nmechanism.308,309\nIII\nB\nManagement of electrical storm\nMild to moderate sedation is recommended in\npatients with electrical storm to alleviate\npsychological distress and reduce sympathetic\ntone.\nI\nC\nAntiarrhythmic therapy with beta-blockers\n(non-selective preferred) in combination with\nintravenous amiodarone is recommended in\npatients with SHD and electrical storm unless\ncontraindicated.317,318\nI\nB\nIntravenous magnesium with supplementation of\npotassium is recommended in patients with\nTdP.295\nI\nC\nIsoproterenol or transvenous pacing to increase\nheart rate is recommended in patients with\nacquired LQT syndrome and recurrent TdP\ndespite correction of precipitating conditions and\nmagnesium.\nI\nC\nCatheter ablation is recommended in patients\npresenting with incessant VT or electrical storm\ndue to SMVT refractory to AADs.330,331\nI\nB\nDeep sedation/intubation should be considered in\npatients with an intractable electrical storm\nrefractory to drug treatment.325\nIIa\nC\nCatheter ablation should be considered in patients\nwith recurrent episodes of PVT/VF triggered by a\nsimilar PVC, non-responsive to medical treatment\nor coronary revascularization.221,332,333\nIIa\nC\nQuinidine may be considered in patients with\nCAD and electrical storm due to recurrent PVT\nwhen other AAD therapy fails.323,324\nIIb\nC\nContinued\nAutonomic modulation may be considered in\npatients with electrical storm refractory to drug\ntreatment and in whom catheter ablation is\nineffective or not possible.326,328,340\nIIb\nC\nInstitution of mechanical circulatory support may\nbe considered in the management of\ndrug-refractory electrical storm and cardiogenic\nshock.335\nIIb\nC\n© ESC 2022\nAAD, anti-arrhythmic drug; CAD, coronary artery disease; DC, direct current; LQT,\nlong QT; PVC, premature ventricular complex; PVT, polymorphic VT; RVOT, right\nventricular\noutﬂow\ntract;\nSHD,\nstructural\nheart\ndisease;\nSMVT,\nsustained\nmonomorphic\nventricular\ntachycardia;\nSVT,\nsupraventricular\ntachycardia;\nTdP,\nTorsades de pointes; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.\naClass of recommendation.\nbLevel of evidence.\nRecommendation Table 10 — Recommendations for\ntreatment with heart failure medication\nRecommendations\nClassa\nLevelb\nOptimal medical treatment including ACE-I/ARB/\nARNIs, MRAs, beta-blockers, and SGLT2\ninhibitors is indicated in all heart failure patients\nwith reduced EF.343–347\nI\nA\n© ESC 2022\nACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;\nARNIs, angiotensin receptor neprilysin inhibitor; EF, ejection fraction; MRA,\nmineralocorticoid receptor antagonists; SGLT2, sodium–glucose co-transporter 2.\naClass of recommendation.\nbLevel of evidence.\n4034\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nTable 8\nAnti-arrhythmic drugs (acute and chronic treatment)\nAnti-arrhythmic\ndrug\nEffects on ECG\nIndications\n(speciﬁc\nindication)\nOral dose per\nday\n(i.v. dose)\nSide effects\nContraindications,\nprecautions, other\nconsiderations\nAmiodarone\nDecreases sinus\nnode frequency,\nprolongs QT\nintervala\nPVC, VT, VF\n200–400 mg\nLoading dose:\n600–1200 mg/\n24 h 8–10 days.\n(Loading dose:\n5 mg/kg in\n20 min–2 h, 2–3\ntimes in 24 h, then\n600–1200 mg/\n24 h 8–10 days)\nCardiac:\nBradycardia, TdP\n(infrequent)\nExtracardiac:\nPhotosensitivity, corneal\ndeposits, hypothyroidism,\nhyperthyroidism,\npulmonary toxicity,\nhepatotoxicity,\npolyneuropathy, skin\ndiscoloration\nPrecautions:\nSinus node dysfunction,\nsevere AV conduction\ndisturbances,\nhyperthyroidism\nOther considerations:\nCan be used in patients with\nheart failure. Increases the\nrisk of myopathy when used\nwith statins\nAdenosine\nTransitory AV block\nRegular wide\ncomplex\ntachycardia of\nunknown origin\n(outﬂow tract\nVT)\nNo oral use\n(6–18 mg bolus)\nChest pain, ﬂushing,\nbronchoconstriction\nContraindications:\nSevere asthma, pre-excited\nAF\nOther considerations:\nAntagonist: theophylline\nAjmaline\nProlongs QRS\nduration and QT\nintervala\nVT\n(unmasking BrS\nECG)\nNo oral use\n(1 mg/kg over\n5–10 min\n(maximum dose\n100 mg) or\n1 mg/kg at\n10 mg/min)\nCardiac:\nVF (rare in suspected BrS),\noccasional TdP, negative\ninotrope\nExtracardiac:\nCholestatic jaundice,\nheadache, nausea,\nthrombocytopenia\nContraindications:\nBrS ECG type I, QT\nprolongation\nBeta-blocker\nDecreases sinus\nnode frequency,\nprolongs PR interval,\nshortens QT interval\nPVC, VT\n(LQTS, CPVT)\nVarious\n(various)\nCardiac:\nBradycardia, AV block,\nhypotension, negative\ninotrope\nExtracardiac:\nFatigue, bronchospasm,\nsexual disturbances,\ndepression, cold\nextremities\nContraindications:\nSevere sinus node\ndysfunction, severe AV\nconduction disturbances,\ndecompensated heart failure,\ncoronary vasospasm, severe\nasthma, BrS\nLandiolol\n(Ultra-short acting\nβ1-selective blocker)\nSee beta-blocker\nVT, electrical\nstorm\nNo oral use\n100 µg/kg bolus in\n1 min, infusion\n10–40 µg/kg/min\n(max 80 µg/kg/\nmin; max 24 h\ntotal dose\n57.6 mg/kg/day)\nSee beta-blocker\nContraindications:\nSee beta-blocker.\nBradycardia, hypotension\nOther considerations:\nLimited experience with its\nuse beyond 24 h\nNadolol\n(Non-selective\nβ1β2 blocker)\nSee beta-blocker\nPVC, VT\n(LQTS, CPVT)\n40–120 mg\nSee beta-blocker\nContraindications:\nSee beta-blocker\nOther considerations:\nPlasma half-life 20–24 h\nPropranolol\n(Non-selective β1β2\nblocker)\nSee beta-blocker\nPVC, VT\n(electrical storm,\nLQTS, CPVT)\n80–320 mg\n(160 mg/24 h)\nSee beta-blocker\nContraindications:\nSee beta-blocker\nDisopyramide\nIncreases sinus node\nfrequency and\nprolongs PR interval,\nQRS duration, and\nQT intervala\nPVC, VT\n250–750 mg\nCardiac:\nNegative inotrope, AV\nblock, pro-arrhythmia\n(MVT, occasional TdP)\nContraindications:\nSevere sinus node\ndysfunction, severe AV\nconduction disturbances,\nsevere intraventricular\nContinued\nESC Guidelines\n4035\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nExtracardiac:\nAnticholinergic effects\nconduction disturbances,\nprior MI, signiﬁcant SHD,\nhypotension\nOther considerations:\nReduces LV outﬂow tract\nobstruction and symptoms in\nHCM\nFlecainide\nProlongs PR interval,\nQRS duration, and\nQT intervala\nPVC, VT\n(unmasking BrS\nECGb)\n200–400 mg\n(1–2 mg/kg over\n10 min)\nCardiac:\nPro-arrhythmia (MVT,\noccasional TdP), negative\ninotrope, sinus\nbradycardia, AV block, 1:1\nAV conduction during\nﬂutter\nExtracardiac:\nCentral nervous system\neffects (e.g. drowsiness,\ndiplopia, headache)\nContraindications:\nPrior MI, signiﬁcant SHD, BrS,\nsevere sinus node\ndysfunction, severe AV or\nintraventricular conduction\ndisturbances, inherited LQTS\n(other than LQTS3), severe\nkidney disease (CrCl\n,35 mL/min/1.73 m2)\nOther considerations:\nDiscontinue if QRS widening\n.25% or bundle branch\nblock\nIsoproterenol\nIncreases sinus node\nfrequency, shortens\nQT interval\n(Electrical storm\nin BrS, idiopathic\nVF, and ERS, TdP,\nbeta-blocker\noverdose;\nacquired LQTS)\nNo oral use\n(0.5–10 µg/min)\nCardiac:\nSinus tachycardia,\nvasodilation\nExtracardiac:\nHeadache, sweating,\ntremor\nContraindications:\nACS, LQTS\nOther considerations:\nShort plasma half time\n(2 min)\nLidocaine\nNo signiﬁcant effects\n(VT/VF\nassociated with\nACS)\nNo oral use\n(50–200 mg bolus,\nthen 2–4 mg/min)\nCardiac:\nSinoatrial arrest\nExtracardiac:\nCentral nervous system\neffects (e.g. drowsiness,\ndizziness)\nPrecautions:\nReduced dose with reduced\nliver blood ﬂow (e.g. shock,\nβ-blockade, severe heart\nfailure)\nOther considerations:\nMore effective with high\npotassium level. Few\nhaemodynamic side effects\nMexiletine\nNo signiﬁcant effects\nPVC, VT\n(LQT3)\n600–1200 mg\nLoading dose:\n400 mg initially\nfollowed by\n600 mg in the ﬁrst\n24 h\nCardiac:\nSinus bradycardia in sinus\nnode dysfunction,\nhypotension\nExtracardiac:\nCentral nervous system\neffects (e.g. tremor,\ndysarthria, dizziness),\ngastrointestinal complaints\nContraindications:\nSinus node dysfunction,\nsevere AV conduction\ndisturbances, severe heart\nfailure\nProcainamide\nProlongs PR interval,\nQRS duration, and\nQT intervala\nVT\n(100 mg bolus,\ncan be repeated\nafter 5 min if no\neffect, max 500–\n750 mg [max\n50 mg/min]. Then,\n2–6 mg/min)\nCardiac:\nSinus bradycardia,\nhypotension, TdP\nExtracardiac:\nRash, myalgia, vasculitis,\nsystemic lupus,\nagranulocytosis\nContraindications:\nSevere sinus node\ndysfunction, severe AV\nconduction disturbances,\nsevere intraventricular\nconduction disturbances,\nsevere LV dysfunction\nhypotension, BrS\nPropafenone\nProlongs PR interval,\nQRS duration, and\nQT intervala\nPVC, VT\n450–900 mg\nCardiac:\nSinus bradycardia, AV\nblock, negative inotrope,\npro-arrhythmia (MVT,\noccasional TdP)\nExtracardiac:\nGastrointestinal\ndisturbances, headache,\ndry mouth\nContraindications:\nPrior MI, signiﬁcant SHD, BrS,\nsevere sinus node dysfunction,\nsevere AV or intraventricular\nconduction disturbances,\nLQTS, signiﬁcant renal or liver\ndisease\nOther considerations:\nDiscontinue if QRS widening\n.25% or bundle branch block\nContinued\n4036\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nQuinidine\nIncreases sinus node\nfrequency and\nprolongs PR interval,\nQRS duration, and\nQT intervala\n(VFc, BrS, SQTS)\n600–1600 mg\nLoading dose:\nStart 200 mg\nevery 3 h until\neffect, max. 3 g in\nﬁrst 24 h\nCardiac:\nHypotension, TdPd\nExtracardiac:\nGastrointestinal\ndisturbances, auditory and\nvisual disturbances,\nconfusion, leukopenia,\nhaemolytic anaemia,\nthrombocytopenia,\nanaphylaxis\nContraindications:\nSevere sinus node\ndysfunction, severe AV or\nintraventricular conduction\ndisturbances, previous MI,\nsigniﬁcant SHD, hypotension,\nLQTS\nRanolazine\nDecreases sinus\nnode frequency,\nprolongs QT\nintervala\nVT\n(LQTS3)\n750–2000 mg\nCardiac:\nSinus bradycardia,\nhypotension\nExtracardiac:\nDizziness, nausea,\nconstipation,\ngastrointestinal\ndisturbance, headache,\nrash\nContraindications:\nSevere sinus node\ndysfunction, severe heart\nfailure, LQTS (other than\nLQTS3)\nPrecautions:\nConcomitant treatments\nassociated with QT interval\nprolongation\nSotalol\nDecreases sinus\nnode frequency,\nprolongs QT\nintervala\nVT\n160–640 mg\n(0.5–1.5 mg/kg in\n10 min. If\nnecessary, can be\nrepeated after\n6 h)\nSee beta-blockers, TdPd\n(.2% of patients, close\nmonitoring of QT interval\nand CrCl)\nContraindications:\nSevere sinus node\ndysfunction, severe AV\nconduction disturbances,\nsevere heart failure with\nreduced LVEF, signiﬁcant\nLVH, CrCl ,30 ml/min,\ncoronary vasospasm, LQTS\nPrecautions:\nConcomitant treatments\nassociated with QT interval\nprolongation, hypokalaemia\nOther considerations:\nPotassium channel blocker\neffects require higher dose\nthan beta-blocker effects\nVerapamil\nProlongs PR interval\n(LV fascicular\ntachycardia)\n120–480 mg\n(5–10 mg in slow\nbolus. If necessary,\ncan be repeated in\n30 min)\nCardiac:\nSinus bradycardia in sinus\nnode dysfunction, AV\nblock, negative inotrope,\nhypotension\nExtracardiac:\nGastrointestinal\ndisturbances, peripheral\noedema, ﬂushing\nContraindications:\nHeart failure with reduced\nLVEF, severe sinus node\ndysfunction, and severe AV\nconduction disturbances, VT\nof unknown origin, ACS,\nWPW syndrome\nOther considerations:\nIncrease the risk of myopathy\nwhen used with statins\n© ESC 2022\nACS, acute coronary syndrome; AF, atrial ﬁbrillation; AV, atrioventricular; BrS, Brugada syndrome; CPVT, catecholaminergic polymorphic ventricular tachycardia; CrCl, creatinine\nclearance; ECG, electrocardiogram; ERS, early repolarization syndrome; HCM, hypertrophic cardiomyopathy; LQTS, long QT syndrome; LV, left ventricular; LVEF, left ventricular\nejection fraction; LVH, left ventricular hypertrophy; MI, myocardial infarction; MVT, monomorphic ventricular tachycardia; PVC, premature ventricular complex; SHD, structural\nheart disease; SQTS, short QT syndrome; TdP, torsades de pointes; VF, ventricular ﬁbrillation; VT, ventricular tachycardia; WPW, Wolff–Parkinson–White.\naPrecaution with concomitant conditions or drugs that prolong QT interval. Should be discontinued if QTc .500 ms. See Figure 13 Algorithm for evaluation before initiation and\nfollow-up of patients requiring drugs associated with QT prolongation.\nbIf ajmaline not available.\ncSubacute MI, multifocal ectopic Purkinje-related premature contractions, ERS, idiopathic VF.\ndProarrhythmic side effects require strong indication in patients without ICD.\nESC Guidelines\n4037\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nModiﬁcation of risk factors, when possible, is important for prevention of\npro-arrhythmia. In patients who require a potentially arrhythmia-\ninducing drug, regular ECG and other tests according to the patient’s\nproﬁle and AAD characteristics are recommended (Figures 12 and 13).\n6.2.2. Device therapy\n6.2.2.1. Implantable cardioverter deﬁbrillator\nICD is an integral part of treating patients surviving a CA due to a VA\nor those deemed to be at high risk thereof. Drawbacks are the high\nup-front device costs, device-associated complications, and the rela-\ntively high number-to-treat needed to prevent one SCD in primary\nprevention.\nA patient-level meta-analysis of the three early ICD trials349–351\ncomparing ICD to medical therapy for secondary prevention of\nSCD demonstrated a 28% mortality reduction (HR 0.72; 95% CI\n0.6–0.87; P = 0.0006) almost entirely due to reduction of arrhythmic\ndeath (HR 0.5; 95% CI 0.37–0.67; P , 0.0001) in the ICD group.352\nTherefore, the use of an ICD for secondary prevention of SCD\nthat occurred in the absence of reversible causes is widely accepted.\nSeveral randomized controlled trials353–356 have established the\nrole of the ICD for primary prevention of SCD in heart failure pa-\ntients with an LVEF ≤35%. The reported mortality reduction has re-\ncently been supported by two large contemporary prospective\nregistries\nenrolling\nmore\nthan\n5000\npatients.357,358\nIn\nthe\nEU-CERT-ICD trial, primary prevention ICD implantation was asso-\nciated with a 27% lower mortality with similar results in CAD and\nDCM.357 Results of the DANISH trial, however, indicate that the\nmortality beneﬁt may be less clear in contemporary patients with\nnon-ischaemic heart failure (see Section 7.1.3.1).359\nIn the work-up for ICD therapy, it is of paramount importance to\nconsider the patient’s life expectancy, quality of life, and comorbidities,\nand to reassess and discuss these issues with the patient at the time of\ngenerator change. There is evidence that patients with end-stage renal\ndisease, with diabetes, and elderly patients beneﬁt less or not at all from\nPatient requiring sodium channel blocking agents\nAssessment of patient\nrisk proﬁle before initiation\nECG 1–2 weeks after initiation\nor increase in dosagee\nInitiate treatmentc\nInitiate treatment on individual decision (risk/beneﬁt)d\nKnown cardiac disease\nor\nECG abnormalities \nor \nAbnormal echocardiogram\nΔQRS > 25%f or\nAbnormal exercise test?\n(new BBB, ΔQRS >25%\nor QRS >130 ms)\nContraindications:\nN\nN\nBrugada syndrome a\nPrior MI (ﬂecainide)b\nSevere LV dysfunction\nSevere valvular heart disease\nSevere bradycardia, BBB, > ﬁrst degree AV block\nPrecaution:\nAny degree of LV dysfunction\nLV hypertrophy\nAny signiﬁcant valvular heart disease\nFirst degree AV block\nProlonged QT interval (disopyramide, quinidine)\nConsider to change to dffierent drug\nConsider to reduce dose\nConsider to measure drug serum level\nY\nY\nContinue treatment\nInform patient about\nwarning symptoms (syncope)\nPeriodic ECG for QRS width evaluation\nControl changes in renal and hepatic function\nBe aware of potential drug interactions\nFigure 12 Algorithm for evaluation before initiation and follow-up of patients requiring sodium channel blocking agents. AV, atrioventricular; BBB, bun-\ndle branch block; ECG, electrocardiogram; LV, left ventricular; MI, myocardial infarction; N, No; Y, Yes. ahttp://www.brugadadrugs.org. bFlecainide, encainide.\ncCo-administration of drugs with AV nodal blocking effect in patients with atrial ﬁbrillation or atrial ﬂutter. dIn implantable cardioverter deﬁbrillator carriers, a\nhigher risk of drug-induced pro-arrhythmia might be accepted. eAccording to the 2020 ESC Guidelines for the diagnosis and management of atrial ﬁbrillation.348\nfA ΔQRS .25% is not an absolute cut-off value but dependent on QRS width before drug initiation and individualized patient risk–beneﬁt considerations.\n4038\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\na primary prevention ICD.357,360–362 Women have been underrepre-\nsented in all primary prevention trials and data suggest that they may\nbeneﬁt less.361 In general, the SCD risk needs to be weighed against\nthe individual’s competing risk of a non-arrhythmic death.363,364\nIn the context of patient-centred medicine, physicians and health-\ncare professionals should engage ICD candidates and recipients in a\njoint decision process. Communication of relevant information, en-\nsuring a good understanding of the beneﬁts, risks, and potential con-\nsequences of different options, to enable the patient to partake in\ndecision-making is mandatory. This shared decision-making process\nshould discuss the different scenarios including primary prevention\nICD implantation, consideration of ICD generator replacement,\nand end-of-life care. Importantly, the perception of ‘good quality of\nlife’ depends on numerous factors that are weighed differently by\npeople with different cultural, religious, and socioeconomic back-\ngrounds.\nAlthough\nclinical\nprediction\nscores,\nsuch\nas\nthe\nMADIT-ICD beneﬁt score,365 may provide helpful additional infor-\nmation, clinical decision-making should not only rely on such scores.\nComplications of ICD therapy include inappropriate therapies,\nlead fractures, and device-related infections. A subcutaneous implan-\ntable cardioverter deﬁbrillator (S-ICD) has been introduced to ad-\ndress problems related to transvenous leads. S-ICD has no\nintravascular lead and therefore cannot deliver ATP. In the\nPRAETORIAN trial, 849 patients with an ICD but no pacing indica-\ntion were randomized to an S-ICD or a transvenous ICD.366 Over a\nmean follow-up of 49 months, non-inferiority was shown for the pri-\nmary endpoint of device-related complications and inappropriate\nshocks. The rate of inappropriate shocks was 9.7% in the S-ICD\ngroup and 7.3% in the ICD group (HR 1.43; 95% CI 0.89–2.30)\nand the rate of device related complications was 5.9% in the S-ICD\nand 9.8% in the ICD group (HR 0.69; 95% CI 0.44–1.09). There\nwas also no difference in the secondary endpoint of death and appro-\npriate shocks, but the trial had not been powered to show non-\ninferiority for this secondary endpoint. Of note, more than 80% of\nthe included patients were in NYHA class I and II and the included\npatients were younger than in prior ICD trials.\nPatient requiring a drug associated with QT prolongationa\nAssessment of patient\n risk profile befof re initiation\nECG at baseline, after 1 d\n,\nay and after1–2\na\nweeks of initiation or increase in dosagec\nContinue treatment\nInform patient about warning symptoms (syncope)\nf\nControl changes in renal and hepatic function\nBe awa\na\nre of potential drug interactions\nInitiate treatment\nQTc >500 ms\nContraindicated: Do not initiate t\n:\nreatment\nStart drug if strong indication with close foll\nf\now-up\nLong QT syndrome or\nbaseline QTc >500 msb\nHypokalaemia/hypomagnesaemia/\nRenal failure/liver failure/\nLV \nL hypertrophy/\nHeart failure/\nAdditional QT prolonging drug\nN\nN\nN\nConsider to change to difff ef rent drug\nIf strong indication, consider to \n,\nreduce dose\nConsider to assess drug serum level\nY\nY\nY\nFigure 13 Algorithm for evaluation before initiation and follow-up of patients requiring drugs associated with QT prolongation. ECG, electrocardio-\ngram; LV, left ventricular; N, No; Y, Yes. ahttp://www.crediblemeds.org. bIf strong indication and no alternative treatment, consult a specialist. cAccording\nto the 2020 ESC Guidelines for the diagnosis and management of atrial ﬁbrillation.348\nESC Guidelines\n4039\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n6.2.2.2. Adding cardiac resynchronization therapy2\nCardiac resynchronization therapy (CRT) does reduce mortality in\nheart failure,367 and careful evaluation of the potential beneﬁt of\nCRT in patients with ICD indication before implantation is manda-\ntory.2 The role of the addition of a deﬁbrillator is less well estab-\nlished.368,369 The ongoing randomized controlled RESET-CRT trial\naims to determine the impact of CRT-deﬁbrillator on overall mortal-\nity and SCD in heart failure patients with a CRT indication.\n6.2.2.3. Wearable cardioverter deﬁbrillator\nThe wearable cardioverter deﬁbrillator (WCD) is an external deﬁb-\nrillator that has been shown to successfully detect and treat VT and\nVF.370 It is therefore suitable for patients who are at risk but tempor-\narily not candidates for an ICD owing, for example, to extraction of\nan infected device and subsequent antibiotic treatment.371 An un-\nsolved problem is the protection of patients in the early phase (40\ndays) after an MI. The VEST trial enrolled 2302 patients with acute\nMI and an LVEF ≤35% and randomized them early in a 2:1 fashion\nto receive a WCD or not under guideline-directed optimal medical\ntreatment (OMT).372 After a follow-up of 90 days there was no dif-\nference in the primary endpoint of arrhythmic death (1.6 vs. 2.4%; RR\n0.67; 95% CI 0.37–1.21; P = 0.18). Concern was raised regarding the\nlow median wear time of 18 h (IQR 3.8–22.7). The median wear time\nwas higher (23.4 h, IQR 22.2–23.8) in a recent multicentre registry\nafter structured patient education.371 However, based on the avail-\nable data, the task force does not recommend routine use of the\nWCD in the early post-MI phase. Nevertheless, the use of the device\nmay be considered in selected post-MI patients deemed to be at high\nrisk for SCD.\nData on the beneﬁt of the WCD for primary prevention of SCD in\nother clinical situations (e.g. acute myocarditis, primary prevention\nindication during pregnancy) are sparse and no recommendations\ncan be currently made.\nRecommendation Table 12 — Recommendations for\nsecondary prevention of sudden cardiac death*\nRecommendations\nClassa\nLevelb\nICD implantation is recommended in patients\nwith documented VF or haemodynamically\nnot-tolerated VT in the absence of reversible\ncauses.349–352\nI\nA\nIn patients with VT/VF, an indication for ICD, and\nno contraindication for amiodarone, amiodarone\nmay be considered when an ICD is not available,\ncontraindicated for concurrent medical reasons,\nor declined by the patient.\nIIb\nC\nIn patients with SMVT or SPVT/VF triggered by a\nPVC with similar morphology and an indication\nfor ICD, catheter ablation may be considered\nwhen an ICD is not available, contraindicated for\nconcurrent medical reasons, or declined by the\npatient.\nIIb\nC\n© ESC 2022\nICD, implantable cardioverter deﬁbrillator; PVC, premature ventricular complex;\nSMVT, sustained monomorphic VT; SPVT, sustained polymorphic VT; VF, ventricular\nﬁbrillation; VT, ventricular tachycardia.\n*For primary prevention and speciﬁc aspects of secondary prevention, go to Section 7.\naClass of recommendation.\nbLevel of evidence.\nRecommendation Table 14 — Recommendations for\nadding cardiac resynchronization therapy to implanta-\nble cardioverter deﬁbrillator\nRecommendations\nClassa\nLevelb\nWhen an ICD is indicated, it is recommended to\nevaluate whether the patient could beneﬁt from\nCRT-deﬁbrillator.367\nI\nC\n© ESC 2022\nCRT, cardiac resynchronization therapy; ICD, implantable cardioverter deﬁbrillator.\naClass of recommendation.\nbLevel of evidence.\nRecommendation Table 11 — Recommendations for\nimplantable cardioverter deﬁbrillator implantation\n(general aspects)\nRecommendations\nClassa\nLevelb\nImplantation of a cardioverter deﬁbrillator is only\nrecommended in patients who have an\nexpectation of good quality survival .1 year.\nI\nC\nIt is not recommended to implant an ICD in\npatients with incessant VAs until the VA is\ncontrolled.\nIII\nC\n© ESC 2022\nICD, implantable cardioverter deﬁbrillator; VA, ventricular arrhythmia.\naClass of recommendation.\nbLevel of evidence.\nRecommendation Table 15 — Recommendations for\nwearable cardioverter deﬁbrillator\nRecommendations\nClassa\nLevelb\nThe WCD should be considered for adult patients\nwith a secondary prevention ICD indication, who\nare temporarily not candidates for ICD\nimplantation.\nIIa\nC\nContinued\nRecommendation Table 13 — Recommendations for\nsubcutaneous implantable cardioverter deﬁbrillator\nRecommendations\nClassa\nLevelb\nSubcutaneous deﬁbrillator should be considered\nas an alternative to transvenous deﬁbrillator in\npatients with an indication for an ICD when pacing\ntherapy for bradycardia, cardiac\nresynchronization, or ATP is not needed.366\nIIa\nB\n© ESC 2022\nATP, anti-tachycardia pacing; ICD, implantable cardioverter deﬁbrillator.\naClass of recommendation.\nbLevel of evidence.\n4040\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n6.2.3. Special aspects of device therapy\n6.2.3.1. Optimization of device programming\nOptimization of ICD programming is essential to minimize the bur-\nden of ICD therapy and to improve patient outcome.373–375 Detailed\nrecommendations are available in expert consensus papers.376,377\nBradycardia mode should be customized to prevent unnecessary\nRV pacing, thus reducing heart failure hospitalizations and all-cause\nmortality378–380 (\nESC CardioMed chapter 43.21).381 A tachy-\ncardia detection programming strategy incorporating prolonged set-\ntings and high rate thresholds (≥188 b.p.m. Advance III trial,382 ≥200\nMADIT-RIT383) reduces ICD therapies and all-cause mortality with-\nout increasing the risk of syncope.373,382,383 The evidence is stronger\nfor primary prevention compared to secondary prevention indica-\ntions382 (\nESC CardioMed chapter 43.21).381 Consistent use\nof SVT/VT discriminators even in rates up to 230 b.p.m. is recom-\nmended in ICD recipients without complete heart block to reduce\ninappropriate therapies.383–385 Proper atrial sensing is a prerequisite\nfor\nactivation\nof\ndual-chamber\ndiscriminators376\n(\nESC\nCardioMed chapter 43.21).381 In general, a multi-zone detection pro-\ngramming is favoured to enable tailored use of detection and therapy\nsettings at different tachycardia rates.383,386 A single-zone program-\nming with a high cut-off rate may be considered in patients with a\nhigh likelihood of VF only (e.g. primary electrical diseases).387 In sub-\ncutaneous ICDs, a dual-zone conﬁguration should be adopted.\nStandardized programming including a lower ‘conditional shock’\nzone with activated discrimination algorithms and a higher ‘shock\nzone’ based on rate criteria only has been shown to reduce inappro-\npriate shock rates without compromising patient safety.388–390\nSystematic use of ATP before shock delivery, also for very fast ven-\ntricular tachyarrhythmias, has been shown to reduce shock therapy\nwithout increase in arrhythmic syncope.375,384,391 Burst ATP is pre-\nferred over ramp due to increased efﬁcacy in ﬁrst tachycardia ter-\nmination.392 Incorporation of remote monitoring into follow-up\npractice of ICD recipients should be promoted to optimize surveil-\nlance of device integrity, to enable prompt detection and manage-\nment\nof\nactionable events,\nand\nto\nprevent\noccurrence\nof\ninappropriate shocks393–396 (\nESC CardioMed chapter 43.\n21).381 The proposed recommendations for optimal device pro-\ngramming are applicable to the majority of ICD recipients.\nCustomization may be needed in individual patients.\n6.2.3.2. Concomitant treatment to avoid inappropriate\nimplantable cardioverter deﬁbrillator therapy\nApart from optimization of device programming, pharmacological\nand/or invasive management may prevent inappropriate ICD\ntherapy. Beta-blockers (carvedilol superior to metoprolol in\nMADIT-CRT) should be titrated to the maximal tolerated dose\nin heart failure patients to reduce the risk of inappropriate ther-\napy.400 In patients with inappropriate therapies due to recurrent\nSVT, catheter ablation should be ﬁrst-line treatment, given its high\nsuccess and low complication rate.302,401–403 In case of AF-related\ninappropriate therapies, unresponsive to optimized pharmaco-\nlogical rate control treatment, individualized treatment strategy\n(rate vs. rhythm) dependent on patient characteristics is sug-\ngested.348 In patients with early AF, adoption of a rhythm control\nstrategy improved patient outcome in the EAST-AFNET 4 trial.404\nIn CRT-deﬁbrillator patients, AV node ablation has been asso-\nciated with reduced inappropriate ICD shocks and lower hospital-\nization\nrates\ncompared\nto\ndrug\ntreatment405\n(\nESC\nCardioMed chapter 41.14).406\nThe WCD may be considered in the early phase\nafter MI in selected patients.371,372\nIIb\nB\n© ESC 2022\nICD, implantable cardioverter deﬁbrillator; WCD, wearable cardioverter deﬁbrillator.\naClass of recommendation.\nbLevel of evidence.\nRecommendation Table 16 — Recommendations for\noptimization of device programming\nRecommendations\nClassa\nLevelb\nOptimization of ICD programming is indicated to\navoid inappropriate and unnecessary therapies\nand to reduce mortality.373–375\nI\nA\nContinued\nIn single- or dual-chamber ICD patients\nwithout bradycardia pacing indications,\nit is recommended to minimize ventricular\npacing.378–380\nI\nA\nProgramming of prolonged detection settings is\nindicated (duration criteria of at least 6–12 s or 30\nintervals).373,382,383\nI\nA\nIt is recommended to program the slowest\ntachycardia therapy zone limit ≥188 b.p.m. in\nprimary prevention ICD patients.382,383\nI\nA\nIn patients with SHD, programming of at least one\nATP therapy is recommended in all\ntachyarrhythmias zones.375,384,391\nI\nA\nIt is recommended to program algorithms for SVT\nvs. VT discrimination for tachycardias with rates\nup to 230 b.p.m.383–385\nI\nB\nIt is recommended to activate lead failure\nalerts.397–399\nI\nB\nRemote monitoring is recommended to reduce\nthe incidence of inappropriate shocks.395\nI\nB\nProgramming of burst ATP as ﬁrst attempt is\nrecommended over ramp ATP.392\nI\nB\nFor S-ICDs, a dual detection zone conﬁguration\nis recommended with activation of discrimination\nalgorithm in the lower conditional shock\nzone.388–390\nI\nB\nFor routine ICD programming, activation of more\nthan one tachycardia detection zone should be\nconsidered.383,386\nIIa\nB\n© ESC 2022\nATP, anti-tachycardia pacing; ICD, implantable cardioverter deﬁbrillator; SHD,\nstructural heart disease; S-ICD, subcutaneous ICD; SVT, supraventricular tachycardia;\nVT, ventricular tachycardia.\naClass of recommendation.\nbLevel of evidence.\nESC Guidelines\n4041\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 31",
          "page": 31,
          "content": "Ambulatory cardiac rhythm monitoring and CMR\nmay be considered in relatives of SADS\ndecedents.223,253,277,281 | IIb | C\nPharmacological testing including epinephrine\nchallenge (if exercise testing is impractical) and\nsodium channel blocker challenge may be\nconsidered in first-degree relatives of SADS\ndecedents with normal baseline testing.223,281 | IIb | B\nIn SADS families without a diagnosis after clinical\nevaluation, follow-up is not recommended for\nasymptomatic adults who can be discharged with\nadvice to return if they develop symptoms or if\nthe family history changes.181,284 | III | C",
          "rows": 3,
          "cols": 3
        },
        {
          "title": "Table on page 31",
          "page": 31,
          "content": "Recommendations | Classa | Levelb\nFamilial evaluation of SADS decedents is\nrecommended:\n• for first-degree relatives\n• for relatives who must carry a mutation based\non analysis of the family history\n• for relatives with suspicious symptoms\n• when the decedent’s age is ,50 years, or if\nthere is other circumstantial data or family\nhistory to suggest heritable\ndisease.223,252,253,277,281 | I | B\nFamilial evaluation of SADS decedents is\nrecommended to include genetic testing when\npost-mortem genetic testing in a SADS decedent\ndetects a pathogenic mutation.183,253,277,281 | I | B\nBaseline familial evaluation of SADS decedents is\nrecommended to include taking a medical history\nand performing physical examination, standard and\nhigh precordial lead ECG, echocardiography, and\nexercise testing.223,252,253,277,281 | I | B\nIn SADS families without a diagnosis after clinical\nevaluation, follow-up is recommended for\nchildren of decedents until they reach\nadulthood.181,284 | I | C\nPharmacological testing with a sodium channel\nblocker should be considered in relatives of SADS\ndecedents who are 16 years or older when\nbaseline testing and/or proband findings increase\nthe suspicion of BrS.277,281 | IIa | B",
          "rows": 6,
          "cols": 3
        },
        {
          "title": "Table on page 33",
          "page": 33,
          "content": "Recommendations | Classa | Levelb\nWithdrawal of offending agents is recommended\nwhenever drug-induced VAs are\nsuspected.293,294,297 | I | B\nInvestigation for reversible causes (e.g. electrolyte\nimbalances, ischaemia, hypoxaemia, fever)c is\nrecommended in patients with VA.292,298 | I | C\nDespite a possible correctable cause for the\npresenting VA, the need for ICD implantation\nshould be considered based on an individual\nevaluation of the risk of subsequent VA/\nSCD.286,296,299 | IIa | C",
          "rows": 4,
          "cols": 3
        },
        {
          "title": "Table on page 37",
          "page": 37,
          "content": "MonomorphicVA\nVA burdenc\nHigh Low\nICD programming optimizationa ICD programming optimizationa\n(Class I) (Class I)\nBeta-blocker/sedation\n(Class I)\nOn amiodarone or\nAmiodarone i.v. amiodarone not desirable N\n(Class I)\nAAD according to\nunderlying disease\nand cardiac function\nY\nRecurrent VA\nRecurrent VA\nCatheter ablation Catheter ablation\n(Class I) (Class I)\nDeep sedation/intubation\n(Class IIa)\nAutonomic modulation\n(Class IIb)\nMechanical circulatory support\n(Class IIb)\nOverdrive pacinge |  | \n |  | ",
          "rows": 2,
          "cols": 3
        },
        {
          "title": "Table on page 37",
          "page": 37,
          "content": "Recommendations |  | Classa | Levelb | \n | Acute management of sustained VT |  |  | \nDC cardioversion is recommended as the\nfirst-line treatment for patients with\nhaemodynamically not-tolerated SMVT.303,339 |  | I | B | \nDC cardioversion is recommended as the\nfirst-line treatment for patients presenting with\ntolerated SMVT provided that the anaesthetic/\nsedation risk is low. |  | I | C | ",
          "rows": 4,
          "cols": 5
        },
        {
          "title": "Table on page 38",
          "page": 38,
          "content": "In patients presenting with a haemodynamically\ntolerated idiopathic VT, treatment with\nintravenous beta-blocker (RVOT VT) or\nverapamil (fascicular VT) is recommended.306,307 |  | I | C | \nIn patients presenting with a regular\nhaemodynamically tolerated wide QRS complex\ntachycardia suspected for SVT, administration of\nadenosine or vagal manoeuvres should be\nconsidered.300 |  | IIa | C | \nIn patients presenting with a haemodynamically\ntolerated SMVT and known or suspected SHD,\nintravenous procainamide should be\nconsidered.303 |  | IIa | B | \nIn patients presenting with a haemodynamically\ntolerated SMVT in the absence of an established\ndiagnosis, intravenous amiodarone may be\nconsidered.303 |  | IIb | B | \nIn patients presenting with a haemodynamically\ntolerated SMVT in the absence of significant SHD,\nflecainide, ajmaline, or sotalol may be\nconsidered.304,305 |  | IIb | C | \nIntravenous verapamil is not recommended in\nbroad QRS complex tachycardia of unknown\nmechanism.308,309 |  | III | B | \n | Management of electrical storm |  |  | \nMild to moderate sedation is recommended in\npatients with electrical storm to alleviate\npsychological distress and reduce sympathetic\ntone. |  | I | C | \nAntiarrhythmic therapy with beta-blockers\n(non-selective preferred) in combination with\nintravenous amiodarone is recommended in\npatients with SHD and electrical storm unless\ncontraindicated.317,318 |  | I | B | \nIntravenous magnesium with supplementation of\npotassium is recommended in patients with\nTdP.295 |  | I | C | \nIsoproterenol or transvenous pacing to increase\nheart rate is recommended in patients with\nacquired LQT syndrome and recurrent TdP\ndespite correction of precipitating conditions and\nmagnesium. |  | I | C | \nCatheter ablation is recommended in patients\npresenting with incessant VT or electrical storm\ndue to SMVT refractory to AADs.330,331 |  | I | B | \nDeep sedation/intubation should be considered in\npatients with an intractable electrical storm\nrefractory to drug treatment.325 |  | IIa | C | \nCatheter ablation should be considered in patients\nwith recurrent episodes of PVT/VF triggered by a\nsimilar PVC, non-responsive to medical treatment\nor coronary revascularization.221,332,333 |  | IIa | C | \nQuinidine may be considered in patients with\nCAD and electrical storm due to recurrent PVT\nwhen other AAD therapy fails.323,324 |  | IIb | C | ",
          "rows": 15,
          "cols": 5
        },
        {
          "title": "Table on page 38",
          "page": 38,
          "content": "Autonomic modulation may be considered in\npatients with electrical storm refractory to drug\ntreatment and in whom catheter ablation is\nineffective or not possible.326,328,340 | IIb | C\nInstitution of mechanical circulatory support may\nbe considered in the management of\ndrug-refractory electrical storm and cardiogenic\nshock.335 | IIb | C",
          "rows": 2,
          "cols": 3
        },
        {
          "title": "Table on page 38",
          "page": 38,
          "content": "Recommendations | Classa | Levelb\nOptimal medical treatment including ACE-I/ARB/\nARNIs, MRAs, beta-blockers, and SGLT2\ninhibitors is indicated in all heart failure patients\nwith reduced EF.343–347 | I | A",
          "rows": 2,
          "cols": 3
        },
        {
          "title": "Table on page 39",
          "page": 39,
          "content": "Anti-arrhythmic\ndrug | Effects on ECG | Indications\n(specific\nindication) | Oral dose per\nday\n(i.v. dose) | Side effects | Contraindications,\nprecautions, other\nconsiderations\nAmiodarone | Decreases sinus\nnode frequency,\nprolongs QT\nintervala | PVC, VT, VF | 200–400 mg\nLoading dose:\n600–1200 mg/\n24 h 8–10 days.\n(Loading dose:\n5 mg/kg in\n20 min–2 h, 2–3\ntimes in 24 h, then\n600–1200 mg/\n24 h 8–10 days) | Cardiac:\nBradycardia, TdP\n(infrequent)\nExtracardiac:\nPhotosensitivity, corneal\ndeposits, hypothyroidism,\nhyperthyroidism,\npulmonary toxicity,\nhepatotoxicity,\npolyneuropathy, skin\ndiscoloration | Precautions:\nSinus node dysfunction,\nsevere AV conduction\ndisturbances,\nhyperthyroidism\nOther considerations:\nCan be used in patients with\nheart failure. Increases the\nrisk of myopathy when used\nwith statins\nAdenosine | Transitory AV block | Regular wide\ncomplex\ntachycardia of\nunknown origin\n(outflow tract\nVT) | No oral use\n(6–18 mg bolus) | Chest pain, flushing,\nbronchoconstriction | Contraindications:\nSevere asthma, pre-excited\nAF\nOther considerations:\nAntagonist: theophylline\nAjmaline | Prolongs QRS\nduration and QT\nintervala | VT\n(unmasking BrS\nECG) | No oral use\n(1 mg/kg over\n5–10 min\n(maximum dose\n100 mg) or\n1 mg/kg at\n10 mg/min) | Cardiac:\nVF (rare in suspected BrS),\noccasional TdP, negative\ninotrope\nExtracardiac:\nCholestatic jaundice,\nheadache, nausea,\nthrombocytopenia | Contraindications:\nBrS ECG type I, QT\nprolongation\nBeta-blocker | Decreases sinus\nnode frequency,\nprolongs PR interval,\nshortens QT interval | PVC, VT\n(LQTS, CPVT) | Various\n(various) | Cardiac:\nBradycardia, AV block,\nhypotension, negative\ninotrope\nExtracardiac:\nFatigue, bronchospasm,\nsexual disturbances,\ndepression, cold\nextremities | Contraindications:\nSevere sinus node\ndysfunction, severe AV\nconduction disturbances,\ndecompensated heart failure,\ncoronary vasospasm, severe\nasthma, BrS\nLandiolol\n(Ultra-short acting\nβ1-selective blocker) | See beta-blocker | VT, electrical\nstorm | No oral use\n100 µg/kg bolus in\n1 min, infusion\n10–40 µg/kg/min\n(max 80 µg/kg/\nmin; max 24 h\ntotal dose\n57.6 mg/kg/day) | See beta-blocker | Contraindications:\nSee beta-blocker.\nBradycardia, hypotension\nOther considerations:\nLimited experience with its\nuse beyond 24 h\nNadolol\n(Non-selective\nβ1β2 blocker) | See beta-blocker | PVC, VT\n(LQTS, CPVT) | 40–120 mg | See beta-blocker | Contraindications:\nSee beta-blocker\nOther considerations:\nPlasma half-life 20–24 h\nPropranolol\n(Non-selective β1β2\nblocker) | See beta-blocker | PVC, VT\n(electrical storm,\nLQTS, CPVT) | 80–320 mg\n(160 mg/24 h) | See beta-blocker | Contraindications:\nSee beta-blocker\nDisopyramide | Increases sinus node\nfrequency and\nprolongs PR interval,\nQRS duration, and\nQT intervala | PVC, VT | 250–750 mg | Cardiac:\nNegative inotrope, AV\nblock, pro-arrhythmia\n(MVT, occasional TdP) | Contraindications:\nSevere sinus node\ndysfunction, severe AV\nconduction disturbances,\nsevere intraventricular",
          "rows": 9,
          "cols": 6
        },
        {
          "title": "Table on page 40",
          "page": 40,
          "content": " |  |  |  | Extracardiac:\nAnticholinergic effects | conduction disturbances,\nprior MI, significant SHD,\nhypotension\nOther considerations:\nReduces LV outflow tract\nobstruction and symptoms in\nHCM\nFlecainide | Prolongs PR interval,\nQRS duration, and\nQT intervala | PVC, VT\n(unmasking BrS\nECGb) | 200–400 mg\n(1–2 mg/kg over\n10 min) | Cardiac:\nPro-arrhythmia (MVT,\noccasional TdP), negative\ninotrope, sinus\nbradycardia, AV block, 1:1\nAV conduction during\nflutter\nExtracardiac:\nCentral nervous system\neffects (e.g. drowsiness,\ndiplopia, headache) | Contraindications:\nPrior MI, significant SHD, BrS,\nsevere sinus node\ndysfunction, severe AV or\nintraventricular conduction\ndisturbances, inherited LQTS\n(other than LQTS3), severe\nkidney disease (CrCl\n,35 mL/min/1.73 m2)\nOther considerations:\nDiscontinue if QRS widening\n.25% or bundle branch\nblock\nIsoproterenol | Increases sinus node\nfrequency, shortens\nQT interval | (Electrical storm\nin BrS, idiopathic\nVF, and ERS, TdP,\nbeta-blocker\noverdose;\nacquired LQTS) | No oral use\n(0.5–10 µg/min) | Cardiac:\nSinus tachycardia,\nvasodilation\nExtracardiac:\nHeadache, sweating,\ntremor | Contraindications:\nACS, LQTS\nOther considerations:\nShort plasma half time\n(2 min)\nLidocaine | No significant effects | (VT/VF\nassociated with\nACS) | No oral use\n(50–200 mg bolus,\nthen 2–4 mg/min) | Cardiac:\nSinoatrial arrest\nExtracardiac:\nCentral nervous system\neffects (e.g. drowsiness,\ndizziness) | Precautions:\nReduced dose with reduced\nliver blood flow (e.g. shock,\nβ-blockade, severe heart\nfailure)\nOther considerations:\nMore effective with high\npotassium level. Few\nhaemodynamic side effects\nMexiletine | No significant effects | PVC, VT\n(LQT3) | 600–1200 mg\nLoading dose:\n400 mg initially\nfollowed by\n600 mg in the first\n24 h | Cardiac:\nSinus bradycardia in sinus\nnode dysfunction,\nhypotension\nExtracardiac:\nCentral nervous system\neffects (e.g. tremor,\ndysarthria, dizziness),\ngastrointestinal complaints | Contraindications:\nSinus node dysfunction,\nsevere AV conduction\ndisturbances, severe heart\nfailure\nProcainamide | Prolongs PR interval,\nQRS duration, and\nQT intervala | VT | (100 mg bolus,\ncan be repeated\nafter 5 min if no\neffect, max 500–\n750 mg [max\n50 mg/min]. Then,\n2–6 mg/min) | Cardiac:\nSinus bradycardia,\nhypotension, TdP\nExtracardiac:\nRash, myalgia, vasculitis,\nsystemic lupus,\nagranulocytosis | Contraindications:\nSevere sinus node\ndysfunction, severe AV\nconduction disturbances,\nsevere intraventricular\nconduction disturbances,\nsevere LV dysfunction\nhypotension, BrS\nPropafenone | Prolongs PR interval,\nQRS duration, and\nQT intervala | PVC, VT | 450–900 mg | Cardiac:\nSinus bradycardia, AV\nblock, negative inotrope,\npro-arrhythmia (MVT,\noccasional TdP)\nExtracardiac:\nGastrointestinal\ndisturbances, headache,\ndry mouth | Contraindications:\nPrior MI, significant SHD, BrS,\nsevere sinus node dysfunction,\nsevere AV or intraventricular\nconduction disturbances,\nLQTS, significant renal or liver\ndisease\nOther considerations:\nDiscontinue if QRS widening\n.25% or bundle branch block",
          "rows": 7,
          "cols": 6
        },
        {
          "title": "Table on page 41",
          "page": 41,
          "content": "Quinidine | Increases sinus node\nfrequency and\nprolongs PR interval,\nQRS duration, and\nQT intervala | (VFc, BrS, SQTS) | 600–1600 mg\nLoading dose:\nStart 200 mg\nevery 3 h until\neffect, max. 3 g in\nfirst 24 h | Cardiac:\nHypotension, TdPd\nExtracardiac:\nGastrointestinal\ndisturbances, auditory and\nvisual disturbances,\nconfusion, leukopenia,\nhaemolytic anaemia,\nthrombocytopenia,\nanaphylaxis | Contraindications:\nSevere sinus node\ndysfunction, severe AV or\nintraventricular conduction\ndisturbances, previous MI,\nsignificant SHD, hypotension,\nLQTS\nRanolazine | Decreases sinus\nnode frequency,\nprolongs QT\nintervala | VT\n(LQTS3) | 750–2000 mg | Cardiac:\nSinus bradycardia,\nhypotension\nExtracardiac:\nDizziness, nausea,\nconstipation,\ngastrointestinal\ndisturbance, headache,\nrash | Contraindications:\nSevere sinus node\ndysfunction, severe heart\nfailure, LQTS (other than\nLQTS3)\nPrecautions:\nConcomitant treatments\nassociated with QT interval\nprolongation\nSotalol | Decreases sinus\nnode frequency,\nprolongs QT\nintervala | VT | 160–640 mg\n(0.5–1.5 mg/kg in\n10 min. If\nnecessary, can be\nrepeated after\n6 h) | See beta-blockers, TdPd\n(.2% of patients, close\nmonitoring of QT interval\nand CrCl) | Contraindications:\nSevere sinus node\ndysfunction, severe AV\nconduction disturbances,\nsevere heart failure with\nreduced LVEF, significant\nLVH, CrCl ,30 ml/min,\ncoronary vasospasm, LQTS\nPrecautions:\nConcomitant treatments\nassociated with QT interval\nprolongation, hypokalaemia\nOther considerations:\nPotassium channel blocker\neffects require higher dose\nthan beta-blocker effects\nVerapamil | Prolongs PR interval | (LV fascicular\ntachycardia) | 120–480 mg\n(5–10 mg in slow\nbolus. If necessary,\ncan be repeated in\n30 min) | Cardiac:\nSinus bradycardia in sinus\nnode dysfunction, AV\nblock, negative inotrope,\nhypotension\nExtracardiac:\nGastrointestinal\ndisturbances, peripheral\noedema, flushing | Contraindications:\nHeart failure with reduced\nLVEF, severe sinus node\ndysfunction, and severe AV\nconduction disturbances, VT\nof unknown origin, ACS,\nWPW syndrome\nOther considerations:\nIncrease the risk of myopathy\nwhen used with statins",
          "rows": 4,
          "cols": 6
        },
        {
          "title": "Table on page 44",
          "page": 44,
          "content": "Recommendations | Classa | Levelb\nImplantation of a cardioverter defibrillator is only\nrecommended in patients who have an\nexpectation of good quality survival .1 year. | I | C\nIt is not recommended to implant an ICD in\npatients with incessant VAs until the VA is\ncontrolled. | III | C",
          "rows": 3,
          "cols": 3
        },
        {
          "title": "Table on page 44",
          "page": 44,
          "content": "Recommendations | Classa | Levelb\nWhen an ICD is indicated, it is recommended to\nevaluate whether the patient could benefit from\nCRT-defibrillator.367 | I | C",
          "rows": 2,
          "cols": 3
        },
        {
          "title": "Table on page 44",
          "page": 44,
          "content": "Recommendations | Classa | Levelb\nICD implantation is recommended in patients\nwith documented VF or haemodynamically\nnot-tolerated VT in the absence of reversible\ncauses.349–352 | I | A\nIn patients with VT/VF, an indication for ICD, and\nno contraindication for amiodarone, amiodarone\nmay be considered when an ICD is not available,\ncontraindicated for concurrent medical reasons,\nor declined by the patient. | IIb | C\nIn patients with SMVT or SPVT/VF triggered by a\nPVC with similar morphology and an indication\nfor ICD, catheter ablation may be considered\nwhen an ICD is not available, contraindicated for\nconcurrent medical reasons, or declined by the\npatient. | IIb | C",
          "rows": 4,
          "cols": 3
        },
        {
          "title": "Table on page 44",
          "page": 44,
          "content": "Recommendations | Classa | Levelb\nSubcutaneous defibrillator should be considered\nas an alternative to transvenous defibrillator in\npatients with an indication for an ICD when pacing\ntherapy for bradycardia, cardiac\nresynchronization, or ATP is not needed.366 | IIa | B",
          "rows": 2,
          "cols": 3
        },
        {
          "title": "Table on page 44",
          "page": 44,
          "content": "Recommendations | Classa | Levelb\nThe WCD should be considered for adult patients\nwith a secondary prevention ICD indication, who\nare temporarily not candidates for ICD\nimplantation. | IIa | C",
          "rows": 2,
          "cols": 3
        },
        {
          "title": "Table on page 45",
          "page": 45,
          "content": "In single- or dual-chamber ICD patients\nwithout bradycardia pacing indications,\nit is recommended to minimize ventricular\npacing.378–380 | I | A\nProgramming of prolonged detection settings is\nindicated (duration criteria of at least 6–12 s or 30\nintervals).373,382,383 | I | A\nIt is recommended to program the slowest\ntachycardia therapy zone limit ≥188 b.p.m. in\nprimary prevention ICD patients.382,383 | I | A\nIn patients with SHD, programming of at least one\nATP therapy is recommended in all\ntachyarrhythmias zones.375,384,391 | I | A\nIt is recommended to program algorithms for SVT\nvs. VT discrimination for tachycardias with rates\nup to 230 b.p.m.383–385 | I | B\nIt is recommended to activate lead failure\nalerts.397–399 | I | B\nRemote monitoring is recommended to reduce\nthe incidence of inappropriate shocks.395 | I | B\nProgramming of burst ATP as first attempt is\nrecommended over ramp ATP.392 | I | B\nFor S-ICDs, a dual detection zone configuration\nis recommended with activation of discrimination\nalgorithm in the lower conditional shock\nzone.388–390 | I | B\nFor routine ICD programming, activation of more\nthan one tachycardia detection zone should be\nconsidered.383,386 | IIa | B",
          "rows": 10,
          "cols": 3
        },
        {
          "title": "Table on page 45",
          "page": 45,
          "content": "Recommendations | Classa | Levelb\nOptimization of ICD programming is indicated to\navoid inappropriate and unnecessary therapies\nand to reduce mortality.373–375 | I | A",
          "rows": 2,
          "cols": 3
        }
      ],
      "keywords": [
        "ct",
        "general",
        "therapies",
        "monitoring",
        "follow-up",
        "diuretic",
        "aspects",
        "treatment",
        "icd",
        "ventricular",
        "arrhythmias"
      ]
    },
    {
      "number": "9",
      "title": "7. Diagnostic evaluation, management, and risk stratification according to clinical presentation and known (likely) \u0006disease",
      "start_page": 48,
      "end_page": 62,
      "content": "6.2.4.1.2. Patients without apparent structural heart disease.\n‘Idiopathic VTs’ is the term for VTs that are not associated with\nSHD or a genetic arrhythmic syndrome. Most idiopathic VTs are\nmediated by triggered activity, but a re-entrant mechanism (involving\nthe LV Purkinje network) explains verapamil-sensitive fascicular\nVTs.523 Three important key features distinguish idiopathic VTs\nfrom VTs associated with SHD. First, idiopathic VTs mostly originate\nfrom a single site and speciﬁc region of the heart (namely the right or\nleft ventricular outﬂow tracts,524,525 along the valve annuli,526–528\npapillary muscle,529 or the LV Purkinje network).523 Second, no de-\ntectable scar is found in idiopathic VTs.530 Finally, idiopathic VTs have\na benign prognosis so that ICD implantation is generally not\nrecommended.466\nThe earliest site of activation during VT is the ablation target for\nfocal sources, while abnormal Purkinje tissue (with diastolic activity\nduring VT) is the ablation target of left fascicular VTs.531,532\nCatheter ablation is curative in most idiopathic VT patients and\nperi-procedural complications are rare.533–537\n6.2.4.2. Autonomic modulation\nThe role of the autonomic nervous system in promoting arrhythmias\nhas long been recognized, leading to the concept of Coumel’s triangle\nof arrhythmogenesis.538\nSympathetic activation has been demonstrated as playing a key\nrole in inducing VAs in some entities, such as congenital LQTS and\nCPVT,539,540 and left cardiac sympathetic denervation was shown\nto be associated with a decrease in the frequency of arrhythmo-\ngenic syncope in congenital LQTS.541,542 The efﬁcacy of cardiac\nsympathetic blockade by different approaches (thoracic epidural\nanaesthesia, percutaneous stellate ganglion anaesthesia, or surgical\nstellate ganglion resection) in reducing the arrhythmia burden in\nrefractory VT/VF has been recognized in several small observation-\nal studies.326,328,340 Further studies are needed to assess which pa-\ntients may beneﬁt from a modulation of the autonomic nervous\nsystem to better control VT/VF.\n7. Diagnostic evaluation,\nmanagement, and risk\nstratiﬁcation according to clinical\npresentation and known (likely)\ndisease\n7.1. Speciﬁc structural heart diseases\n7.1.1. Coronary artery disease\n7.1.1.1. Acute coronary syndromes and vasospasm\n7.1.1.1.1. Acute coronary syndromes. SCD is a major cause of\nmortality in ACS, mostly caused by sustained VAs, in particular\nVF. The majority of studies have reported on patients with\nSTEMI. Of patients with STEMI, 4–12% develop VA within the\nﬁrst 48 h after the onset of symptoms.69,543,544 Pre-reperfusion\nVAs are more common than reperfusion-induced or post-\nreperfusion arrhythmias in STEMI.545 Haemodynamic instability,\ncardiogenic shock, LVEF , 40%, and the sum of ST-segment de-\nviations in all leads are independent predictors of VA both in\nSTEMI and non-STEMI.69,546 In addition, an early repolarization\npattern has been associated with increased risk of VAs and\nSCD in ACS.547\nPrevention of ventricular arrhythmias in ST elevation myocardial\ninfarction\nUrgent reperfusion is the most important therapy,292,548 as acute\nischaemia triggers arrhythmias. Beta-blocker treatment is also\nrecommended to prevent VA.3,549 In a recent randomized trial of pa-\ntients with STEMI, early intravenous metoprolol before percutan-\neous coronary intervention reduced the incidence of arrhythmias\nin the acute phase and was not associated with an increase in adverse\nevents.550 Prophylactic treatment with AADs has not proven bene-\nﬁcial, and may even be harmful.322 Correction of electrolyte imbal-\nances is strongly recommended.289\nManagement of sustained ventricular tachycardia and ventricular\nﬁbrillation in acute coronary syndrome\nElectrical cardioversion or deﬁbrillation is the intervention of\nchoice to acutely terminate VAs in ACS patients (Figure 14).205,339\nRecurrent sustained VT, especially when polymorphic, or recurrent\nVF can indicate incomplete reperfusion or recurrence of acute is-\nchaemia. In this case, immediate coronary angiography is indicated.3\nFor recurrent PVT degenerating into VF, beta-blockers are recom-\nmended.551,552 In addition, deep sedation may be helpful to reduce\nepisodes of VT or VF.553 Intravenous amiodarone should be consid-\nered to acutely suppress recurrent haemodynamically relevant VAs,\nalthough there is a paucity of controlled studies for amiodarone dur-\ning STEMI554 and the evidence in this setting is mainly extrapolated\nfrom studies of OHCA.555 If treatment with beta-blockers and amio-\ndarone is not effective, lidocaine may be considered.322 The use of\nother AADs in ACS is not recommended.549,556 In haemodynamic-\nally unstable patients with refractory VA, mechanical circulatory sup-\nport may be considered.336,557 For VA in the context of relative\nbradycardia or pause-related, pacing may be effective to prevent\nre-initiation.\nThe prognostic signiﬁcance of early ventricular arrhythmias\nEarly VAs are deﬁned as VT/VF occurring within 48 h after a\nSTEMI. In the contemporary percutaneous coronary intervention\n(PCI)-based revascularization era, almost all VA occur within the ﬁrst\n24 h.558 Early VA have been associated with an up to six-fold increase\nin in-hospital mortality, whereas long-term prognosis seems not to\nbe signiﬁcantly affected.543,559,560 In a prospective cohort study, pa-\ntients with VF during the acute STEMI phase had low and very similar\nincidence of late SCD as compared with VF-free patients during\n5-year observation.560 Of note, early monomorphic VT was asso-\nciated with signiﬁcantly higher incidence of adequate ICD interven-\ntions compared with early VF, and was an independent predictor\nof death during long-term follow-up.561 Thus, the prognostic signiﬁ-\ncance of VT and VF occurring in the acute phase of MI may be differ-\nent. The impact of VA occurring late after reperfusion (.48 h) on\nlate SCD is less clear.\nPodolecki et al.559 recently demonstrated that long-term all-cause\nmortality after STEMI was predicted by VA occurring late after re-\nperfusion (.48 h after reperfusion), while early reperfusion VAs\ndid not affect 5-year outcome. Further studies are required to clarify\n4044\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nthe impact of VA occurring .48 h after STEMI on late SCD in con-\ntemporary patients undergoing acute PCI.\n7.1.1.1.2. Vasospasm. Coronary artery spasms might have an im-\nportant role in the pathogenesis of VA. The long-term prognosis\nPrevention and treatment of  VAs in the acute phase of STEMI\nBeta-blocker i.v. prior to PCI, if not contraindicateda,b\n(Class IIa)\nUrgent CAG and revascularizationa\n(Class I)\nFurther revascularization if appropriatea\n(Class I)\nRepletion of K+, Mg2+ a\n(Class I)\nBeta-blocker i.v.b\n(Class I)\nAmiodarone i.v.\n(Class IIa)\nLidocaine i.v.\n(Class IIb)\nDeep sedation/intubation c\n(Class IIb)\nSedation (for comfort)c\n(Class I)\nVA\nRecurrent VA\nAutonomic modulationc\n(Class IIb)\nCatheter ablationd\n(Class IIa)\nMechanical circulatory support c\n(Class IIb)\nOverdrive pacinga\n(Class IIa)\nRecurrent VA\nFigure 14 Algorithm for the prevention and management of ventricular arrhythmias in ST-elevation myocardial infarction. CAG, coronary angiogram; PCI,\npercutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; VA, ventricular arrhythmias. aThe 2017 ESC Guidelines for the management of\nacute myocardial infarction in patients presenting with ST-segment elevation.3 bIntravenous beta-blockers must be avoided in patients with hypotension, acute\nheart failure, AV block or severe bradycardia. cFlowchart for the management of electrical storm. dIf similar PVC triggers recurrent polymorphic VA.\nESC Guidelines\n4045\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nof patients with variant angina who survive a CA is worse than in\nother patients with variant angina.562,563 In a recent multicentre\nEuropean survey,564 patients with life-threatening VAs secondary\nto coronary vasospasm were at high risk for recurrence, especially\nwhen insufﬁcient medical therapy was administered. While calcium\nchannel blockers (CCB) are capable of suppressing episodes, beta-\nblockers may trigger VAs. As medical intervention and multiple vaso-\ndilator drugs may not be sufﬁciently protective, placement of an ICD\nshould still be considered in SCA survivors with variant angina.\n7.1.1.2. Early after myocardial infarction\nThe ﬁrst weeks after a STEMI carry the highest risk both for all-\ncause death and for SCD, particularly in patients with reduced\nLVEF.565,566 For this reason, early assessment of LVEF, i.e. before\ndischarge, is recommended.567,568 Early routine prophylactic ICD\nimplantation in the ﬁrst 40 days after MI did not reduce mortality\nin post-MI patients with reduced LVEF in two randomized trials\n(DINAMIT and IRIS),569,570 and is therefore not recommended.\nEarly assessment by further non-invasive tests, apart from LVEF\nmeasurement, has also not proven to be useful for risk stratiﬁca-\ntion with regard to SCD.571 Limited evidence suggests that invasive\nrisk stratiﬁcation by PES in the early post-MI phase may be helpful\nfor identiﬁcation of high-risk patients with reduced LVEF.572\nHowever, the utility of this approach has not been conﬁrmed so\nfar in randomized studies. The PROTECT-ICD randomized trial\n(NCT03588286) is currently examining whether PES may guide\nthe decision on ICD implantation in patients with reduced EF in\nthe early phase after STEMI.\nReverse remodelling following an MI is associated with signiﬁ-\ncantly lower rates of death, SCA, and other adverse clinical out-\ncomes.573,574\nTherefore,\nassessment\nof\nthe\nindication\nfor\nprophylactic ICD implantation, usually performed by repeat echo-\ncardiography, should take place in the post-remodelling phase of\nthe MI after the ﬁrst 6 weeks in patients with a pre-discharge\nLVEF ≤40%. Reassessment of the LVEF before 6 weeks following\nMI may not discriminate between myocardial stunning and\nremodelling.\nIn the early post-MI phase, electrical storm and/or recurrent\nepisodes of PVT or VF are immediately life-threatening condi-\ntions. In this setting, it is important to exclude ischaemia as\nthe triggering factor for the arrhythmias. If medical treatment\nis not sufﬁcient to suppress the arrhythmic episodes, catheter\nablation is potentially effective particularly if the episodes are fo-\ncally triggered by similar PVCs.332,575 If PVT recurs despite beta-\nblocker and amiodarone treatment, suppression by quinidine\ntherapy has been reported.323\n7.1.1.3. Chronic coronary artery disease\n7.1.1.3.1. Primary prevention of sudden cardiac death in patients\nwith reduced ejection fraction. Forty days after STEMI, approxi-\nmately 5% of patients will have an LVEF ≤35%.576 These patients\nare at risk for SCD. Therefore, in patients with LVEF ≤35% and\nRecommendation Table 22 — Recommendations for\ntreatment of ventricular arrhythmias in acute coron-\nary syndrome and vasospasm\nRecommendations\nClassa\nLevelb\nTreatment of VAs in ACS\nIntravenous beta-blocker treatment is indicated\nfor patients with recurrent PVT/VF during STEMI\nunless contraindicated.551,552\nI\nB\nIntravenous amiodarone treatment should be\nconsidered for patients with recurrent PVT/VF\nduring the acute phase of ACS.552,554,555\nIIa\nC\nIntravenous lidocaine may be considered for the\ntreatment of recurrent PVT/VF not responding to\nbeta-blockers or amiodarone, or if amiodarone is\ncontraindicated during the acute phase of ACS.554\nIIb\nC\nProphylactic treatment with AADs (other than\nbeta-blockers) is not recommended in ACS.322\nIII\nB\nVasospasm\nIn SCA survivors with coronary artery\nspasm, implantation of an ICD should be\nconsidered.562–564\nIIa\nC\n© ESC 2022\nAAD, anti-arrhythmic drug; ACS, acute coronary syndrome; ICD, implantable cardioverter\ndeﬁbrillator; PVT, polymorphic ventricular tachycardia; SCA, sudden cardiac arrest;\nSTEMI, ST elevation myocardial infarction; VA, ventricular arrhythmia; VF,\nventricular ﬁbrillation.\naClass of recommendation.\nbLevel of evidence.\nRecommendation Table 23 — Recommendations for\nrisk stratiﬁcation and treatment of ventricular ar-\nrhythmias early after myocardial infarction\nRecommendations\nClassa\nLevelb\nRisk stratiﬁcation\nEarly (before discharge) assessment of LVEF is\nrecommended in all patients with acute MI.567,568\nI\nB\nIn patients with pre-discharge LVEF ≤40%,\nre-evaluation of LVEF 6–12 weeks after MI is\nrecommended to assess the potential need for\nprimary prevention ICD implantation.568,573,574\nI\nC\nTreatment of VAs\nCatheter ablation should be considered in patients\nwith recurrent episodes of PVT/VF triggered by a\nsimilar PVC non-responsive to medical treatment\nor coronary revascularization in the subacute\nphase of MI.332\nIIa\nC\n© ESC 2022\nICD, implantable cardioverter deﬁbrillator; LVEF, left ventricular ejection fraction; MI,\nmyocardial infarction; PVC, premature ventricular complex; PVT, polymorphic\nventricular tachycardia; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation.\naClass of recommendation.\nbLevel of evidence.\n4046\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nheart failure symptoms NYHA class II and III, primary preventive\nICD implantation is recommended.356 ICD implantation should\nalso be considered for asymptomatic patients with an EF ≤30%.354\nIn this population, mortality reduction by an ICD has been\ndemonstrated in four RCTs.353–356 In patients with CAD, a\nreduced LVEF (≤40%), and asymptomatic NSVT, inducibility by\nPES identiﬁes patients who beneﬁt from an ICD, independent\nfrom NYHA class.355\nSince the publication of the aforementioned trials, early revascu-\nlarization strategies and modern heart failure medication have re-\nduced the overall risk of SCD in heart failure patients.577 Although\ntotal mortality has been reduced, the relative reduction by the\nICD is a consistent 27%, which has been corroborated in two\nrecent large prospective registry studies enrolling 2327 European\npatients between 2014 and 2018 (EU-CERT-ICD)357 and 2610\nSwedish patients enrolled between 2000 and 2016 (SwedeHF\nregistry).358\n7.1.1.3.2. Primary prevention of sudden cardiac death in patients with\npreserved or mildly reduced ejection fraction. There are no data sup-\nporting primary prophylactic ICD implantation in post-infarct pa-\ntients with preserved or mildly reduced LVEF. These patients are\nheterogeneous with regard to their potential arrhythmic substrate,\nand efforts are under way to identify those with the highest risk\nfor SCD. PES is recommended in post-infarct patients in whom syn-\ncope remains unexplained after non-invasive evaluation to guide pa-\ntient management (Figure 15).146\nIn the PRESERVE-EF study, 41 of 575 post-infarct patients with an\nLVEF ≥40% and one non-invasive ECG risk factor more than 40 days\npost-MI were inducible for VT/VF during PES and received an ICD.151\nDuring the 32-month follow-up period, no SCD occurred and 9 of\n37 ICD patients received an appropriate ICD therapy. However,\nthe role of appropriate ICD treatment as surrogate for SCD in pa-\ntients with preserved LVEF is unknown, and randomized trials are\nneeded. Prophylactic treatment with AADs other than beta-blockers\nis not indicated regardless of the LVEF.556,578,579\n7.1.1.3.3. Secondary prevention of sudden cardiac death. The\nthree pivotal secondary prevention ICD trials enrolled 1866 pa-\ntients\nbetween\n1990\nand\n1997.349–351\nA\npatient-level\nRecommendation Table 24 — Recommendations for\nrisk stratiﬁcation, sudden cardiac death prevention,\nand treatment of ventricular arrhythmias in chronic\ncoronary artery disease\nRecommendations\nClassa\nLevelb\nRisk stratiﬁcation and primary prevention of SCD\nIn patients with syncope and previous STEMI, PES\nis indicated when syncope remains unexplained\nafter non-invasive evaluation.146,584\nI\nC\nICD therapy is recommended in patients\nwith CAD, symptomatic heart failure (NYHA\nclass II–III), and LVEF ≤35% despite ≥3 months\nof OMT.354,356\nI\nA\nICD therapy should be considered in patients with\nCAD, NYHA class I, and LVEF ≤30% despite ≥3\nmonths of OMT.354\nIIa\nB\nICD implantation should be considered in patients\nwith CAD, LVEF ≤40% despite ≥3 months of\nOMT, and NSVT, if they are inducible for SMVT by\nPES.355\nIIa\nB\nIn patients with CAD, prophylactic treatment\nwith AADs other than beta-blockers is not\nrecommended.556,578,579\nIII\nA\nSecondary prevention of SCD and treatment of VAs\nICD implantation is recommended in patients\nwithout ongoing ischaemia with documented VF\nor haemodynamically not-tolerated VT occurring\nlater than 48 h after MI.349–351\nI\nA\nIn patients with CAD and recurrent, symptomatic\nSMVT, or ICD shocks for SMVT despite chronic\namiodarone therapy, catheter ablation is\nrecommended in preference to escalating AAD\ntherapy.471\nI\nB\nContinued\nThe addition of oral amiodarone or\nbeta-blocker replacement by sotalol should be\nconsidered in patients with CAD with\nrecurrent, symptomatic SMVT, or ICD shocks\nfor SMVT while on beta-blocker\ntreatment.318,581\nIIa\nB\nIn patients with CAD and haemodynamically\nwell-tolerated SMVT and LVEF ≥40%, catheter\nablationinexperiencedcentresshouldbeconsidered\nas an alternative to ICD therapy, provided that\nestablished endpoints have been reached.c,480,580\nIIa\nC\nICD implantation should be considered in patients\nwith a haemodynamically tolerated SMVT and an\nLVEF ≥40% if VT ablation fails, is not available, or is\nnot desired.\nIIa\nC\nCatheter ablation should be considered in patients\nwith CAD and recurrent, symptomatic SMVT, or\nICD shocks for SMVT despite beta-blockers or\nsotalol treatment.471\nIIa\nC\nIn patients with CAD eligible for ICD implantation,\ncatheter ablation may be considered just before (or\nimmediately after) ICD implantation to decrease\nsubsequent VT burden and ICD shocks.484,485,582,583\nIIb\nB\n© ESC 2022\nAAD, anti-arrhythmic drug; CAD, coronary artery disease; ICD, implantable\ncardioverter deﬁbrillator; LVEF, left ventricular ejection fraction; MI, myocardial\ninfarction; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart\nAssociation; OMT, optimal medical therapy; PES, programmed electrical stimulation;\nSCD, sudden cardiac death; SMVT, sustained monomorphic ventricular tachycardia;\nSTEMI, ST elevation myocardial infarction; VA, ventricular arrhythmia; VF, ventricular\nﬁbrillation; VT, ventricular tachycardia.\naClass of recommendation.\nbLevel of evidence.\ncVT non-inducibility and elimination of electrograms consistent with conduction delay.\nESC Guidelines\n4047\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nmeta-analysis demonstrated a 28% mortality reduction (HR 0.72;\n95% CI 0.60–0.87; P = 0.0006) almost entirely due to reduction\nof arrhythmic death (HR 0.50; 95% CI 0.37–0.67; P , 0.0001) in\nthe ICD group.352 This translates to an extension of survival of\n4.4 months over a mean follow-up of 6 years by the ICD.\nAround 80% of the study population suffered from CAD.\nPatients with well-tolerated SMVT were excluded from secondary\nprevention trials (Figure 16).\n7.1.1.3.4. Management of patients with haemodynamically toler-\nated ventricular tachycardia and preserved and mildly reduced\nejection fraction. With the better understanding of the mechanisms\nof VT after MI, as well as improved ablation and imaging technologies,\ncatheter ablation has become an option for the treatment of haemo-\ndynamically well-tolerated VT in selected post-MI patients with pre-\nserved or mildly reduced EF, even without ICD back-up. One small\nmonocentric retrospective trial studied patients with CAD, LVEF\n.40%, and haemodynamically tolerated VT who underwent cath-\neter ablation as ﬁrst-line therapy.580 The investigators could abolish\n90% of the clinical and 58% of all inducible VTs. Subsequently, 42% of\nthe patients received an ICD. After a mean follow-up of 3.8 years,\n42% of the patients died irrespective of the presence or absence\nof an ICD (P = 0.47).\nA larger multicentre retrospective study looked at 166 patients\nwith an LVEF .30% presenting with well-tolerated SMVT, which\nwere treated by catheter ablation only, and compared the out-\ncome to a control group of 378 patients implanted with an\nICD.480 Of the 166 patients undergoing ablation as ﬁrst therapy,\n55% suffered from CAD. The mean LVEF was 50%, and after a\nmean follow-up of 32 months, overall mortality did not differ be-\ntween the groups (12%).\nThese data suggest that either ICD implantation or ablation in ex-\nperienced centres should be considered in patients with a preserved\nor mildly reduced EF presenting with haemodynamically tolerated\nSMVT. Of note, although ICDs have been commonly implanted in\nthis population, the secondary preventive ICD trials failed to show\na survival beneﬁt in patients with an LVEF ≥35%.352 Although\nSMVT is rarely caused by ischaemia and revascularization alone\nNSVT or\nunexplained syncope\nNYHA class ≥II\nLVEF\nL\n≤30%\nLVEF \nL\n≤35%\nLVEF 36–40%\nL\nN\nN\nN\nPatient with chronic CAD\nLVEF\nL\nevaluation 6–12 weeks after acute MI\nin patients with LVEF\nL\n≤40% at discharge\n(Class I) \nILR implantationa\n(Class I)\nPES\n(Class I)\nICD\n(Class I)\nNo SMVT inducible\nand unexplained syncope\nSMVT inducible\nICD implantation\n(Class IIa)\nFollow-up\nICD implantation\n(Class IIa)\nY\nY\nY\nFigure 15 Algorithm for risk stratiﬁcation and primary prevention of sudden cardiac death in patients with chronic coronary artery disease and reduced\nejection fraction. CAD, coronary artery disease; ICD, implantable cardioverter deﬁbrillator; ILR, implantable loop recorder; LVEF, left ventricular ejection\nfraction; MI, myocardial infarction; N, No; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; PES, programmed electrical\nstimulation; SMVT, sustained monomorphic ventricular tachycardia; Y, Yes. aThe 2018 ESC Guidelines for the diagnosis and management of syncope.1\n4048\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\ndoes not prevent VT recurrence, exclusion or treatment of signiﬁ-\ncant CAD before catheter ablation is reasonable.\n7.1.1.3.5. Management of recurrent ventricular tachycardia in im-\nplantable cardioverter deﬁbrillator carriers. Frequent, symptomat-\nic VT in ICD recipients should be treated medically with either\namiodarone or sotalol.318,581 In patients with CAD in whom SMVT\nrecurs while on amiodarone treatment, catheter ablation is recom-\nmended over escalation of AAD therapy. In the VANISH trial, the\ncomposite endpoint of death, VT storm, and appropriate ICD ther-\napy was reached signiﬁcantly less often in the ablation group as com-\npared to the escalated amiodarone-therapy group over a mean\nfollow-up of 28 months (59% vs. 68.5%; HR 0.72; 95% CI 0.53–\n0.98; P = 0.04).471 The ongoing VANISH2 trial (ClinicalTrials.gov\nIdentiﬁer: NCT02830360) addresses the question of whether cath-\neter ablation as ﬁrst-line treatment is superior to AAD therapy in\npost-MI patients with SMVT.\nPreventive VT ablation after a ﬁrst documented SMVT, which was\nfollowed by ICD implantation, reduced neither mortality nor hospi-\ntalizations for arrhythmia or worsening heart failure when compared\nto a deferred ablation strategy only after the third ICD shock.582\nHowever, in patients who present with a ﬁrst VT episode and in\nwhom an ICD is indicated, catheter ablation performed immediately\nbefore or shortly after ICD implantation may be considered to de-\ncrease subsequent VT and ICD shocks.484,485,583\n7.1.1.4. Coronary anomalies\nAnomalous aortic origin of a coronary artery, either the left or\nthe right, arising from the opposite sinus of Valsalva, is associated\nwith an increased risk of SCD, especially in individuals ,35 years\nduring or following vigorous exercise.585 Anomalous aortic origin\nof the left coronary artery is less common but more malignant\nthan anomalous aortic origin of the right coronary artery. Other\nrisk factors for SCD are interarterial course between the aorta\nand pulmonary artery, slit-like shaped oriﬁce, high oriﬁce, acute-\nangle take-off, and intramural course and its length.585,586\nIndications for surgical intervention, especially in asymptomatic pa-\ntients, are based on the evaluation of high-risk anatomy by CTA and\nthe assessment of exercise-induced ischaemia using advanced im-\naging modalities.586–588 Cardiac stress imaging is also indicated to\nevaluate exercise-induced ischaemia after surgical intervention, es-\npecially in patients with an aborted CA.588\nSMVT in a patient with chronic CAD\nICD implantation\n(Class I)\nCatheter ablation\n(Class IIb)\nCatheter ablation\n(Class IIa)\nAmiodaroneb\n(Class IIa)\nCatheter ablation\n(Class IIa)\nAmiodarone\n(Class IIa)\nCatheter ablation\n(Class I)\nY\nY\nN\nN\nHaemodynamically\ntolerated\nOn amiodarone\nGo to flowchart\nelectrical storm\n(Figure 11)\nSymptomatic SMVT\nSMVT in ICD carriersa\nFirst presentation\nElectrical storm\nLVE\nL\nF\n<40%\n≥40%\nSotalolc\n(Class IIa)\nICD implantationb\n(Class IIa)\nFigure 16 Algorithm for the management of sustained monomorphic ventricular tachycardia in patients with chronic coronary artery disease. CAD,\ncoronary artery disease; ICD, implantable cardioverter deﬁbrillator; LVEF, left ventricular ejection fraction; N, No; SMVT, sustained monomorphic ven-\ntricular tachycardia; Y, Yes. aIncessant ventricular tachycardia in monitor zone: consider catheter ablation. bIf catheter ablation is not available, not suc-\ncessful or not desired by the patient. cTo reduce ICD shocks.\nESC Guidelines\n4049\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n7.1.2. Idiopathic premature ventricular complexes/\nventricular tachycardia and premature ventricular\ncomplex-induced cardiomyopathy\n7.1.2.1. Idiopathic premature ventricular complexes/ventricular\ntachycardia\nPVCs/VT in patients without SHD are deﬁned as idiopathic\n(Figure 17). In patients with presumed idiopathic PVCs/VT based\non a negative history and normal physical examination, 12-lead\nECG and transthoracic echocardiography are important ﬁrst diag-\nnostic steps to exclude underlying SHD. Twenty-four-hour ECG\nHolter monitoring is usually performed to determine the PVC burden.\nMultiform PVCs at prolonged ECG monitoring and subtle changes on\nECG or echocardiography need to be recognized.589 CMR should be\nperformed whenever ECG and echocardiography are inconclusive to\nrule out SHD, or the clinical presentation raises suspicion for SHD.590,591\nPatients need to be treated when PVCs/VT are symptomatic or\nassociated with deterioration of cardiac function. The clinical course\nand responses to different treatments have been mostly studied in\nthose originating from the RVOT or the left fascicles.\nSeveral drugs have been used to treat idiopathic PVCs/VT.\nRecommendations are based on small or non-controlled series.\nBeta-blockers and CCBs are the most-studied drugs and both have\nbeen shown to be effective at arrhythmia suppression.304 The evi-\ndence for ﬂecainide is scarce.592 In case of a higher burden of\nPVCs with higher heart rate or during exercise, beta-blockers should\nbe preferred.593 If there is not such a correlation, the use of ﬂecainide\nor CCB drugs have been associated with more effective PVC sup-\npression. Beta-blockers should also be selected when a focal trig-\ngered activity mechanism is suspected. CCB should be the drug of\nchoice for fascicular PVC/VT. Although data are lacking, beta-\nblockers or CCBs are considered ﬁrst choice for PVCs with an origin\noutside the RVOT or the left fascicles because ﬂecainide may have\nproarrhythmic side effects. Amiodarone is associated with severe\nsystemic toxicity and should be used only if ablation or other drugs\nfail or cannot be used.594 A summary of the recommendations for the\ntreatment of idiopathic PVCs/VT and PVC-induced or aggravated\ncardiomyopathy with AADs is provided in Table 9.\nA high success rate of catheter ablation of idiopathic PVCs/VT has\nbeen reported with rare complications, particularly for the RVOT\nand fascicular types.535 In a randomized study including patients\nwith RVOT PVCs, ablation was superior to AAD therapy for\narrhythmia suppression with no differences in complications.595\nAblation is therefore recommended as the ﬁrst-line therapy for\nRVOT and fascicular PVCs/VT. The available information for other\nforms of idiopathic PVCs/VT is limited and mostly restricted to the\nacute success of ablation, which, in general, is lower and associated\nwith more recurrences than for RVOT and fascicular PVCs/VT.540\nIn addition, access to and ablation at speciﬁc locations (e.g. sinus of\nValsalva, LV summit) may increase the risk for procedural complica-\ntions. Therefore, when the 12-lead ECG is highly suspicious of a\nPVC/VT source outside the RVOT or left fascicles, the level of rec-\nommendation for ablation is lower.\nIn general, treatment of children should be similar to that of adults.\nHowever, ablation should be deferred in young and small children due\nto the risk of complications and the relatively larger size of the ablation\nlesion as compared to the child’s heart.596,597 Verapamil is not recom-\nmended as the ﬁrst-line therapy in children ,1 year old because it has\nbeen associated with hypotension in some case reports.542 Of note, all\nreported patients had either heart failure, overdosing of verapamil, or\nother concurrent AADs at the time verapamil was given.598\nPatients may present with asymptomatic frequent PVCs/VTs.\nOnly a minority of patients with .1000 PVCs per day will develop\nventricular dysfunction after 5 years follow-up.599 A PVC burden\nof 10% seems to be the minimal threshold for development of LV\ndysfunction,\nwith\nhigher\nrisk\nwhen\nthe\nPVC\nburden\nis\n.20%.535,600,601 Regular assessment of LVEF in this setting is there-\nfore indicated. To date, there are no data supporting the beneﬁt of\narrhythmia treatment for asymptomatic patients with preserved\nventricular function. In addition, PVC burden often decreases spon-\ntaneously over time, particularly in children.599,602 In selected pa-\ntients, e.g. patients who do not want to be followed, catheter\nablation may be considered. In patients with PVC burden , 10%, re-\nevaluation may be appropriate in case of development of new symp-\ntoms or change in patient condition.\nRecommendation Table 25 — Recommendations for\nsudden cardiac death prevention in patients with coron-\nary anomalies\nRecommendations\nClassa\nLevelb\nDiagnostic evaluation\nCardiac stress imaging during physical exercise is\nrecommended in addition to cardiopulmonary\nexercise test in patients with anomalous aortic\norigin of a coronary artery with an interarterial\ncourse to conﬁrm/exclude myocardial ischaemia.587\nI\nC\nCardiac stress imaging during physical exercise is\nrecommended in addition to cardiopulmonary\nexercise test after surgery in patients with\nanomalous aortic origin of a coronary artery with\na history of aborted CA.\nI\nC\nTreatment\nSurgery is recommended in patients with\nanomalous aortic origin of a coronary artery with\nCA, syncope suspected to be due to VAs, or angina\nwhen other causes have been excluded.585,586,588\nI\nC\nSurgery should be considered in asymptomatic\npatients with anomalous aortic origin of a\ncoronary artery and evidence of myocardial\nischaemia or abnormal aortic origin of the left\ncoronary artery with high-risk\nanatomy.c,585,586,588\nIIa\nC\n© ESC 2022\nCA, cardiac arrest; VA, ventricular arrhythmia.\naClass of recommendation.\nbLevel of evidence.\ncHigh-risk anatomy is deﬁned as interarterial course, slit-like shaped oriﬁce, high oriﬁce,\nacute-angle take-off, and intramural course and its length.\n4050\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nPatient with PVCs / MonomorphicVT and non-apparent SHDa\nECG, Holte\n,\nr, and echoca\n,\nrdiogram\nAssessment\nAssessment\n>20% PVCs\nRV\nR OT / Fascicular PVC/VT\nO\nd\nSymptomsc\n>10% PVCs\nDischargee\nGo to flowchart\nPVC-induced\ncardio\nr\nmyopathy\n(Figure 18)\nSHD or PVC-induced cardiomyopathy\nCMR (Class IIa)\nInconclusive or atypical presentationb\nCatheter ablation\n(Class I)\nBeta-blockers,\nk\nCCB or \nFlecainide\n(Class IIa)\nBeta-blocker\nk  o\nr r CCB\n(Class I)\nFlecainide\n(Class IIa)\nCatheter ablation\n(Class IIa)\nRegular\nfoll\nf\now-up LVEF\nL\n(Class I)\nStructural abnormal heart\nIdiopathic PVC/VT\nStructural normal heart\nRegular\nfoll\nf\now-up LVEF\nL\n(Class I)\nCatheter ablation\n(Class IIb)\nY\nY\nY\nY\nN\nN\nN\nN\nFigure 17 Algorithm for the management of patients with idiopathic premature ventricular complexes/ventricular tachycardia and non-apparent struc-\ntural heart disease. CCB, calcium channel blocker; CMR, cardiac magnetic resonance; ECG, electrocardiogram; LVEF, left ventricular ejection fraction; N, No;\nPVC, premature ventricular complex; RVOT, right ventricular outﬂow tract; SHD, structural heart disease; VT, ventricular tachycardia; Y, Yes. aNon-apparent\nSHD is deﬁned by lack of signiﬁcant abnormalities in physical examination, basal ECG, and echocardiogram. bAtypical presentation: e.g. older age, right bundle\nbranch block morphology, sustained monomorphic VT consistent with re-entry. cSymptoms should be relevant and related to PVC/VT. dOrigin suspected by\nECG or conﬁrmed during electrophysiological evaluation. eConsider re-evaluation in case of new symptoms or changes in patient clinical condition.\nTable 9\nSummary of the recommendations for the treatment of patients with frequent idiopathic premature ven-\ntricular complexes/ventricular tachycardia or premature ventricular complex-induced cardiomyopathy\nAblation\nBeta-blocker\nCCB\nFlecainide\nAmiodarone\nRVOT/fascicular PVC/VT:\nSymptomatic, normal LV function\nClass I\nClass IIa\nClass IIa\nClass IIa\nClass III\nPVC/VT other than RVOT/fascicular:\nSymptomatic, normal LV function\nClass IIa\nClass I\nClass I\nClass IIa\nClass III\nRVOT/fascicular PVC/VT:\nLV dysfunction\nClass I\nClass IIa\nClass IIIa\nClass IIab\nClass IIa\nPVC/VT other than RVOT/fascicular:\nLV dysfunction\nClass I\nClass IIa\nClass IIIa\nClass IIab\nClass IIa\nPVC:\nBurden .20%, asymptomatic, normal LV function\nClass IIb\nClass III\n© ESC 2022\nCCB, calcium channel blocker; LV, left ventricular; PVC, premature ventricular complex; RVOT, right ventricular outﬂow tract; VT, ventricular tachycardia.\naIntravenous calcium channel blockers.\nbIn selected patients (only moderate LV dysfunction).\nESC Guidelines\n4051\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n7.1.2.2. Premature ventricular complex-induced/-aggravated\ncardiomyopathy\nThe importance of PVC-induced cardiomyopathy as a second-\nary and reversible cause of LV dysfunction in patients without\nSHD has been recognized.607,608 The patient’s medical and\nfamily history, 12-lead ECG, Holter-ECG, and echocardiog-\nraphy form the cornerstones of the evaluation of patients\nwith\nsuspected\nPVC-induced\ncardiomyopathy\n(Figure\n18).\nPVC burden has been shown to be the strongest independent\npredictor of PVC-induced cardiomyopathy in several stud-\nies.600,609–611 Day-by-day ﬂuctuations of PVC burden have\nbeen reported in patients undergoing 14-day monitoring, but\nmost data are based on 24-h registrations.611 A PVC burden of\nat least 10% appears to be the minimal threshold for develop-\nment of PVC-induced cardiomyopathy, and the risk increases fur-\nther with a PVC burden .20%.600,611 In patients with a PVC\nburden ,10%, other cardiomyopathy aetiologies should be sus-\npected and further diagnostic work-up undertaken. In such pa-\ntients, Holter-ECG should be repeated to assess ﬂuctuations in\nPVC burden. Factors predicting adverse LV remodelling in pa-\ntients with frequent PVCs include superior PVC axis, epicardial\norigin,\nNSVT,\nshorter\ncoupling\ninterval,\nand\nmale\ngen-\nder.535,611–613\nFrequent PVCs can also aggravate LV dysfunction in patients with\nSHD. In such cases, LV dysfunction can either be a direct conse-\nquence of PVCs as in PVC-induced cardiomyopathy, or due to the\nlimiting effect of PVCs on optimal biventricular pacing in CRT pa-\ntients. Parameters such as smaller LV end diastolic diameter and\nshorter\nintrinsic\nQRS\nduration\nmight\nhelp\nto\ndistinguish\nPVC-induced cardiomyopathy from PVC-aggravated cardiomyop-\nathy.614 CMR should be considered for patients suspected to have\nPVC-induced cardiomyopathy to exclude subtle forms of SHD.590,615\nIn a patient with frequent PVCs, the presence of LGE suggests SHD\nwith frequent PVCs rather than PVC-induced cardiomyopathy, in\nwhich LGE is mostly absent. Given that PVCs with a RBBB morphology\nhave been reported to show a stronger association with LGE,616 those\npatients should be particularly considered for CMR.\nThe diagnosis of PVC-induced cardiomyopathy vs. PVC-aggravated\ncardiomyopathy can be conﬁrmed only after LVEF improvement/nor-\nmalization (reverse remodelling) following suppression of the PVCs.\nCatheter ablation of the PVCs is very efﬁcient, with reported suc-\ncess rates of 75–90%, and is considered ﬁrst-line treatment for\nPVC-induced cardiomyopathy.535,600,609,610,612,617–620 Factors af-\nfecting acute ablation success and clinical outcome include the site\nof origin of PVCs (highest for outﬂow tract PVCs), the number of\nPVC morphologies, and the absence of LGE on CMR.535,610,614 In pa-\ntients with SHD, catheter ablation of frequent monomorphic PVCs\nhas also been shown to improve LVEF in patients with both CAD and\ncardiomyopathies with and without CRT.609,617,621–623 Similarly, the\nuse of anti-arrhythmic medications for PVC suppression has been\nshown to improve LVEF. In one RCT, amiodarone resulted in a bet-\nter PVC suppression and a higher LVEF improvement compared to\nplacebo.624 Sodium channel blockers can also effectively suppress\nPVCs.625 In one study, ﬂecainide reduced the PVC burden from\n36% to 10% and resulted in LVEF increase from 37% to 49%.626\nRecommendation Table 26 — Recommendations for\nthe management of patients with idiopathic prema-\nture ventricular complexes/ventricular tachycardia\nRecommendations\nClassa\nLevelb\nGeneral recommendations\nRegular assessment of ventricular function of\npatients with PVC burden .10% and normal\nventricular function is indicated.602,603\nI\nC\nIn patients with PVCs/VT and a\npresentation not typical for an idiopathic\norigin,c CMR should be considered,\ndespite a normal echocardiogram.195\nIIa\nC\nTreatment\nCatheter ablation as ﬁrst-line treatment is\nrecommended for symptomatic idiopathic VT/\nPVCs from the RVOT or the left\nfascicles.d,535,595,596,604\nI\nB\nBeta-blockers or non-dihydropyridine CCBs are\nindicated in symptomatic patients with idiopathic\nVT/PVCs from an origin other than the RVOT or\nthe left fascicles.304,593\nI\nC\nBeta-blockers, non-dihydropyridine CCBs, or\nﬂecainide should be considered when catheter\nablation is not available, desired, or is particularly\nrisky in symptomatic patients with idiopathic VT/\nPVCs from the RVOT or the left\nfascicles.304,592,593\nIIa\nB\nCatheter ablation or ﬂecainide should be\nconsidered in symptomatic patients with\nidiopathic VT/PVCs from an origin other than the\nRVOT or the left fascicles.535,604,605\nIIa\nC\nCatheter ablation may be considered for\nidiopathic VT/PVCs in asymptomatic patients with\nrepeatedly more than 20% of PVCs per day at\nfollow-up.535,600,601\nIIb\nB\nCatheter ablation of idiopathic VT/PVCs is not\nrecommended in children ,5 years of age or\n,10 kg weight except when previous medical\ntherapy fails or when VT is not haemodynamically\ntolerated.597\nIII\nC\nAmiodarone as a ﬁrst-line treatment is not\nrecommended in patients with idiopathic VTs/\nPVCs.594\nIII\nC\nVerapamil is not recommended in children ,1 year\nof age with PVC/VT, particularly if they have signs of\nheart failure or concurrent use of other AADs.606\nIII\nC\n© ESC 2022\nAAD, anti-arrhythmic drug; CCB, calcium channel blocker; CMR, cardiac magnetic\nresonance; PVC, premature ventricular complex; RVOT, right ventricular outﬂow tract;\nSMVT, sustained monomorphic ventricular tachycardia; VT, ventricular tachycardia.\naClass of recommendation.\nbLevel of evidence.\ncIncluding but not limited to older age, right bundle branch block (RBBB) morphology,\nSMVT consistent with re-entry.\ndLevel of evidence C for VT/PVCs from left fascicles.\n4052\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nWhile ﬂecainide have a more favourable adverse effect proﬁle re-\ngarding organ toxicity, increased mortality has previously been\nshown in patients with MI.556 For selected patients with suspected\nPVC-induced cardiomyopathy and PVC-aggravated cardiomyopathy,\nﬂecainide can still be considered, particularly if an ICD is in place\n(Table 9).\nA rare monogenetic cause of PVC-induced cardiomyopathy, re-\nferred to as multifocal ectopic Purkinje-related premature contrac-\ntions, has been reported. It is characterized by a DCM phenotype\nand the presence of numerous PVCs with RBBB and/or left bundle\nbranch block (LBBB) morphologies and an increased risk of SCD.627\nPathogenic mutations in the SCN5A gene lead to a gain of function\nof the sodium channel responsible for hyperexcitability of the fasci-\ncular Purkinje system.627,628 Limited data suggest that patients with\nmultifocal ectopic Purkinje-related premature contractions do not\nrespond to beta-blockers but might beneﬁt from therapy with ﬂe-\ncainide, quinidine, or amiodarone.627–631\nN\nN\nN\nN\nPatient with PVC-Burden >10% and mildly reduced or reduced LVEF\nL\nCMR\n(Class IIa)\nSuspected PVC induced\ncardiomyopathy\nSHD aggravated\na\nby\nfrequent PVC’s\nFurther evaluation\naccording to\nmost like\nk ly diagnosis\n(suspicious) CAD,\nvalvular heart disease or\ninflammatory heart disease\nLV dysfunction\nL\nexplained by underlying\nheart disease\nKnown SHD\nLGE\nFollow-up\nY\nY\nY\nY\nAmiodarone\n(Class IIa)\nCatheter ablation\n(Class IIa)\nCatheter ablation\n(Class I)\nAAD\n(Class IIa)\nFigure 18 Algorithm for the management of patients with premature ventricular complex-induced/-aggravated cardiomyopathy. AAD, anti-arrhythmic\ndrug; CAD, coronary artery disease; CMR, cardiac magnetic resonance; LGE, late gadolinium enhancement; LV, left ventricular; LVEF, left ventricular ejec-\ntion fraction; N, No; PVC, premature ventricular complex; SHD, structural heart disease; Y, Yes.\nRecommendation Table 27 — Recommendations for\nthe management of patients with premature ventricular\ncomplex-induced or premature ventricular complex-\naggravated cardiomyopathy\nRecommendation\nClassa\nLevelb\nDiagnostic evaluation\nIn patients with an unexplained reduced EF and a\nPVC burden of at least 10%, PVC-induced\ncardiomyopathy should be considered.600,609,610\nIIa\nC\nIn patients with suspected PVC-induced\ncardiomyopathy, CMR should be\nconsidered.590,615\nIIa\nB\nTreatment\nIn patients with a cardiomyopathy suspected to be\ncaused by frequent and predominately\nmonomorphic PVCs, catheter ablation is\nrecommended.535,600,609,612,617,618,620\nI\nC\nContinued\nESC Guidelines\n4053\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n7.1.3. Cardiomyopathies\n7.1.3.1. Dilated cardiomyopathy and hypokinetic non-dilated\ncardiomyopathy\nDCM is characterized by LV dilatation and systolic dysfunction unex-\nplained by CAD or abnormal loading conditions.632 The true preva-\nlence is difﬁcult to estimate. Older studies reported a prevalence of 1\nin 2700 individuals.633\nHistoric data in adults with DCM showed a 1-year mortality of\n20–25% and a 50% survival at 5 years.634 Recent trials of DCM pa-\ntients with systolic heart failure and OMT report 5-year mortality\nrates in the range of 21–28%.356,359 SCD occurs in up to 12% of pa-\ntients with DCM and still accounts for 25–35% of all deaths.359,634,635\nIn children, the annual incidence of DCM is 0.57 cases per\n100 000.636 The prognosis in children is poor, with a 5-year incidence\nof heart transplantation or heart failure-related death of 40%.\nHowever, in contrast to adults, the incidence of SCD in paediatric\nDCM patients is much lower, with a 5-year incidence of 2.4–3% as\nreported in two large paediatric cardiomyopathy registries from\nthe United States and Australia.637,638\nCauses of DCM can be genetic or acquired.639 Genetic predisposition\nmay also interact with extrinsic factors such as in peri-partum, alcoholic,\nor chemotherapy-related cardiomyopathies.639 The phenotype, par-\nticularly of genetic aetiologies, can change over time and/or may not\nmeet standard disease criteria at the time of disease manifestation. As\na consequence, a new category of a hypokinetic non-dilated cardio-\nmyopathy (HNDCM) has been proposed.639\n7.1.3.1.1. Diagnostic evaluation and risk stratiﬁcation. An algo-\nrithm for risk stratiﬁcation and primary prevention of SCD in pa-\ntients with DCM/HNDCM is presented in Figure 19.\nCareful diagnostic work-up, including genetic testing and CMR,\nshould be considered to identify the underlying cause for\naetiology-oriented risk stratiﬁcation and treatment.341,639\nPathogenic mutations are identiﬁed in 25–55% of DCM pa-\ntients,634,639,640 most often with autosomal dominant inherit-\nance. Truncated mutations in the titin gene (TTN) are most\nfrequently found, followed by LMNA, sarcomeric, and desmo-\nsomal mutations. Mutations in genes such as LMNA, PLN,\nRBM20, and FLNC are associated with a higher risk of VA and\nSCD.641–645 Carriers of desmosomal and LMNA variants experi-\nenced the highest rate of VA/SCD, which was independent of the\nLVEF in one series.645\nThe yield of genetic testing is particularly high in DCM patients with\nfamilial forms of DCM or SCD in a ﬁrst-degree relative at younger age.\nAn inherited DCM is also more likely in patients who present at young\nage or with signs suspicious for a speciﬁc aetiology (e.g. prolonged AV\nconduction for LMNA) (Figure 20).634,639,640,646 First-degree relatives\nof DCM/HNDCM patients should undergo clinical diagnostic evalu-\nation, especially if an inherited cause is suspected.\nDiscrimination between high- and low-risk patients for SCD\nremains challenging. Beyond LVEF and NYHA class,357,359,635,647–650\nrecent data suggest that both genetic and CMR ﬁndings can contrib-\nute to risk stratiﬁcation. A meta-analysis of 29 studies combining\n2948 patients studied the role of CMR in patients with DCM.129\nLGE was signiﬁcantly associated with the arrhythmic endpoint,\neven when including only studies that performed multivariate analysis\n(HR 6.7; P , 0.001). Interestingly, the association between LGE and\nthe arrhythmic endpoint remained signiﬁcant among patients with\nmean LVEF .35%. Similarly, a recent study of 1020 consecutive pa-\ntients with DCM and CMR observed that LGE and LVEF were both\nrisk markers for all-cause mortality and cardiac death, but only LGE\nwas signiﬁcantly associated with SCD risk.651\nSCD risk stratiﬁcation has been reﬁned in the subgroup of patients\nwith LMNA mutations, which represent 5–10% of all DCM patients.\nLMNA mutations are associated with early atrial and ventricular ar-\nrhythmias, premature conduction disease, a high risk of SCD, and\nprogression to end-stage heart failure.80,642,652,653 In a multicentre\nregistry of 269 LMNA mutation carriers, NSVT, LVEF ,45% at ﬁrst\nevaluation, male sex, and non-missense mutations were identiﬁed as\nindependent risk factors for VA.652 VA occurred only in persons with\nat least two of these risk factors. The risk stratiﬁcation was subse-\nquently externally validated.653 Another study, which involved 589\nLMNA mutation carriers, identiﬁed AV block as an additional predict-\nor. Recently a risk calculator has been developed (https://lmna-risk-\nvta.fr/) to predict the risk of life-threatening VA (C-index of 0.776\n[95% CI: 0.711–0.842]).80 In patients with a 5-year estimated risk\n≥10% and a manifest cardiac phenotype (NSVT, LVEF , 50%, or\nAV conduction delay), a primary prevention ICD implantation should\nbe considered to avoid potential over-implantation in mutation carriers\nwithout a cardiac phenotype. In LMNA mutation carriers with a DCM\nphenotype, high-intensity exercise has been associated with a high risk\nof SCD and impaired LVEF and is therefore not recommended.654,655\nA risk score for VA prediction has been recently proposed for pa-\ntients with DCM or ARVC related to the p.Arg14del mutation in the\nPLN gene.656 Validation studies are needed before it can be recom-\nmended for clinical use.\nBeyond genetics and CMR, additional SCD predictors have been\nsuggested, often derived from small cohorts with no or few replica-\ntion studies. An unexplained syncope requires further evaluation and\nPES may determine the underlying cause. The risk for arrhythmic\nIn patients with a cardiomyopathy suspected to be\ncaused by frequent and predominately\nmonomorphic PVCs, treatment with AADsc should\nbe considered if catheter ablation is not desired,\nsuspected to be high-risk, or unsuccessful.624,626\nIIa\nC\nIn patients with SHD in whom predominately\nmonomorphic frequent PVCs are suspected to be\ncontributing to the cardiomyopathy, AAD\n(amiodarone) treatment or catheter ablation\nshould be considered. 617,621,622,624\nIIa\nB\nIn non-responders to CRT with frequent,\npredominately monomorphic PVCs limiting\noptimal biventricular pacing despite\npharmacological therapy, catheter ablation or\nAADs should be considered.623\nIIa\nC\n© ESC 2022\nAAD, anti-arrhythmic drug; CMR, cardiac magnetic resonance; CRT, cardiac\nresynchronization therapy; EF, ejection fraction; ICD, implantable cardioverter\ndeﬁbrillator; LV, left ventricular; PVC, premature ventricular complex; SHD,\nstructural heart disease.\naClass of recommendation.\nbLevel of evidence.\ncFlecainide only in selected patients (ICD recipients, only moderate LV dysfunction).\n4054\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nevents in DCM patients with a low LVEF and an unexplained syncope\nwas similar to those with prior CA657 and high, independent from\nthe outcome of PES.148 However, data in DCM patients with a mildly\nreduced EF suggest an incremental value of PES. Among DCM pa-\ntients with an EF ≥40% and an unexplained syncope, who underwent\nICD implantation after a positive PES, 80% had appropriate ICD\ntherapy during follow-up. No SCD or symptomatic VA occurred\nin non-inducible patients.146\n7.1.3.1.2. Primary prevention of sudden cardiac death. In patients\nwith DCM/HNDCM, OMT according to current 2021 ESC\nGuidelines for the diagnosis and treatment of acute and chronic\nheart failure is mandatory.342 Re-evaluation of cardiac function and\nclinical status after 3 months’ OMT is required before primary pre-\nvention ICD implantation. LV function is more likely to improve in\nDCM caused by myocarditis or TTN mutations.\nThe efﬁcacy of primary prevention ICDs in DCM patients with\nHFrEF has been addressed in six RCTs.635\nFive studies were published between 2002 and 2005 (CAT,\nAMIOVIRT, DEFINITE, COMPANION, and SCD-HeFT). The\nﬁrst three were smaller studies enrolling only DCM patients,\nwhereas\nSCD-HeFT\nand\nCOMPANION\nwere\nlarger\nand\nPatient with DCM/HNDCM\nSuspicious of cause requiring specific treatment\nFamily history of DCM/HNDCM or \nfamily history of SCD (<50 y, first-degree relative) or \nAV block <50 y\n5-year risk ofVA ≥10% \nand LVEF <50%\nor NSVT\nor AV conduction delay\nPathogenic \nmutation LMNA\nICD implantation\n(Class IIa)\nICD implantation\n(Class IIa)\nICD implantation\n(Class IIa)\nICD implantation\n(Class IIa)\nGenetic testing\n(Class IIa)\n(Class I)\nGo to specific sections\nfor specific aetiology-directed management,\nespecially for inflammatory diseases\nCMR (Class IIa)\nAnnual\nreevaluation\nLVEF\n≥2 risk factorsa\nSMVT inducible\nPES (Class IIa)\nILRb (Class I)\nFollow-up\nUnexplained syncope\nY\nY\nY\nY\nY\nY\nN\nN\nN\nN\nN\nN\n≤35%\n36–50%\nFigure 19 Algorithm for risk stratiﬁcation and primary prevention of sudden cardiac death in patients with dilated cardiomyopathy/hypokinetic non-\ndilated cardiomyopathy. AV, atrioventricular; CMR, cardiac magnetic resonance; DCM, dilated cardiomyopathy; HNDCM, hypokinetic non-dilated car-\ndiomyopathy; ICD, implantable cardioverter deﬁbrillator; ILR, implantable loop recorder; LMNA: lamin A/C gene; LVEF, left ventricular ejection fraction;\nN, No; NSVT, non-sustained ventricular tachycardia; PES, programmed electrical stimulation; SCD, sudden cardiac death; SMVT, sustained monomorphic\nventricular tachycardia; VA, ventricular arrhythmias; Y, Yes. aRisk factors: unexplained syncope, pathogenic variants in PLN, FLNC, or RBM20, LGE on\nCMR, inducible SMVT at PES. bThe 2018 ESC Guidelines for the diagnosis and management of syncope.1\nESC Guidelines\n4055\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nincluded patients with CAD and DCM. The COMPANION study\ndiffered from the others as it compared CRT-deﬁbrillator,\nCRT-pacemaker, and OMT. A meta-analysis of the ﬁve trials\n(1854 patients with DCM) demonstrated a 31% reduction in all-\ncause mortality with ICD relative to medical therapy (RR 0.69\n[95% CI 0.55, 0.87], P , 0.002).658 This effect persisted when\nCOMPANION was excluded.\nMore recently, the DANISH trial enrolled 1116 symptomatic patients\n(NYHA class II or III) with non-ischaemic systolic heart failure (LVEF ≤\n35%). Patients were randomized to ICD or no ICD after OMT.359 No\nreduction in the primary endpoint of all-cause death for patients\nrandomized to ICD therapy (HR 0.87; 95% CI 0.68–1.12; P = 0.28)\nwas observed, despite a signiﬁcant reduction in SCD in the ICD group\n(HR 0.50; 95% CI 0.31–0.82; P = 0.005). Potential explanations are the\nlow SCD rate in the trial (4.3% in the ICD group and 8.2% in the control\ngroup), the excellent medical treatment (.90% of patients on ACE in-\nhibitors and beta-blockers, .50% on MRA), and the high prevalence\n(58%) of CRT. A meta-analysis of all six primary prevention trials still de-\nmonstrated a reduction, although lower, in overall mortality with ICD\ntherapy (RR 0.76; 95% CI 0.65–0.91; P= 0.002).635 In a sensitivity ana-\nlysis, the beneﬁt of ICD therapy was maintained after the removal of any\nsingle study from the pooled analysis.\nECG sinus rhythm – Small amplitude P waves and first degree AV block\nECG VT – RBBB-like, inferior axis (LV summit origin)\nCMR – Mid-wall septal LGE\n4-chamber\nShort axis\nI\nII\nIII\nV1\nV2\nV3\naVR\naVL\naVF\nV4\nV5\nV6\nI\nII\nIII\nV1\nV2\nV3\naVR\naVL\naVF\nV4\nV5\nV6\nFigure 20 Typical features of dilated cardiomyopathy associated with lamin A/C gene mutation with ventricular arrhythmias. AV, atrioventricular; CMR,\ncardiac magnetic resonance; ECG, electrocardiogram; LGE, late gadolinium enhancement; LV, left ventricle; RBBB, right bundle branch block; VT, ven-\ntricular tachycardia.\n4056\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nThe results of the DANISH trial emphasize the need for further\nreﬁning the indication for primary prevention ICDs in contempor-\nary DCM patients. Age and comorbidity need to be considered.635\nIn the DANISH trial, ICD implantation was associated with a signiﬁ-\ncantly lower rate of death in younger patients.359 A further analysis\nof the DANISH data647 showed an association between reduced\nall-cause mortality and ICDs in patients ≤70 years of age (HR,\n0.70; 95% CI 0.51–0.96; P = 0.03), but not in patients .70 years\nof age.\nProspective studies evaluating the beneﬁt of ICDs in DCM/\nHNDCM patients with intermediate LV dysfunction, but with\nrisk factors that have been associated with VA and SCD (including\nLGE on CMR, pathogenic mutations in PLN, FLNC, RBM20, unex-\nplained\nsyncope,\nand\ninducibility\nof\nSMVT),\nare\nlack-\ning.129,641,643,644,659–662 Given the limitation of LVEF as the only\nrisk marker in DCM/HNDCM, this panel of experts shares the\nopinion that in the presence of a combination of risk markers an\nICD should be considered.\n7.1.3.1.3. Secondary prevention of sudden cardiac death and\nmanagement of ventricular arrhythmias. Three randomized trials\n(AVID, CASH, and CIDS) have compared ICD therapy and medical\ntreatment for secondary prevention in patients after aborted CA or\nnot-tolerated VT.349,351,352 The three trials enrolled a total of 1963\npatients, of whom only 292 (14.8%) had non-ischaemic aetiologies. A\nsigniﬁcant reduction in death from any cause in patients with ICDs\nwas demonstrated, which was almost entirely due to a 50% reduc-\ntion in arrhythmic death.352 In the subgroup of patients with cardio-\nmyopathies there was a similar but non-signiﬁcant trend in the\nreduction of death.352 RCTs have excluded patients with haemo-\ndynamically tolerated VT. In DCM patients the VT substrate is less\nwell deﬁned, and disease progression needs to be considered.\nTherefore, despite the lack of data, this panel of experts shares the\nopinion that an ICD should also be considered in DCM patients\nwith haemodynamically tolerated VT.\nOptimization of ICD programming (see Section 6.2.3.1) can re-\nduce ICD shocks delivered in response to VT, but additional therapy\nto reduce symptomatic VA episodes is often required. In the OPTIC\ntrial, 412 patients with ICD implantation within 21 days of VT/VF\nwere randomized to amiodarone plus beta-blockers, sotalol alone,\nor beta-blocker alone. ICD shock rates after one year were 10.3%,\n24.3%, and 38.5%, respectively. The higher efﬁcacy of amiodarone\nplus beta-blockers compared to sotalol needs to be weighed against\nthe higher rate of medication-related adverse events on an individual\nbasis.318 Although only limited data are available, sodium channel\nblockers may control VT in SHD and may be beneﬁcial in ICD reci-\npients without advanced heart failure. The majority of SMVT is due\nto scar-related re-entry, which can be targeted by catheter ablation.\nAcute ablation outcome has been reported to be similar for CAD\nand DCM.497,663 However, VT recurrence rates are usually higher\nin DCM patients (VT-free survival 40.5% in DCM vs. 57% in CAD\nat 1 year).497 After multiple procedures in 36% of the patients, long-\nterm freedom of VT could be achieved in 69% of cases in a retro-\nspective, single-centre cohort of 282 patients treated between\n1999 and 2014.664\nEpicardial ablation is needed in 27–30% of the procedures.497,664\nOutcome is particularly poor, and bailout strategies (transcoronary\nethanol ablation, bipolar ablation, surgical ablation) may be re-\nquired in patients with pathogenic mutations (LMNA gene) and\nin those with deep intramural, anteroseptal substrate loca-\ntions.499,665,666 Considering the complexity of the ablation pro-\ncedure, DCM patients should therefore be treated only in\nspecialized centres.\nRecommendation Table 28 — Recommendations\nfor risk stratiﬁcation, sudden cardiac death preven-\ntion, and treatment of ventricular arrhythmias in\ndilated\ncardiomyopathy/hypokinetic\nnon-dilated\ncardiomyopathy\nRecommendation\nClassa\nLevelb\nDiagnostic evaluation and general recommendations\nGenetic testing (including at least LMNA, PLN,\nRBM20, and FLNC genes) is recommended in\npatients with DCM/HNDCM and AV conduction\ndelay at ,50 years, or who have a family history of\nDCM/HNDCM or SCD in a ﬁrst-degree relative\n(at age ,50 years).641–645\nI\nB\nCMR with LGE should be considered in DCM/\nHNDCM patients for assessing the aetiology and\nthe risk of VA/SCD.129,651,667\nIIa\nB\nGenetic testing (including at least LMNA, PLN,\nRBM20, and FLNC genes) should be considered for\nrisk stratiﬁcation in patients with apparently\nsporadic DCM/HNDCM, who present at young\nage, or with signs suspicious for an inherited\naetiology.641–645\nIIa\nC\nParticipation in high-intensity exercise including\ncompetitive sports is not recommended for\nindividuals with DCM/HNDCM and a LMNA\nmutation.655\nIII\nC\nRisk stratiﬁcation and primary prevention of SCD\nICD implantation should be considered in patients\nwith DCM/HNDCM, symptomatic heart failure\n(NYHA class II–III), and LVEF ≤35% after ≥3\nmonths of OMT.357,359,635,650\nIIa\nA\nICD implantation should be considered in DCM/\nHNDCM patients with a pathogenic mutation in\nLMNA gene, if the estimated 5-year risk of\nlife-threatening VA is ≥10%c and in the presence\nof NSVT or LVEF , 50% or AV conduction\ndelay.80,652,653\nIIa\nB\nICD implantation should be considered in DCM/\nHNDCM patients with a LVEF ,50% and ≥2 risk\nfactors (syncope, LGE on CMR, inducible SMVT at\nPES, pathogenic mutations in LMNA,d PLN, FLNC,\nand RBM20 genes).\nIIa\nC\nIn DCM/HNDM patients, electrophysiological\nevaluation should be considered when syncope\nremains unexplained after non-invasive\nevaluation.661,668\nIIa\nC\nContinued\nESC Guidelines\n4057\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n7.1.3.2. Arrhythmogenic right ventricular cardiomyopathy\nARVC is an inherited disease characterized by ﬁbrofatty myocardial\nreplacement.670 The prevalence ranges from 1:1000 to 1:5000 indi-\nviduals, with male predominance among probands.671 Patients with\nSCD/VF at ﬁrst presentation are typically younger (median age 23\n[range 13–57]) compared to those who present with a SMVT\n(median age 36 years [range 14–78]).672\nARVC is caused by pathogenic mutations in desmosomal genes\nand less commonly in non-desmosomal genes. Genetic testing is in-\ndicated and identiﬁcation of a mutation (in up to 73% of probands) is\na major criterion for the diagnosis.116,671 In 4–16% compound/\ndigenic mutations are found, which have been associated with an in-\ncreased risk of VA at younger age.672,673 The disease penetrance in\nﬁrst-degree relatives is 28–58%,674,675 supporting regular clinical\nevaluation of relatives.\nARVC is characterized by a predominant RV involvement. The\n2010 revised international diagnostic task force criteria are based\non a multiparametric strategy116 (Figure 21). Tissue characterization\nby CMR was not included. However, RV fatty inﬁltration and LV LGE\nare frequently observed (in 29–53% and 35.5–45% of probands, re-\nspectively) and may be present before patients meet major task force\nimaging criteria.676–678 Both wall motion alterations and pre-/\npost-contrast signal abnormalities have been suggested to en-\nhance the diagnostic accuracy of CMR for ARVC.679 The identiﬁ-\ncation of biventricular and left-dominant involvement in ARVC\npatients680,681 has recently led to the proposed term ‘arrhythmo-\ngenic cardiomyopathy’.682\nRestriction from high-intensity exercise is regarded as a preventive\ntool in clinically affected ARVC patients to reduce the risk of VAs and\ndisease progression.683–685 Whether sport restriction is beneﬁcial in\nall mutation carriers without disease expression has not been evalu-\nated in prospective cohorts, but avoidance of competitive, high-\nintensity exercise seems to be reasonable.686,687 SCD and VA occur\ndisproportionately\nduring\nexercise\nin\naffected\npatients,\nand\nhigh-dose isoproterenol infusion may provoke PVT in .90% of\nARVC patients, supporting the role of sympathetic stimulation for\narrhythmogeneity.152,688,689 Whether beta-blockers can prevent\nspontaneous VA is, however, unclear. Limited data suggest a poten-\ntial beneﬁcial role of atenolol.690\n7.1.3.2.1. Risk stratiﬁcation. In ARVC patients not implanted with\nICDs, CA occurs in 4.6–6.1%, while 23% of patients experience a\nnon-fatal SMVT during an average follow-up of 8–11 years.691–694\nWhether a SMVT is acutely life-threatening depends on the VT cycle\nlength, cardiac function, and the circumstances under which VT oc-\ncurs. Among deﬁnite/probable ARVC patients considered at high risk\nfor VA, 23–48% will experience appropriate ICD intervention during\na mean follow-up of 4.7 years. In 16–19% of cases, ICD intervention\nis triggered by fast VT ≥250 b.p.m. or VF, which is considered as sur-\nrogate for a life-threatening event.695–698 In a large cohort of 864\nARVC patients (38.8% with a prior VA), 43% had VT/VF during a me-\ndian follow-up of 5.75 years, but only 10.8% a potentially life-\nthreatening event. Thus, in 3 out of 4 ARVC patients, ICD therapy\nis appropriate but may not be considered acutely life-saving. This is\nrelevant because risk prediction algorithms and models are based\non combined arrhythmic endpoints, which are often equated with\nICD indications to prevent SCD. This is particularly important for\nthe young ARVC patients with a lifetime risk of ICD-related\ncomplications.695,699\nRandomized studies of ICD therapy for secondary prevention are\nlacking, but the high rates of appropriate ICD therapy triggered by\nfast VT/VF episodes in patients implanted after CA or haemodynam-\nically poorly tolerated VT strongly suggest a survival beneﬁt from\nICD.700 In patients who present with a haemodynamically tolerated\nVT, the survival beneﬁt from ICD is less clear.691,700–702 Identiﬁcation\nof ARVC patients at risk for SCD is difﬁcult, and the evidence sup-\nporting risk factors for life-threatening VAs is limited. Arrhythmic\nsyncope was a predictor for subsequent events in most series of pa-\ntients\nwith\ndeﬁnitive\nARVC\n(pooled\nHR\n3.67;\nCI\n2.75–\n4.9)81,696,701,703 and, in these patients, an ICD should be considered.\nRV and LV dysfunction have been associated with a higher arrhyth-\nmic risk.675,704 Cut-off values are difﬁcult to determine but, in\nSecondary prevention of SCD and treatment of VAs\nICD implantation is recommended in patients\nwith DCM/HNDCM, who survive SCA due to VT/\nVF or experience haemodynamically\nnot-tolerated SMVT.349,351,352\nI\nB\nCatheter ablation in specialized centres should be\nconsidered in patients with DCM/HNDCM and\nrecurrent, symptomatic SMVT or ICD shocks for\nSMVT, in whom AADs are ineffective,\ncontraindicated, or not tolerated.481,497,664,669\nIIa\nC\nThe addition of oral amiodarone or replacement of\nbeta-blockers by sotalol should be considered in\npatients with DCM/HNDCM and an ICD who\nexperience recurrent, symptomatic VA despite\noptimal device programming and beta-blocker\ntreatment.318\nIIa\nB\nICD implantation should be considered in patients\nwith DCM/HNDCM and haemodynamically\ntolerated SMVT.\nIIa\nC\nManagement of relatives of a patient or SCD victim with\nDCM/HNDCM\nIn a ﬁrst-degree relative of a DCM/HNDCM\npatient, an ECG and an echocardiogram are\nrecommended if:\n•theindexpatientwasdiagnosed,50yearsofageor\nhasclinicalfeaturessuggestiveofaninheritedcause,or\n• there is family history of DCM/HNDCM, or\npremature unexpected SD.646\nI\nC\nIn a ﬁrst-degree relative of a patient with\napparently sporadic DCM/HNDCM, an ECG and\nan echocardiogram may be considered.646\nIIb\nC\n© ESC 2022\nAAD, anti-arrhythmic drug; AV, atrioventricular; CMR, cardiac magnetic resonance; DCM,\ndilated cardiomyopathy; ECG, electrocardiogram; HNDCM, hypokinetic non-dilated\ncardiomyopathy; ICD, implantable cardioverter deﬁbrillator; LGE, late gadolinium\nenhancement; LVEF, left ventricular ejection fraction; NSVT, non-sustained ventricular\ntachycardia; NYHA, New York Heart Association; OMT, optimal medical therapy; PES,\nprogrammed electrical stimulation; SCA, sudden cardiac arrest; SCD, sudden cardiac\ndeath; SD, sudden death; SMVT, sustained monomorphic ventricular tachycardia; VA,\nventricular arrhythmia; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.\naClass of recommendation.\nbLevel of evidence.\ncBased on the risk calculator https://lmna-risk-vta.fr/\ndSee speciﬁc recommendations for LMNA.\n4058\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 50",
          "page": 50,
          "content": "Recommendations |  | Classa | Levelb | \n | Treatment of VAs in ACS |  |  | \nIntravenous beta-blocker treatment is indicated\nfor patients with recurrent PVT/VF during STEMI\nunless contraindicated.551,552 |  | I | B | \nIntravenous amiodarone treatment should be\nconsidered for patients with recurrent PVT/VF\nduring the acute phase of ACS.552,554,555 |  | IIa | C | \nIntravenous lidocaine may be considered for the\ntreatment of recurrent PVT/VF not responding to\nbeta-blockers or amiodarone, or if amiodarone is\ncontraindicated during the acute phase of ACS.554 |  | IIb | C | \nProphylactic treatment with AADs (other than\nbeta-blockers) is not recommended in ACS.322 |  | III | B | \n | Vasospasm |  |  | \nIn SCA survivors with coronary artery\nspasm, implantation of an ICD should be\nconsidered.562–564 |  | IIa | C | ",
          "rows": 8,
          "cols": 5
        },
        {
          "title": "Table on page 50",
          "page": 50,
          "content": "Recommendations |  | Classa | Levelb | \n | Risk stratification |  |  | \nEarly (before discharge) assessment of LVEF is\nrecommended in all patients with acute MI.567,568 |  | I | B | \nIn patients with pre-discharge LVEF ≤40%,\nre-evaluation of LVEF 6–12 weeks after MI is\nrecommended to assess the potential need for\nprimary prevention ICD implantation.568,573,574 |  | I | C | \n | Treatment of VAs |  |  | \nCatheter ablation should be considered in patients\nwith recurrent episodes of PVT/VF triggered by a\nsimilar PVC non-responsive to medical treatment\nor coronary revascularization in the subacute\nphase of MI.332 |  | IIa | C | ",
          "rows": 6,
          "cols": 5
        },
        {
          "title": "Table on page 51",
          "page": 51,
          "content": "The addition of oral amiodarone or\nbeta-blocker replacement by sotalol should be\nconsidered in patients with CAD with\nrecurrent, symptomatic SMVT, or ICD shocks\nfor SMVT while on beta-blocker\ntreatment.318,581 | IIa | B\nIn patients with CAD and haemodynamically\nwell-tolerated SMVT and LVEF ≥40%, catheter\nablationinexperiencedcentresshouldbeconsidered\nas an alternative to ICD therapy, provided that\nestablished endpoints have been reached.c,480,580 | IIa | C\nICD implantation should be considered in patients\nwith a haemodynamically tolerated SMVT and an\nLVEF ≥40% if VT ablation fails, is not available, or is\nnot desired. | IIa | C\nCatheter ablation should be considered in patients\nwith CAD and recurrent, symptomatic SMVT, or\nICD shocks for SMVT despite beta-blockers or\nsotalol treatment.471 | IIa | C\nIn patients with CAD eligible for ICD implantation,\ncatheter ablation may be considered just before (or\nimmediately after) ICD implantation to decrease\nsubsequent VT burden and ICD shocks.484,485,582,583 | IIb | B",
          "rows": 5,
          "cols": 3
        },
        {
          "title": "Table on page 51",
          "page": 51,
          "content": "Recommendations |  | Classa | Levelb | \n | Risk stratification and primary prevention of SCD |  |  | \nIn patients with syncope and previous STEMI, PES\nis indicated when syncope remains unexplained\nafter non-invasive evaluation.146,584 |  | I | C | \nICD therapy is recommended in patients\nwith CAD, symptomatic heart failure (NYHA\nclass II–III), and LVEF ≤35% despite ≥3 months\nof OMT.354,356 |  | I | A | \nICD therapy should be considered in patients with\nCAD, NYHA class I, and LVEF ≤30% despite ≥3\nmonths of OMT.354 |  | IIa | B | \nICD implantation should be considered in patients\nwith CAD, LVEF ≤40% despite ≥3 months of\nOMT, and NSVT, if they are inducible for SMVT by\nPES.355 |  | IIa | B | \nIn patients with CAD, prophylactic treatment\nwith AADs other than beta-blockers is not\nrecommended.556,578,579 |  | III | A | \n | Secondary prevention of SCD and treatment of VAs |  |  | \nICD implantation is recommended in patients\nwithout ongoing ischaemia with documented VF\nor haemodynamically not-tolerated VT occurring\nlater than 48 h after MI.349–351 |  | I | A | \nIn patients with CAD and recurrent, symptomatic\nSMVT, or ICD shocks for SMVT despite chronic\namiodarone therapy, catheter ablation is\nrecommended in preference to escalating AAD\ntherapy.471 |  | I | B | ",
          "rows": 10,
          "cols": 5
        },
        {
          "title": "Table on page 54",
          "page": 54,
          "content": "Recommendations |  | Classa | Levelb | \n | Diagnostic evaluation |  |  | \nCardiac stress imaging during physical exercise is\nrecommended in addition to cardiopulmonary\nexercise test in patients with anomalous aortic\norigin of a coronary artery with an interarterial\ncourse to confirm/exclude myocardial ischaemia.587 |  | I | C | \nCardiac stress imaging during physical exercise is\nrecommended in addition to cardiopulmonary\nexercise test after surgery in patients with\nanomalous aortic origin of a coronary artery with\na history of aborted CA. |  | I | C | \n | Treatment |  |  | \nSurgery is recommended in patients with\nanomalous aortic origin of a coronary artery with\nCA, syncope suspected to be due to VAs, or angina\nwhen other causes have been excluded.585,586,588 |  | I | C | \nSurgery should be considered in asymptomatic\npatients with anomalous aortic origin of a\ncoronary artery and evidence of myocardial\nischaemia or abnormal aortic origin of the left\ncoronary artery with high-risk\nanatomy.c,585,586,588 |  | IIa | C | ",
          "rows": 7,
          "cols": 5
        },
        {
          "title": "Table on page 55",
          "page": 55,
          "content": " | Ablation | Beta-blocker | CCB | Flecainide | Amiodarone\nRVOT/fascicular PVC/VT:\nSymptomatic, normal LV function | Class I | Class IIa | Class IIa | Class IIa | Class III\nPVC/VT other than RVOT/fascicular:\nSymptomatic, normal LV function | Class IIa | Class I | Class I | Class IIa | Class III\nRVOT/fascicular PVC/VT:\nLV dysfunction | Class I | Class IIa | Class IIIa | Class IIab | Class IIa\nPVC/VT other than RVOT/fascicular:\nLV dysfunction | Class I | Class IIa | Class IIIa | Class IIab | Class IIa\nPVC:\nBurden .20%, asymptomatic, normal LV function | Class IIb |  |  |  | Class III",
          "rows": 6,
          "cols": 6
        },
        {
          "title": "Table on page 56",
          "page": 56,
          "content": "Recommendations |  | Classa | Levelb | \n | General recommendations |  |  | \nRegular assessment of ventricular function of\npatients with PVC burden .10% and normal\nventricular function is indicated.602,603 |  | I | C | \nIn patients with PVCs/VT and a\npresentation not typical for an idiopathic\norigin,c CMR should be considered,\ndespite a normal echocardiogram.195 |  | IIa | C | \n | Treatment |  |  | \nCatheter ablation as first-line treatment is\nrecommended for symptomatic idiopathic VT/\nPVCs from the RVOT or the left\nfascicles.d,535,595,596,604 |  | I | B | \nBeta-blockers or non-dihydropyridine CCBs are\nindicated in symptomatic patients with idiopathic\nVT/PVCs from an origin other than the RVOT or\nthe left fascicles.304,593 |  | I | C | \nBeta-blockers, non-dihydropyridine CCBs, or\nflecainide should be considered when catheter\nablation is not available, desired, or is particularly\nrisky in symptomatic patients with idiopathic VT/\nPVCs from the RVOT or the left\nfascicles.304,592,593 |  | IIa | B | \nCatheter ablation or flecainide should be\nconsidered in symptomatic patients with\nidiopathic VT/PVCs from an origin other than the\nRVOT or the left fascicles.535,604,605 |  | IIa | C | \nCatheter ablation may be considered for\nidiopathic VT/PVCs in asymptomatic patients with\nrepeatedly more than 20% of PVCs per day at\nfollow-up.535,600,601 |  | IIb | B | \nCatheter ablation of idiopathic VT/PVCs is not\nrecommended in children ,5 years of age or\n,10 kg weight except when previous medical\ntherapy fails or when VT is not haemodynamically\ntolerated.597 |  | III | C | \nAmiodarone as a first-line treatment is not\nrecommended in patients with idiopathic VTs/\nPVCs.594 |  | III | C | \nVerapamil is not recommended in children ,1 year\nof age with PVC/VT, particularly if they have signs of\nheart failure or concurrent use of other AADs.606 |  | III | C | ",
          "rows": 13,
          "cols": 5
        },
        {
          "title": "Table on page 57",
          "page": 57,
          "content": "Recommendation |  | Classa | Levelb | \n | Diagnostic evaluation |  |  | \nIn patients with an unexplained reduced EF and a\nPVC burden of at least 10%, PVC-induced\ncardiomyopathy should be considered.600,609,610 |  | IIa | C | \nIn patients with suspected PVC-induced\ncardiomyopathy, CMR should be\nconsidered.590,615 |  | IIa | B | \n | Treatment |  |  | \nIn patients with a cardiomyopathy suspected to be\ncaused by frequent and predominately\nmonomorphic PVCs, catheter ablation is\nrecommended.535,600,609,612,617,618,620 |  | I | C | ",
          "rows": 6,
          "cols": 5
        },
        {
          "title": "Table on page 58",
          "page": 58,
          "content": "In patients with a cardiomyopathy suspected to be\ncaused by frequent and predominately\nmonomorphic PVCs, treatment with AADsc should\nbe considered if catheter ablation is not desired,\nsuspected to be high-risk, or unsuccessful.624,626 | IIa | C\nIn patients with SHD in whom predominately\nmonomorphic frequent PVCs are suspected to be\ncontributing to the cardiomyopathy, AAD\n(amiodarone) treatment or catheter ablation\nshould be considered. 617,621,622,624 | IIa | B\nIn non-responders to CRT with frequent,\npredominately monomorphic PVCs limiting\noptimal biventricular pacing despite\npharmacological therapy, catheter ablation or\nAADs should be considered.623 | IIa | C",
          "rows": 3,
          "cols": 3
        },
        {
          "title": "Table on page 61",
          "page": 61,
          "content": "Recommendation |  | Classa | Levelb | \n | Diagnostic evaluation and general recommendations |  |  | \nGenetic testing (including at least LMNA, PLN,\nRBM20, and FLNC genes) is recommended in\npatients with DCM/HNDCM and AV conduction\ndelay at ,50 years, or who have a family history of\nDCM/HNDCM or SCD in a first-degree relative\n(at age ,50 years).641–645 |  | I | B | \nCMR with LGE should be considered in DCM/\nHNDCM patients for assessing the aetiology and\nthe risk of VA/SCD.129,651,667 |  | IIa | B | \nGenetic testing (including at least LMNA, PLN,\nRBM20, and FLNC genes) should be considered for\nrisk stratification in patients with apparently\nsporadic DCM/HNDCM, who present at young\nage, or with signs suspicious for an inherited\naetiology.641–645 |  | IIa | C | \nParticipation in high-intensity exercise including\ncompetitive sports is not recommended for\nindividuals with DCM/HNDCM and a LMNA\nmutation.655 |  | III | C | \n | Risk stratification and primary prevention of SCD |  |  | \nICD implantation should be considered in patients\nwith DCM/HNDCM, symptomatic heart failure\n(NYHA class II–III), and LVEF ≤35% after ≥3\nmonths of OMT.357,359,635,650 |  | IIa | A | \nICD implantation should be considered in DCM/\nHNDCM patients with a pathogenic mutation in\nLMNA gene, if the estimated 5-year risk of\nlife-threatening VA is ≥10%c and in the presence\nof NSVT or LVEF , 50% or AV conduction\ndelay.80,652,653 |  | IIa | B | \nICD implantation should be considered in DCM/\nHNDCM patients with a LVEF ,50% and ≥2 risk\nfactors (syncope, LGE on CMR, inducible SMVT at\nPES, pathogenic mutations in LMNA,d PLN, FLNC,\nand RBM20 genes). |  | IIa | C | \nIn DCM/HNDM patients, electrophysiological\nevaluation should be considered when syncope\nremains unexplained after non-invasive\nevaluation.661,668 |  | IIa | C | ",
          "rows": 11,
          "cols": 5
        },
        {
          "title": "Table on page 62",
          "page": 62,
          "content": " | Secondary prevention of SCD and treatment of VAs |  |  | \nICD implantation is recommended in patients\nwith DCM/HNDCM, who survive SCA due to VT/\nVF or experience haemodynamically\nnot-tolerated SMVT.349,351,352 |  | I | B | \nCatheter ablation in specialized centres should be\nconsidered in patients with DCM/HNDCM and\nrecurrent, symptomatic SMVT or ICD shocks for\nSMVT, in whom AADs are ineffective,\ncontraindicated, or not tolerated.481,497,664,669 |  | IIa | C | \nThe addition of oral amiodarone or replacement of\nbeta-blockers by sotalol should be considered in\npatients with DCM/HNDCM and an ICD who\nexperience recurrent, symptomatic VA despite\noptimal device programming and beta-blocker\ntreatment.318 |  | IIa | B | \nICD implantation should be considered in patients\nwith DCM/HNDCM and haemodynamically\ntolerated SMVT. |  | IIa | C | \n | Management of relatives of a patient or SCD victim with\nDCM/HNDCM |  |  | \nIn a first-degree relative of a DCM/HNDCM\npatient, an ECG and an echocardiogram are\nrecommended if:\n•theindexpatientwasdiagnosed,50yearsofageor\nhasclinicalfeaturessuggestiveofaninheritedcause,or\n• there is family history of DCM/HNDCM, or\npremature unexpected SD.646 |  | I | C | \nIn a first-degree relative of a patient with\napparently sporadic DCM/HNDCM, an ECG and\nan echocardiogram may be considered.646 |  | IIb | C | ",
          "rows": 8,
          "cols": 5
        }
      ],
      "keywords": [
        "evaluation",
        "ct",
        "prognosis",
        "diagnostic",
        "management",
        "stratification",
        "risk",
        "according",
        "disease",
        "ablation",
        "presentation",
        "likely",
        "known",
        "clinical",
        "icd"
      ]
    },
    {
      "number": "10",
      "title": "8. Special aspects in selected populations",
      "start_page": 92,
      "end_page": 94,
      "content": "8. Special aspects in selected\npopulations\n8.1. Pregnant patients and peri-partum\ncardiomyopathy\nPregnancy and the post-partum period contribute a signiﬁcant risk in\nwomen with arrhythmic heart disease and is covered in the 2018\nESC Guidelines for the management of cardiovascular diseases during\npregnancy.1076–1080 New-onset VT may present during pregnancy and\nrisk of recurrent VT is higher in patients with previous VT and SHD.1081\nPeri-partum cardiomyopathy (PPCM) should be ruled out in the case\nof new-onset VT during the last 6 weeks of pregnancy or in the early\npost-partum period.1082 A genetic contribution may be present in up\nto 20% of patients with PPCM (in particular titin-truncating var-\niants)1083 and future studies should reveal if genetic testing plays a\nrole in PPCM patients with a positive family history.\n8.1.1. Electrocardioversion and implantable\ncardioverter deﬁbrillator therapy in pregnancy\nCardioversion seems safe in all phases of pregnancy and case reports\nshow neither compromise in fetal blood ﬂow nor initiation of pre-\nterm labour.1084 Foetal heart rate should be routinely controlled\nafter cardioversion.1085 If an ICD is indicated, ICD implantation\nshould be performed beyond 8 weeks of gestation with radiation\nprotection by experienced operator teams.1086 Echocardiographic\nguidance or a 3D mapping system may be helpful in ICD implantation\nto avoid radiation.1087,1088 In pregnant patients with existing ICD,\nroutine ICD interrogation is recommended prior to delivery. In pa-\ntients with PPCM, thresholds for early ICD implantations are higher\nthan in other conditions because of a high rate of spontaneous recov-\nery after delivery.1089 WCD have been suggested to temporarily\nprevent SCD during the ﬁrst 3–6 months after diagnosis of PPCM\nwith LVEF ≤35%, while awaiting recovery.1090,1091\n8.1.2. Pharmacological treatment\nPharmacological treatment of arrhythmias and heart failure in pregnant\nwomen should follow treatment in non-pregnant patients with avoid-\nance of drugs contraindicated in pregnancy, such as ACE inhibitors,\nARB inhibitors/ARNI and renin inhibitors.1080,1082,1092,1093 The ﬁrst tri-\nmester is associated with the greatest teratogenic risk. Start of pharma-\ncological therapy is advised to begin at the latest possible point in the\npregnancy and with the lowest effective dose. Drug exposure in the se-\ncond and third trimestera may confer adverse effects on foetal growth\nand development as well as increasing the risk of pro-arrhythmia.\nIt is recommended to check drugs and safety data before initiation of\na new drug during pregnancy, according to the 2018 ESC Guidelines for\nthe management of cardiovascular diseases during pregnancy.1080 From\nthis list, AADs can be summarized as followed:\n• Well tolerated: sotalol, oral verapamil\n• Use only if potential beneﬁt outweighs potential risk: bi-\nsoprolol, carvedilol, digoxin, diltiazem (possible teratogenic ef-\nfects), disopyramide (uterine contractions), ﬂecainide, lidocaine,\nmetoprolol, nadolol, propranolol, verapamil IV, quinidine\n• Inadequate\ndata:\nIvabradine,\nmexiletine,\nproprafenone,\nvernakalant\n• Contraindicated: amiodarone, atenolol, dronedarone.\nIn LQTS (LQT2 in particular), risk of cardiac events increases sub-\nstantially in the post-partum period (up to one year after deliv-\nery).1094 Therefore, it is important to continue beta-blocker\ntherapy\nthroughout\npregnancy\nand\npost-partum.955,1094,1095\nContinuation of beta-blocker treatment is recommended in LQTS\nand CPVT1096 and should be considered in ARVC.1097–1099 No add-\nitional risk by pregnancy is known in women with BrS1100,1101\n(\nESC CardioMed chapter 53.6).1102\nIn patients with PPCM, use of bromocriptine as disease-speciﬁc\ntherapy in addition to standard heart failure therapy has shown\npromising results in two clinical trials.1103,1104\n8.1.3. Catheter ablation\nIn planned pregnancies, symptomatic tachyarrhythmia should be\ntreated by catheter ablation before pregnancy. If catheter ablation\nis indicated in a pregnant patient, one should avoid the procedure\nin the ﬁrst trimester, and electroanatomical mapping-guided proce-\ndures should be preferred.1105,1106\nRecommendation Table 47 — Recommendations for\nthe prevention of sudden cardiac death and manage-\nment of ventricular arrhythmia during pregnancy\nRecommendations\nClassa\nLevelb\nAcute management of VA\nDuring pregnancy, electrical cardioversion is\nrecommended for sustained VT.1084\nI\nC\nFor acute conversion of haemodynamically\ntolerated SMVT during pregnancy, a beta-blocker,\nsotalol, ﬂecainide, procainamide, or overdrive\nventricular pacing should be considered.\nIIa\nC\nLong-term management of VA\nIf ICD implantation is indicated during pregnancy,\nimplantation is recommended with optimal\nradiation protection.1087,1107\nI\nC\nContinuation of beta-blockers is recommended\nduring pregnancy and post-partum in women with\nLQTS or CPVT.955,1094–1096\nI\nC\nContinuation of beta-blockers should be\nconsidered during pregnancy in women with\nARVC.1097–1099\nIIa\nC\nOral metoprolol, propranolol, or verapamil\nshould be considered for long-term management\nof idiopathic sustained VT during pregnancy.\nIIa\nC\nCatheter ablation using non-ﬂuoroscopic mapping\nsystems should be considered, preferably after the\nﬁrst trimester, in women with highly symptomatic\nrecurrent SMVT refractory or who are intolerant\nto AADs.1105\nIIa\nC\n© ESC 2022\nAAD, anti-arrhythmic drug; ARVC, arrhythmogenic right ventricular cardiomyopathy;\nCPVT, catecholaminergic polymorphic ventricular tachycardia; ICD, implantable\ncardioverter deﬁbrillator; LQTS, long QT syndrome; SMVT, sustained monomorphic\nVT; VA, ventricular arrhythmia; VT, ventricular tachycardia.\naClass of recommendation.\nbLevel of evidence.\n4088\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n8.2. Heart transplantation\nPatients listed for HTX are exposed to an SCD risk and have a high\nincidence of VA. Data from large registries suggest a survival beneﬁt\nfrom ICDs.1108–1111 The only randomized study including patients\nlisted for HTX was prematurely stopped because of low enrol-\nment.1112 There are no data regarding the role of WCD in patients\nlisted for HTX. The median expected time on the waiting list, 8–16\nmonths, needs to be considered.1108,1110 However, this panel shares\nthe opinion that a WCD may be an alternative for an ICD in selected\npatients waiting for HTX.371,1113\nIn post-HTX patients, SCD is responsible for around 10% of\ndeaths.1114,1115 Transplant rejection and allograft vasculopathy are\nassociated with SCD1114,1116,1117; therefore, ICD implantation may\nbe appropriate in selected high-risk patients.1118\n8.3. Sudden cardiac death in athletes\nThe incidence of SCD in athletes increases with age.4,1120 In appar-\nently healthy athletes (.35 years), the estimated incidence of SCD\nranges from 2 to 6.3 per 100 000 participant-years. In comparison,\nin young competitive athletes (≤35 years) the incidence of fatal\nevents is signiﬁcantly lower, 0.4–3 per 100 000 participant-\nyears.46,47,1120 Women athletes are at low risk of SCD; on average,\n1 in 14 SCD in athletes occurs in women.1121\nPre-participation cardiovascular evaluation offers the potential\nto identify athletes at-risk for cardiovascular disease before on-\nset of symptoms.1122–1126 The evaluation protocol needs to be\nadapted to the age of the athlete to account for age-speciﬁc car-\ndiovascular disease.1125 Pre-participation evaluation, including\nmedical history, physical examination, and ECG, appears effect-\nive in identifying cardiovascular disease in young athletes (≤35\nyears of age) by identiﬁcation of relevant symptoms (e.g. exer-\ntional syncope) or ECG abnormalities consistent with inheritable\ncardiomyopathies or channelopathies.1127–1130 Although echo-\ncardiography can increase the sensitivity of screening for SHD,\nit is unfeasible as a routine test in mass screening. More cardio-\nvascular diseases are identiﬁed by serial (annual) evaluations of\nadolescent athletes.1129,1131 The prevalence of false-positive re-\nsults strongly depends on the criteria used to deﬁne an ECG\nas ‘abnormal’.1132,1133 Additional tests, such as echocardiog-\nraphy, 24-hour Holter monitoring, stress testing, and CMR, are\nrequested for athletes who had positive ﬁndings at the initial\nevaluation. Athletes diagnosed with clinically relevant cardiovas-\ncular\ndisease\nare\nmanaged\naccording\nto\navailable\nESC\nGuidelines.4,1134–1136\nIn middle-aged/senior athletes, the most common cause of\nSCD is CAD.1125,1137 Before engaging in a vigorous physical\nactivity, asymptomatic middle-aged/senior athletes should be\nevaluated\nusing\nrisk\nscore\nsystems\nsuch\nas\nthe\nESC\nSCORE2.4,65\nExcellent rates of survival with favourable neurological outcome\nafter CA has been reported in sports centres equipped with\nAED.1137,1138 This justiﬁes the efforts for implementing emergency\nprograms for SCD prevention, with distribution of AED in sports\narenas and training of coaches and staff to perform CPR and\ndeﬁbrillation.1139\nRecommendation Table 48 — Recommendations for\nthe prevention of sudden cardiac death before and\nafter heart transplantation\nRecommendations\nClassa\nLevelb\nPrior to heart transplant\nIn patients awaiting heart transplantation, ICD\nimplantation for primary prevention should be\nconsidered.1108,1111,1112\nIIa\nC\nIn patients awaiting heart transplantation, WCD\nmay be considered.1109,1113,1119\nIIb\nC\nPost heart transplant\nIn selected transplanted patients with cardiac\nallograft vasculopathy or treated rejection, ICD\nimplantation may be considered.1114,1116\nIIb\nC\n© ESC 2022\nICD, implantable cardioverter deﬁbrillator; WCD, wearable cardioverter deﬁbrillator.\naClass of recommendation.\nbLevel of evidence.\nRecommendation Table 49 — Recommendations for\nrisk stratiﬁcation and prevention of sudden cardiac\ndeath in athletes\nRecommendations\nClassa\nLevelb\nIn athletes with positive medical history, abnormal\nphysical examination, or ECG alterations, further\ninvestigations including echocardiography and/or\nCMR to conﬁrm (or exclude) an underlying\ndisease are recommended.1123,1133,1135\nI\nC\nIt is recommended that athletes diagnosed with a\ncardiovascular disease associated with SCD are\nmanaged according to current guidelines for\nsports eligibility.\nI\nC\nIt is recommended that staff at sporting facilities\nare trained in CPR and in the use of AED.93,1137\nI\nC\nPre-participation cardiovascular evaluation of\ncompetitive athletes should be\nconsidered.46,1122,1123,1127\nIIa\nC\nIt should be considered that cardiovascular\nevaluation of young (,35 years) competitive\nathletes includes history, physical examination,\nand 12-lead ECG.1123,1126,1130,1140\nIIa\nC\nThe cardiovascular risk of middle-aged and elderly\nindividuals should be evaluated before engaging in\nstrenuous sports through established scores such\nas the SCORE2 risk chart.46,1141,1142\nIIa\nC\n© ESC 2022\nAED, automated external deﬁbrillator; CMR, cardiac magnetic resonance; CPR,\ncardiopulmonary resuscitation; ECG, electrocardiogram; SCD, sudden cardiac death.\naClass of recommendation.\nbLevel of evidence.\nESC Guidelines\n4089\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n8.4. Wolff–Parkinson–White syndrome\nIn patients with Wolff–Parkinson–White (WPW) syndrome, the\nmost common arrhythmia is AV re-entry tachycardia (AVRT;\n80%), followed by AF (20–30%). SCD secondary to pre-excited AF\nresulting in VF is the most feared manifestation of WPW syndrome.\nThe risk of CA/VF in untreated WPW patients has been estimated at\n0.9–2.4 per 1000 person-year.1143,1144 The management of WPW\npatients has recently been reviewed in the 2019 ESC Guidelines\nfor the management of patients with SVT302 and updated with a par-\nticular focus on athletes in 2020.1145 In patients with ventricular\npre-excitation and symptomatic AVRT, catheter ablation is recom-\nmended (class I). In asymptomatic patients with ventricular\npre-excitation, both invasive (class IIa) and non-invasive (class IIb)\nassessment are options for risk stratiﬁcation for SCD. While cath-\neter ablation is recommended for asymptomatic accessory pathways\nwith high-risk features (class I), clinical follow-up (class IIa), or cath-\neter ablations (class IIb) are options based on informed patient\nchoice. This decision should take into account the location of the ac-\ncessory pathway, the local ablation experience and the fact that\nsymptomatic arrhythmias will frequently develop during follow-\nup.1146 For the paediatric population, SVT due to WPW can usually\nbe managed pharmacologically, and accessory pathways often lose\nantegrade conduction in the ﬁrst years of life.1147 In children with\nasymptomatic accessory pathways, risk stratiﬁcation is not recom-\nmend before the age of 8 years.1148\n8.5. Prevention of sudden cardiac death\nin the elderly\nAge is a strong risk factor for death. In several studies, advanced\nage was one of the factors associated with a reduced expected\nbeneﬁt from ICD treatment. In patients with ischaemic cardiomy-\nopathy enrolled in MADIT-II trial, a risk scheme composed of 5\nclinical factors including age .70 years was predictive of the ab-\nsence of long-term beneﬁt conferred by the ICD.1149 In a recent\nanalysis of ICD patients enrolled in four MADIT studies, age ,75\nyears was a predictor of VT/VF whereas age ≥75 years was a pre-\ndictor of non-arrhythmic mortality.365 Consistently, in the recent\nrandomized DANISH trial in patients with non-ischaemic heart\nfailure, the association between the ICD and survival decreased\nlinearly with increasing age, while an age cut-off at ≤70 years\nyielded the highest survival.647 Contemporary non-randomized\ndata corroborate these ﬁndings. In the EU-CERT-ICD prospect-\nive cohort study in patients with CAD or cardiomyopathies\nwith indication for primary prevention ICD implantation, no\nICD beneﬁt was observed in patients aged ≥75 years.357 In con-\ntrast, there was a signiﬁcant survival beneﬁt in patients aged\n,75 years. Further retrospective data are in line with this\nobservation.1150\nBiological age may vary in part according to comorbidities.\nIndeed, comorbidities signiﬁcantly inﬂuence survival of ICD recipi-\nents and a high comorbidity index is associated with less survival\ngain in primary or secondary prevention ICD patients.1149,1151\nTherefore, a simple age cut-off cannot guide the decision on ICD\nimplantation adequately and the ICD indication in elderly patients\nshould be based on a personalized assessment considering the\noverall condition and comorbidities.\n9. Key messages\n9.1. General aspects\n• Increased availability of public access deﬁbrillators and community\ntraining in basic life support are key elements to improve survival of\nout-of-hospital cardiac arrest victims.\n• Risk calculators for SCD and VA implemented in clinical practice\nneed to meet agreed high standards for the development, external\nvalidation, and reporting of prediction models.\n• Patients with genetic cardiomyopathies and arrhythmia syndromes\nrequire genetic testing as a routine part of their care.\n• Genetic testing and counselling require access to an expert multi-\ndisciplinary team.\n• A systematic workup of cardiac arrest survivors requires a multi-\nmodal approach.\n• A comprehensive autopsy is recommended in all cases of sudden\ndeath under 50 years and is desirable in all sudden death victims.\n• Clinical and genetic evaluation of SADS decedents and their fam-\nilies leads to a diagnosis of genetic heart disease in a substantial\nproportion of families.\n• An electrical storm refractory to drug treatment requires the avail-\nability of advanced catheter ablation techniques, mechanical circu-\nlatory support, and autonomic modulation.\n• When considering ICD therapy beneﬁt, competing risk factors for\nnon-arrhythmic death and the patient’s wishes and quality of life\nneed to be taken into account.\n9.2. Structural heart disease\n• Catheter ablation is recommended in CAD patients with recurrent\nsymptomatic SMVT despite chronic amiodarone therapy.\n• Catheter ablation is the ﬁrst-line treatment for PVC-induced\ncardiomyopathy.\n• In HNDCM/DCM patients, indication for primary prevention\nICD implantation should not be restricted to an LVEF ≤35%.\nAdditional risk factors (e.g. CMR and genetics) are important to\nconsider.\n• Patients with an LMNA mutation require speciﬁc risk stratiﬁcation\nfor SCD.\n• ARVC patients have a high rate of appropriate ICD interventions\nwhich may not necessarily be classiﬁed as lifesaving.\nRecommendation Table 50 — Recommendations for\nimplantable cardioverter deﬁbrillator implantation in\nthe elderly\nRecommendations\nClassa\nLevelb\nIn elderly patients in whom a beneﬁt from the\ndeﬁbrillator is not expected due to the patient’s\nage and comorbidities, omission of ICD\nimplantation for primary prevention may be\nconsidered.647,1150,1152\nIIb\nB\n© ESC 2022\nICD, implantable cardioverter deﬁbrillator.\naClass of recommendation.\nbLevel of evidence.\n4090\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 92",
          "page": 92,
          "content": "Recommendations | Classa | Levelb | \nAcute management of VA |  |  | \nDuring pregnancy, electrical cardioversion is\nrecommended for sustained VT.1084 | I | C | \nFor acute conversion of haemodynamically\ntolerated SMVT during pregnancy, a beta-blocker,\nsotalol, flecainide, procainamide, or overdrive\nventricular pacing should be considered. | IIa | C | \nLong-term management of VA |  |  | \nIf ICD implantation is indicated during pregnancy,\nimplantation is recommended with optimal\nradiation protection.1087,1107 | I | C | \nContinuation of beta-blockers is recommended\nduring pregnancy and post-partum in women with\nLQTS or CPVT.955,1094–1096 | I | C | \nContinuation of beta-blockers should be\nconsidered during pregnancy in women with\nARVC.1097–1099 | IIa | C | \nOral metoprolol, propranolol, or verapamil\nshould be considered for long-term management\nof idiopathic sustained VT during pregnancy. | IIa | C | \nCatheter ablation using non-fluoroscopic mapping\nsystems should be considered, preferably after the\nfirst trimester, in women with highly symptomatic\nrecurrent SMVT refractory or who are intolerant\nto AADs.1105 | IIa | C | ",
          "rows": 10,
          "cols": 4
        },
        {
          "title": "Table on page 93",
          "page": 93,
          "content": "Recommendations |  | Classa | Levelb | \n | Prior to heart transplant |  |  | \nIn patients awaiting heart transplantation, ICD\nimplantation for primary prevention should be\nconsidered.1108,1111,1112 |  | IIa | C | \nIn patients awaiting heart transplantation, WCD\nmay be considered.1109,1113,1119 |  | IIb | C | \n | Post heart transplant |  |  | \nIn selected transplanted patients with cardiac\nallograft vasculopathy or treated rejection, ICD\nimplantation may be considered.1114,1116 |  | IIb | C | ",
          "rows": 6,
          "cols": 5
        },
        {
          "title": "Table on page 93",
          "page": 93,
          "content": "Recommendations | Classa | Levelb\nIn athletes with positive medical history, abnormal\nphysical examination, or ECG alterations, further\ninvestigations including echocardiography and/or\nCMR to confirm (or exclude) an underlying\ndisease are recommended.1123,1133,1135 | I | C\nIt is recommended that athletes diagnosed with a\ncardiovascular disease associated with SCD are\nmanaged according to current guidelines for\nsports eligibility. | I | C\nIt is recommended that staff at sporting facilities\nare trained in CPR and in the use of AED.93,1137 | I | C\nPre-participation cardiovascular evaluation of\ncompetitive athletes should be\nconsidered.46,1122,1123,1127 | IIa | C\nIt should be considered that cardiovascular\nevaluation of young (,35 years) competitive\nathletes includes history, physical examination,\nand 12-lead ECG.1123,1126,1130,1140 | IIa | C\nThe cardiovascular risk of middle-aged and elderly\nindividuals should be evaluated before engaging in\nstrenuous sports through established scores such\nas the SCORE2 risk chart.46,1141,1142 | IIa | C",
          "rows": 7,
          "cols": 3
        },
        {
          "title": "Table on page 94",
          "page": 94,
          "content": "Recommendations | Classa | Levelb\nIn elderly patients in whom a benefit from the\ndefibrillator is not expected due to the patient’s\nage and comorbidities, omission of ICD\nimplantation for primary prevention may be\nconsidered.647,1150,1152 | IIb | B",
          "rows": 2,
          "cols": 3
        }
      ],
      "keywords": [
        "cardiomyopathy",
        "ct",
        "echo",
        "ace inhibitor",
        "arb",
        "heart failure",
        "selected",
        "risk",
        "aspects",
        "populations",
        "treatment",
        "special",
        "icd",
        "diagnosis"
      ]
    },
    {
      "number": "11",
      "title": "9. Key messages",
      "start_page": 94,
      "end_page": 95,
      "content": "8.4. Wolff–Parkinson–White syndrome\nIn patients with Wolff–Parkinson–White (WPW) syndrome, the\nmost common arrhythmia is AV re-entry tachycardia (AVRT;\n80%), followed by AF (20–30%). SCD secondary to pre-excited AF\nresulting in VF is the most feared manifestation of WPW syndrome.\nThe risk of CA/VF in untreated WPW patients has been estimated at\n0.9–2.4 per 1000 person-year.1143,1144 The management of WPW\npatients has recently been reviewed in the 2019 ESC Guidelines\nfor the management of patients with SVT302 and updated with a par-\nticular focus on athletes in 2020.1145 In patients with ventricular\npre-excitation and symptomatic AVRT, catheter ablation is recom-\nmended (class I). In asymptomatic patients with ventricular\npre-excitation, both invasive (class IIa) and non-invasive (class IIb)\nassessment are options for risk stratiﬁcation for SCD. While cath-\neter ablation is recommended for asymptomatic accessory pathways\nwith high-risk features (class I), clinical follow-up (class IIa), or cath-\neter ablations (class IIb) are options based on informed patient\nchoice. This decision should take into account the location of the ac-\ncessory pathway, the local ablation experience and the fact that\nsymptomatic arrhythmias will frequently develop during follow-\nup.1146 For the paediatric population, SVT due to WPW can usually\nbe managed pharmacologically, and accessory pathways often lose\nantegrade conduction in the ﬁrst years of life.1147 In children with\nasymptomatic accessory pathways, risk stratiﬁcation is not recom-\nmend before the age of 8 years.1148\n8.5. Prevention of sudden cardiac death\nin the elderly\nAge is a strong risk factor for death. In several studies, advanced\nage was one of the factors associated with a reduced expected\nbeneﬁt from ICD treatment. In patients with ischaemic cardiomy-\nopathy enrolled in MADIT-II trial, a risk scheme composed of 5\nclinical factors including age .70 years was predictive of the ab-\nsence of long-term beneﬁt conferred by the ICD.1149 In a recent\nanalysis of ICD patients enrolled in four MADIT studies, age ,75\nyears was a predictor of VT/VF whereas age ≥75 years was a pre-\ndictor of non-arrhythmic mortality.365 Consistently, in the recent\nrandomized DANISH trial in patients with non-ischaemic heart\nfailure, the association between the ICD and survival decreased\nlinearly with increasing age, while an age cut-off at ≤70 years\nyielded the highest survival.647 Contemporary non-randomized\ndata corroborate these ﬁndings. In the EU-CERT-ICD prospect-\nive cohort study in patients with CAD or cardiomyopathies\nwith indication for primary prevention ICD implantation, no\nICD beneﬁt was observed in patients aged ≥75 years.357 In con-\ntrast, there was a signiﬁcant survival beneﬁt in patients aged\n,75 years. Further retrospective data are in line with this\nobservation.1150\nBiological age may vary in part according to comorbidities.\nIndeed, comorbidities signiﬁcantly inﬂuence survival of ICD recipi-\nents and a high comorbidity index is associated with less survival\ngain in primary or secondary prevention ICD patients.1149,1151\nTherefore, a simple age cut-off cannot guide the decision on ICD\nimplantation adequately and the ICD indication in elderly patients\nshould be based on a personalized assessment considering the\noverall condition and comorbidities.\n9. Key messages\n9.1. General aspects\n• Increased availability of public access deﬁbrillators and community\ntraining in basic life support are key elements to improve survival of\nout-of-hospital cardiac arrest victims.\n• Risk calculators for SCD and VA implemented in clinical practice\nneed to meet agreed high standards for the development, external\nvalidation, and reporting of prediction models.\n• Patients with genetic cardiomyopathies and arrhythmia syndromes\nrequire genetic testing as a routine part of their care.\n• Genetic testing and counselling require access to an expert multi-\ndisciplinary team.\n• A systematic workup of cardiac arrest survivors requires a multi-\nmodal approach.\n• A comprehensive autopsy is recommended in all cases of sudden\ndeath under 50 years and is desirable in all sudden death victims.\n• Clinical and genetic evaluation of SADS decedents and their fam-\nilies leads to a diagnosis of genetic heart disease in a substantial\nproportion of families.\n• An electrical storm refractory to drug treatment requires the avail-\nability of advanced catheter ablation techniques, mechanical circu-\nlatory support, and autonomic modulation.\n• When considering ICD therapy beneﬁt, competing risk factors for\nnon-arrhythmic death and the patient’s wishes and quality of life\nneed to be taken into account.\n9.2. Structural heart disease\n• Catheter ablation is recommended in CAD patients with recurrent\nsymptomatic SMVT despite chronic amiodarone therapy.\n• Catheter ablation is the ﬁrst-line treatment for PVC-induced\ncardiomyopathy.\n• In HNDCM/DCM patients, indication for primary prevention\nICD implantation should not be restricted to an LVEF ≤35%.\nAdditional risk factors (e.g. CMR and genetics) are important to\nconsider.\n• Patients with an LMNA mutation require speciﬁc risk stratiﬁcation\nfor SCD.\n• ARVC patients have a high rate of appropriate ICD interventions\nwhich may not necessarily be classiﬁed as lifesaving.\nRecommendation Table 50 — Recommendations for\nimplantable cardioverter deﬁbrillator implantation in\nthe elderly\nRecommendations\nClassa\nLevelb\nIn elderly patients in whom a beneﬁt from the\ndeﬁbrillator is not expected due to the patient’s\nage and comorbidities, omission of ICD\nimplantation for primary prevention may be\nconsidered.647,1150,1152\nIIb\nB\n© ESC 2022\nICD, implantable cardioverter deﬁbrillator.\naClass of recommendation.\nbLevel of evidence.\n4090\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n• A validated risk calculator (HCM Risk-Kids score) is useful to assess\nthe risk for SCD in HCM patients younger than 16 years.\n• Myotonic dystrophy patients with palpitations suspected of ar-\nrhythmia, syncope or aborted sudden death need to be evaluated\nby invasive electrophysiological study.\n• In patients with repaired tetralogy of Fallot and monomorphic VT,\ncatheter ablation is the preferred treatment.\n9.3. Primary electrical disease\n• Nadolol or propranolol are the preferred beta-blockers in LQTS\nand CPVT patients.\n• In asymptomatic LQTS patients the arrhythmic risk (1-2-3 Risk cal-\nculator) may be useful to calculate.\n• A type 1 Brugada ECG pattern provoked by sodium channel\nblocker test in the absence of other ﬁndings does not diagnose\nthe BrS.\n• SCD risk stratiﬁcation in asymptomatic BrS patients with a spon-\ntaneous type 1 pattern remains controversial.\n• Routine catheter ablation is not recommended in asymptomatic\nBrS patients.\n• The diagnosis of idiopathic VF requires exclusion of an\nunderlying\nstructural,\nchannelopathic,\nor\nmetabolic\naetiology.\n• ERP can be a benign ﬁnding and is distinct from ERS.\n• Left cardiac denervation plays an important role in the manage-\nment of CPVT and LQTS patients.\n10. Gaps in evidence\n10.1. General aspects\n• Accurate screening tests to detect heart conditions associated\nwith SCD in asymptomatic individuals in the general population\nare required.\n• In patients with SHD, the optimal time interval between repeated\nnon-invasive and invasive prognostic tests, in case of a negative\ntest, is unknown.\n• Improved assessment of genetic variants of uncertain signiﬁcance\nand likely pathogenic variants is needed.\n• The utility of polygenic risk scores in patients at risk of SCD re-\nquires investigation.\n10.2. Structural heart disease—general\n• The long-term safety and efﬁcacy of S-ICDs is unknown.\n• The role of primary preventive ICD therapy in patients with SHD\nand mildly reduced or preserved ejection fraction has not been\nstudied systematically.\n• The optimal techniques to undertake VT substrate mapping and\nablation in SHD remain to be determined.\n• The role of ICD implantation in end-stage heart failure patients\nsupported by current-generation, continuous-ﬂow LVADs is\nunclear.\n10.3. Idiopathic premature ventricular\ncomplexes/ventricular tachycardia\n• The beneﬁcial role of catheter ablation or anti-arrhythmic drug\ntreatment in patients with asymptomatic, frequent PVCs and pre-\nserved cardiac function needs to be determined.\n10.4. Coronary artery disease\n• It is unknown which patients with chronic CAD and severely im-\npaired LVEF are at low risk for SCD.\n• The role of LGE-CMR for risk stratiﬁcation for SCD in chronic\nCAD is unclear.\n• RCTs are needed to determine the role of ICDs after successful\nVT ablation in chronic CAD with mildly reduced or preserved\nLVEF.\n10.5. Cardiomyopathies\n• It is unknown if PVC-induced cardiomyopathy is a diagnosis on its\nown or if an underlying predisposition is needed.\n• The predictive value of LGE-CMR ﬁndings (e.g. pattern and\namount of LGE) for individual risk stratiﬁcation for SCD in patients\nwith cardiac sarcoidosis, HCM, and DCM/HNDC is unclear.\n• Studies are needed to determine the role of PES in patients with\ncardiac sarcoidosis and DCM/HNDC who have a mildly reduced\nor preserved cardiac function and LGE on CMR.\n• Prospective data on the association between intensity and dur-\nation of exercise and manifestation and severity of the phenotype\nin healthy ARVC mutation carriers are lacking.\n• The beneﬁcial role of ICDs after successful ablation in ARVC pa-\ntients who present with haemodynamically tolerated VT needs\nto be studied.\n• Data on clinical outcome, predictors for arrhythmic events, and in-\ndication for treatment, including ICD therapy, in patients with bi-\nventricular and left-dominant arrhythmogenic cardiomyopathy are\nrequired.\n10.6. Valvular heart disease\n• There is a lack of knowledge to identify patients with MVP at risk\nfor VA and SCD.\n10.7. Congenital heart disease\n• There is a lack of knowledge regarding the absolute risk for VA and\nSCD in CHD that have undergone repair with contemporary sur-\ngical approaches.\n10.8. Primary electrical disease\n• Robust evidence is required to support the prophylactic use of the\nICD on top of medical therapy with beta-blockers and gene-\nspeciﬁc therapy in LQTS patients.\n• More data are required to determine the role of LCSD and ICD in\nhigh-risk LQTS patients who do not tolerate medical therapy.\nESC Guidelines\n4091\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 94",
          "page": 94,
          "content": "Recommendations | Classa | Levelb\nIn elderly patients in whom a benefit from the\ndefibrillator is not expected due to the patient’s\nage and comorbidities, omission of ICD\nimplantation for primary prevention may be\nconsidered.647,1150,1152 | IIb | B",
          "rows": 2,
          "cols": 3
        }
      ],
      "keywords": [
        "ct",
        "asymptomatic",
        "messages",
        "follow-up",
        "class ii",
        "class i",
        "risk",
        "symptomatic",
        "ablation",
        "treatment",
        "indication",
        "icd"
      ]
    },
    {
      "number": "12",
      "title": "10. Gaps in evidence",
      "start_page": 95,
      "end_page": 96,
      "content": "• A validated risk calculator (HCM Risk-Kids score) is useful to assess\nthe risk for SCD in HCM patients younger than 16 years.\n• Myotonic dystrophy patients with palpitations suspected of ar-\nrhythmia, syncope or aborted sudden death need to be evaluated\nby invasive electrophysiological study.\n• In patients with repaired tetralogy of Fallot and monomorphic VT,\ncatheter ablation is the preferred treatment.\n9.3. Primary electrical disease\n• Nadolol or propranolol are the preferred beta-blockers in LQTS\nand CPVT patients.\n• In asymptomatic LQTS patients the arrhythmic risk (1-2-3 Risk cal-\nculator) may be useful to calculate.\n• A type 1 Brugada ECG pattern provoked by sodium channel\nblocker test in the absence of other ﬁndings does not diagnose\nthe BrS.\n• SCD risk stratiﬁcation in asymptomatic BrS patients with a spon-\ntaneous type 1 pattern remains controversial.\n• Routine catheter ablation is not recommended in asymptomatic\nBrS patients.\n• The diagnosis of idiopathic VF requires exclusion of an\nunderlying\nstructural,\nchannelopathic,\nor\nmetabolic\naetiology.\n• ERP can be a benign ﬁnding and is distinct from ERS.\n• Left cardiac denervation plays an important role in the manage-\nment of CPVT and LQTS patients.\n10. Gaps in evidence\n10.1. General aspects\n• Accurate screening tests to detect heart conditions associated\nwith SCD in asymptomatic individuals in the general population\nare required.\n• In patients with SHD, the optimal time interval between repeated\nnon-invasive and invasive prognostic tests, in case of a negative\ntest, is unknown.\n• Improved assessment of genetic variants of uncertain signiﬁcance\nand likely pathogenic variants is needed.\n• The utility of polygenic risk scores in patients at risk of SCD re-\nquires investigation.\n10.2. Structural heart disease—general\n• The long-term safety and efﬁcacy of S-ICDs is unknown.\n• The role of primary preventive ICD therapy in patients with SHD\nand mildly reduced or preserved ejection fraction has not been\nstudied systematically.\n• The optimal techniques to undertake VT substrate mapping and\nablation in SHD remain to be determined.\n• The role of ICD implantation in end-stage heart failure patients\nsupported by current-generation, continuous-ﬂow LVADs is\nunclear.\n10.3. Idiopathic premature ventricular\ncomplexes/ventricular tachycardia\n• The beneﬁcial role of catheter ablation or anti-arrhythmic drug\ntreatment in patients with asymptomatic, frequent PVCs and pre-\nserved cardiac function needs to be determined.\n10.4. Coronary artery disease\n• It is unknown which patients with chronic CAD and severely im-\npaired LVEF are at low risk for SCD.\n• The role of LGE-CMR for risk stratiﬁcation for SCD in chronic\nCAD is unclear.\n• RCTs are needed to determine the role of ICDs after successful\nVT ablation in chronic CAD with mildly reduced or preserved\nLVEF.\n10.5. Cardiomyopathies\n• It is unknown if PVC-induced cardiomyopathy is a diagnosis on its\nown or if an underlying predisposition is needed.\n• The predictive value of LGE-CMR ﬁndings (e.g. pattern and\namount of LGE) for individual risk stratiﬁcation for SCD in patients\nwith cardiac sarcoidosis, HCM, and DCM/HNDC is unclear.\n• Studies are needed to determine the role of PES in patients with\ncardiac sarcoidosis and DCM/HNDC who have a mildly reduced\nor preserved cardiac function and LGE on CMR.\n• Prospective data on the association between intensity and dur-\nation of exercise and manifestation and severity of the phenotype\nin healthy ARVC mutation carriers are lacking.\n• The beneﬁcial role of ICDs after successful ablation in ARVC pa-\ntients who present with haemodynamically tolerated VT needs\nto be studied.\n• Data on clinical outcome, predictors for arrhythmic events, and in-\ndication for treatment, including ICD therapy, in patients with bi-\nventricular and left-dominant arrhythmogenic cardiomyopathy are\nrequired.\n10.6. Valvular heart disease\n• There is a lack of knowledge to identify patients with MVP at risk\nfor VA and SCD.\n10.7. Congenital heart disease\n• There is a lack of knowledge regarding the absolute risk for VA and\nSCD in CHD that have undergone repair with contemporary sur-\ngical approaches.\n10.8. Primary electrical disease\n• Robust evidence is required to support the prophylactic use of the\nICD on top of medical therapy with beta-blockers and gene-\nspeciﬁc therapy in LQTS patients.\n• More data are required to determine the role of LCSD and ICD in\nhigh-risk LQTS patients who do not tolerate medical therapy.\nESC Guidelines\n4091\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n• Improved diagnostic and risk stratiﬁcation tools for asymptomatic\nBrugada patients and suspected early repolarization syndrome are\nneeded.\n• The role of endo-epicardial mapping to identify localized structural\nalterations potentially related to IVF and targeted catheter ablation\nneeds to be further studied.\n• Long-term data are required on the efﬁcacy of the ICD vs. no ICD\nin CPVT survivors of cardiac arrest.\n• It is poorly understood why women are at low risk of\nsport-related SCD.\n11. ‘What to do’ and ‘what not to do’ messages from the Guidelines\nRecommendations\nClassa\nLevelb\nRecommendations for public basic life support and access to automated external deﬁbrillator\nIt is recommended that public access deﬁbrillation be available at sites where cardiac arrest is more likely to occur.c\nI\nB\nPrompt CPR by bystanders is recommended at OHCA.\nI\nB\nIt is recommended to promote community training in basic life support to increase bystander CPR rate and AED use.\nI\nB\nRecommendations for genetic testing\nGenetic testing is recommended when a condition is diagnosed in a living or deceased individual with a likely genetic basis and a risk of VA\nand SCD.\nI\nB\nWhen a putative causative variant is ﬁrst identiﬁed, evaluation for pathogenicity is recommended using an internationally accepted\nframework.\nI\nC\nWhen a Class IV or Class V variant has been identiﬁed in a living or deceased individual with a condition that carries a risk of VA and SCD,\ngenetic testing of ﬁrst-degree and symptomatic relatives and obligate carriers is recommended.\nI\nC\nIt is recommended that genetic testing and counselling on its potential consequences should be undertaken by an expert\nmultidisciplinary team.\nI\nC\nIt is recommended that Class III variants (of uncertain signiﬁcance) and Class IV variants should be evaluated for segregation in families\nwhere possible, and the variant re-evaluated periodically.\nI\nC\nIt is not recommended to undertake genetic testing in index patients with insufﬁcient evidence of a genetic disease.\nIII\nC\nRecommendations for evaluation of patients presenting with newly documented ventricular arrhythmia\nIn patients with newly documented VA (frequent PVCs, NSVT, SMVT), a baseline 12-lead ECG, recording of the VA on 12-lead ECG,\nwhenever possible, and an echocardiogram are recommended as ﬁrst-line evaluation.\nI\nC\nRecommendations for evaluation of sudden cardiac arrest survivors\nThe investigation of a SCA survivor without obvious extra-cardiac cause is recommended to be overseen by a multidisciplinary team.\nI\nB\nIn electrically unstable patients after SCA, with suspicion of ongoing myocardial ischaemia, a coronary angiogram is indicated.\nI\nC\nIn SCA survivors, collection of blood samples at presentation is recommended for potential toxicology and genetic testing.\nI\nB\nRetrieval of recordings from CIEDs and wearable monitors is recommended for all SCA survivors.\nI\nB\nIn SCA survivors, repeated 12-lead ECGs during stable rhythm (including high precordial lead ECG) as well as continuous cardiac\nmonitoring are recommended.\nI\nB\nEchocardiography is recommended for evaluation of cardiac structure and function in all SCA survivors.\nI\nC\nCoronary imaging and CMR with LGE are recommended for evaluation of cardiac structure and function in all SCA survivors without a\nclear underlying cause.\nI\nB\nSodium channel blocker test and exercise testing is recommended in SCA survivors without a clear underlying cause.\nI\nB\nContinued\n4092\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 96",
          "page": 96,
          "content": "Recommendations |  | Classa | Levelb | \n | Recommendations for public basic life support and access to automated external defibrillator |  |  | \nIt is recommended that public access defibrillation be available at sites where cardiac arrest is more likely to occur.c |  | I | B | \nPrompt CPR by bystanders is recommended at OHCA. |  | I | B | \nIt is recommended to promote community training in basic life support to increase bystander CPR rate and AED use. |  | I | B | \n | Recommendations for genetic testing |  |  | \nGenetic testing is recommended when a condition is diagnosed in a living or deceased individual with a likely genetic basis and a risk of VA\nand SCD. |  | I | B | \nWhen a putative causative variant is first identified, evaluation for pathogenicity is recommended using an internationally accepted\nframework. |  | I | C | \nWhen a Class IV or Class V variant has been identified in a living or deceased individual with a condition that carries a risk of VA and SCD,\ngenetic testing of first-degree and symptomatic relatives and obligate carriers is recommended. |  | I | C | \nIt is recommended that genetic testing and counselling on its potential consequences should be undertaken by an expert\nmultidisciplinary team. |  | I | C | \nIt is recommended that Class III variants (of uncertain significance) and Class IV variants should be evaluated for segregation in families\nwhere possible, and the variant re-evaluated periodically. |  | I | C | \nIt is not recommended to undertake genetic testing in index patients with insufficient evidence of a genetic disease. |  | III | C | \n | Recommendations for evaluation of patients presenting with newly documented ventricular arrhythmia |  |  | \nIn patients with newly documented VA (frequent PVCs, NSVT, SMVT), a baseline 12-lead ECG, recording of the VA on 12-lead ECG,\nwhenever possible, and an echocardiogram are recommended as first-line evaluation. |  | I | C | \n | Recommendations for evaluation of sudden cardiac arrest survivors |  |  | \nThe investigation of a SCA survivor without obvious extra-cardiac cause is recommended to be overseen by a multidisciplinary team. |  | I | B | \nIn electrically unstable patients after SCA, with suspicion of ongoing myocardial ischaemia, a coronary angiogram is indicated. |  | I | C | \nIn SCA survivors, collection of blood samples at presentation is recommended for potential toxicology and genetic testing. |  | I | B | \nRetrieval of recordings from CIEDs and wearable monitors is recommended for all SCA survivors. |  | I | B | \nIn SCA survivors, repeated 12-lead ECGs during stable rhythm (including high precordial lead ECG) as well as continuous cardiac\nmonitoring are recommended. |  | I | B | \nEchocardiography is recommended for evaluation of cardiac structure and function in all SCA survivors. |  | I | C | \nCoronary imaging and CMR with LGE are recommended for evaluation of cardiac structure and function in all SCA survivors without a\nclear underlying cause. |  | I | B | \nSodium channel blocker test and exercise testing is recommended in SCA survivors without a clear underlying cause. |  | I | B | ",
          "rows": 23,
          "cols": 5
        }
      ],
      "keywords": [
        "cardiomyopathy",
        "ct",
        "asymptomatic",
        "heart failure",
        "mild",
        "gaps",
        "risk",
        "severe",
        "symptomatic",
        "ablation",
        "evidence",
        "treatment",
        "icd",
        "diagnosis"
      ]
    },
    {
      "number": "13",
      "title": "11. ‘What to do’ and ‘what not to do’ messages from the Guidelines",
      "start_page": 96,
      "end_page": 103,
      "content": "• Improved diagnostic and risk stratiﬁcation tools for asymptomatic\nBrugada patients and suspected early repolarization syndrome are\nneeded.\n• The role of endo-epicardial mapping to identify localized structural\nalterations potentially related to IVF and targeted catheter ablation\nneeds to be further studied.\n• Long-term data are required on the efﬁcacy of the ICD vs. no ICD\nin CPVT survivors of cardiac arrest.\n• It is poorly understood why women are at low risk of\nsport-related SCD.\n11. ‘What to do’ and ‘what not to do’ messages from the Guidelines\nRecommendations\nClassa\nLevelb\nRecommendations for public basic life support and access to automated external deﬁbrillator\nIt is recommended that public access deﬁbrillation be available at sites where cardiac arrest is more likely to occur.c\nI\nB\nPrompt CPR by bystanders is recommended at OHCA.\nI\nB\nIt is recommended to promote community training in basic life support to increase bystander CPR rate and AED use.\nI\nB\nRecommendations for genetic testing\nGenetic testing is recommended when a condition is diagnosed in a living or deceased individual with a likely genetic basis and a risk of VA\nand SCD.\nI\nB\nWhen a putative causative variant is ﬁrst identiﬁed, evaluation for pathogenicity is recommended using an internationally accepted\nframework.\nI\nC\nWhen a Class IV or Class V variant has been identiﬁed in a living or deceased individual with a condition that carries a risk of VA and SCD,\ngenetic testing of ﬁrst-degree and symptomatic relatives and obligate carriers is recommended.\nI\nC\nIt is recommended that genetic testing and counselling on its potential consequences should be undertaken by an expert\nmultidisciplinary team.\nI\nC\nIt is recommended that Class III variants (of uncertain signiﬁcance) and Class IV variants should be evaluated for segregation in families\nwhere possible, and the variant re-evaluated periodically.\nI\nC\nIt is not recommended to undertake genetic testing in index patients with insufﬁcient evidence of a genetic disease.\nIII\nC\nRecommendations for evaluation of patients presenting with newly documented ventricular arrhythmia\nIn patients with newly documented VA (frequent PVCs, NSVT, SMVT), a baseline 12-lead ECG, recording of the VA on 12-lead ECG,\nwhenever possible, and an echocardiogram are recommended as ﬁrst-line evaluation.\nI\nC\nRecommendations for evaluation of sudden cardiac arrest survivors\nThe investigation of a SCA survivor without obvious extra-cardiac cause is recommended to be overseen by a multidisciplinary team.\nI\nB\nIn electrically unstable patients after SCA, with suspicion of ongoing myocardial ischaemia, a coronary angiogram is indicated.\nI\nC\nIn SCA survivors, collection of blood samples at presentation is recommended for potential toxicology and genetic testing.\nI\nB\nRetrieval of recordings from CIEDs and wearable monitors is recommended for all SCA survivors.\nI\nB\nIn SCA survivors, repeated 12-lead ECGs during stable rhythm (including high precordial lead ECG) as well as continuous cardiac\nmonitoring are recommended.\nI\nB\nEchocardiography is recommended for evaluation of cardiac structure and function in all SCA survivors.\nI\nC\nCoronary imaging and CMR with LGE are recommended for evaluation of cardiac structure and function in all SCA survivors without a\nclear underlying cause.\nI\nB\nSodium channel blocker test and exercise testing is recommended in SCA survivors without a clear underlying cause.\nI\nB\nContinued\n4092\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nRecommendations for evaluation of sudden death victims\nInvestigation of unexpected SD, especially in case of suspicion of inherited disease, should be made a public health priority.\nI\nB\nIn cases of SD, it is recommended to collect a detailed description of circumstances of death, symptoms prior to death, the family\nhistory, and to review prior medical ﬁles.\nI\nB\nA comprehensive autopsy is recommended, ideally, in all cases of unexpected SD, and always in those under 50 years of age.\nI\nB\nIn cases of SCD, it is recommended to retain samples suitable for DNA extraction and consult a cardiac pathologist when an inherited\ncause is suspected or the cause of death unexplained.\nI\nB\nToxicology screens are recommended in SD cases with uncertain cause of death.\nI\nB\nFor SCD where the cause is known or suspected to be heritable, genetic testing targeted to the cause is recommended.\nI\nB\nFollowing SADS, post-mortem genetic testing targeted to primary electrical disease is recommended when the decedent is young (,50\nyears of age) and/or the circumstances and/or family history support a primary electrical disease.\nI\nB\nWhen an autopsy diagnoses possible heritable cardiac disease, it is recommended to refer ﬁrst-degree relatives for cardiac assessment in\na specialized clinic.\nI\nB\nIn non-autopsied cases of SD where inherited cardiac disease is suspected, it is recommended to refer ﬁrst-degree relatives for cardiac\nassessment in a specialized clinic.\nI\nB\nRecommendations for evaluation of relatives of sudden arrhythmic death syndrome decedents\nFollowing SADS, hypothesis-free post-mortem genetic testing using exome or genome sequencing is not recommended.\nIII\nB\nFamilial evaluation of SADS decedents is recommended:\n• for ﬁrst-degree relatives\n• for relatives who must carry a mutation based on analysis of the family history\n• for relatives with suspicious symptoms\n• when the decedent’s age is ,50 years or if there are other circumstantial data or family history to suggest heritable disease.\nI\nB\nFamilial evaluation of SADS decedents is recommended to include genetic testing when post-mortem genetic testing in a SADS\ndecedent detects a pathogenic mutation.\nI\nB\nBaseline familial evaluation of SADS decedents is recommended to include taking a medical history and performing physical examination,\nstandard- and high-precordial lead ECG, echocardiography, and exercise testing.\nI\nB\nIn SADS families without a diagnosis after clinical evaluation, follow-up is recommended for children of decedents until they reach\nadulthood.\nI\nC\nIn SADS families without a diagnosis after clinical evaluation, follow-up is not recommended for asymptomatic adults who can be\ndischarged with advice to return if they develop symptoms or if the family history changes.\nIII\nC\nRecommendations for treatment of reversible conditions\nWithdrawal of offending agents is recommended whenever drug-induced VA are suspected.\nI\nB\nInvestigation for reversible causes (e.g. electrolyte imbalances, ischaemia, hypoxaemia, fever)d is recommended in patients with VA.\nI\nC\nRecommendations for the acute treatment of sustained ventricular tachycardia and electrical storm\nDC cardioversion is recommended as the ﬁrst-line treatment for patients with haemodynamically not-tolerated SMVT.\nI\nB\nDC cardioversion is recommended as the ﬁrst-line treatment for patients presenting with tolerated SMVT provided that the\nanaesthetic/sedation risk is low.\nI\nC\nIn patients presenting with a haemodynamically tolerated idiopathic VT, treatment with intravenous beta-blocker (RVOT VT) or\nverapamil (fascicular VT) is recommended.\nI\nC\nIntravenous verapamil is not recommended in broad QRS complex tachycardia of unknown mechanism.\nIII\nB\nMild to moderate sedation is recommended in patients with electrical storm to alleviate psychological distress and reduce sympathetic\ntone.\nI\nC\nAntiarrhythmic therapy with beta-blockers (non-selective preferred) in combination with intravenous amiodarone is recommended in\npatients with SHD and electrical storm unless contraindicated.\nI\nB\nContinued\nESC Guidelines\n4093\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nIntravenous magnesium with supplementation of potassium is recommended in patients with TdP.\nI\nC\nIsoproterenol or transvenous pacing to increase heart rate is recommended in patients with acquired LQT syndrome and recurrent\nTdP despite correction of precipitating conditions and magnesium.\nI\nC\nCatheter ablation is recommended in patients presenting with incessant VT or electrical storm due to SMVT refractory to AADs.\nI\nB\nRecommendations for treatment with heart failure medication\nOptimal medical treatment including ACE-I/ARB/ARNIs, MRAs, beta-blockers, and SGLT2 inhibitors is indicated in all heart failure\npatients with reduced EF.\nI\nA\nRecommendations for implantable cardioverter deﬁbrillation implantation (general aspects)\nImplantation of a cardioverter deﬁbrillator is only recommended in patients who have an expectation of good quality survival .1 year.\nI\nC\nIt is not recommended to implant an ICD in patients with incessant VAs until the VA is controlled.\nIII\nC\nRecommendations for secondary prevention of sudden cardiac death\nICD implantation is recommended in patients with documented VF or haemodynamically not-tolerated VT in the absence of reversible\ncauses.\nI\nA\nRecommendations for adding cardiac resynchronization therapy to implantable cardioverter deﬁbrillator\nWhen an ICD is indicated, it is recommended to evaluate whether the patient could beneﬁt from CRT-deﬁbrillator.\nI\nC\nRecommendations for optimization of device programming\nOptimization of ICD programming is indicated to avoid inappropriate and unnecessary therapies and to reduce mortality.\nI\nA\nIn single- or dual-chamber ICD patients without bradycardia pacing indications, it is recommended to minimize ventricular pacing.\nI\nA\nProgramming of prolonged detection settings is indicated (duration criteria of at least 6–12 s or 30 intervals).\nI\nA\nIt is recommended to program the slowest tachycardia therapy zone limit ≥188 b.p.m. in primary prevention ICD patients.\nI\nA\nIn patients with SHD, programming of at least one ATP therapy is recommended in all tachyarrhythmias zones.\nI\nA\nIt is recommended to program algorithms for SVT vs. VT discrimination for tachycardias with rates up to 230 b.p.m.\nI\nB\nIt is recommended to activate lead failure alerts.\nI\nB\nRemote monitoring is recommended to reduce the incidence of inappropriate shocks.\nI\nB\nProgramming of burst ATP as a ﬁrst attempt is recommended over ramp ATP.\nI\nB\nFor S-ICDs, a dual detection zone conﬁguration is recommended with activation of discrimination algorithm in the lower conditional\nshock zone\nI\nB\nRecommendations for concomitant treatment to avoid inappropriate implantable cardioverter deﬁbrillator therapy\nCatheter ablation is recommended for ICD patients with recurrent SVT resulting in inappropriate ICD therapies.\nI\nC\nPharmacological treatment or catheter ablation is recommended in patients with AF-related inappropriate ICD therapies despite\noptimal ICD programming.\nI\nC\nRecommendation for psychosocial management after implantable cardioverter deﬁbrillator implantation\nAssessment of psychological status and treatment of distress is recommended in ICD patients.\nI\nC\nCommunication between patient and physician/healthcare professional is recommended to address ICD-related concerns and to\ndiscuss quality-of-life issues before ICD implantation and during disease progression.\nI\nC\nContinued\n4094\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nRecommendations for prevention of implantable cardioverter deﬁbrillator complications\nSingle-chamber ICD is recommended over dual-chamber ICD in primary prevention patients without current or expected indication\nfor atrial or AV sequential pacing due to a lower risk of device-related complications.\nI\nA\nRecommendations for end-of-life issues in implantable cardioverter deﬁbrillator carriers\nInformed discussion with patient and family about ICD deactivation options and shared decision-making is indicated prior to\nimplantation and in case of signiﬁcant health status deterioration.\nI\nC\nRecommendations for treatment of ventricular arrhythmia in acute coronary syndrome and vasospasm\nIntravenous beta-blocker treatment is indicated for patients with recurrent PVT/VF during STEMI unless contraindicated.\nI\nB\nProphylactic treatment with AADs (other than beta-blockers) is not recommended in ACS.\nIII\nB\nRecommendations for risk stratiﬁcation and treatment of ventricular arrhythmia early after myocardial infarction\nEarly (before discharge) assessment of LVEF is recommended in all patients with acute MI.\nI\nB\nIn patients with pre-discharge LVEF ≤40%, re-evaluation of LVEF 6–12 weeks after MI is recommended to assess the potential need for\nprimary prevention ICD implantation.\nI\nC\nRecommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmia in chronic\ncoronary artery disease\nIn patients with syncope and previous STEMI, PES is indicated when syncope remains unexplained after non-invasive evaluation.\nI\nC\nICD therapy is recommended in patients with CAD, symptomatic heart failure (NYHA class II–III), and LVEF ≤35% despite ≥3 months\nof OMT.\nI\nA\nIn patients with CAD, prophylactic treatment with AADs other than beta-blockers is not recommended.\nIII\nA\nICD implantation is recommended in patients without ongoing ischaemia with documented VF or haemodynamically not-tolerated VT\noccurring later than 48 h after MI.\nI\nA\nIn patients with CAD and recurrent, symptomatic SMVT or ICD shocks for SMVT despite chronic amiodarone therapy, catheter\nablation is recommended in preference to escalating AAD therapy.\nI\nB\nRecommendations for sudden cardiac death prevention in patients with coronary anomalies\nCardiac stress imaging during physical exercise is recommended in addition to cardiopulmonary exercise test in patients with anomalous\naortic origin of a coronary artery with an interarterial course to conﬁrm/exclude myocardial ischaemia.\nI\nC\nCardiac stress imaging during physical exercise is recommended in addition to cardiopulmonary exercise test after surgery in patients\nwith anomalous aortic origin of a coronary artery with a history of aborted CA.\nI\nC\nSurgery is recommended in patients with anomalous aortic origin of a coronary artery with CA, syncope suspected to be due to VAs or\nangina when other causes have been excluded.\nI\nC\nRecommendations for the management of patients with idiopathic premature ventricular complexes/ventricular tachycardia\nRegular assessment of ventricular function of patients with PVC burden .10% and normal ventricular function is indicated.\nI\nC\nCatheter ablation as ﬁrst-line treatment is recommended for symptomatic idiopathic VT/PVCs from the RVOT or the left fascicles.e\nI\nB\nBeta-blockers or non-dihydropyridine CCB are indicated in symptomatic patients with idiopathic VT/PVCs from an origin other than\nthe RVOT or the left fascicles.\nI\nC\nCatheter ablation is not recommended in children ,5 years of age or ,10 kg weight except when previous medical therapy fails or\nwhen VT is not haemodynamically tolerated.\nIII\nC\nAmiodarone as a ﬁrst-line treatment is not recommended in patients with idiopathic VTs/PVCs.\nIII\nC\nVerapamil is not recommended in children ,1 year of age with PVC/VT, particularly if they have signs of heart failure or concurrent use\nof other AADs.\nIII\nC\nRecommendations for the management of patients with premature ventricular complex-induced or aggravated cardiomyopathy\nIn patients with a cardiomyopathy suspected to be caused by frequent and predominately monomorphic PVCs, catheter ablation is\nrecommended.\nI\nC\nContinued\nESC Guidelines\n4095\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nRecommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmia in dilated\ncardiomyopathy/hypokinetic non-dilated cardiomyopathy\nGenetic testing (including at least LMNA, PLN, RBM20, and FLNC genes) is recommended in patients with DCM/HNDCM and AV\nconduction delay at ,50 years, or who have a family history of DCM/HNDCM or SCD in a ﬁrst-degree relative (at age ,50 years).\nI\nB\nParticipation in high-intensity exercise including competitive sports is not recommended for individuals with DCM/HNDCM and a\nLMNA mutation.\nIII\nC\nICD implantation is recommended in patients with DCM/HNDCM, who survive SCA due to VT/VF or experience haemodynamically\nnot-tolerated SMVT.\nI\nB\nIn a ﬁrst-degree relative of a DCM/HNDCM patient, an ECG, and an echocardiogram are recommended if:\n• the index patient was diagnosed ,50 years of age or has clinical features suggestive of an inherited cause, or\n• there is family history of DCM/HNDCM, or premature unexpected SD.\nI\nC\nRecommendations for diagnostic, risk stratiﬁcation, sudden cardiac death prevention and treatment of ventricular arrhythmia in\narrhythmogenic right ventricular cardiomyopathy\nIn patients with suspected ARVC, CMR is recommended.\nI\nB\nIn patients with a suspected or deﬁnite diagnosis of ARVC, genetic counselling and testing are recommended.\nI\nB\nAvoidance of high-intensity exercise is recommended in patients with a deﬁnite diagnosis of ARVC.\nI\nB\nICD implantation is recommended in ARVC patients with haemodynamically not-tolerated VT or VF.\nI\nC\nIn patients with ARVC and non-sustained or sustained VAs, beta-blocker therapy is recommended.\nI\nC\nIn a ﬁrst-degree relative of a patient with ARVC, ECG, and echocardiogram are recommended.\nI\nC\nRecommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmia in hypertrophic\ncardiomyopathy\nCMR with LGE is recommended in HCM patients for diagnostic work-up.\nI\nB\nGenetic counselling and testing are recommended in HCM patients.\nI\nB\nIt is recommended that the 5-year risk of SCD is assessed at ﬁrst evaluation and at 1–3-year intervals or when there is a change in clinical\nstatus.\nI\nC\nICD implantation is recommended in HCM patients with haemodynamically not-tolerated VT or VF.\nI\nB\nIn a ﬁrst-degree relative of a patient with HCM, ECG, and echocardiogram are recommended.\nI\nC\nRecommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmia in\nneuromuscular diseases\nAnnual follow-up with at least a 12-lead ECG is recommended in patients with muscular dystrophies, even in the concealed phase of the\ndisease.\nI\nC\nIt is recommended that patients with neuromuscular disorders who have VAs or ventricular dysfunction are treated in the same way for\narrhythmia as patients without neuromuscular disorders.\nI\nC\nInvasive electrophysiological evaluation is recommended in patients with myotonic dystrophy and palpitations or syncope suggestive of\nVA, VT, or surviving a CA.\nI\nC\nICD implantation is recommended in patients with myotonic dystrophy and SMVT or aborted CA not caused by BBR-VT.\nI\nC\nIn myotonic dystrophy patients, serial electrophysiological evaluation of AV conduction and arrhythmia induction is not recommended\nwithout arrhythmia suspicion or progression of ECG conduction disorders.\nIII\nC\nIn symptomatic patients with BBR-VT, catheter ablation is recommended.\nI\nC\nIn patients with myotonic dystrophy undergoing ablation for BBR-VT, pacemaker/ICD implantation is recommended.\nI\nC\nContinued\n4096\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nRecommendations for sudden cardiac death prevention, and treatment of ventricular arrhythmia in myocarditis\nIn conﬁrmed or clinically suspected acute myocarditis, it is recommended that patients who present with life-threatening VA are\nreferred to a specialized centre.\nI\nC\nIn patients with haemodynamically not-tolerated SMVT occurring in the chronic phase of myocarditis, an ICD implantation is\nrecommended.\nI\nC\nRecommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmia in cardiac\nsarcoidosis\nICD implantation is recommended in patients with cardiac sarcoidosis who have an LVEF ≤35%.\nI\nB\nICD implantation is recommended in patients with cardiac sarcoidosis who (a) have documented sustained VT, or (2) aborted CA.\nI\nB\nRecommendations for sudden cardiac death prevention, and treatment of ventricular arrhythmia in valvular heart disease\nPES with standby catheter ablation is recommended in patients with aortic valve disease and SMVT to identify and ablate BBR-VT,\nespecially if it occurs following a valve intervention.\nI\nC\nIn patients with valvular heart disease and persistent LV dysfunction after surgical correction (if possible) it is recommended that ICD\nimplantation for primary prevention follows DCM/HNDCM recommendations.\nI\nC\nRecommendations for sudden cardiac death prevention, and treatment of ventricular arrhythmia in congenital heart disease\nIn adults with CHD with biventricular physiology and a left systemic ventricle presenting with symptomatic heart failure (NYHA II/III)\nand EF ≤35% despite ≥3 months of OMT, ICD implantation is indicated.\nI\nC\nIn patients with CHD presenting with sustained VAs, evaluation for residual or new anatomical abnormalities is recommended.\nI\nB\nIn patients with CHD with not-tolerated VT/aborted CA due to VF, ICD implantation is indicated after exclusion of reversible causes.\nI\nC\nIn patients with repaired TOF who present with SMVT or recurrent, symptomatic appropriate ICD therapy for SMVT, catheter ablation\nperformed in specialized centres is recommended.\nI\nC\nRecommendations for management of patients with idiopathic ventricular ﬁbrillation\nIt is recommended that idiopathic VF is diagnosed in a SCA survivor, preferably with documentation of VF, after exclusion of an\nunderlying structural, channelopathic, metabolic, or toxicological aetiology.\nI\nB\nICD implantation is recommended in idiopathic VF.\nI\nB\nRecommendations for management of patients with long QT syndrome\nIt is recommended that LQTS is diagnosed with either QTc ≥480 ms in repeated 12-lead ECGs with or without symptoms or LQTS\ndiagnostic score .3.\nI\nC\nIn patients with clinically diagnosed long QT syndrome, genetic testing, and genetic counselling are recommended.\nI\nC\nIt is recommended that LQTS is diagnosed in the presence of a pathogenic mutation, irrespective of the QT duration.\nI\nC\nRoutine diagnostic testing with epinephrine challenge is not recommended in LQTS.\nIII\nC\nThe following is recommended in LQTS:\n• Avoid QT-prolonging drugs.f\n• Avoid and correct electrolyte abnormalities.\n• Avoid genotype-speciﬁc triggers for arrhythmias.\nI\nC\nBeta-blockers, ideally non-selective beta-blockers (nadolol or propranolol), are recommended in LQTS patients with documented QT\ninterval prolongation, to reduce risk of arrhythmic events.\nI\nB\nMexiletine is indicated in LQT3 patients with a prolonged QT interval.\nI\nC\nICD implantation in addition to beta-blockers is recommended in LQTS patients with CA.\nI\nB\nICD implantation is recommended in patients with LQTS who are symptomaticg while receiving beta-blockers and genotype-speciﬁc\ntherapies.\nI\nC\nContinued\nESC Guidelines\n4097\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nLCSD is indicated in patients with symptomaticg LQTS when: (a) ICD therapy is contraindicated or declined; (b) patient is on\nbeta-blockers and genotype-speciﬁc therapies with an ICD and experiences multiple shocks or syncope due to VA.\nI\nC\nInvasive electrophysiologic study is not recommended in LQTS.\nIII\nC\nRecommendations for management of patients with Andersen–Tawil syndrome\nGenetic testing is recommended in patients with suspected Andersen–Tawil syndrome.\nI\nC\nICD implantation is recommended in patients with Andersen–Tawil syndrome after aborted CA not tolerated sustained VT.\nI\nC\nRecommendations for management of patients with Brugada syndrome\nIt is recommended that BrS is diagnosed in patients with no other heart disease and a spontaneous type 1 Brugada ECG pattern.\nI\nC\nIt is recommended that BrS is diagnosed in patients with no other heart disease who have survived a CA due to VF or PVT and exhibit a\ntype 1 Brugada ECG induced by sodium channel blocker challenge or during fever.\nI\nC\nGenetic testing for SCN5A gene is recommended for probands with BrS.\nI\nC\nSodium channel blocker test is not recommended in patients with a prior type I Brugada pattern.\nIII\nC\nThe following is recommended in all patients with BrS:\n(a) Avoidance of drugs that may induce ST-segment elevation in right precordial leads (http://www.brugadadrugs.org).\n(b) Avoidance of cocaine, cannabis, and excessive alcohol intake.\n(c) Treatment of fever with antipyretic drugs.\nI\nC\nICD implantation is recommended in patients with BrS who:\n(a) Are survivors of an aborted CA, and/or\n(b) Have documented spontaneous sustained VT.\nI\nC\nCatheter ablation in asymptomatic BrS patients is not recommended.\nIII\nC\nRecommendations for management of patients with early repolarizaton pattern/syndrome\nIt is recommended that the ERP is diagnosed as J-point elevation of ≥1 mm in two adjacent inferior and/or lateral ECG leads.\nI\nC\nIt is recommended that the ERS is diagnosed in a patient resuscitated from unexplained VF/PVT in the presence of ERP.\nI\nC\nClinical evaluation is not recommended routinely in asymptomatic subjects with ERP.\nIII\nC\nICD implantation is recommended in patients with a diagnosis of ERS who have survived a CA.\nI\nB\nICD implantation is not recommended in asymptomatic patients with an isolated ERP.\nIII\nC\nRecommendations for management of patients with catecholaminergic polymorphic ventricular tachycardia\nIt is recommended that CPVT is diagnosed in the presence of a structurally normal heart, normal ECG, and exercise- or\nemotion-induced bidirectional or PVT.\nI\nC\nIt is recommended that CPVT is diagnosed in patients who are carriers of a mutation in disease-causing genes.\nI\nC\nGenetic testing and genetic counselling are indicated in patients with clinical suspicion or clinical diagnosis of CPVT.\nI\nC\nAvoidance of competitive sports, strenuous exercise, and exposure to stressful environments is recommended in all patients with\nCPVT.\nI\nC\nBeta-blockers, ideally non-selective (nadolol or propranolol), are recommended in all patients with a clinical diagnosis of CPVT.\nI\nC\nICD implantation combined with beta-blockers and ﬂecainide is recommended in CPVT patients after aborted CA.\nI\nC\nPES is not recommended for stratiﬁcation of SCD risk.\nIII\nC\nContinued\n4098\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n12. Quality indicators\nQuality indicators (QIs) are tools that may be used to evaluate care qual-\nity, including structural aspects, process, and outcomes of care.1153 They\nserve as a mechanism for enhancing adherence to guideline recommen-\ndations, through associated quality improvement initiatives and the\nbenchmarking of care providers.1154,1155 As such, the role of QIs in im-\nproving care and outcomes is increasingly recognized by healthcare au-\nthorities, professional organizations, payers, and the public.1153\nThe ESC understands the need for measuring and reporting qual-\nity and outcomes of cardiovascular care, and has established meth-\nods for the development of the ESC QIs for the quantiﬁcation of\ncare and outcomes for cardiovascular disease.1153 In parallel with\nthe writing of this Clinical Practice Guideline document, a process\nhas been initiated to develop QIs for patients with, or at risk of,\nVA or SCD using the ESC methodology and through the collabor-\nation with domain experts and the European Heart Rhythm\nAssociation. These QIs, alongside their speciﬁcations and develop-\nment process, will be published separately.\n13. Supplementary data\nSupplementary data is available at European Heart Journal online.\n14. Data availability statement\nNo new data were generated or analysed in support of this research.\n15. Author information\nAuthor/task force Member Afﬁliations:\nMarta de Riva, Cardiology, Leiden University Medical Centre,\nLeiden,\nNetherlands;\nBo\nGregers\nWinkel,\nCardiology,\nRecommendations for management of patients with short QT syndrome\nIt is recommended that SQTS is diagnosed in the presence of a QTc ≤360 ms and one or more of the following: (a) a pathogenic\nmutation, (b) a family history of SQTS, (c) survival from a VT/VF episode in the absence of heart disease.\nI\nC\nGenetic testing is indicated in patients diagnosed with SQTS.\nI\nC\nICD implantation is recommended in patients with a diagnosis of SQTS who: (a) are survivors of an aborted CA, and/or (b) have\ndocumented spontaneous sustained VT.\nI\nC\nPES is not recommended for SCD risk stratiﬁcation in SQTS patients.\nIII\nC\nRecommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy\nDuring pregnancy, electrical cardioversion is recommended for sustained VT.\nI\nC\nIf ICD implantation is indicated during pregnancy, implantation is recommended with optimal radiation protection.\nI\nC\nContinuation of beta-blockers is recommended during pregnancy and post-partum in patients with LQTS or CPVT.\nI\nC\nRecommendations for risk stratiﬁcation and prevention of sudden cardiac death in athletes\nIn athletes with positive medical history, abnormal physical examination, or ECG alterations, further investigations including\nechocardiography and/or CMR to conﬁrm (or exclude) an underlying disease are recommended.\nI\nC\nIt is recommended that athletes diagnosed with a cardiovascular disease associated with SCD are managed according to current\nguidelines for sports eligibility.\nI\nC\nIt is recommended that staff at sporting facilities are trained in CPR and in the use of AED.\nI\nC\n© ESC 2022\nAAD, anti-arrhythmic drug; ACE-I, angiotensin-converting-enzyme inhibitor; AED, automated external deﬁbrillator; ARB, angiotensin receptor blockers; ARNIs, angiotensin receptor\nneprilysin\ninhibitor;\nARVC,\narrhythmogenic\nright\nventricular\ncardiomyopathy;\nATP,\nanti-tachycardia\npacing;\nAV,\natrioventricular;\nBBR-VT,\nbundle\nbranch\nre-entry;\nBrS, Brugada syndrome; CA, cardiac arrest; CAD, coronary artery disease; CCB, calcium channel blocker; CHD, congenital heart disease; CIED, cardiac implantable electronic\ndevices; CMR, cardiac magnetic resonance; CPR, cardiopulmonary resuscitation; CPVT, catecholaminergic polymorphic ventricular tachycardia; CRT, cardiac resynchronization\ntherapy; DC, direct current; DCM, dilated cardiomyopathy; ECG, electrocardiogram; EF, ejection fraction; ERP, early repolarization pattern; ERS, early repolarization syndrome;\nHCM, hypertrophic cardiomyopathy; HNDCM, hypokinetic non-dilated cardiomyopathy; ICD, implantable cardioverter deﬁbrillator; CAD, coronary artery disease; ILR, implantable\nloop recorder; LCSD, left cardiac sympathetic denervation; LGE, late gadolinium enhancement; LQTS, long QT syndrome; LV, left ventricular; LVEF, left ventricular ejection fraction;\nMRA, mineralocorticoid receptor antagonist; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; OHCA, out-of-hospital cardiac arrest; OMT,\noptimal medical therapy; PES, programmed electrical stimulation; PVC, premature ventricular complex; PVT, polymorphic ventricular tachycardia; RVOT, right ventricular outﬂow\ntract; SADS, sudden arrhythmic death syndrome; SCA, sudden cardiac arrest; SCD, sudden cardiac death; SD, sudden death; SGLT2, sodium–glucose co-transporter 2; SHD,\nstructural heart disease; SMVT, sustained monomorphic ventricular tachycardia; SQT, short QT syndrome; STEMI, ST-elevation myocardial infarction; SVT, supraventricular\ntachycardia; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.\naClass of recommendation.\nbLevel of evidence.\ncShopping malls, stadiums, public transport stations, casinos.\ndList not exhaustive.\neLOE C for VT/PVCs from left fascicles.\nfhttp://www.crediblemeds.org\ngArrhythmic syncope or haemodynamically non-tolerated VA\nESC Guidelines\n4099\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 96",
          "page": 96,
          "content": "Recommendations |  | Classa | Levelb | \n | Recommendations for public basic life support and access to automated external defibrillator |  |  | \nIt is recommended that public access defibrillation be available at sites where cardiac arrest is more likely to occur.c |  | I | B | \nPrompt CPR by bystanders is recommended at OHCA. |  | I | B | \nIt is recommended to promote community training in basic life support to increase bystander CPR rate and AED use. |  | I | B | \n | Recommendations for genetic testing |  |  | \nGenetic testing is recommended when a condition is diagnosed in a living or deceased individual with a likely genetic basis and a risk of VA\nand SCD. |  | I | B | \nWhen a putative causative variant is first identified, evaluation for pathogenicity is recommended using an internationally accepted\nframework. |  | I | C | \nWhen a Class IV or Class V variant has been identified in a living or deceased individual with a condition that carries a risk of VA and SCD,\ngenetic testing of first-degree and symptomatic relatives and obligate carriers is recommended. |  | I | C | \nIt is recommended that genetic testing and counselling on its potential consequences should be undertaken by an expert\nmultidisciplinary team. |  | I | C | \nIt is recommended that Class III variants (of uncertain significance) and Class IV variants should be evaluated for segregation in families\nwhere possible, and the variant re-evaluated periodically. |  | I | C | \nIt is not recommended to undertake genetic testing in index patients with insufficient evidence of a genetic disease. |  | III | C | \n | Recommendations for evaluation of patients presenting with newly documented ventricular arrhythmia |  |  | \nIn patients with newly documented VA (frequent PVCs, NSVT, SMVT), a baseline 12-lead ECG, recording of the VA on 12-lead ECG,\nwhenever possible, and an echocardiogram are recommended as first-line evaluation. |  | I | C | \n | Recommendations for evaluation of sudden cardiac arrest survivors |  |  | \nThe investigation of a SCA survivor without obvious extra-cardiac cause is recommended to be overseen by a multidisciplinary team. |  | I | B | \nIn electrically unstable patients after SCA, with suspicion of ongoing myocardial ischaemia, a coronary angiogram is indicated. |  | I | C | \nIn SCA survivors, collection of blood samples at presentation is recommended for potential toxicology and genetic testing. |  | I | B | \nRetrieval of recordings from CIEDs and wearable monitors is recommended for all SCA survivors. |  | I | B | \nIn SCA survivors, repeated 12-lead ECGs during stable rhythm (including high precordial lead ECG) as well as continuous cardiac\nmonitoring are recommended. |  | I | B | \nEchocardiography is recommended for evaluation of cardiac structure and function in all SCA survivors. |  | I | C | \nCoronary imaging and CMR with LGE are recommended for evaluation of cardiac structure and function in all SCA survivors without a\nclear underlying cause. |  | I | B | \nSodium channel blocker test and exercise testing is recommended in SCA survivors without a clear underlying cause. |  | I | B | ",
          "rows": 23,
          "cols": 5
        },
        {
          "title": "Table on page 97",
          "page": 97,
          "content": " | Recommendations for evaluation of sudden death victims |  |  | \nInvestigation of unexpected SD, especially in case of suspicion of inherited disease, should be made a public health priority. |  | I | B | \nIn cases of SD, it is recommended to collect a detailed description of circumstances of death, symptoms prior to death, the family\nhistory, and to review prior medical files. |  | I | B | \nA comprehensive autopsy is recommended, ideally, in all cases of unexpected SD, and always in those under 50 years of age. |  | I | B | \nIn cases of SCD, it is recommended to retain samples suitable for DNA extraction and consult a cardiac pathologist when an inherited\ncause is suspected or the cause of death unexplained. |  | I | B | \nToxicology screens are recommended in SD cases with uncertain cause of death. |  | I | B | \nFor SCD where the cause is known or suspected to be heritable, genetic testing targeted to the cause is recommended. |  | I | B | \nFollowing SADS, post-mortem genetic testing targeted to primary electrical disease is recommended when the decedent is young (,50\nyears of age) and/or the circumstances and/or family history support a primary electrical disease. |  | I | B | \nWhen an autopsy diagnoses possible heritable cardiac disease, it is recommended to refer first-degree relatives for cardiac assessment in\na specialized clinic. |  | I | B | \nIn non-autopsied cases of SD where inherited cardiac disease is suspected, it is recommended to refer first-degree relatives for cardiac\nassessment in a specialized clinic. |  | I | B | \n | Recommendations for evaluation of relatives of sudden arrhythmic death syndrome decedents |  |  | \nFollowing SADS, hypothesis-free post-mortem genetic testing using exome or genome sequencing is not recommended. |  | III | B | \nFamilial evaluation of SADS decedents is recommended:\n• for first-degree relatives\n• for relatives who must carry a mutation based on analysis of the family history\n• for relatives with suspicious symptoms\n• when the decedent’s age is ,50 years or if there are other circumstantial data or family history to suggest heritable disease. |  | I | B | \nFamilial evaluation of SADS decedents is recommended to include genetic testing when post-mortem genetic testing in a SADS\ndecedent detects a pathogenic mutation. |  | I | B | \nBaseline familial evaluation of SADS decedents is recommended to include taking a medical history and performing physical examination,\nstandard- and high-precordial lead ECG, echocardiography, and exercise testing. |  | I | B | \nIn SADS families without a diagnosis after clinical evaluation, follow-up is recommended for children of decedents until they reach\nadulthood. |  | I | C | \nIn SADS families without a diagnosis after clinical evaluation, follow-up is not recommended for asymptomatic adults who can be\ndischarged with advice to return if they develop symptoms or if the family history changes. |  | III | C | \n | Recommendations for treatment of reversible conditions |  |  | \nWithdrawal of offending agents is recommended whenever drug-induced VA are suspected. |  | I | B | \nInvestigation for reversible causes (e.g. electrolyte imbalances, ischaemia, hypoxaemia, fever)d is recommended in patients with VA. |  | I | C | \n | Recommendations for the acute treatment of sustained ventricular tachycardia and electrical storm |  |  | \nDC cardioversion is recommended as the first-line treatment for patients with haemodynamically not-tolerated SMVT. |  | I | B | \nDC cardioversion is recommended as the first-line treatment for patients presenting with tolerated SMVT provided that the\nanaesthetic/sedation risk is low. |  | I | C | \nIn patients presenting with a haemodynamically tolerated idiopathic VT, treatment with intravenous beta-blocker (RVOT VT) or\nverapamil (fascicular VT) is recommended. |  | I | C | \nIntravenous verapamil is not recommended in broad QRS complex tachycardia of unknown mechanism. |  | III | B | \nMild to moderate sedation is recommended in patients with electrical storm to alleviate psychological distress and reduce sympathetic\ntone. |  | I | C | \nAntiarrhythmic therapy with beta-blockers (non-selective preferred) in combination with intravenous amiodarone is recommended in\npatients with SHD and electrical storm unless contraindicated. |  | I | B | ",
          "rows": 27,
          "cols": 5
        },
        {
          "title": "Table on page 98",
          "page": 98,
          "content": "Intravenous magnesium with supplementation of potassium is recommended in patients with TdP. |  | I | C | \nIsoproterenol or transvenous pacing to increase heart rate is recommended in patients with acquired LQT syndrome and recurrent\nTdP despite correction of precipitating conditions and magnesium. |  | I | C | \nCatheter ablation is recommended in patients presenting with incessant VT or electrical storm due to SMVT refractory to AADs. |  | I | B | \n | Recommendations for treatment with heart failure medication |  |  | \nOptimal medical treatment including ACE-I/ARB/ARNIs, MRAs, beta-blockers, and SGLT2 inhibitors is indicated in all heart failure\npatients with reduced EF. |  | I | A | \n | Recommendations for implantable cardioverter defibrillation implantation (general aspects) |  |  | \nImplantation of a cardioverter defibrillator is only recommended in patients who have an expectation of good quality survival .1 year. |  | I | C | \nIt is not recommended to implant an ICD in patients with incessant VAs until the VA is controlled. |  | III | C | \n | Recommendations for secondary prevention of sudden cardiac death |  |  | \nICD implantation is recommended in patients with documented VF or haemodynamically not-tolerated VT in the absence of reversible\ncauses. |  | I | A | \n | Recommendations for adding cardiac resynchronization therapy to implantable cardioverter defibrillator |  |  | \nWhen an ICD is indicated, it is recommended to evaluate whether the patient could benefit from CRT-defibrillator. |  | I | C | \n | Recommendations for optimization of device programming |  |  | \nOptimization of ICD programming is indicated to avoid inappropriate and unnecessary therapies and to reduce mortality. |  | I | A | \nIn single- or dual-chamber ICD patients without bradycardia pacing indications, it is recommended to minimize ventricular pacing. |  | I | A | \nProgramming of prolonged detection settings is indicated (duration criteria of at least 6–12 s or 30 intervals). |  | I | A | \nIt is recommended to program the slowest tachycardia therapy zone limit ≥188 b.p.m. in primary prevention ICD patients. |  | I | A | \nIn patients with SHD, programming of at least one ATP therapy is recommended in all tachyarrhythmias zones. |  | I | A | \nIt is recommended to program algorithms for SVT vs. VT discrimination for tachycardias with rates up to 230 b.p.m. |  | I | B | \nIt is recommended to activate lead failure alerts. |  | I | B | \nRemote monitoring is recommended to reduce the incidence of inappropriate shocks. |  | I | B | \nProgramming of burst ATP as a first attempt is recommended over ramp ATP. |  | I | B | \nFor S-ICDs, a dual detection zone configuration is recommended with activation of discrimination algorithm in the lower conditional\nshock zone |  | I | B | \n | Recommendations for concomitant treatment to avoid inappropriate implantable cardioverter defibrillator therapy |  |  | \nCatheter ablation is recommended for ICD patients with recurrent SVT resulting in inappropriate ICD therapies. |  | I | C | \nPharmacological treatment or catheter ablation is recommended in patients with AF-related inappropriate ICD therapies despite\noptimal ICD programming. |  | I | C | \n | Recommendation for psychosocial management after implantable cardioverter defibrillator implantation |  |  | \nAssessment of psychological status and treatment of distress is recommended in ICD patients. |  | I | C | \nCommunication between patient and physician/healthcare professional is recommended to address ICD-related concerns and to\ndiscuss quality-of-life issues before ICD implantation and during disease progression. |  | I | C | ",
          "rows": 29,
          "cols": 5
        },
        {
          "title": "Table on page 99",
          "page": 99,
          "content": " | Recommendations for prevention of implantable cardioverter defibrillator complications |  |  | \nSingle-chamber ICD is recommended over dual-chamber ICD in primary prevention patients without current or expected indication\nfor atrial or AV sequential pacing due to a lower risk of device-related complications. |  | I | A | \n | Recommendations for end-of-life issues in implantable cardioverter defibrillator carriers |  |  | \nInformed discussion with patient and family about ICD deactivation options and shared decision-making is indicated prior to\nimplantation and in case of significant health status deterioration. |  | I | C | \n | Recommendations for treatment of ventricular arrhythmia in acute coronary syndrome and vasospasm |  |  | \nIntravenous beta-blocker treatment is indicated for patients with recurrent PVT/VF during STEMI unless contraindicated. |  | I | B | \nProphylactic treatment with AADs (other than beta-blockers) is not recommended in ACS. |  | III | B | \n | Recommendations for risk stratification and treatment of ventricular arrhythmia early after myocardial infarction |  |  | \nEarly (before discharge) assessment of LVEF is recommended in all patients with acute MI. |  | I | B | \nIn patients with pre-discharge LVEF ≤40%, re-evaluation of LVEF 6–12 weeks after MI is recommended to assess the potential need for\nprimary prevention ICD implantation. |  | I | C | \n | Recommendations for risk stratification, sudden cardiac death prevention, and treatment of ventricular arrhythmia in chronic\ncoronary artery disease |  |  | \nIn patients with syncope and previous STEMI, PES is indicated when syncope remains unexplained after non-invasive evaluation. |  | I | C | \nICD therapy is recommended in patients with CAD, symptomatic heart failure (NYHA class II–III), and LVEF ≤35% despite ≥3 months\nof OMT. |  | I | A | \nIn patients with CAD, prophylactic treatment with AADs other than beta-blockers is not recommended. |  | III | A | \nICD implantation is recommended in patients without ongoing ischaemia with documented VF or haemodynamically not-tolerated VT\noccurring later than 48 h after MI. |  | I | A | \nIn patients with CAD and recurrent, symptomatic SMVT or ICD shocks for SMVT despite chronic amiodarone therapy, catheter\nablation is recommended in preference to escalating AAD therapy. |  | I | B | \n | Recommendations for sudden cardiac death prevention in patients with coronary anomalies |  |  | \nCardiac stress imaging during physical exercise is recommended in addition to cardiopulmonary exercise test in patients with anomalous\naortic origin of a coronary artery with an interarterial course to confirm/exclude myocardial ischaemia. |  | I | C | \nCardiac stress imaging during physical exercise is recommended in addition to cardiopulmonary exercise test after surgery in patients\nwith anomalous aortic origin of a coronary artery with a history of aborted CA. |  | I | C | \nSurgery is recommended in patients with anomalous aortic origin of a coronary artery with CA, syncope suspected to be due to VAs or\nangina when other causes have been excluded. |  | I | C | \n | Recommendations for the management of patients with idiopathic premature ventricular complexes/ventricular tachycardia |  |  | \nRegular assessment of ventricular function of patients with PVC burden .10% and normal ventricular function is indicated. |  | I | C | \nCatheter ablation as first-line treatment is recommended for symptomatic idiopathic VT/PVCs from the RVOT or the left fascicles.e |  | I | B | \nBeta-blockers or non-dihydropyridine CCB are indicated in symptomatic patients with idiopathic VT/PVCs from an origin other than\nthe RVOT or the left fascicles. |  | I | C | \nCatheter ablation is not recommended in children ,5 years of age or ,10 kg weight except when previous medical therapy fails or\nwhen VT is not haemodynamically tolerated. |  | III | C | \nAmiodarone as a first-line treatment is not recommended in patients with idiopathic VTs/PVCs. |  | III | C | \nVerapamil is not recommended in children ,1 year of age with PVC/VT, particularly if they have signs of heart failure or concurrent use\nof other AADs. |  | III | C | \n | Recommendations for the management of patients with premature ventricular complex-induced or aggravated cardiomyopathy |  |  | \nIn patients with a cardiomyopathy suspected to be caused by frequent and predominately monomorphic PVCs, catheter ablation is\nrecommended. |  | I | C | ",
          "rows": 29,
          "cols": 5
        },
        {
          "title": "Table on page 100",
          "page": 100,
          "content": " | Recommendations for risk stratification, sudden cardiac death prevention, and treatment of ventricular arrhythmia in dilated\ncardiomyopathy/hypokinetic non-dilated cardiomyopathy |  |  | \nGenetic testing (including at least LMNA, PLN, RBM20, and FLNC genes) is recommended in patients with DCM/HNDCM and AV\nconduction delay at ,50 years, or who have a family history of DCM/HNDCM or SCD in a first-degree relative (at age ,50 years). |  | I | B | \nParticipation in high-intensity exercise including competitive sports is not recommended for individuals with DCM/HNDCM and a\nLMNA mutation. |  | III | C | \nICD implantation is recommended in patients with DCM/HNDCM, who survive SCA due to VT/VF or experience haemodynamically\nnot-tolerated SMVT. |  | I | B | \nIn a first-degree relative of a DCM/HNDCM patient, an ECG, and an echocardiogram are recommended if:\n• the index patient was diagnosed ,50 years of age or has clinical features suggestive of an inherited cause, or\n• there is family history of DCM/HNDCM, or premature unexpected SD. |  | I | C | \n | Recommendations for diagnostic, risk stratification, sudden cardiac death prevention and treatment of ventricular arrhythmia in\narrhythmogenic right ventricular cardiomyopathy |  |  | \nIn patients with suspected ARVC, CMR is recommended. |  | I | B | \nIn patients with a suspected or definite diagnosis of ARVC, genetic counselling and testing are recommended. |  | I | B | \nAvoidance of high-intensity exercise is recommended in patients with a definite diagnosis of ARVC. |  | I | B | \nICD implantation is recommended in ARVC patients with haemodynamically not-tolerated VT or VF. |  | I | C | \nIn patients with ARVC and non-sustained or sustained VAs, beta-blocker therapy is recommended. |  | I | C | \nIn a first-degree relative of a patient with ARVC, ECG, and echocardiogram are recommended. |  | I | C | \n | Recommendations for risk stratification, sudden cardiac death prevention, and treatment of ventricular arrhythmia in hypertrophic\ncardiomyopathy |  |  | \nCMR with LGE is recommended in HCM patients for diagnostic work-up. |  | I | B | \nGenetic counselling and testing are recommended in HCM patients. |  | I | B | \nIt is recommended that the 5-year risk of SCD is assessed at first evaluation and at 1–3-year intervals or when there is a change in clinical\nstatus. |  | I | C | \nICD implantation is recommended in HCM patients with haemodynamically not-tolerated VT or VF. |  | I | B | \nIn a first-degree relative of a patient with HCM, ECG, and echocardiogram are recommended. |  | I | C | \n | Recommendations for risk stratification, sudden cardiac death prevention, and treatment of ventricular arrhythmia in\nneuromuscular diseases |  |  | \nAnnual follow-up with at least a 12-lead ECG is recommended in patients with muscular dystrophies, even in the concealed phase of the\ndisease. |  | I | C | \nIt is recommended that patients with neuromuscular disorders who have VAs or ventricular dysfunction are treated in the same way for\narrhythmia as patients without neuromuscular disorders. |  | I | C | \nInvasive electrophysiological evaluation is recommended in patients with myotonic dystrophy and palpitations or syncope suggestive of\nVA, VT, or surviving a CA. |  | I | C | \nICD implantation is recommended in patients with myotonic dystrophy and SMVT or aborted CA not caused by BBR-VT. |  | I | C | \nIn myotonic dystrophy patients, serial electrophysiological evaluation of AV conduction and arrhythmia induction is not recommended\nwithout arrhythmia suspicion or progression of ECG conduction disorders. |  | III | C | \nIn symptomatic patients with BBR-VT, catheter ablation is recommended. |  | I | C | \nIn patients with myotonic dystrophy undergoing ablation for BBR-VT, pacemaker/ICD implantation is recommended. |  | I | C | ",
          "rows": 26,
          "cols": 5
        },
        {
          "title": "Table on page 101",
          "page": 101,
          "content": " | Recommendations for sudden cardiac death prevention, and treatment of ventricular arrhythmia in myocarditis |  |  | \nIn confirmed or clinically suspected acute myocarditis, it is recommended that patients who present with life-threatening VA are\nreferred to a specialized centre. |  | I | C | \nIn patients with haemodynamically not-tolerated SMVT occurring in the chronic phase of myocarditis, an ICD implantation is\nrecommended. |  | I | C | \n | Recommendations for risk stratification, sudden cardiac death prevention, and treatment of ventricular arrhythmia in cardiac\nsarcoidosis |  |  | \nICD implantation is recommended in patients with cardiac sarcoidosis who have an LVEF ≤35%. |  | I | B | \nICD implantation is recommended in patients with cardiac sarcoidosis who (a) have documented sustained VT, or (2) aborted CA. |  | I | B | \n | Recommendations for sudden cardiac death prevention, and treatment of ventricular arrhythmia in valvular heart disease |  |  | \nPES with standby catheter ablation is recommended in patients with aortic valve disease and SMVT to identify and ablate BBR-VT,\nespecially if it occurs following a valve intervention. |  | I | C | \nIn patients with valvular heart disease and persistent LV dysfunction after surgical correction (if possible) it is recommended that ICD\nimplantation for primary prevention follows DCM/HNDCM recommendations. |  | I | C | \n | Recommendations for sudden cardiac death prevention, and treatment of ventricular arrhythmia in congenital heart disease |  |  | \nIn adults with CHD with biventricular physiology and a left systemic ventricle presenting with symptomatic heart failure (NYHA II/III)\nand EF ≤35% despite ≥3 months of OMT, ICD implantation is indicated. |  | I | C | \nIn patients with CHD presenting with sustained VAs, evaluation for residual or new anatomical abnormalities is recommended. |  | I | B | \nIn patients with CHD with not-tolerated VT/aborted CA due to VF, ICD implantation is indicated after exclusion of reversible causes. |  | I | C | \nIn patients with repaired TOF who present with SMVT or recurrent, symptomatic appropriate ICD therapy for SMVT, catheter ablation\nperformed in specialized centres is recommended. |  | I | C | \n | Recommendations for management of patients with idiopathic ventricular fibrillation |  |  | \nIt is recommended that idiopathic VF is diagnosed in a SCA survivor, preferably with documentation of VF, after exclusion of an\nunderlying structural, channelopathic, metabolic, or toxicological aetiology. |  | I | B | \nICD implantation is recommended in idiopathic VF. |  | I | B | \n | Recommendations for management of patients with long QT syndrome |  |  | \nIt is recommended that LQTS is diagnosed with either QTc ≥480 ms in repeated 12-lead ECGs with or without symptoms or LQTS\ndiagnostic score .3. |  | I | C | \nIn patients with clinically diagnosed long QT syndrome, genetic testing, and genetic counselling are recommended. |  | I | C | \nIt is recommended that LQTS is diagnosed in the presence of a pathogenic mutation, irrespective of the QT duration. |  | I | C | \nRoutine diagnostic testing with epinephrine challenge is not recommended in LQTS. |  | III | C | \nThe following is recommended in LQTS:\n• Avoid QT-prolonging drugs.f\n• Avoid and correct electrolyte abnormalities.\n• Avoid genotype-specific triggers for arrhythmias. |  | I | C | \nBeta-blockers, ideally non-selective beta-blockers (nadolol or propranolol), are recommended in LQTS patients with documented QT\ninterval prolongation, to reduce risk of arrhythmic events. |  | I | B | \nMexiletine is indicated in LQT3 patients with a prolonged QT interval. |  | I | C | \nICD implantation in addition to beta-blockers is recommended in LQTS patients with CA. |  | I | B | \nICD implantation is recommended in patients with LQTS who are symptomaticg while receiving beta-blockers and genotype-specific\ntherapies. |  | I | C | ",
          "rows": 27,
          "cols": 5
        },
        {
          "title": "Table on page 102",
          "page": 102,
          "content": "LCSD is indicated in patients with symptomaticg LQTS when: (a) ICD therapy is contraindicated or declined; (b) patient is on\nbeta-blockers and genotype-specific therapies with an ICD and experiences multiple shocks or syncope due to VA. |  | I | C | \nInvasive electrophysiologic study is not recommended in LQTS. |  | III | C | \n | Recommendations for management of patients with Andersen–Tawil syndrome |  |  | \nGenetic testing is recommended in patients with suspected Andersen–Tawil syndrome. |  | I | C | \nICD implantation is recommended in patients with Andersen–Tawil syndrome after aborted CA not tolerated sustained VT. |  | I | C | \n | Recommendations for management of patients with Brugada syndrome |  |  | \nIt is recommended that BrS is diagnosed in patients with no other heart disease and a spontaneous type 1 Brugada ECG pattern. |  | I | C | \nIt is recommended that BrS is diagnosed in patients with no other heart disease who have survived a CA due to VF or PVT and exhibit a\ntype 1 Brugada ECG induced by sodium channel blocker challenge or during fever. |  | I | C | \nGenetic testing for SCN5A gene is recommended for probands with BrS. |  | I | C | \nSodium channel blocker test is not recommended in patients with a prior type I Brugada pattern. |  | III | C | \nThe following is recommended in all patients with BrS:\n(a) Avoidance of drugs that may induce ST-segment elevation in right precordial leads (http://www.brugadadrugs.org).\n(b) Avoidance of cocaine, cannabis, and excessive alcohol intake.\n(c) Treatment of fever with antipyretic drugs. |  | I | C | \nICD implantation is recommended in patients with BrS who:\n(a) Are survivors of an aborted CA, and/or\n(b) Have documented spontaneous sustained VT. |  | I | C | \nCatheter ablation in asymptomatic BrS patients is not recommended. |  | III | C | \n | Recommendations for management of patients with early repolarizaton pattern/syndrome |  |  | \nIt is recommended that the ERP is diagnosed as J-point elevation of ≥1 mm in two adjacent inferior and/or lateral ECG leads. |  | I | C | \nIt is recommended that the ERS is diagnosed in a patient resuscitated from unexplained VF/PVT in the presence of ERP. |  | I | C | \nClinical evaluation is not recommended routinely in asymptomatic subjects with ERP. |  | III | C | \nICD implantation is recommended in patients with a diagnosis of ERS who have survived a CA. |  | I | B | \nICD implantation is not recommended in asymptomatic patients with an isolated ERP. |  | III | C | \n | Recommendations for management of patients with catecholaminergic polymorphic ventricular tachycardia |  |  | \nIt is recommended that CPVT is diagnosed in the presence of a structurally normal heart, normal ECG, and exercise- or\nemotion-induced bidirectional or PVT. |  | I | C | \nIt is recommended that CPVT is diagnosed in patients who are carriers of a mutation in disease-causing genes. |  | I | C | \nGenetic testing and genetic counselling are indicated in patients with clinical suspicion or clinical diagnosis of CPVT. |  | I | C | \nAvoidance of competitive sports, strenuous exercise, and exposure to stressful environments is recommended in all patients with\nCPVT. |  | I | C | \nBeta-blockers, ideally non-selective (nadolol or propranolol), are recommended in all patients with a clinical diagnosis of CPVT. |  | I | C | \nICD implantation combined with beta-blockers and flecainide is recommended in CPVT patients after aborted CA. |  | I | C | \nPES is not recommended for stratification of SCD risk. |  | III | C | ",
          "rows": 27,
          "cols": 5
        },
        {
          "title": "Table on page 103",
          "page": 103,
          "content": " | Recommendations for management of patients with short QT syndrome |  |  | \nIt is recommended that SQTS is diagnosed in the presence of a QTc ≤360 ms and one or more of the following: (a) a pathogenic\nmutation, (b) a family history of SQTS, (c) survival from a VT/VF episode in the absence of heart disease. |  | I | C | \nGenetic testing is indicated in patients diagnosed with SQTS. |  | I | C | \nICD implantation is recommended in patients with a diagnosis of SQTS who: (a) are survivors of an aborted CA, and/or (b) have\ndocumented spontaneous sustained VT. |  | I | C | \nPES is not recommended for SCD risk stratification in SQTS patients. |  | III | C | \n | Recommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy |  |  | \nDuring pregnancy, electrical cardioversion is recommended for sustained VT. |  | I | C | \nIf ICD implantation is indicated during pregnancy, implantation is recommended with optimal radiation protection. |  | I | C | \nContinuation of beta-blockers is recommended during pregnancy and post-partum in patients with LQTS or CPVT. |  | I | C | \n | Recommendations for risk stratification and prevention of sudden cardiac death in athletes |  |  | \nIn athletes with positive medical history, abnormal physical examination, or ECG alterations, further investigations including\nechocardiography and/or CMR to confirm (or exclude) an underlying disease are recommended. |  | I | C | \nIt is recommended that athletes diagnosed with a cardiovascular disease associated with SCD are managed according to current\nguidelines for sports eligibility. |  | I | C | \nIt is recommended that staff at sporting facilities are trained in CPR and in the use of AED. |  | I | C | ",
          "rows": 13,
          "cols": 5
        }
      ],
      "keywords": [
        "ct",
        "echo",
        "asymptomatic",
        "class iii",
        "messages",
        "class ii",
        "class i",
        "risk",
        "symptomatic",
        "guidelines",
        "ablation",
        "what",
        "icd",
        "recommendation"
      ]
    },
    {
      "number": "14",
      "title": "12. Quality indicators",
      "start_page": 103,
      "end_page": 103,
      "content": "12. Quality indicators\nQuality indicators (QIs) are tools that may be used to evaluate care qual-\nity, including structural aspects, process, and outcomes of care.1153 They\nserve as a mechanism for enhancing adherence to guideline recommen-\ndations, through associated quality improvement initiatives and the\nbenchmarking of care providers.1154,1155 As such, the role of QIs in im-\nproving care and outcomes is increasingly recognized by healthcare au-\nthorities, professional organizations, payers, and the public.1153\nThe ESC understands the need for measuring and reporting qual-\nity and outcomes of cardiovascular care, and has established meth-\nods for the development of the ESC QIs for the quantiﬁcation of\ncare and outcomes for cardiovascular disease.1153 In parallel with\nthe writing of this Clinical Practice Guideline document, a process\nhas been initiated to develop QIs for patients with, or at risk of,\nVA or SCD using the ESC methodology and through the collabor-\nation with domain experts and the European Heart Rhythm\nAssociation. These QIs, alongside their speciﬁcations and develop-\nment process, will be published separately.\n13. Supplementary data\nSupplementary data is available at European Heart Journal online.\n14. Data availability statement\nNo new data were generated or analysed in support of this research.\n15. Author information\nAuthor/task force Member Afﬁliations:\nMarta de Riva, Cardiology, Leiden University Medical Centre,\nLeiden,\nNetherlands;\nBo\nGregers\nWinkel,\nCardiology,\nRecommendations for management of patients with short QT syndrome\nIt is recommended that SQTS is diagnosed in the presence of a QTc ≤360 ms and one or more of the following: (a) a pathogenic\nmutation, (b) a family history of SQTS, (c) survival from a VT/VF episode in the absence of heart disease.\nI\nC\nGenetic testing is indicated in patients diagnosed with SQTS.\nI\nC\nICD implantation is recommended in patients with a diagnosis of SQTS who: (a) are survivors of an aborted CA, and/or (b) have\ndocumented spontaneous sustained VT.\nI\nC\nPES is not recommended for SCD risk stratiﬁcation in SQTS patients.\nIII\nC\nRecommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy\nDuring pregnancy, electrical cardioversion is recommended for sustained VT.\nI\nC\nIf ICD implantation is indicated during pregnancy, implantation is recommended with optimal radiation protection.\nI\nC\nContinuation of beta-blockers is recommended during pregnancy and post-partum in patients with LQTS or CPVT.\nI\nC\nRecommendations for risk stratiﬁcation and prevention of sudden cardiac death in athletes\nIn athletes with positive medical history, abnormal physical examination, or ECG alterations, further investigations including\nechocardiography and/or CMR to conﬁrm (or exclude) an underlying disease are recommended.\nI\nC\nIt is recommended that athletes diagnosed with a cardiovascular disease associated with SCD are managed according to current\nguidelines for sports eligibility.\nI\nC\nIt is recommended that staff at sporting facilities are trained in CPR and in the use of AED.\nI\nC\n© ESC 2022\nAAD, anti-arrhythmic drug; ACE-I, angiotensin-converting-enzyme inhibitor; AED, automated external deﬁbrillator; ARB, angiotensin receptor blockers; ARNIs, angiotensin receptor\nneprilysin\ninhibitor;\nARVC,\narrhythmogenic\nright\nventricular\ncardiomyopathy;\nATP,\nanti-tachycardia\npacing;\nAV,\natrioventricular;\nBBR-VT,\nbundle\nbranch\nre-entry;\nBrS, Brugada syndrome; CA, cardiac arrest; CAD, coronary artery disease; CCB, calcium channel blocker; CHD, congenital heart disease; CIED, cardiac implantable electronic\ndevices; CMR, cardiac magnetic resonance; CPR, cardiopulmonary resuscitation; CPVT, catecholaminergic polymorphic ventricular tachycardia; CRT, cardiac resynchronization\ntherapy; DC, direct current; DCM, dilated cardiomyopathy; ECG, electrocardiogram; EF, ejection fraction; ERP, early repolarization pattern; ERS, early repolarization syndrome;\nHCM, hypertrophic cardiomyopathy; HNDCM, hypokinetic non-dilated cardiomyopathy; ICD, implantable cardioverter deﬁbrillator; CAD, coronary artery disease; ILR, implantable\nloop recorder; LCSD, left cardiac sympathetic denervation; LGE, late gadolinium enhancement; LQTS, long QT syndrome; LV, left ventricular; LVEF, left ventricular ejection fraction;\nMRA, mineralocorticoid receptor antagonist; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; OHCA, out-of-hospital cardiac arrest; OMT,\noptimal medical therapy; PES, programmed electrical stimulation; PVC, premature ventricular complex; PVT, polymorphic ventricular tachycardia; RVOT, right ventricular outﬂow\ntract; SADS, sudden arrhythmic death syndrome; SCA, sudden cardiac arrest; SCD, sudden cardiac death; SD, sudden death; SGLT2, sodium–glucose co-transporter 2; SHD,\nstructural heart disease; SMVT, sustained monomorphic ventricular tachycardia; SQT, short QT syndrome; STEMI, ST-elevation myocardial infarction; SVT, supraventricular\ntachycardia; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.\naClass of recommendation.\nbLevel of evidence.\ncShopping malls, stadiums, public transport stations, casinos.\ndList not exhaustive.\neLOE C for VT/PVCs from left fascicles.\nfhttp://www.crediblemeds.org\ngArrhythmic syncope or haemodynamically non-tolerated VA\nESC Guidelines\n4099\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 103",
          "page": 103,
          "content": " | Recommendations for management of patients with short QT syndrome |  |  | \nIt is recommended that SQTS is diagnosed in the presence of a QTc ≤360 ms and one or more of the following: (a) a pathogenic\nmutation, (b) a family history of SQTS, (c) survival from a VT/VF episode in the absence of heart disease. |  | I | C | \nGenetic testing is indicated in patients diagnosed with SQTS. |  | I | C | \nICD implantation is recommended in patients with a diagnosis of SQTS who: (a) are survivors of an aborted CA, and/or (b) have\ndocumented spontaneous sustained VT. |  | I | C | \nPES is not recommended for SCD risk stratification in SQTS patients. |  | III | C | \n | Recommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy |  |  | \nDuring pregnancy, electrical cardioversion is recommended for sustained VT. |  | I | C | \nIf ICD implantation is indicated during pregnancy, implantation is recommended with optimal radiation protection. |  | I | C | \nContinuation of beta-blockers is recommended during pregnancy and post-partum in patients with LQTS or CPVT. |  | I | C | \n | Recommendations for risk stratification and prevention of sudden cardiac death in athletes |  |  | \nIn athletes with positive medical history, abnormal physical examination, or ECG alterations, further investigations including\nechocardiography and/or CMR to confirm (or exclude) an underlying disease are recommended. |  | I | C | \nIt is recommended that athletes diagnosed with a cardiovascular disease associated with SCD are managed according to current\nguidelines for sports eligibility. |  | I | C | \nIt is recommended that staff at sporting facilities are trained in CPR and in the use of AED. |  | I | C | ",
          "rows": 13,
          "cols": 5
        }
      ],
      "keywords": [
        "echocardiography",
        "ct",
        "echo",
        "indicators",
        "quality",
        "risk",
        "icd",
        "diagnosis",
        "recommendation"
      ]
    },
    {
      "number": "15",
      "title": "13. Supplementary data",
      "start_page": 103,
      "end_page": 103,
      "content": "12. Quality indicators\nQuality indicators (QIs) are tools that may be used to evaluate care qual-\nity, including structural aspects, process, and outcomes of care.1153 They\nserve as a mechanism for enhancing adherence to guideline recommen-\ndations, through associated quality improvement initiatives and the\nbenchmarking of care providers.1154,1155 As such, the role of QIs in im-\nproving care and outcomes is increasingly recognized by healthcare au-\nthorities, professional organizations, payers, and the public.1153\nThe ESC understands the need for measuring and reporting qual-\nity and outcomes of cardiovascular care, and has established meth-\nods for the development of the ESC QIs for the quantiﬁcation of\ncare and outcomes for cardiovascular disease.1153 In parallel with\nthe writing of this Clinical Practice Guideline document, a process\nhas been initiated to develop QIs for patients with, or at risk of,\nVA or SCD using the ESC methodology and through the collabor-\nation with domain experts and the European Heart Rhythm\nAssociation. These QIs, alongside their speciﬁcations and develop-\nment process, will be published separately.\n13. Supplementary data\nSupplementary data is available at European Heart Journal online.\n14. Data availability statement\nNo new data were generated or analysed in support of this research.\n15. Author information\nAuthor/task force Member Afﬁliations:\nMarta de Riva, Cardiology, Leiden University Medical Centre,\nLeiden,\nNetherlands;\nBo\nGregers\nWinkel,\nCardiology,\nRecommendations for management of patients with short QT syndrome\nIt is recommended that SQTS is diagnosed in the presence of a QTc ≤360 ms and one or more of the following: (a) a pathogenic\nmutation, (b) a family history of SQTS, (c) survival from a VT/VF episode in the absence of heart disease.\nI\nC\nGenetic testing is indicated in patients diagnosed with SQTS.\nI\nC\nICD implantation is recommended in patients with a diagnosis of SQTS who: (a) are survivors of an aborted CA, and/or (b) have\ndocumented spontaneous sustained VT.\nI\nC\nPES is not recommended for SCD risk stratiﬁcation in SQTS patients.\nIII\nC\nRecommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy\nDuring pregnancy, electrical cardioversion is recommended for sustained VT.\nI\nC\nIf ICD implantation is indicated during pregnancy, implantation is recommended with optimal radiation protection.\nI\nC\nContinuation of beta-blockers is recommended during pregnancy and post-partum in patients with LQTS or CPVT.\nI\nC\nRecommendations for risk stratiﬁcation and prevention of sudden cardiac death in athletes\nIn athletes with positive medical history, abnormal physical examination, or ECG alterations, further investigations including\nechocardiography and/or CMR to conﬁrm (or exclude) an underlying disease are recommended.\nI\nC\nIt is recommended that athletes diagnosed with a cardiovascular disease associated with SCD are managed according to current\nguidelines for sports eligibility.\nI\nC\nIt is recommended that staff at sporting facilities are trained in CPR and in the use of AED.\nI\nC\n© ESC 2022\nAAD, anti-arrhythmic drug; ACE-I, angiotensin-converting-enzyme inhibitor; AED, automated external deﬁbrillator; ARB, angiotensin receptor blockers; ARNIs, angiotensin receptor\nneprilysin\ninhibitor;\nARVC,\narrhythmogenic\nright\nventricular\ncardiomyopathy;\nATP,\nanti-tachycardia\npacing;\nAV,\natrioventricular;\nBBR-VT,\nbundle\nbranch\nre-entry;\nBrS, Brugada syndrome; CA, cardiac arrest; CAD, coronary artery disease; CCB, calcium channel blocker; CHD, congenital heart disease; CIED, cardiac implantable electronic\ndevices; CMR, cardiac magnetic resonance; CPR, cardiopulmonary resuscitation; CPVT, catecholaminergic polymorphic ventricular tachycardia; CRT, cardiac resynchronization\ntherapy; DC, direct current; DCM, dilated cardiomyopathy; ECG, electrocardiogram; EF, ejection fraction; ERP, early repolarization pattern; ERS, early repolarization syndrome;\nHCM, hypertrophic cardiomyopathy; HNDCM, hypokinetic non-dilated cardiomyopathy; ICD, implantable cardioverter deﬁbrillator; CAD, coronary artery disease; ILR, implantable\nloop recorder; LCSD, left cardiac sympathetic denervation; LGE, late gadolinium enhancement; LQTS, long QT syndrome; LV, left ventricular; LVEF, left ventricular ejection fraction;\nMRA, mineralocorticoid receptor antagonist; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; OHCA, out-of-hospital cardiac arrest; OMT,\noptimal medical therapy; PES, programmed electrical stimulation; PVC, premature ventricular complex; PVT, polymorphic ventricular tachycardia; RVOT, right ventricular outﬂow\ntract; SADS, sudden arrhythmic death syndrome; SCA, sudden cardiac arrest; SCD, sudden cardiac death; SD, sudden death; SGLT2, sodium–glucose co-transporter 2; SHD,\nstructural heart disease; SMVT, sustained monomorphic ventricular tachycardia; SQT, short QT syndrome; STEMI, ST-elevation myocardial infarction; SVT, supraventricular\ntachycardia; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.\naClass of recommendation.\nbLevel of evidence.\ncShopping malls, stadiums, public transport stations, casinos.\ndList not exhaustive.\neLOE C for VT/PVCs from left fascicles.\nfhttp://www.crediblemeds.org\ngArrhythmic syncope or haemodynamically non-tolerated VA\nESC Guidelines\n4099\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 103",
          "page": 103,
          "content": " | Recommendations for management of patients with short QT syndrome |  |  | \nIt is recommended that SQTS is diagnosed in the presence of a QTc ≤360 ms and one or more of the following: (a) a pathogenic\nmutation, (b) a family history of SQTS, (c) survival from a VT/VF episode in the absence of heart disease. |  | I | C | \nGenetic testing is indicated in patients diagnosed with SQTS. |  | I | C | \nICD implantation is recommended in patients with a diagnosis of SQTS who: (a) are survivors of an aborted CA, and/or (b) have\ndocumented spontaneous sustained VT. |  | I | C | \nPES is not recommended for SCD risk stratification in SQTS patients. |  | III | C | \n | Recommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy |  |  | \nDuring pregnancy, electrical cardioversion is recommended for sustained VT. |  | I | C | \nIf ICD implantation is indicated during pregnancy, implantation is recommended with optimal radiation protection. |  | I | C | \nContinuation of beta-blockers is recommended during pregnancy and post-partum in patients with LQTS or CPVT. |  | I | C | \n | Recommendations for risk stratification and prevention of sudden cardiac death in athletes |  |  | \nIn athletes with positive medical history, abnormal physical examination, or ECG alterations, further investigations including\nechocardiography and/or CMR to confirm (or exclude) an underlying disease are recommended. |  | I | C | \nIt is recommended that athletes diagnosed with a cardiovascular disease associated with SCD are managed according to current\nguidelines for sports eligibility. |  | I | C | \nIt is recommended that staff at sporting facilities are trained in CPR and in the use of AED. |  | I | C | ",
          "rows": 13,
          "cols": 5
        }
      ],
      "keywords": [
        "echocardiography",
        "ct",
        "echo",
        "risk",
        "supplementary",
        "data",
        "icd",
        "diagnosis",
        "recommendation"
      ]
    },
    {
      "number": "16",
      "title": "14. Data availability statement",
      "start_page": 103,
      "end_page": 103,
      "content": "12. Quality indicators\nQuality indicators (QIs) are tools that may be used to evaluate care qual-\nity, including structural aspects, process, and outcomes of care.1153 They\nserve as a mechanism for enhancing adherence to guideline recommen-\ndations, through associated quality improvement initiatives and the\nbenchmarking of care providers.1154,1155 As such, the role of QIs in im-\nproving care and outcomes is increasingly recognized by healthcare au-\nthorities, professional organizations, payers, and the public.1153\nThe ESC understands the need for measuring and reporting qual-\nity and outcomes of cardiovascular care, and has established meth-\nods for the development of the ESC QIs for the quantiﬁcation of\ncare and outcomes for cardiovascular disease.1153 In parallel with\nthe writing of this Clinical Practice Guideline document, a process\nhas been initiated to develop QIs for patients with, or at risk of,\nVA or SCD using the ESC methodology and through the collabor-\nation with domain experts and the European Heart Rhythm\nAssociation. These QIs, alongside their speciﬁcations and develop-\nment process, will be published separately.\n13. Supplementary data\nSupplementary data is available at European Heart Journal online.\n14. Data availability statement\nNo new data were generated or analysed in support of this research.\n15. Author information\nAuthor/task force Member Afﬁliations:\nMarta de Riva, Cardiology, Leiden University Medical Centre,\nLeiden,\nNetherlands;\nBo\nGregers\nWinkel,\nCardiology,\nRecommendations for management of patients with short QT syndrome\nIt is recommended that SQTS is diagnosed in the presence of a QTc ≤360 ms and one or more of the following: (a) a pathogenic\nmutation, (b) a family history of SQTS, (c) survival from a VT/VF episode in the absence of heart disease.\nI\nC\nGenetic testing is indicated in patients diagnosed with SQTS.\nI\nC\nICD implantation is recommended in patients with a diagnosis of SQTS who: (a) are survivors of an aborted CA, and/or (b) have\ndocumented spontaneous sustained VT.\nI\nC\nPES is not recommended for SCD risk stratiﬁcation in SQTS patients.\nIII\nC\nRecommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy\nDuring pregnancy, electrical cardioversion is recommended for sustained VT.\nI\nC\nIf ICD implantation is indicated during pregnancy, implantation is recommended with optimal radiation protection.\nI\nC\nContinuation of beta-blockers is recommended during pregnancy and post-partum in patients with LQTS or CPVT.\nI\nC\nRecommendations for risk stratiﬁcation and prevention of sudden cardiac death in athletes\nIn athletes with positive medical history, abnormal physical examination, or ECG alterations, further investigations including\nechocardiography and/or CMR to conﬁrm (or exclude) an underlying disease are recommended.\nI\nC\nIt is recommended that athletes diagnosed with a cardiovascular disease associated with SCD are managed according to current\nguidelines for sports eligibility.\nI\nC\nIt is recommended that staff at sporting facilities are trained in CPR and in the use of AED.\nI\nC\n© ESC 2022\nAAD, anti-arrhythmic drug; ACE-I, angiotensin-converting-enzyme inhibitor; AED, automated external deﬁbrillator; ARB, angiotensin receptor blockers; ARNIs, angiotensin receptor\nneprilysin\ninhibitor;\nARVC,\narrhythmogenic\nright\nventricular\ncardiomyopathy;\nATP,\nanti-tachycardia\npacing;\nAV,\natrioventricular;\nBBR-VT,\nbundle\nbranch\nre-entry;\nBrS, Brugada syndrome; CA, cardiac arrest; CAD, coronary artery disease; CCB, calcium channel blocker; CHD, congenital heart disease; CIED, cardiac implantable electronic\ndevices; CMR, cardiac magnetic resonance; CPR, cardiopulmonary resuscitation; CPVT, catecholaminergic polymorphic ventricular tachycardia; CRT, cardiac resynchronization\ntherapy; DC, direct current; DCM, dilated cardiomyopathy; ECG, electrocardiogram; EF, ejection fraction; ERP, early repolarization pattern; ERS, early repolarization syndrome;\nHCM, hypertrophic cardiomyopathy; HNDCM, hypokinetic non-dilated cardiomyopathy; ICD, implantable cardioverter deﬁbrillator; CAD, coronary artery disease; ILR, implantable\nloop recorder; LCSD, left cardiac sympathetic denervation; LGE, late gadolinium enhancement; LQTS, long QT syndrome; LV, left ventricular; LVEF, left ventricular ejection fraction;\nMRA, mineralocorticoid receptor antagonist; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; OHCA, out-of-hospital cardiac arrest; OMT,\noptimal medical therapy; PES, programmed electrical stimulation; PVC, premature ventricular complex; PVT, polymorphic ventricular tachycardia; RVOT, right ventricular outﬂow\ntract; SADS, sudden arrhythmic death syndrome; SCA, sudden cardiac arrest; SCD, sudden cardiac death; SD, sudden death; SGLT2, sodium–glucose co-transporter 2; SHD,\nstructural heart disease; SMVT, sustained monomorphic ventricular tachycardia; SQT, short QT syndrome; STEMI, ST-elevation myocardial infarction; SVT, supraventricular\ntachycardia; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.\naClass of recommendation.\nbLevel of evidence.\ncShopping malls, stadiums, public transport stations, casinos.\ndList not exhaustive.\neLOE C for VT/PVCs from left fascicles.\nfhttp://www.crediblemeds.org\ngArrhythmic syncope or haemodynamically non-tolerated VA\nESC Guidelines\n4099\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 103",
          "page": 103,
          "content": " | Recommendations for management of patients with short QT syndrome |  |  | \nIt is recommended that SQTS is diagnosed in the presence of a QTc ≤360 ms and one or more of the following: (a) a pathogenic\nmutation, (b) a family history of SQTS, (c) survival from a VT/VF episode in the absence of heart disease. |  | I | C | \nGenetic testing is indicated in patients diagnosed with SQTS. |  | I | C | \nICD implantation is recommended in patients with a diagnosis of SQTS who: (a) are survivors of an aborted CA, and/or (b) have\ndocumented spontaneous sustained VT. |  | I | C | \nPES is not recommended for SCD risk stratification in SQTS patients. |  | III | C | \n | Recommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy |  |  | \nDuring pregnancy, electrical cardioversion is recommended for sustained VT. |  | I | C | \nIf ICD implantation is indicated during pregnancy, implantation is recommended with optimal radiation protection. |  | I | C | \nContinuation of beta-blockers is recommended during pregnancy and post-partum in patients with LQTS or CPVT. |  | I | C | \n | Recommendations for risk stratification and prevention of sudden cardiac death in athletes |  |  | \nIn athletes with positive medical history, abnormal physical examination, or ECG alterations, further investigations including\nechocardiography and/or CMR to confirm (or exclude) an underlying disease are recommended. |  | I | C | \nIt is recommended that athletes diagnosed with a cardiovascular disease associated with SCD are managed according to current\nguidelines for sports eligibility. |  | I | C | \nIt is recommended that staff at sporting facilities are trained in CPR and in the use of AED. |  | I | C | ",
          "rows": 13,
          "cols": 5
        }
      ],
      "keywords": [
        "echocardiography",
        "ct",
        "echo",
        "statement",
        "risk",
        "data",
        "availability",
        "icd",
        "diagnosis",
        "recommendation"
      ]
    },
    {
      "number": "17",
      "title": "15. Author information",
      "start_page": 103,
      "end_page": 104,
      "content": "12. Quality indicators\nQuality indicators (QIs) are tools that may be used to evaluate care qual-\nity, including structural aspects, process, and outcomes of care.1153 They\nserve as a mechanism for enhancing adherence to guideline recommen-\ndations, through associated quality improvement initiatives and the\nbenchmarking of care providers.1154,1155 As such, the role of QIs in im-\nproving care and outcomes is increasingly recognized by healthcare au-\nthorities, professional organizations, payers, and the public.1153\nThe ESC understands the need for measuring and reporting qual-\nity and outcomes of cardiovascular care, and has established meth-\nods for the development of the ESC QIs for the quantiﬁcation of\ncare and outcomes for cardiovascular disease.1153 In parallel with\nthe writing of this Clinical Practice Guideline document, a process\nhas been initiated to develop QIs for patients with, or at risk of,\nVA or SCD using the ESC methodology and through the collabor-\nation with domain experts and the European Heart Rhythm\nAssociation. These QIs, alongside their speciﬁcations and develop-\nment process, will be published separately.\n13. Supplementary data\nSupplementary data is available at European Heart Journal online.\n14. Data availability statement\nNo new data were generated or analysed in support of this research.\n15. Author information\nAuthor/task force Member Afﬁliations:\nMarta de Riva, Cardiology, Leiden University Medical Centre,\nLeiden,\nNetherlands;\nBo\nGregers\nWinkel,\nCardiology,\nRecommendations for management of patients with short QT syndrome\nIt is recommended that SQTS is diagnosed in the presence of a QTc ≤360 ms and one or more of the following: (a) a pathogenic\nmutation, (b) a family history of SQTS, (c) survival from a VT/VF episode in the absence of heart disease.\nI\nC\nGenetic testing is indicated in patients diagnosed with SQTS.\nI\nC\nICD implantation is recommended in patients with a diagnosis of SQTS who: (a) are survivors of an aborted CA, and/or (b) have\ndocumented spontaneous sustained VT.\nI\nC\nPES is not recommended for SCD risk stratiﬁcation in SQTS patients.\nIII\nC\nRecommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy\nDuring pregnancy, electrical cardioversion is recommended for sustained VT.\nI\nC\nIf ICD implantation is indicated during pregnancy, implantation is recommended with optimal radiation protection.\nI\nC\nContinuation of beta-blockers is recommended during pregnancy and post-partum in patients with LQTS or CPVT.\nI\nC\nRecommendations for risk stratiﬁcation and prevention of sudden cardiac death in athletes\nIn athletes with positive medical history, abnormal physical examination, or ECG alterations, further investigations including\nechocardiography and/or CMR to conﬁrm (or exclude) an underlying disease are recommended.\nI\nC\nIt is recommended that athletes diagnosed with a cardiovascular disease associated with SCD are managed according to current\nguidelines for sports eligibility.\nI\nC\nIt is recommended that staff at sporting facilities are trained in CPR and in the use of AED.\nI\nC\n© ESC 2022\nAAD, anti-arrhythmic drug; ACE-I, angiotensin-converting-enzyme inhibitor; AED, automated external deﬁbrillator; ARB, angiotensin receptor blockers; ARNIs, angiotensin receptor\nneprilysin\ninhibitor;\nARVC,\narrhythmogenic\nright\nventricular\ncardiomyopathy;\nATP,\nanti-tachycardia\npacing;\nAV,\natrioventricular;\nBBR-VT,\nbundle\nbranch\nre-entry;\nBrS, Brugada syndrome; CA, cardiac arrest; CAD, coronary artery disease; CCB, calcium channel blocker; CHD, congenital heart disease; CIED, cardiac implantable electronic\ndevices; CMR, cardiac magnetic resonance; CPR, cardiopulmonary resuscitation; CPVT, catecholaminergic polymorphic ventricular tachycardia; CRT, cardiac resynchronization\ntherapy; DC, direct current; DCM, dilated cardiomyopathy; ECG, electrocardiogram; EF, ejection fraction; ERP, early repolarization pattern; ERS, early repolarization syndrome;\nHCM, hypertrophic cardiomyopathy; HNDCM, hypokinetic non-dilated cardiomyopathy; ICD, implantable cardioverter deﬁbrillator; CAD, coronary artery disease; ILR, implantable\nloop recorder; LCSD, left cardiac sympathetic denervation; LGE, late gadolinium enhancement; LQTS, long QT syndrome; LV, left ventricular; LVEF, left ventricular ejection fraction;\nMRA, mineralocorticoid receptor antagonist; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; OHCA, out-of-hospital cardiac arrest; OMT,\noptimal medical therapy; PES, programmed electrical stimulation; PVC, premature ventricular complex; PVT, polymorphic ventricular tachycardia; RVOT, right ventricular outﬂow\ntract; SADS, sudden arrhythmic death syndrome; SCA, sudden cardiac arrest; SCD, sudden cardiac death; SD, sudden death; SGLT2, sodium–glucose co-transporter 2; SHD,\nstructural heart disease; SMVT, sustained monomorphic ventricular tachycardia; SQT, short QT syndrome; STEMI, ST-elevation myocardial infarction; SVT, supraventricular\ntachycardia; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.\naClass of recommendation.\nbLevel of evidence.\ncShopping malls, stadiums, public transport stations, casinos.\ndList not exhaustive.\neLOE C for VT/PVCs from left fascicles.\nfhttp://www.crediblemeds.org\ngArrhythmic syncope or haemodynamically non-tolerated VA\nESC Guidelines\n4099\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nRigshospitalet,\nCopenhagen,\nDenmark,\nEuropean\nReference\nNetworks for rare, low prevalence and complex diseases of the\nheart, ERN-GUARD HEART; Elijah R. Behr, Cardiovascular\nClinical\nAcademic\nGroup,\nCardiology\nSection,\nSt\nGeorge’s,\nUniversity of London, London, United Kingdom, Department of\nCardiology, St George’s University Hospitals NHS Foundation\nTrust, London, United Kingdom, and Cardiology, Mayo Clinic\nHealthcare, London, United Kingdom; Nico A. Blom, Paediatric\nCardiology,\nLeiden\nUniversity\nMedical\nCentre,\nLeiden,\nNetherlands, and Paediatric Cardiology, Amsterdam University\nMedical Center, Amsterdam, Netherlands; Philippe Charron,\nAPHP, Centre de Référence des Maladies Cardiaques Héréditaires\nou Rares, Hôpital Pitié-Salpêtrière, Paris, France, UMR_S 1166, and\nICAN Institute for Cardiometabolism, and Nutrition, Sorbonne\nUniversité, Paris, France, and European Reference Networks for\nrare,\nlow\nprevalence\nand\ncomplex\ndiseases\nof\nthe\nheart,\nERN-Guard\nHEART,\nParis,\nFrance;\nDomenico\nCorrado,\nDepartment of Cardiac, Thoracic and Vascular Sciences and Public\nHealth, University of Padova, Padova, Italy; Nikolaos Dagres,\nDepartment\nof\nElectrophysiology,\nHeart\nCenter\nLeipzig\nat\nUniversity of Leipzig, Leipzig, Germany; Christian de Chillou,\nDepartment of Cardiology, CHRU-Nancy, Nancy, France, and\nIADI, INSERM U1254, Université de Lorraine, Nancy, France; Lars\nEckardt,\nDepartment\nof\nCardiology\nII—Electrophysiology,\nUniversity Hospital Münster, Münster, Germany; Tim Friede,\nDepartment of Medical Statistics, University Medical Center\nGoettingen, Goettingen, Germany, and Partner Site Goettingen,\nDZHK (German Center for Cardiovascular Research), Goettingen,\nGermany; Kristina H. Haugaa, Department of Cardiology, Oslo\nUniversity Hospital, Rikshospitalet, Oslo, Norway, and Faculty of\nMedicine, University of Oslo, Oslo, Norway; Mélèze Hocini,\nCardiology Department, Liryc Institute, Pessac, France, Hopital\nCardiologique du Haut Lévêque, Pessac, France, and Université de\nBordeaux, Bordeaux, France; Pier D. Lambiase, Institute of\nCardiovascular\nScience,\nUniversity\nCollege,\nLondon,\nUnited\nKingdom, Barts Heart Centre, St Bartholomews Hospital, London,\nUnited Kingdom, and Heart, Vascular and Thoracic Institute,\nCleveland\nClinic,\nLondon,\nUnited\nKingdom;\nEloi\nMarijon,\nCardiology Department, European Georges Pompidou Hospital,\nParis, France; Jose L. Merino, Arrhythmia and Electrophysiology\nRobotic Unit, La Paz University Hospital, Universidad Autonoma,\nIdiPaz, Madrid, Spain, Cardiology Department, Hospital Ruber Juan\nBravo, Madrid, Spain, and Cardiac Electrophysiology, Hospital\nViamed Santa Elena, Madrid, Spain; Petr Peichl, Cardiology\nDepartment, IKEM, Prague, Czech Republic; Silvia G. Priori,\nMolecular Medicine Department, University of Pavia, Pavia, Italy,\nMolecular\nCardiology\nDepartment,\nIstituti\nClinici\nScientiﬁci\nMaugeri\nSpA\nSB,\nPavia,\nItaly,\nand\nMolecular\nCardiology\nDepartment, Centro Nacional de Investigaciones Cardiovasculares\nCarlos III (CNIC), Madrid, Spain, European Reference Networks\nfor rare, low prevalence and complex diseases of the heart, ERN-\nGUARD HEART; Tobias Reichlin, Department of Cardiology,\nInselspital—University Hospital Bern, University of Bern, Bern,\nSwitzerland;\nJeanette\nSchulz-Menger,\nCardiology,\nECRC,\nCharité—Universitätsmedizin Berlin, corporate member of Freie\nUniversität Berlin and Humboldt-Universität zu Berlin, Berlin,\nGermany, Cardiology, Helios Clinics Berlin-Buch, Berlin, Germany,\nand DZHK Partnersite Berlin, Charité, Berlin, Germany; Christian\nSticherling, Department of Cardiology, University Hospital Basel,\nUniversity of Basel, Basel, Switzerland; Stylianos Tzeis, Cardiology\nDepartment, Mitera Hospital, Hygeia Group, Athens, Greece; Axel\nVerstrael (Belgium), ESC Patient Forum, Sophia Antipolis, France;\nand Maurizio Volterrani, Department of Cardiology, IRCCS San\nRaffaele Roma, Rome, Italy, and Professor of Exercise Science and\nMedicine, San Raffaele Telematic University of Rome, Rome.\n16. Appendix\nESC Scientiﬁc Document Group\nIncludes Document Reviewers and ESC National Cardiac\nSocieties.\nDocument Reviewers: Maja Cikes (CPG Review Coordinator)\n(Croatia), Paulus Kirchhof (CPG Review Coordinator) (Germany),\nMagdy Abdelhamid (Egypt), Victor Aboyans (France), Elena Arbelo\n(Spain), Fernando Arribas (Spain), Riccardo Asteggiano (Italy), Cristina\nBasso (Italy), Axel Bauer (Austria), Emanuele Bertaglia (Italy), Tor\nBiering-Sørensen (Denmark), Carina Blomström-Lundqvist (Sweden),\nMichael A. Borger (Germany), Jelena Čelutkienė (Lithuania), Bernard\nCosyns\n(Belgium),\nVolkmar\nFalk\n(Germany),\nLaurent\nFauchier\n(France), Bulent Gorenek (Turkey), Sigrun Halvorsen (Norway),\nRobert Hatala (Slovakia), Hein Heidbuchel (Belgium), Stefan Kaab\n(Germany), Aleksandra Konradi (Russian Federation), Konstantinos\nC. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf\nLandmesser (Germany), Basil S. Lewis (Israel), Ales Linhart (Czech\nRepublic), Maja-Lisa Løchen (Norway), Lars H. Lund (Sweden),\nAndreas Metzner (Germany), Richard Mindham (United Kingdom),\nJens Cosedis Nielsen (Denmark), Tone M. Norekvål (Norway),\nMonica Patten (Germany), Eva Prescott (Denmark), Amina Rakisheva\n(Kazakhstan), Carol Ann Remme (Netherlands), Ivo Roca-Luque\n(Spain), Andrea Sarkozy (Belgium), Daniel Scherr (Austria), Marta\nSitges (Spain), Rhian M. Touyz (Canada/United Kingdom), Nicolas Van\nMieghem (Netherlands), Vedran Velagic (Croatia), Sami Viskin (Israel),\nand Paul G. A. Volders (Netherlands).\nESC National Cardiac Societies actively involved in the re-\nview process of the 2022 ESC Guidelines for the management of pa-\ntients with ventricular arrhythmias and the prevention of sudden\ncardiac death.\nAlgeria: Algerian Society of Cardiology, Brahim Kichou; Armenia:\nArmenian Cardiologists Association, Mihran Martirosyan; Austria:\nAustrian\nSociety\nof\nCardiology,\nDaniel\nScherr;\nAzerbaijan:\nAzerbaijan Society of Cardiology, Farid Aliyev; Belgium: Belgian\nSociety of Cardiology, Rik Willems; Bosnia and Herzegovina:\nAssociation of Cardiologists of Bosnia and Herzegovina, Nabil Naser;\nBulgaria: Bulgarian Society of Cardiology, Tchavdar Shalganov;\nCroatia: Croatian Cardiac Society, Davor Milicic; Cyprus: Cyprus\nSociety of Cardiology, Theodoros Christophides; Czech Republic:\nCzech Society of Cardiology, Josef Kautzner; Denmark: Danish\nSociety of Cardiology, Jim Hansen; Egypt: Egyptian Society of\nCardiology, Lamyaa Allam; Estonia: Estonian Society of Cardiology,\nPriit Kampus; Finland: Finnish Cardiac Society, Juhani Junttila;\nFrance:\nFrench\nSociety\nof\nCardiology,\nChristophe\nLeclercq;\nGeorgia: Georgian Society of Cardiology, Kakhaber Etsadashvili;\nGermany: German Cardiac Society, Daniel Steven; Greece:\nHellenic Society of Cardiology, Konstantinos Gatzoulis; Hungary:\n4100\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 103",
          "page": 103,
          "content": " | Recommendations for management of patients with short QT syndrome |  |  | \nIt is recommended that SQTS is diagnosed in the presence of a QTc ≤360 ms and one or more of the following: (a) a pathogenic\nmutation, (b) a family history of SQTS, (c) survival from a VT/VF episode in the absence of heart disease. |  | I | C | \nGenetic testing is indicated in patients diagnosed with SQTS. |  | I | C | \nICD implantation is recommended in patients with a diagnosis of SQTS who: (a) are survivors of an aborted CA, and/or (b) have\ndocumented spontaneous sustained VT. |  | I | C | \nPES is not recommended for SCD risk stratification in SQTS patients. |  | III | C | \n | Recommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy |  |  | \nDuring pregnancy, electrical cardioversion is recommended for sustained VT. |  | I | C | \nIf ICD implantation is indicated during pregnancy, implantation is recommended with optimal radiation protection. |  | I | C | \nContinuation of beta-blockers is recommended during pregnancy and post-partum in patients with LQTS or CPVT. |  | I | C | \n | Recommendations for risk stratification and prevention of sudden cardiac death in athletes |  |  | \nIn athletes with positive medical history, abnormal physical examination, or ECG alterations, further investigations including\nechocardiography and/or CMR to confirm (or exclude) an underlying disease are recommended. |  | I | C | \nIt is recommended that athletes diagnosed with a cardiovascular disease associated with SCD are managed according to current\nguidelines for sports eligibility. |  | I | C | \nIt is recommended that staff at sporting facilities are trained in CPR and in the use of AED. |  | I | C | ",
          "rows": 13,
          "cols": 5
        }
      ],
      "keywords": [
        "echocardiography",
        "ct",
        "echo",
        "information",
        "risk",
        "author",
        "icd",
        "diagnosis",
        "recommendation"
      ]
    },
    {
      "number": "18",
      "title": "Appendix",
      "start_page": 104,
      "end_page": 105,
      "content": "Rigshospitalet,\nCopenhagen,\nDenmark,\nEuropean\nReference\nNetworks for rare, low prevalence and complex diseases of the\nheart, ERN-GUARD HEART; Elijah R. Behr, Cardiovascular\nClinical\nAcademic\nGroup,\nCardiology\nSection,\nSt\nGeorge’s,\nUniversity of London, London, United Kingdom, Department of\nCardiology, St George’s University Hospitals NHS Foundation\nTrust, London, United Kingdom, and Cardiology, Mayo Clinic\nHealthcare, London, United Kingdom; Nico A. Blom, Paediatric\nCardiology,\nLeiden\nUniversity\nMedical\nCentre,\nLeiden,\nNetherlands, and Paediatric Cardiology, Amsterdam University\nMedical Center, Amsterdam, Netherlands; Philippe Charron,\nAPHP, Centre de Référence des Maladies Cardiaques Héréditaires\nou Rares, Hôpital Pitié-Salpêtrière, Paris, France, UMR_S 1166, and\nICAN Institute for Cardiometabolism, and Nutrition, Sorbonne\nUniversité, Paris, France, and European Reference Networks for\nrare,\nlow\nprevalence\nand\ncomplex\ndiseases\nof\nthe\nheart,\nERN-Guard\nHEART,\nParis,\nFrance;\nDomenico\nCorrado,\nDepartment of Cardiac, Thoracic and Vascular Sciences and Public\nHealth, University of Padova, Padova, Italy; Nikolaos Dagres,\nDepartment\nof\nElectrophysiology,\nHeart\nCenter\nLeipzig\nat\nUniversity of Leipzig, Leipzig, Germany; Christian de Chillou,\nDepartment of Cardiology, CHRU-Nancy, Nancy, France, and\nIADI, INSERM U1254, Université de Lorraine, Nancy, France; Lars\nEckardt,\nDepartment\nof\nCardiology\nII—Electrophysiology,\nUniversity Hospital Münster, Münster, Germany; Tim Friede,\nDepartment of Medical Statistics, University Medical Center\nGoettingen, Goettingen, Germany, and Partner Site Goettingen,\nDZHK (German Center for Cardiovascular Research), Goettingen,\nGermany; Kristina H. Haugaa, Department of Cardiology, Oslo\nUniversity Hospital, Rikshospitalet, Oslo, Norway, and Faculty of\nMedicine, University of Oslo, Oslo, Norway; Mélèze Hocini,\nCardiology Department, Liryc Institute, Pessac, France, Hopital\nCardiologique du Haut Lévêque, Pessac, France, and Université de\nBordeaux, Bordeaux, France; Pier D. Lambiase, Institute of\nCardiovascular\nScience,\nUniversity\nCollege,\nLondon,\nUnited\nKingdom, Barts Heart Centre, St Bartholomews Hospital, London,\nUnited Kingdom, and Heart, Vascular and Thoracic Institute,\nCleveland\nClinic,\nLondon,\nUnited\nKingdom;\nEloi\nMarijon,\nCardiology Department, European Georges Pompidou Hospital,\nParis, France; Jose L. Merino, Arrhythmia and Electrophysiology\nRobotic Unit, La Paz University Hospital, Universidad Autonoma,\nIdiPaz, Madrid, Spain, Cardiology Department, Hospital Ruber Juan\nBravo, Madrid, Spain, and Cardiac Electrophysiology, Hospital\nViamed Santa Elena, Madrid, Spain; Petr Peichl, Cardiology\nDepartment, IKEM, Prague, Czech Republic; Silvia G. Priori,\nMolecular Medicine Department, University of Pavia, Pavia, Italy,\nMolecular\nCardiology\nDepartment,\nIstituti\nClinici\nScientiﬁci\nMaugeri\nSpA\nSB,\nPavia,\nItaly,\nand\nMolecular\nCardiology\nDepartment, Centro Nacional de Investigaciones Cardiovasculares\nCarlos III (CNIC), Madrid, Spain, European Reference Networks\nfor rare, low prevalence and complex diseases of the heart, ERN-\nGUARD HEART; Tobias Reichlin, Department of Cardiology,\nInselspital—University Hospital Bern, University of Bern, Bern,\nSwitzerland;\nJeanette\nSchulz-Menger,\nCardiology,\nECRC,\nCharité—Universitätsmedizin Berlin, corporate member of Freie\nUniversität Berlin and Humboldt-Universität zu Berlin, Berlin,\nGermany, Cardiology, Helios Clinics Berlin-Buch, Berlin, Germany,\nand DZHK Partnersite Berlin, Charité, Berlin, Germany; Christian\nSticherling, Department of Cardiology, University Hospital Basel,\nUniversity of Basel, Basel, Switzerland; Stylianos Tzeis, Cardiology\nDepartment, Mitera Hospital, Hygeia Group, Athens, Greece; Axel\nVerstrael (Belgium), ESC Patient Forum, Sophia Antipolis, France;\nand Maurizio Volterrani, Department of Cardiology, IRCCS San\nRaffaele Roma, Rome, Italy, and Professor of Exercise Science and\nMedicine, San Raffaele Telematic University of Rome, Rome.\n16. Appendix\nESC Scientiﬁc Document Group\nIncludes Document Reviewers and ESC National Cardiac\nSocieties.\nDocument Reviewers: Maja Cikes (CPG Review Coordinator)\n(Croatia), Paulus Kirchhof (CPG Review Coordinator) (Germany),\nMagdy Abdelhamid (Egypt), Victor Aboyans (France), Elena Arbelo\n(Spain), Fernando Arribas (Spain), Riccardo Asteggiano (Italy), Cristina\nBasso (Italy), Axel Bauer (Austria), Emanuele Bertaglia (Italy), Tor\nBiering-Sørensen (Denmark), Carina Blomström-Lundqvist (Sweden),\nMichael A. Borger (Germany), Jelena Čelutkienė (Lithuania), Bernard\nCosyns\n(Belgium),\nVolkmar\nFalk\n(Germany),\nLaurent\nFauchier\n(France), Bulent Gorenek (Turkey), Sigrun Halvorsen (Norway),\nRobert Hatala (Slovakia), Hein Heidbuchel (Belgium), Stefan Kaab\n(Germany), Aleksandra Konradi (Russian Federation), Konstantinos\nC. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf\nLandmesser (Germany), Basil S. Lewis (Israel), Ales Linhart (Czech\nRepublic), Maja-Lisa Løchen (Norway), Lars H. Lund (Sweden),\nAndreas Metzner (Germany), Richard Mindham (United Kingdom),\nJens Cosedis Nielsen (Denmark), Tone M. Norekvål (Norway),\nMonica Patten (Germany), Eva Prescott (Denmark), Amina Rakisheva\n(Kazakhstan), Carol Ann Remme (Netherlands), Ivo Roca-Luque\n(Spain), Andrea Sarkozy (Belgium), Daniel Scherr (Austria), Marta\nSitges (Spain), Rhian M. Touyz (Canada/United Kingdom), Nicolas Van\nMieghem (Netherlands), Vedran Velagic (Croatia), Sami Viskin (Israel),\nand Paul G. A. Volders (Netherlands).\nESC National Cardiac Societies actively involved in the re-\nview process of the 2022 ESC Guidelines for the management of pa-\ntients with ventricular arrhythmias and the prevention of sudden\ncardiac death.\nAlgeria: Algerian Society of Cardiology, Brahim Kichou; Armenia:\nArmenian Cardiologists Association, Mihran Martirosyan; Austria:\nAustrian\nSociety\nof\nCardiology,\nDaniel\nScherr;\nAzerbaijan:\nAzerbaijan Society of Cardiology, Farid Aliyev; Belgium: Belgian\nSociety of Cardiology, Rik Willems; Bosnia and Herzegovina:\nAssociation of Cardiologists of Bosnia and Herzegovina, Nabil Naser;\nBulgaria: Bulgarian Society of Cardiology, Tchavdar Shalganov;\nCroatia: Croatian Cardiac Society, Davor Milicic; Cyprus: Cyprus\nSociety of Cardiology, Theodoros Christophides; Czech Republic:\nCzech Society of Cardiology, Josef Kautzner; Denmark: Danish\nSociety of Cardiology, Jim Hansen; Egypt: Egyptian Society of\nCardiology, Lamyaa Allam; Estonia: Estonian Society of Cardiology,\nPriit Kampus; Finland: Finnish Cardiac Society, Juhani Junttila;\nFrance:\nFrench\nSociety\nof\nCardiology,\nChristophe\nLeclercq;\nGeorgia: Georgian Society of Cardiology, Kakhaber Etsadashvili;\nGermany: German Cardiac Society, Daniel Steven; Greece:\nHellenic Society of Cardiology, Konstantinos Gatzoulis; Hungary:\n4100\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nHungarian Society of Cardiology, László Gellér; Iceland: Icelandic\nSociety of Cardiology, David O. Arnar; Ireland: Irish Cardiac Society,\nJoseph Galvin, European Reference Networks for rare, low prevalence\nand complex diseases of the heart, ERN-GUARD HEART; Israel: Israel\nHeart Society, Moti Haim; Italy: Italian Federation of Cardiology, Carlo\nPappone; Kosovo (Republic of): Kosovo Society of Cardiology,\nShpend Elezi; Kyrgyzstan: Kyrgyz Society of Cardiology, Alina\nKerimkulova; Latvia: Latvian Society of Cardiology, Oskars Kalejs;\nLebanon: Lebanese Society of Cardiology, Ali Rabah; Lithuania:\nLithuanian Society of Cardiology, Aras Puodziukynas; Luxembourg:\nLuxembourg Society of Cardiology, Carlo Dimmer; Malta: Maltese\nCardiac Society, Mark Adrian Sammut; Moldova (Republic of):\nMoldavian Society of Cardiology, Lilia David; Montenegro:\nMontenegro Society of Cardiology, Aneta Boskovic; Morocco:\nMoroccan\nSociety\nof\nCardiology,\nAbdelhamid\nMoustaghﬁr;\nNetherlands: Netherlands Society of Cardiology, Alexander\nH. Maass; North Macedonia: North Macedonian Society of\nCardiology,\nLidija\nPoposka;\nNorway:\nNorwegian\nSociety\nof\nCardiology, Ole Christian Mjolstad; Poland: Polish Cardiac Society,\nPrzemysław Mitkowski; Portugal: Portuguese Society of Cardiology,\nLeonor Parreira; Romania: Romanian Society of Cardiology, Dragos\nCozma; Russian Federation: Russian Society of Cardiology, Elena\nGolukhova; San Marino: San Marino Society of Cardiology,\nRoberto Bini; Serbia: Cardiology Society of Serbia, Sinisa Stojkovic;\nSlovakia: Slovak Society of Cardiology, Peter Hlivak; Slovenia:\nSlovenian Society of Cardiology, Andrej Pernat; Spain: Spanish\nSociety of Cardiology, Nicasio Perez Castellano; Sweden: Swedish\nSociety of Cardiology, Pyotr G. Platonov; Switzerland: Swiss\nSociety of Cardiology, Firat Duru; Syrian Arab Republic: Syrian\nCardiovascular Association, Ahmad Rasheed Al Saadi; Tunisia:\nTunisian Society of Cardiology and Cardio-Vascular Surgery, Sana\nOuali; Turkey: Turkish Society of Cardiology, Sabri Demircan;\nUkraine: Ukrainian Association of Cardiology, Oleg Sychov; and\nUnited Kingdom of Great Britain and Northern Ireland:\nBritish Cardiovascular Society, Alistair Slade.\nESC Clinical Practice Guidelines (CPG) Committee:\nColin Baigent (Chairperson) (United Kingdom), Magdy Abdelhamid\n(Egypt),\nVictor\nAboyans\n(France),\nSotiris\nAntoniou\n(United\nKingdom), Elena Arbelo (Spain), Riccardo Asteggiano (Italy), Andreas\nBaumbach (United Kingdom), Michael A. Borger (Germany), Jelena\nČelutkienė (Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet\n(France), Volkmar Falk (Germany), Laurent Fauchier (France), Chris\nP. Gale (United Kingdom), Sigrun Halvorsen (Norway), Bernard Iung\n(France), Tiny Jaarsma (Sweden), Aleksandra Konradi (Russian\nFederation), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha\n(United Kingdom), Ulf Landmesser (Germany), Basil S. Lewis (Israel),\nAles Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Richard\nMindham (United Kingdom), Jens Cosedis Nielsen (Denmark),\nSteffen E. Petersen (United Kingdom), Eva Prescott (Denmark),\nAmina Rakisheva (Kazakhstan), Marta Sitges (Spain), and Rhian\nM. Touyz (Canada/United Kingdom).\n17. References\n1. Brignole M, Moya A, de Lange FJ, Deharo J-C, Elliott PM, Fanciulli A, et al. 2018 ESC\nGuidelines for the diagnosis and management of syncope. Eur Heart J 2018;39:\n1883–1948.\n2. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al.\n2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur\nHeart J 2021;42:3427–3520.\n3. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017\nESC Guidelines for the management of acute myocardial infarction in patients pre-\nsenting with ST-segment elevation: the task force for the management of acute\nmyocardial infarction in patients presenting with ST-segment elevation of the\nEuropean Society of Cardiology (ESC). Eur Heart J 2018;39:119–177.\n4. Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, et al. 2020 ESC\nGuidelines on sports cardiology and exercise in patients with cardiovascular dis-\nease. Eur Heart J 2021;42:17–96.\n5. Wahbi K, Babuty D, Probst V, Wissocque L, Labombarda F, Porcher R, et al.\nIncidence and predictors of sudden death, major conduction defects and sustained\nventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1. Eur\nHeart J 2017;38:751–758.\n6. Bucci E, Testa M, Licchelli L, Frattari A, El Halabieh NA, Gabriele E, et al. A 34-year\nlongitudinal study on long-term cardiac outcomes in DM1 patients with normal\nECG at baseline at an Italian clinical centre. J Neurol 2018;265:885–895.\n7. Chong-Nguyen C, Wahbi K, Algalarrondo V, Bécane HM, Radvanyi-Hoffman H,\nArnaud P, et al. Association between mutation size and cardiac involvement in\nmyotonic dystrophy type 1: an analysis of the DM1-heart registry. Circ Cardiovasc\nGenet 2017;10:e001526.\n8. Sabovic M, Medica I, Logar N, Mandić E, Zidar J, Peterlin B. Relation of CTG expan-\nsion and clinical variables to electrocardiogram conduction abnormalities and sud-\nden death in patients with myotonic dystrophy. Neuromuscul Disord 2003;13:\n822–826.\n9. Clarke\nNR,\nKelion\nAD,\nNixon\nJ,\nHilton-Jones\nD,\nForfar\nJC.\nDoes\ncytosine-thymine-guanine (CTG) expansion size predict cardiac events and elec-\ntrocardiographic progression in myotonic dystrophy? Heart 2001;86:411–416.\n10. Melacini P, Villanova C, Menegazzo E, Novelli G, Danieli G, Rizzoli G, et al.\nCorrelation between cardiac involvement and CTG trinucleotide repeat length\nin myotonic dystrophy. J Am Coll Cardiol 1995;25:239–245.\n11. Lazarus A, Varin J, Ounnoughene Z, Radvanyi H, Junien C, Coste J, et al.\nRelationships among electrophysiological ﬁndings and clinical status, heart function,\nand extent of DNA mutation in myotonic dystrophy. Circulation 1999;99:\n1041–1046.\n12. Sansone VA, Brigonzi E, Schoser B, Villani S, Gaeta M, De Ambroggi G, et al. The\nfrequency and severity of cardiac involvement in myotonic dystrophy type 2\n(DM2): long-term outcomes. Int J Cardiol 2013;168:1147–1153.\n13. Breton R, Mathieu J. Usefulness of clinical and electrocardiographic data for pre-\ndicting adverse cardiac events in patients with myotonic dystrophy. Can J Cardiol\n2009;25:e23–e27.\n14. Hermans MCE, Faber CG, Bekkers SCAM, de Die-Smulders CEM, Gerrits MM,\nMerkies ISJ, et al. Structural and functional cardiac changes in myotonic dystrophy\ntype1: a cardiovascular magnetic resonance study.J Cardiovasc Magn Reson 2012;14:48.\n15. Schmacht L, Traber J, Grieben U, Utz W, Dieringer MA, Kellman P, et al. Cardiac\ninvolvement in myotonic dystrophy type 2 patients with preserved ejection frac-\ntion: detection by cardiovascular magnetic resonance. Circ Cardiovasc Imaging\n2016;9:e004615.\n16. Groh WJ, Groh MR, Saha C, Kincaid JC, Simmons Z, Ciafaloni E, et al.\nElectrocardiographic abnormalities and sudden death in myotonic dystrophy\ntype 1. N Engl J Med 2008;358:2688–2697.\n17. Bhakta D, Groh MR, Shen C, Pascuzzi RM, Groh WJ. Increased mortality with left\nventricular systolic dysfunction and heart failure in adults with myotonic dystrophy\ntype 1. Am Heart J 2010;160:1137–1141.\n18. Petri H, Ahtarovski KA, Vejlstrup N, Vissing J, Witting N, Køber L, et al. Myocardial\nﬁbrosis in patients with myotonic dystrophy type 1: a cardiovascular magnetic res-\nonance study. J Cardiovasc Magn Reson 2014;16:59.\n19. Myerburg RJ, Junttila MJ. Sudden cardiac death caused by coronary heart disease.\nCirculation 2012;125:1043–1052.\n20. Stecker EC, Reinier K, Marijon E, Narayanan K, Teodorescu C, Uy-Evanado A, et al.\nPublic health burden of sudden cardiac death in the United States. Circ Arrhythm\nElectrophysiol 2014;7:212–217.\n21. Chen LY, Sotoodehnia N, Bůžková P, Lopez FL, Yee LM, Heckbert SR, et al. Atrial\nﬁbrillation and the risk of sudden cardiac death: the atherosclerosis risk in commu-\nnities study and cardiovascular health study. JAMA Intern Med 2013;173:29–35.\n22. Marijon E, Uy-Evanado A, Dumas F, Karam N, Reinier K, Teodorescu C, et al.\nWarning symptoms are associated with survival from sudden cardiac arrest. Ann\nIntern Med 2016;164:23–29.\n23. Glinge C, Jabbari R, Risgaard B, Lynge TH, Engstrøm T, Albert CM, et al. Symptoms\nbefore sudden arrhythmic death syndrome: a nationwide study among the young in\nDenmark. J Cardiovasc Electrophysiol 2015;26:761–767.\n24. Ågesen FN, Lynge TH, Blanche P, Banner J, Prescott E, Jabbari R, et al. Temporal\ntrends and sex differences in sudden cardiac death in the Copenhagen City\nHeart Study. Heart 2021;107:1303–1309.\nESC Guidelines\n4101\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "ct",
        "appendix"
      ]
    },
    {
      "number": "19",
      "title": "References",
      "start_page": 105,
      "end_page": 105,
      "content": "Hungarian Society of Cardiology, László Gellér; Iceland: Icelandic\nSociety of Cardiology, David O. Arnar; Ireland: Irish Cardiac Society,\nJoseph Galvin, European Reference Networks for rare, low prevalence\nand complex diseases of the heart, ERN-GUARD HEART; Israel: Israel\nHeart Society, Moti Haim; Italy: Italian Federation of Cardiology, Carlo\nPappone; Kosovo (Republic of): Kosovo Society of Cardiology,\nShpend Elezi; Kyrgyzstan: Kyrgyz Society of Cardiology, Alina\nKerimkulova; Latvia: Latvian Society of Cardiology, Oskars Kalejs;\nLebanon: Lebanese Society of Cardiology, Ali Rabah; Lithuania:\nLithuanian Society of Cardiology, Aras Puodziukynas; Luxembourg:\nLuxembourg Society of Cardiology, Carlo Dimmer; Malta: Maltese\nCardiac Society, Mark Adrian Sammut; Moldova (Republic of):\nMoldavian Society of Cardiology, Lilia David; Montenegro:\nMontenegro Society of Cardiology, Aneta Boskovic; Morocco:\nMoroccan\nSociety\nof\nCardiology,\nAbdelhamid\nMoustaghﬁr;\nNetherlands: Netherlands Society of Cardiology, Alexander\nH. Maass; North Macedonia: North Macedonian Society of\nCardiology,\nLidija\nPoposka;\nNorway:\nNorwegian\nSociety\nof\nCardiology, Ole Christian Mjolstad; Poland: Polish Cardiac Society,\nPrzemysław Mitkowski; Portugal: Portuguese Society of Cardiology,\nLeonor Parreira; Romania: Romanian Society of Cardiology, Dragos\nCozma; Russian Federation: Russian Society of Cardiology, Elena\nGolukhova; San Marino: San Marino Society of Cardiology,\nRoberto Bini; Serbia: Cardiology Society of Serbia, Sinisa Stojkovic;\nSlovakia: Slovak Society of Cardiology, Peter Hlivak; Slovenia:\nSlovenian Society of Cardiology, Andrej Pernat; Spain: Spanish\nSociety of Cardiology, Nicasio Perez Castellano; Sweden: Swedish\nSociety of Cardiology, Pyotr G. Platonov; Switzerland: Swiss\nSociety of Cardiology, Firat Duru; Syrian Arab Republic: Syrian\nCardiovascular Association, Ahmad Rasheed Al Saadi; Tunisia:\nTunisian Society of Cardiology and Cardio-Vascular Surgery, Sana\nOuali; Turkey: Turkish Society of Cardiology, Sabri Demircan;\nUkraine: Ukrainian Association of Cardiology, Oleg Sychov; and\nUnited Kingdom of Great Britain and Northern Ireland:\nBritish Cardiovascular Society, Alistair Slade.\nESC Clinical Practice Guidelines (CPG) Committee:\nColin Baigent (Chairperson) (United Kingdom), Magdy Abdelhamid\n(Egypt),\nVictor\nAboyans\n(France),\nSotiris\nAntoniou\n(United\nKingdom), Elena Arbelo (Spain), Riccardo Asteggiano (Italy), Andreas\nBaumbach (United Kingdom), Michael A. Borger (Germany), Jelena\nČelutkienė (Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet\n(France), Volkmar Falk (Germany), Laurent Fauchier (France), Chris\nP. Gale (United Kingdom), Sigrun Halvorsen (Norway), Bernard Iung\n(France), Tiny Jaarsma (Sweden), Aleksandra Konradi (Russian\nFederation), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha\n(United Kingdom), Ulf Landmesser (Germany), Basil S. Lewis (Israel),\nAles Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Richard\nMindham (United Kingdom), Jens Cosedis Nielsen (Denmark),\nSteffen E. Petersen (United Kingdom), Eva Prescott (Denmark),\nAmina Rakisheva (Kazakhstan), Marta Sitges (Spain), and Rhian\nM. Touyz (Canada/United Kingdom).\n17. References\n1. Brignole M, Moya A, de Lange FJ, Deharo J-C, Elliott PM, Fanciulli A, et al. 2018 ESC\nGuidelines for the diagnosis and management of syncope. Eur Heart J 2018;39:\n1883–1948.\n2. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al.\n2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur\nHeart J 2021;42:3427–3520.\n3. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017\nESC Guidelines for the management of acute myocardial infarction in patients pre-\nsenting with ST-segment elevation: the task force for the management of acute\nmyocardial infarction in patients presenting with ST-segment elevation of the\nEuropean Society of Cardiology (ESC). Eur Heart J 2018;39:119–177.\n4. Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, et al. 2020 ESC\nGuidelines on sports cardiology and exercise in patients with cardiovascular dis-\nease. Eur Heart J 2021;42:17–96.\n5. Wahbi K, Babuty D, Probst V, Wissocque L, Labombarda F, Porcher R, et al.\nIncidence and predictors of sudden death, major conduction defects and sustained\nventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1. Eur\nHeart J 2017;38:751–758.\n6. Bucci E, Testa M, Licchelli L, Frattari A, El Halabieh NA, Gabriele E, et al. A 34-year\nlongitudinal study on long-term cardiac outcomes in DM1 patients with normal\nECG at baseline at an Italian clinical centre. J Neurol 2018;265:885–895.\n7. Chong-Nguyen C, Wahbi K, Algalarrondo V, Bécane HM, Radvanyi-Hoffman H,\nArnaud P, et al. Association between mutation size and cardiac involvement in\nmyotonic dystrophy type 1: an analysis of the DM1-heart registry. Circ Cardiovasc\nGenet 2017;10:e001526.\n8. Sabovic M, Medica I, Logar N, Mandić E, Zidar J, Peterlin B. Relation of CTG expan-\nsion and clinical variables to electrocardiogram conduction abnormalities and sud-\nden death in patients with myotonic dystrophy. Neuromuscul Disord 2003;13:\n822–826.\n9. Clarke\nNR,\nKelion\nAD,\nNixon\nJ,\nHilton-Jones\nD,\nForfar\nJC.\nDoes\ncytosine-thymine-guanine (CTG) expansion size predict cardiac events and elec-\ntrocardiographic progression in myotonic dystrophy? Heart 2001;86:411–416.\n10. Melacini P, Villanova C, Menegazzo E, Novelli G, Danieli G, Rizzoli G, et al.\nCorrelation between cardiac involvement and CTG trinucleotide repeat length\nin myotonic dystrophy. J Am Coll Cardiol 1995;25:239–245.\n11. Lazarus A, Varin J, Ounnoughene Z, Radvanyi H, Junien C, Coste J, et al.\nRelationships among electrophysiological ﬁndings and clinical status, heart function,\nand extent of DNA mutation in myotonic dystrophy. Circulation 1999;99:\n1041–1046.\n12. Sansone VA, Brigonzi E, Schoser B, Villani S, Gaeta M, De Ambroggi G, et al. The\nfrequency and severity of cardiac involvement in myotonic dystrophy type 2\n(DM2): long-term outcomes. Int J Cardiol 2013;168:1147–1153.\n13. Breton R, Mathieu J. Usefulness of clinical and electrocardiographic data for pre-\ndicting adverse cardiac events in patients with myotonic dystrophy. Can J Cardiol\n2009;25:e23–e27.\n14. Hermans MCE, Faber CG, Bekkers SCAM, de Die-Smulders CEM, Gerrits MM,\nMerkies ISJ, et al. Structural and functional cardiac changes in myotonic dystrophy\ntype1: a cardiovascular magnetic resonance study.J Cardiovasc Magn Reson 2012;14:48.\n15. Schmacht L, Traber J, Grieben U, Utz W, Dieringer MA, Kellman P, et al. Cardiac\ninvolvement in myotonic dystrophy type 2 patients with preserved ejection frac-\ntion: detection by cardiovascular magnetic resonance. Circ Cardiovasc Imaging\n2016;9:e004615.\n16. Groh WJ, Groh MR, Saha C, Kincaid JC, Simmons Z, Ciafaloni E, et al.\nElectrocardiographic abnormalities and sudden death in myotonic dystrophy\ntype 1. N Engl J Med 2008;358:2688–2697.\n17. Bhakta D, Groh MR, Shen C, Pascuzzi RM, Groh WJ. Increased mortality with left\nventricular systolic dysfunction and heart failure in adults with myotonic dystrophy\ntype 1. Am Heart J 2010;160:1137–1141.\n18. Petri H, Ahtarovski KA, Vejlstrup N, Vissing J, Witting N, Køber L, et al. Myocardial\nﬁbrosis in patients with myotonic dystrophy type 1: a cardiovascular magnetic res-\nonance study. J Cardiovasc Magn Reson 2014;16:59.\n19. Myerburg RJ, Junttila MJ. Sudden cardiac death caused by coronary heart disease.\nCirculation 2012;125:1043–1052.\n20. Stecker EC, Reinier K, Marijon E, Narayanan K, Teodorescu C, Uy-Evanado A, et al.\nPublic health burden of sudden cardiac death in the United States. Circ Arrhythm\nElectrophysiol 2014;7:212–217.\n21. Chen LY, Sotoodehnia N, Bůžková P, Lopez FL, Yee LM, Heckbert SR, et al. Atrial\nﬁbrillation and the risk of sudden cardiac death: the atherosclerosis risk in commu-\nnities study and cardiovascular health study. JAMA Intern Med 2013;173:29–35.\n22. Marijon E, Uy-Evanado A, Dumas F, Karam N, Reinier K, Teodorescu C, et al.\nWarning symptoms are associated with survival from sudden cardiac arrest. Ann\nIntern Med 2016;164:23–29.\n23. Glinge C, Jabbari R, Risgaard B, Lynge TH, Engstrøm T, Albert CM, et al. Symptoms\nbefore sudden arrhythmic death syndrome: a nationwide study among the young in\nDenmark. J Cardiovasc Electrophysiol 2015;26:761–767.\n24. Ågesen FN, Lynge TH, Blanche P, Banner J, Prescott E, Jabbari R, et al. Temporal\ntrends and sex differences in sudden cardiac death in the Copenhagen City\nHeart Study. Heart 2021;107:1303–1309.\nESC Guidelines\n4101\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "surgery",
        "arb",
        "references",
        "ct"
      ]
    },
    {
      "number": "20",
      "title": "References",
      "start_page": 105,
      "end_page": 119,
      "content": "Hungarian Society of Cardiology, László Gellér; Iceland: Icelandic\nSociety of Cardiology, David O. Arnar; Ireland: Irish Cardiac Society,\nJoseph Galvin, European Reference Networks for rare, low prevalence\nand complex diseases of the heart, ERN-GUARD HEART; Israel: Israel\nHeart Society, Moti Haim; Italy: Italian Federation of Cardiology, Carlo\nPappone; Kosovo (Republic of): Kosovo Society of Cardiology,\nShpend Elezi; Kyrgyzstan: Kyrgyz Society of Cardiology, Alina\nKerimkulova; Latvia: Latvian Society of Cardiology, Oskars Kalejs;\nLebanon: Lebanese Society of Cardiology, Ali Rabah; Lithuania:\nLithuanian Society of Cardiology, Aras Puodziukynas; Luxembourg:\nLuxembourg Society of Cardiology, Carlo Dimmer; Malta: Maltese\nCardiac Society, Mark Adrian Sammut; Moldova (Republic of):\nMoldavian Society of Cardiology, Lilia David; Montenegro:\nMontenegro Society of Cardiology, Aneta Boskovic; Morocco:\nMoroccan\nSociety\nof\nCardiology,\nAbdelhamid\nMoustaghﬁr;\nNetherlands: Netherlands Society of Cardiology, Alexander\nH. Maass; North Macedonia: North Macedonian Society of\nCardiology,\nLidija\nPoposka;\nNorway:\nNorwegian\nSociety\nof\nCardiology, Ole Christian Mjolstad; Poland: Polish Cardiac Society,\nPrzemysław Mitkowski; Portugal: Portuguese Society of Cardiology,\nLeonor Parreira; Romania: Romanian Society of Cardiology, Dragos\nCozma; Russian Federation: Russian Society of Cardiology, Elena\nGolukhova; San Marino: San Marino Society of Cardiology,\nRoberto Bini; Serbia: Cardiology Society of Serbia, Sinisa Stojkovic;\nSlovakia: Slovak Society of Cardiology, Peter Hlivak; Slovenia:\nSlovenian Society of Cardiology, Andrej Pernat; Spain: Spanish\nSociety of Cardiology, Nicasio Perez Castellano; Sweden: Swedish\nSociety of Cardiology, Pyotr G. Platonov; Switzerland: Swiss\nSociety of Cardiology, Firat Duru; Syrian Arab Republic: Syrian\nCardiovascular Association, Ahmad Rasheed Al Saadi; Tunisia:\nTunisian Society of Cardiology and Cardio-Vascular Surgery, Sana\nOuali; Turkey: Turkish Society of Cardiology, Sabri Demircan;\nUkraine: Ukrainian Association of Cardiology, Oleg Sychov; and\nUnited Kingdom of Great Britain and Northern Ireland:\nBritish Cardiovascular Society, Alistair Slade.\nESC Clinical Practice Guidelines (CPG) Committee:\nColin Baigent (Chairperson) (United Kingdom), Magdy Abdelhamid\n(Egypt),\nVictor\nAboyans\n(France),\nSotiris\nAntoniou\n(United\nKingdom), Elena Arbelo (Spain), Riccardo Asteggiano (Italy), Andreas\nBaumbach (United Kingdom), Michael A. Borger (Germany), Jelena\nČelutkienė (Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet\n(France), Volkmar Falk (Germany), Laurent Fauchier (France), Chris\nP. Gale (United Kingdom), Sigrun Halvorsen (Norway), Bernard Iung\n(France), Tiny Jaarsma (Sweden), Aleksandra Konradi (Russian\nFederation), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha\n(United Kingdom), Ulf Landmesser (Germany), Basil S. Lewis (Israel),\nAles Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Richard\nMindham (United Kingdom), Jens Cosedis Nielsen (Denmark),\nSteffen E. Petersen (United Kingdom), Eva Prescott (Denmark),\nAmina Rakisheva (Kazakhstan), Marta Sitges (Spain), and Rhian\nM. Touyz (Canada/United Kingdom).\n17. References\n1. Brignole M, Moya A, de Lange FJ, Deharo J-C, Elliott PM, Fanciulli A, et al. 2018 ESC\nGuidelines for the diagnosis and management of syncope. Eur Heart J 2018;39:\n1883–1948.\n2. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al.\n2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur\nHeart J 2021;42:3427–3520.\n3. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017\nESC Guidelines for the management of acute myocardial infarction in patients pre-\nsenting with ST-segment elevation: the task force for the management of acute\nmyocardial infarction in patients presenting with ST-segment elevation of the\nEuropean Society of Cardiology (ESC). Eur Heart J 2018;39:119–177.\n4. Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, et al. 2020 ESC\nGuidelines on sports cardiology and exercise in patients with cardiovascular dis-\nease. Eur Heart J 2021;42:17–96.\n5. Wahbi K, Babuty D, Probst V, Wissocque L, Labombarda F, Porcher R, et al.\nIncidence and predictors of sudden death, major conduction defects and sustained\nventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1. Eur\nHeart J 2017;38:751–758.\n6. Bucci E, Testa M, Licchelli L, Frattari A, El Halabieh NA, Gabriele E, et al. A 34-year\nlongitudinal study on long-term cardiac outcomes in DM1 patients with normal\nECG at baseline at an Italian clinical centre. J Neurol 2018;265:885–895.\n7. Chong-Nguyen C, Wahbi K, Algalarrondo V, Bécane HM, Radvanyi-Hoffman H,\nArnaud P, et al. Association between mutation size and cardiac involvement in\nmyotonic dystrophy type 1: an analysis of the DM1-heart registry. Circ Cardiovasc\nGenet 2017;10:e001526.\n8. Sabovic M, Medica I, Logar N, Mandić E, Zidar J, Peterlin B. Relation of CTG expan-\nsion and clinical variables to electrocardiogram conduction abnormalities and sud-\nden death in patients with myotonic dystrophy. Neuromuscul Disord 2003;13:\n822–826.\n9. Clarke\nNR,\nKelion\nAD,\nNixon\nJ,\nHilton-Jones\nD,\nForfar\nJC.\nDoes\ncytosine-thymine-guanine (CTG) expansion size predict cardiac events and elec-\ntrocardiographic progression in myotonic dystrophy? Heart 2001;86:411–416.\n10. Melacini P, Villanova C, Menegazzo E, Novelli G, Danieli G, Rizzoli G, et al.\nCorrelation between cardiac involvement and CTG trinucleotide repeat length\nin myotonic dystrophy. J Am Coll Cardiol 1995;25:239–245.\n11. Lazarus A, Varin J, Ounnoughene Z, Radvanyi H, Junien C, Coste J, et al.\nRelationships among electrophysiological ﬁndings and clinical status, heart function,\nand extent of DNA mutation in myotonic dystrophy. Circulation 1999;99:\n1041–1046.\n12. Sansone VA, Brigonzi E, Schoser B, Villani S, Gaeta M, De Ambroggi G, et al. The\nfrequency and severity of cardiac involvement in myotonic dystrophy type 2\n(DM2): long-term outcomes. Int J Cardiol 2013;168:1147–1153.\n13. Breton R, Mathieu J. Usefulness of clinical and electrocardiographic data for pre-\ndicting adverse cardiac events in patients with myotonic dystrophy. Can J Cardiol\n2009;25:e23–e27.\n14. Hermans MCE, Faber CG, Bekkers SCAM, de Die-Smulders CEM, Gerrits MM,\nMerkies ISJ, et al. Structural and functional cardiac changes in myotonic dystrophy\ntype1: a cardiovascular magnetic resonance study.J Cardiovasc Magn Reson 2012;14:48.\n15. Schmacht L, Traber J, Grieben U, Utz W, Dieringer MA, Kellman P, et al. Cardiac\ninvolvement in myotonic dystrophy type 2 patients with preserved ejection frac-\ntion: detection by cardiovascular magnetic resonance. Circ Cardiovasc Imaging\n2016;9:e004615.\n16. Groh WJ, Groh MR, Saha C, Kincaid JC, Simmons Z, Ciafaloni E, et al.\nElectrocardiographic abnormalities and sudden death in myotonic dystrophy\ntype 1. N Engl J Med 2008;358:2688–2697.\n17. Bhakta D, Groh MR, Shen C, Pascuzzi RM, Groh WJ. Increased mortality with left\nventricular systolic dysfunction and heart failure in adults with myotonic dystrophy\ntype 1. Am Heart J 2010;160:1137–1141.\n18. Petri H, Ahtarovski KA, Vejlstrup N, Vissing J, Witting N, Køber L, et al. Myocardial\nﬁbrosis in patients with myotonic dystrophy type 1: a cardiovascular magnetic res-\nonance study. J Cardiovasc Magn Reson 2014;16:59.\n19. Myerburg RJ, Junttila MJ. Sudden cardiac death caused by coronary heart disease.\nCirculation 2012;125:1043–1052.\n20. Stecker EC, Reinier K, Marijon E, Narayanan K, Teodorescu C, Uy-Evanado A, et al.\nPublic health burden of sudden cardiac death in the United States. Circ Arrhythm\nElectrophysiol 2014;7:212–217.\n21. Chen LY, Sotoodehnia N, Bůžková P, Lopez FL, Yee LM, Heckbert SR, et al. Atrial\nﬁbrillation and the risk of sudden cardiac death: the atherosclerosis risk in commu-\nnities study and cardiovascular health study. JAMA Intern Med 2013;173:29–35.\n22. Marijon E, Uy-Evanado A, Dumas F, Karam N, Reinier K, Teodorescu C, et al.\nWarning symptoms are associated with survival from sudden cardiac arrest. Ann\nIntern Med 2016;164:23–29.\n23. Glinge C, Jabbari R, Risgaard B, Lynge TH, Engstrøm T, Albert CM, et al. Symptoms\nbefore sudden arrhythmic death syndrome: a nationwide study among the young in\nDenmark. J Cardiovasc Electrophysiol 2015;26:761–767.\n24. Ågesen FN, Lynge TH, Blanche P, Banner J, Prescott E, Jabbari R, et al. Temporal\ntrends and sex differences in sudden cardiac death in the Copenhagen City\nHeart Study. Heart 2021;107:1303–1309.\nESC Guidelines\n4101\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n25. Winkel BG, Holst AG, Theilade J, Kristensen IB, Thomsen JL, Ottesen GL, et al.\nNationwide study of sudden cardiac death in persons aged 1–35 years. Eur Heart\nJ 2011;32:983–990.\n26. Pilmer CM, Kirsh JA, Hildebrandt D, Krahn AD, Gow RM. Sudden cardiac death in\nchildren and adolescents between 1 and 19 years of age. Heart Rhythm 2014;11:\n239–245.\n27. Risgaard B, Winkel BG, Jabbari R, Behr ER, Ingemann-Hansen O, Thomsen JL, et al.\nBurden of sudden cardiac death in persons aged 1 to 49 years: nationwide study in\nDenmark. Circ Arrhythm Electrophysiol 2014;7:205–211.\n28. Fishman GI, Chugh SS, DiMarco JP, Albert CM, Anderson ME, Bonow RO, et al.\nSudden cardiac death prediction and prevention report from a national heart,\nlung, and blood institute and heart rhythm society workshop. Circulation 2010;\n122:2335–2348.\n29. Wong CX, Brown A, Lau DH, Chugh SS, Albert CM, Kalman JM, et al. Epidemiology\nof sudden cardiac death: global and regional perspectives. Heart Lung Circ 2019;28:\n6–14.\n30. Bougouin W, Lamhaut L, Marijon E, Jost D, Dumas F, Deye N, et al. Characteristics\nand prognosis of sudden cardiac death in Greater Paris: population-based approach\nfrom the Paris Sudden Death Expertise Center (Paris-SDEC). Intensive Care Med\n2014;40:846–854.\n31. Deo R, Albert CM. Epidemiology and genetics of sudden cardiac death. Circulation\n2012;125:620–637.\n32. Gerber Y, Jacobsen SJ, Frye RL, Weston SA, Killian JM, Roger VL. Secular trends in\ndeaths from cardiovascular diseases: a 25-year community study. Circulation 2006;\n113:2285–2292.\n33. Krahn AD, Connolly SJ, Roberts RS, Gent M, ATMA Investigators. Diminishing pro-\nportional risk of sudden death with advancing age: implications for prevention of\nsudden death. Am Heart J 2004;147:837–840.\n34. Becker LB, Han BH, Meyer PM, Wright FA, Rhodes KV, Smith DW, et al. Racial dif-\nferences in the incidence of cardiac arrest and subsequent survival. The CPR\nChicago Project. N Engl J Med 1993;329:600–606.\n35. Zhao D, Post WS, Blasco-Colmenares E, Cheng A, Zhang Y, Deo R, et al. Racial\ndifferences in sudden cardiac death. Circulation 2019;139:1688–1697.\n36. de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, van Ree JW, Daemen\nMJ, Houben LG, et al. Out-of-hospital cardiac arrest in the 1990’s: a population-\nbased study in the Maastricht area on incidence, characteristics and survival. J Am\nColl Cardiol 1997;30:1500–1505.\n37. Lynge TH, Risgaard B, Banner J, Nielsen JL, Jespersen T, Stampe NK, et al.\nNationwide burden of sudden cardiac death: a study of 54,028 deaths in\nDenmark. Heart Rhythm 2021;18:1657–1665.\n38. Atwood C, Eisenberg MS, Herlitz J, Rea TD. Incidence of EMS-treated\nout-of-hospital cardiac arrest in Europe. Resuscitation 2005;67:75–80.\n39. Empana J-P, Blom MT, Böttiger BW, Dagres N, Dekker JM, Gislason G, et al.\nDeterminants of occurrence and survival after sudden cardiac arrest—a\nEuropean perspective: The ESCAPE-NET project. Resuscitation 2018;124:7–13.\n40. Fox CS, Evans JC, Larson MG, Kannel WB, Levy D. Temporal trends in coronary\nheart disease mortality and sudden cardiac death from 1950 to 1999: the\nFramingham Heart Study. Circulation 2004;110:522–527.\n41. Niemeijer MN, van den Berg ME, Leening MJG, Hofman A, Franco OH, Deckers\nJW, et al. Declining incidence of sudden cardiac death from 1990–2010 in a general\nmiddle-aged and elderly population: the Rotterdam Study. Heart Rhythm 2015;12:\n123–129.\n42. Lynge TH, Nielsen JL, Blanche P, Gislason G, Torp-Pedersen C, Winkel BG, et al.\nDecline in incidence of sudden cardiac death in the young: a 10-year nationwide\nstudy of 8756 deaths in Denmark. Europace 2019;21:909–917.\n43. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United\nStates, 1989 to 1998. Circulation 2001;104:2158–2163.\n44. Dudas K, Lappas G, Stewart S, Rosengren A. Trends in out-of-hospital deaths due\nto coronary heart disease in Sweden (1991 to 2006). Circulation 2011;123:46–52.\n45. Harmon KG, Asif IM, Maleszewski JJ, Owens DS, Prutkin JM, Salerno JC, et al.\nIncidence, cause, and comparative frequency of sudden cardiac death in national\ncollegiate athletic association athletes: a decade in review. Circulation 2015;132:\n10–19.\n46. Risgaard B, Winkel BG, Jabbari R, Glinge C, Ingemann-Hansen O, Thomsen JL, et al.\nSports-related sudden cardiac death in a competitive and a noncompetitive athlete\npopulation aged 12 to 49 years: data from an unselected nationwide study in\nDenmark. Heart Rhythm 2014;11:1673–1681.\n47. Holst AG, Winkel BG, Theilade J, Kristensen IB, Thomsen JL, Ottesen GL, et al.\nIncidence and etiology of sports-related sudden cardiac death in Denmark—impli-\ncations for preparticipation screening. Heart Rhythm 2010;7:1365–1371.\n48. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young\ncompetitive athletes: analysis of 1866 deaths in the United States, 1980–2006.\nCirculation 2009;119:1085–1092.\n49. Corrado D, Basso C, Thiene G. Sudden cardiac death in athletes: what is the role of\nscreening? Curr Opin Cardiol 2012;27:41–48.\n50. Albert CM, Mittleman MA, Chae CU, Lee IM, Hennekens CH, Manson JE.\nTriggering of sudden death from cardiac causes by vigorous exertion. N Engl J\nMed 2000;343:1355–1361.\n51. Siscovick DS, Weiss NS, Fletcher RH, Lasky T. The incidence of primary cardiac ar-\nrest during vigorous exercise. N Engl J Med 1984;311:874–877.\n52. Marijon E, Tafﬂet M, Celermajer DS, Dumas F, Perier M-C, Mustaﬁc H, et al.\nSports-related sudden death in the general population. Circulation 2011;124:\n672–681.\n53. Heidbuchel H, Willems R, Jordaens L, Olshansky B, Carre F, Lozano IF, et al.\nIntensive recreational athletes in the prospective multinational ICD sports safety\nregistry: results from the European cohort. Eur J Prev Cardiol 2019;26:764–775.\n54. Marijon E, Bougouin W, Périer M-C, Celermajer DS, Jouven X. Incidence of sports-\nrelated sudden death in France by speciﬁc sports and sex. JAMA 2013;310:642–643.\n55. Marijon E, Uy-Evanado A, Reinier K, Teodorescu C, Narayanan K, Jouven X, et al.\nSudden cardiac arrest during sports activity in middle age. Circulation 2015;131:\n1384–1391.\n56. Bagnall RD, Weintraub RG, Ingles J, Duﬂou J, Yeates L, Lam L, et al. A prospective\nstudy of sudden cardiac death among children and young adults. N Engl J Med 2016;\n374:2441–2452.\n57. Wisten A, Forsberg H, Krantz P, Messner T. Sudden cardiac death in 15-35-year\nolds in Sweden during 1992-99. J Intern Med 2002;252:529–536.\n58. Chugh SS, Jui J, Gunson K, Stecker EC, John BT, Thompson B, et al. Current burden\nof sudden cardiac death: multiple source surveillance versus retrospective death\ncertiﬁcate-based review in a large US. community. J Am Coll Cardiol 2004;44:\n1268–1275.\n59. Winkel BG, Risgaard B, Sadjadieh G, Bundgaard H, Haunsø S, Tfelt-Hansen J.\nSudden cardiac death in children (1–18 years): symptoms and causes of death in\na nationwide setting. Eur Heart J 2014;35:868–875.\n60. Byrne R, Constant O, Smyth Y, Callagy G, Nash P, Daly K, et al. Multiple source\nsurveillance incidence and aetiology of out-of-hospital sudden cardiac death in a\nrural population in the West of Ireland. Eur Heart J 2008;29:1418–1423.\n61. Eckart RE, Shry EA, Burke AP, McNear JA, Appel DA, Castillo-Rojas LM, et al.\nSudden death in young adults an autopsy-based series of a population undergoing\nactive surveillance. J Am Coll Cardiol 2011;58:1254–1261.\n62. Waldmann V, Karam N, Bougouin W, Sharifzadehgan A, Dumas F, Narayanan K,\net al. Burden of coronary artery disease as a cause of sudden cardiac arrest in\nthe young. J Am Coll Cardiol 2019;73:2118–2120.\n63. Waldmann V, Karam N, Rischard J, Bougouin W, Sharifzadehgan A, Dumas F, et al.\nLow rates of immediate coronary angiography among young adults resuscitated\nfrom sudden cardiac arrest. Resuscitation 2020;147:34–42.\n64. Lloyd-Jones DM, Wilson PWF, Larson MG, Beiser A, Leip EP, D’Agostino RB, et al.\nFramingham risk score and prediction of lifetime risk for coronary heart disease.\nAm J Cardiol 2004;94:20–24.\n65. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021\nESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J\n2021;42:3227–3337.\n66. Jouven X, Desnos M, Guerot C, Ducimetière P. Predicting sudden death in the\npopulation: the Paris Prospective Study I. Circulation 1999;99:1978–1983.\n67. Dekker LRC, Bezzina CR, Henriques JPS, Tanck MW, Koch KT, Alings MW, et al.\nFamilial sudden death is an important risk factor for primary ventricular ﬁbrillation:\na case-control study in acute myocardial infarction patients. Circulation 2006;114:\n1140–1145.\n68. Kaikkonen KS, Kortelainen M-L, Linna E, Huikuri HV. Family history and the risk of\nsudden cardiac death as a manifestation of an acute coronary event. Circulation\n2006;114:1462–1467.\n69. Jabbari R, Engstrøm T, Glinge C, Risgaard B, Jabbari J, Winkel BG, et al. Incidence\nand risk factors of ventricular ﬁbrillation before primary angioplasty in patients\nwith ﬁrst ST-elevation myocardial infarction: a nationwide study in Denmark. J\nAm Heart Assoc 2015;4:e001399.\n70. Friedlander Y, Siscovick DS, Weinmann S, Austin MA, Psaty BM, Lemaitre RN, et al.\nFamily history as a risk factor for primary cardiac arrest. Circulation 1998;97:\n155–160.\n71. Deo R, Norby FL, Katz R, Sotoodehnia N, Adabag S, DeFilippi CR, et al.\nDevelopment and validation of a sudden cardiac death prediction model for the\ngeneral population. Circulation 2016;134:806–816.\n72. Aro AL, Reinier K, Rusinaru C, Uy-Evanado A, Darouian N, Phan D, et al. Electrical\nrisk score beyond the left ventricular ejection fraction: prediction of sudden cardiac\ndeath in the Oregon Sudden Unexpected Death Study and the Atherosclerosis\nRisk in Communities Study. Eur Heart J 2017;38:3017–3025.\n73. Waks JW, Sitlani CM, Soliman EZ, Kabir M, Ghafoori E, Biggs ML, et al. Global elec-\ntric heterogeneity risk score for prediction of sudden cardiac death in the general\npopulation: the Atherosclerosis Risk in Communities (ARIC) and Cardiovascular\nHealth (CHS) studies. Circulation 2016;133:2222–2234.\n4102\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n74. Yoshinaga M, Ushinohama H, Sato S, Tauchi N, Horigome H, Takahashi H, et al.\nElectrocardiographic screening of 1-month-old infants for identifying prolonged\nQT intervals. Circ Arrhythm Electrophysiol 2013;6:932–938.\n75. Yoshinaga M, Kucho Y, Sarantuya J, Ninomiya Y, Horigome H, Ushinohama H, et al.\nGenetic characteristics of children and adolescents with long-QT syndrome diag-\nnosed by school-based electrocardiographic screening programs. Circ Arrhythm\nElectrophysiol 2014;7:107–112.\n76. Jørgensen T, Jacobsen RK, Toft U, Aadahl M, Glümer C, Pisinger C. Effect of screen-\ning and lifestyle counselling on incidence of ischaemic heart disease in general popu-\nlation: Inter99 randomised trial. BMJ 2014;348:g3617.\n77. Boas R, Sappler N, von Stülpnagel L, Klemm M, Dixen U, Thune JJ, et al. Periodic\nrepolarization dynamics identiﬁes ICD-responders in non-ischemic cardiomyop-\nathy: a DANISH substudy. Circulation 2022;145:754–764.\n78. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left\nventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy.\nN Engl J Med 2000;342:1778–1785.\n79. Barsheshet A, Goldenberg I, O-Uchi J, Moss AJ, Jons C, Shimizu W, et al. Mutations\nin cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events:\nimplications for mutation-speciﬁc response to β-blocker therapy in type 1 long-QT\nsyndrome. Circulation 2012;125:1988–1996.\n80. Wahbi K, Ben Yaou R, Gandjbakhch E, Anselme F, Gossios T, Lakdawala NK, et al.\nDevelopment and validation of a new risk prediction score for life-threatening ven-\ntricular tachyarrhythmias in laminopathies. Circulation 2019;140:293–302.\n81. Cadrin-Tourigny J, Bosman LP, Nozza A, Wang W, Tadros R, Bhonsale A, et al. A\nnew prediction model for ventricular arrhythmias in arrhythmogenic right ventricu-\nlar cardiomyopathy. Eur Heart J 2019;40:1850–1858.\n82. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, et al. Risk\nstratiﬁcation in the long-QT syndrome. N Engl J Med 2003;348:1866–1874.\n83. Miron A, Lafreniere-Roula M, Steve Fan C-P, Armstrong KR, Dragulescu A, Papaz\nT, et al. A validated model for sudden cardiac death risk prediction in pediatric\nhypertrophic cardiomyopathy. Circulation 2020;142:217–229.\n84. Norrish G, Ding T, Field E, Ziólkowska L, Olivotto I, Limongelli G, et al.\nDevelopment of a novel risk prediction model for sudden cardiac death in child-\nhood hypertrophic cardiomyopathy (HCM risk-kids). JAMA Cardiol 2019;4:\n918–927.\n85. O’Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, et al. A novel\nclinical risk prediction model for sudden cardiac death in hypertrophic cardiomy-\nopathy (HCM risk-SCD). Eur Heart J 2014;35:2010–2020.\n86. Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven\nsteps for development and an ABCD for validation. Eur Heart J 2014;35:\n1925–1931.\n87. Collins GS, Reitsma JB, Altman DG, Moons KGM, TRIPOD Group. Transparent re-\nporting of a multivariable prediction model for individual prognosis or diagnosis\n(TRIPOD): the TRIPOD statement. Circulation 2015;131:211–219.\n88. Alba AC, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux PJ, et al.\nDiscrimination and calibration of clinical prediction models: users’ guides to the\nmedical literature. JAMA 2017;318:1377–1384.\n89. Yan S, Gan Y, Jiang N, Wang R, Chen Y, Luo Z, et al. The global survival rate among\nadult out-of-hospital cardiac arrest patients who received cardiopulmonary resus-\ncitation: a systematic review and meta-analysis. Crit Care 2020;24:61.\n90. Hallstrom AP, Ornato JP, Weisfeldt M, Travers A, Christenson J, McBurnie MA,\net al. Public-access deﬁbrillation and survival after out-of-hospital cardiac arrest.\nN Engl J Med 2004;351:637–646.\n91. Nakashima T, Noguchi T, Tahara Y, Nishimura K, Yasuda S, Onozuka D, et al.\nPublic-access\ndeﬁbrillation\nand\nneurological\noutcomes\nin\npatients\nwith\nout-of-hospital cardiac arrest in Japan: a population-based cohort study. Lancet\n2019;394:2255–2262.\n92. Pollack RA, Brown SP, Rea T, Aufderheide T, Barbic D, Buick JE, et al. Impact of\nbystander automated external deﬁbrillator use on survival and functional outcomes\nin shockable observed public cardiac arrests. Circulation 2018;137:2104–2113.\n93. Kragholm K, Wissenberg M, Mortensen RN, Hansen SM, Malta Hansen C,\nThorsteinsson K, et al. Bystander efforts and 1-year outcomes in out-of-hospital\ncardiac arrest. N Engl J Med 2017;376:1737–1747.\n94. Kitamura T, Kiyohara K, Sakai T, Matsuyama T, Hatakeyama T, Shimamoto T, et al.\nPublic-access deﬁbrillation and out-of-hospital cardiac arrest in Japan. N Engl J Med\n2016;375:1649–1659.\n95. Hasselqvist-Ax I, Riva G, Herlitz J, Rosenqvist M, Hollenberg J, Nordberg P, et al.\nEarly cardiopulmonary resuscitation in out-of-hospital cardiac arrest. N Engl J\nMed 2015;372:2307–2315.\n96. Marijon E, Bougouin W, Celermajer DS, Perier M-C, Benameur N, Lamhaut L, et al.\nMajor regional disparities in outcomes after sudden cardiac arrest during sports.\nEur Heart J 2013;34:3632–3640.\n97. Karam N, Narayanan K, Bougouin W, Benameur N, Beganton F, Jost D, et al. Major\nregional differences in Automated External Deﬁbrillator placement and Basic Life\nSupport training in France: further needs for coordinated implementation.\nResuscitation 2017;118:49–54.\n98. Mpotos N, De Wever B, Cleymans N, Raemaekers J, Loeys T, Herregods L, et al.\nRepetitive sessions of formative self-testing to refresh CPR skills: a randomised\nnon-inferiority trial. Resuscitation 2014;85:1282–1286.\n99. Gundry JW, Comess KA, DeRook FA, Jorgenson D, Bardy GH. Comparison of na-\nive sixth-grade children with trained professionals in the use of an automated ex-\nternal deﬁbrillator. Circulation 1999;100:1703–1707.\n100. Blewer AL, Putt ME, Becker LB, Riegel BJ, Li J, Leary M, et al. Video-only cardiopul-\nmonary resuscitation education for high-risk families before hospital discharge: a\nmulticenter pragmatic trial. Circ Cardiovasc Qual Outcomes 2016;9:740–748.\n101. Ringh M, Rosenqvist M, Hollenberg J, Jonsson M, Fredman D, Nordberg P, et al.\nMobile-phone dispatch of laypersons for CPR in out-of-hospital cardiac arrest. N\nEngl J Med 2015;372:2316–2325.\n102. Stroop R, Kerner T, Strickmann B, Hensel M. Mobile phone-based alerting of\nCPR-trained volunteers simultaneously with the ambulance can reduce the\nresuscitation-free interval and improve outcome after out-of-hospital cardiac ar-\nrest: a German, population-based cohort study. Resuscitation 2020;147:57–64.\n103. Lee SY, Shin SD, Lee YJ, Song KJ, Hong KJ, Ro YS, et al. Text message alert system\nand resuscitation outcomes after out-of-hospital cardiac arrest: a before-and-after\npopulation-based study. Resuscitation 2019;138:198–207.\n104. Fordyce CB, Hansen CM, Kragholm K, Dupre ME, Jollis JG, Roettig ML, et al.\nAssociation of public health initiatives with outcomes for out-of-hospital cardiac ar-\nrest at home and in public locations. JAMA Cardiol 2017;2:1226–1235.\n105. Andelius L, Malta Hansen C, Lippert FK, Karlsson L, Torp-Pedersen C, Kjær Ersbøll\nA, et al. Smartphone activation of citizen responders to facilitate deﬁbrillation in\nout-of-hospital cardiac arrest. J Am Coll Cardiol 2020;76:43–53.\n106. Ranthe MF, Winkel BG, Andersen EW, Risgaard B, Wohlfahrt J, Bundgaard H, et al.\nRisk of cardiovascular disease in family members of young sudden cardiac death vic-\ntims. Eur Heart J 2013;34:503–511.\n107. Patton KK, Sotoodehnia N, DeFilippi C, Siscovick DS, Gottdiener JS, Kronmal RA.\nN-terminal pro-B-type natriuretic peptide is associated with sudden cardiac death\nrisk: the Cardiovascular Health Study. Heart Rhythm 2011;8:228–233.\n108. Everett BM, Moorthy MV, Tikkanen JT, Cook NR, Albert CM. Markers of myocar-\ndial stress, myocardial injury, and subclinical inﬂammation and the risk of sudden\ndeath. Circulation 2020;142:1148–1158.\n109. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, et al. B-type natri-\nuretic peptide predicts sudden death in patients with chronic heart failure.\nCirculation 2002;105:2392–2397.\n110. Scott PA, Barry J, Roberts PR, Morgan JM. Brain natriuretic peptide for the predic-\ntion of sudden cardiac death and ventricular arrhythmias: a meta-analysis. Eur J\nHeart Fail 2009;11:958–966.\n111. Ahmad T, Fiuzat M, Neely B, Neely ML, Pencina MJ, Kraus WE, et al. Biomarkers of\nmyocardial stress and ﬁbrosis as predictors of mode of death in patients with\nchronic heart failure. JACC Heart Fail 2014;2:260–268.\n112. Goldberger JJ, Cain ME, Hohnloser SH, Kadish AH, Knight BP, Lauer MS, et al.\nAmerican Heart Association/American College of Cardiology Foundation/Heart\nRhythm Society scientiﬁc statement on noninvasive risk stratiﬁcation techniques\nfor identifying patients at risk for sudden cardiac death: a scientiﬁc statement\nfrom\nthe\nAmerican\nHeart\nAssociation\nCouncil\non\nClinical\nCardiology\nCommittee\non\nElectrocardiography\nand\nArrhythmias\nand\nCouncil\non\nEpidemiology and Prevention. Circulation 2008;118:1497–1518.\n113. Varma N, Cygankiewicz I, Turakhia MP, Heidbuchel H, Hu Y-F, Chen LY, et al. 2021\nISHNE/HRS/EHRA/APHRS expert collaborative statement on mHealth in arrhyth-\nmia management: digital medical tools for heart rhythm professionals: from the\ninternational society for holter and noninvasive electrocardiology/heart rhythm so-\nciety/European heart rhythm association/Asia-Paciﬁc heart rhythm society. Circ\nArrhythm Electrophysiol 2021;14:e009204.\n114. Solbiati M, Casazza G, Dipaola F, Barbic F, Caldato M, Montano N, et al. The diag-\nnostic yield of implantable loop recorders in unexplained syncope: a systematic re-\nview and meta-analysis. Int J Cardiol 2017;231:170–176.\n115. Gatzoulis KA, Arsenos P, Trachanas K, Dilaveris P, Antoniou C, Tsiachris D, et al.\nSignal-averaged electrocardiography: past, present, and future. J Arrhythmia 2018;\n34:222–229.\n116. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis\nof arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modiﬁca-\ntion of the task force criteria. Eur Heart J 2010;31:806–814.\n117. Giudicessi JR, Ackerman MJ. Exercise testing oversights underlie missed and delayed\ndiagnosis of catecholaminergic polymorphic ventricular tachycardia in young sud-\nden cardiac arrest survivors. Heart Rhythm 2019;16:1232–1239.\n118. Roston TM, Kallas D, Davies B, Franciosi S, De Souza AM, Laksman ZW, et al. Burst\nexercise testing can unmask arrhythmias in patients with incompletely penetrant\ncatecholaminergic polymorphic ventricular tachycardia. JACC Clin Electrophysiol\n2021;7:437–441.\nESC Guidelines\n4103\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n119. Sy RW, van der Werf C, Chattha IS, Chockalingam P, Adler A, Healey JS, et al.\nDerivation and validation of a simple exercise-based algorithm for prediction of\ngenetic testing in relatives of LQTS probands. Circulation 2011;124:2187–2194.\n120. Binder T. Transthoracic echocardiography and the standard examination of\nspeciﬁc cardiac structures. ESC CardioMed. 3rd ed. Oxford University Press;\n2022. p425–431.\n121. Haugaa KH, Basso C, Badano LP, Bucciarelli-Ducci C, Cardim N, Gaemperli O, et al.\nComprehensive multi-modality imaging approach in arrhythmogenic cardiomyop-\nathy—an\nexpert\nconsensus\ndocument\nof\nthe\nEuropean\nAssociation\nof\nCardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2017;18:237–253.\n122. Haugaa KH, Grenne BL, Eek CH, Ersboll M, Valeur N, Svendsen JH, et al. Strain\nechocardiography improves risk prediction of ventricular arrhythmias after myo-\ncardial infarction. JACC Cardiovasc Imaging 2013;6:841–850.\n123. Haugaa KH, Hasselberg NE, Edvardsen T. Mechanical dispersion by strain echocar-\ndiography: a predictor of ventricular arrhythmias in subjects with lamin A/C muta-\ntions. JACC Cardiovasc Imaging 2015;8:104–106.\n124. Ersboll M, Valeur N, Andersen MJ, Mogensen UM, Vinther M, Svendsen JH, et al.\nEarly echocardiographic deformation analysis for the prediction of sudden cardiac\ndeath and life-threatening arrhythmias after myocardial infarction. JACC Cardiovasc\nImaging 2013;6:851–860.\n125. Biering-Sørensen T, Knappe D, Pouleur A-C, Claggett B, Wang PJ, Moss AJ, et al.\nRegional longitudinal deformation improves prediction of ventricular tachyarrhyth-\nmias in patients with heart failure with reduced ejection fraction: a MADIT-CRT\nsubstudy\n(Multicenter\nAutomatic\nDeﬁbrillator\nImplantation\nTrial-Cardiac\nResynchronization Therapy). Circ Cardiovasc Imaging 2017;10:e005096.\n126. Garg R, Friedrich MG. Cardiomyopathies. ESC CardioMed. 3rd ed. Oxford\nUniversity Press; 2022, p510–515.\n127. Borgquist R, Haugaa KH, Gilljam T, Bundgaard H, Hansen J, Eschen O, et al. The\ndiagnostic performance of imaging methods in ARVC using the 2010 task force cri-\nteria. Eur Heart J Cardiovasc Imaging 2014;15:1219–1225.\n128. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014\nESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy:\nthe\ntask\nforce\nfor\nthe\nDiagnosis\nand\nManagement\nof\nHypertrophic\nCardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;\n35:2733–2779.\n129. Di Marco A, Anguera I, Schmitt M, Klem I, Neilan TG, White JA, et al. Late gado-\nlinium enhancement and the risk for ventricular arrhythmias or sudden death in di-\nlated cardiomyopathy: systematic review and meta-analysis. JACC Heart Fail 2017;5:\n28–38.\n130. Dejgaard LA, Skjølsvik ET, Lie ØH, Ribe M, Stokke MK, Hegbom F, et al. The mitral\nannulus disjunction arrhythmic syndrome. J Am Coll Cardiol 2018;72:1600–1609.\n131. Basso C, Iliceto S, Thiene G, Perazzolo Marra M. Mitral valve prolapse, ventricular\narrhythmias, and sudden death. Circulation 2019;140:952–964.\n132. Achenbach S. Technology of cardiac computed tomography. ESC CardioMed. 3rd\ned. Oxford University Press; 2022, p537–541.\n133. Meijboom WB, van Mieghem CAG, Mollet NR, Pugliese F, Weustink AC, van Pelt\nN, et al. 64-Slice computed tomography coronary angiography in patients with high,\nintermediate, or low pretest probability of signiﬁcant coronary artery disease. J Am\nColl Cardiol 2007;50:1469–1475.\n134. Douglas PS, Hoffmann U, Patel MR, Mark DB, Al-Khalidi HR, Cavanaugh B, et al.\nOutcomes of anatomical versus functional testing for coronary artery disease. N\nEngl J Med 2015;372:1291–1300.\n135. Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, et al. Executive summary:\nHRS/EHRA/APHRS expert consensus statement on the diagnosis and management\nof patients with inherited primary arrhythmia syndromes. Europace 2013;15:\n1389–1406.\n136. Govindan M, Batchvarov VN, Raju H, Shanmugam N, Bizrah M, Bastiaenen R, et al.\nUtility of high and standard right precordial leads during ajmaline testing for the\ndiagnosis of Brugada syndrome. Heart 2010;96:1904–1908.\n137. Churet M, Luttoo K, Hocini M, Haïssaguerre M, Sacher F, Duchateau J. Diagnostic\nreproducibility of epinephrine drug challenge interpretation in suspected long QT\nsyndrome. J Cardiovasc Electrophysiol 2019;30:896–901.\n138. Rolf S. The ajmaline challenge in Brugada syndrome: diagnostic impact, safety, and\nrecommended protocol. Eur Heart J 2003;24:1104–1112.\n139. Tadros R, Nannenberg EA, Lieve KV, Škorić-Milosavljević D, Lahrouchi N, Lekanne\nDeprez RH, et al. Yield and pitfalls of ajmaline testing in the evaluation of unex-\nplained cardiac arrest and sudden unexplained death: single-center experience\nwith 482 families. JACC Clin Electrophysiol 2017;3:1400–1408.\n140. Meregalli PG, Ruijter JM, Hofman N, Bezzina CR, Wilde AAM, Tan HL. Diagnostic\nvalue of ﬂecainide testing in unmasking SCN5A-related Brugada syndrome.\nJ Cardiovasc Electrophysiol 2006;17:857–864.\n141. Krahn AD, Healey JS, Chauhan VS, Birnie DH, Champagne J, Sanatani S, et al.\nEpinephrine infusion in the evaluation of unexplained cardiac arrest and familial sud-\nden death: from the cardiac arrest survivors with preserved Ejection Fraction\nRegistry. Circ Arrhythm Electrophysiol 2012;5:933–940.\n142. Sueda S, Kohno H, Ochi T, Uraoka T. Overview of the acetylcholine spasm provo-\ncation test. Clin Cardiol 2015;38:430–438.\n143. Takagi Y, Yasuda S, Takahashi J, Tsunoda R, Ogata Y, Seki A, et al. Clinical implica-\ntions of provocation tests for coronary artery spasm: safety, arrhythmic complica-\ntions, and prognostic impact: multicentre registry study of the Japanese Coronary\nSpasm Association. Eur Heart J 2013;34:258–267.\n144. Garratt CJ, Antoniou A, Grifﬁth MJ, Ward DE, Camm AJ. Use of intravenous ad-\nenosine in sinus rhythm as a diagnostic test for latent preexcitation. Am J Cardiol\n1990;65:868–873.\n145. Bourke JP, Richards DA, Ross DL, Wallace EM, McGuire MA, Uther JB. Routine\nprogrammed electrical stimulation in survivors of acute myocardial infarction for\nprediction of spontaneous ventricular tachyarrhythmias during follow-up: results,\noptimal stimulation protocol and cost-effective screening. J Am Coll Cardiol 1991;\n18:780–788.\n146. Gatzoulis KA, Tsiachris D, Arsenos P, Archontakis S, Dilaveris P, Vouliotis A, et al.\nPrognostic value of programmed ventricular stimulation for sudden death in se-\nlected high risk patients with structural heart disease and preserved systolic func-\ntion. Int J Cardiol 2014;176:1449–1451.\n147. Gatzoulis KA, Vouliotis A-I, Tsiachris D, Salourou M, Archontakis S, Dilaveris P,\net al. Primary prevention of sudden cardiac death in a nonischemic dilated cardio-\nmyopathy population: reappraisal of the role of programmed ventricular stimula-\ntion. Circ Arrhythm Electrophysiol 2013;6:504–512.\n148. Brilakis ES, Shen WK, Hammill SC, Hodge DO, Rea RF, Lexvold NY, et al. Role of\nprogrammed ventricular stimulation and implantable cardioverter deﬁbrillators in\npatients with idiopathic dilated cardiomyopathy and syncope. Pacing Clin\nElectrophysiol 2001;24:1623–1630.\n149. Brembilla-Perrot B, Suty-Selton C, Beurrier D, Houriez P, Nippert M, de la Chaise\nAT, et al. Differences in mechanisms and outcomes of syncope in patients with cor-\nonary disease or idiopathic left ventricular dysfunction as assessed by electrophy-\nsiologic testing. J Am Coll Cardiol 2004;44:594–601.\n150. Schmitt C, Barthel P, Ndrepepa G, Schreieck J, Plewan A, Schömig A, et al. Value of\nprogrammed ventricular stimulation for prophylactic internal cardioverter-\ndeﬁbrillator implantation in postinfarction patients preselected by noninvasive\nrisk stratiﬁers. J Am Coll Cardiol 2001;37:1901–1907.\n151. Gatzoulis KA, Tsiachris D, Arsenos P, Antoniou C-K, Dilaveris P, Sideris S, et al.\nArrhythmic risk stratiﬁcation in post-myocardial infarction patients with preserved\nejection fraction: the PRESERVE EF study. Eur Heart J 2019;40:2940–2949.\n152. Denis A, Sacher F, Derval N, Lim HS, Cochet H, Shah AJ, et al. Diagnostic value of\nisoproterenol testing in arrhythmogenic right ventricular cardiomyopathy. Circ\nArrhythm Electrophysiol 2014;7:590–597.\n153. Merino JL, Carmona JR, Fernández-Lozano I, Peinado R, Basterra N, Sobrino JA.\nMechanisms of sustained ventricular tachycardia in myotonic dystrophy: implica-\ntions for catheter ablation. Circulation 1998;98:541–546.\n154. Pezawas T, Stix G, Kastner J, Wolzt M, Mayer C, Moertl D, et al. Unexplained syn-\ncope in patients with structural heart disease and no documented ventricular ar-\nrhythmias:\nvalue\nof\nelectrophysiologically\nguided\nimplantable\ncardioverter\ndeﬁbrillator therapy. Europace 2003;5:305–312.\n155. Sroubek J, Probst V, Mazzanti A, Delise P, Hevia JC, Ohkubo K, et al. Programmed\nventricular stimulation for risk stratiﬁcation in the Brugada syndrome: a pooled ana-\nlysis. Circulation 2016;133:622–630.\n156. Nayyar S, Downar E, Bhaskaran AP, Massé S, Nanthakumar K. Signature signal\nstrategy: electrogram-based ventricular tachycardia mapping. Heart Rhythm 2020;\n17:2000–2009.\n157. Lazarus A, Varin J, Babuty D, Anselme F, Coste J, Duboc D. Long-term follow-up of\narrhythmias in patients with myotonic dystrophy treated by pacing: a multicenter\ndiagnostic pacemaker study. J Am Coll Cardiol 2002;40:1645–1652.\n158. Tandri H, Asimaki A, Abraham T, Dalal D, Tops L, Jain R, et al. Prolonged RV endo-\ncardial activation duration: a novel marker of arrhythmogenic right ventricular dys-\nplasia/cardiomyopathy. Heart Rhythm 2009;6:769–775.\n159. Gomes J, Finlay M, Ahmed AK, Ciaccio EJ, Asimaki A, Safﬁtz JE, et al.\nElectrophysiological abnormalities precede overt structural changes in arrhythmo-\ngenic right ventricular cardiomyopathy due to mutations in desmoplakin-A com-\nbined murine and human study. Eur Heart J 2012;33:1942–1953.\n160. Orini M, Graham AJ, Srinivasan NT, Campos FO, Hanson BM, Chow A, et al.\nEvaluation of the reentry vulnerability index to predict ventricular tachycardia cir-\ncuits using high-density contact mapping. Heart Rhythm 2020;17:576–583.\n161. Jackson N, Gizurarson S, Viswanathan K, King B, Massé S, Kusha M, et al.\nDecrement evoked potential mapping: basis of a mechanistic strategy for ventricu-\nlar tachycardia ablation. Circ Arrhythm Electrophysiol 2015;8:1433–1442.\n162. Avella A, d’Amati G, Pappalardo A, Re F, Silenzi PF, Laurenzi F, et al. Diagnostic va-\nlue of endomyocardial biopsy guided by electroanatomic voltage mapping in ar-\nrhythmogenic\nright\nventricular\ncardiomyopathy/dysplasia.\nJ\nCardiovasc\nElectrophysiol 2008;19:1127–1134.\n163. Wilde AAM, Behr ER. Genetic testing for inherited cardiac disease. Nat Rev Cardiol\n2013;10:571–583.\n4104\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n164. Hosseini SM, Kim R, Udupa S, Costain G, Jobling R, Liston E, et al. Reappraisal of\nreported genes for sudden arrhythmic death: evidence-based evaluation of gene\nvalidity for Brugada syndrome. Circulation 2018;138:1195–1205.\n165. Ingles J, Goldstein J, Thaxton C, Caleshu C, Corty EW, Crowley SB, et al. Evaluating\nthe clinical validity of hypertrophic cardiomyopathy genes. Circ Genom Precis Med\n2019;12:e002460.\n166. Adler A, Novelli V, Amin AS, Abiusi E, Care M, Nannenberg EA, et al. An inter-\nnational, multicentered, evidence-based reappraisal of genes reported to cause\ncongenital long QT syndrome. Circulation 2020;141:418–428.\n167. Risgaard B, Jabbari R, Refsgaard L, Holst AG, Haunsø S, Sadjadieh A, et al. High\nprevalence of genetic variants previously associated with Brugada syndrome in\nnew exome data. Clin Genet 2013;84:489–495.\n168. James CA, Jongbloed JDH, Hershberger RE, Morales A, Judge DP, Syrris P, et al. An\ninternational evidence based reappraisal of genes associated with arrhythmogenic\nright ventricular cardiomyopathy (ARVC) using the ClinGen framework. Circ\nGenom Precis Med 2021;14:e003273.\n169. Lahrouchi N, Tadros R, Crotti L, Mizusawa Y, Postema PG, Beekman L, et al.\nTransethnic genome-wide association study provides insights in the genetic archi-\ntecture and heritability of long QT syndrome. Circulation 2020;142:324–338.\n170. Wijeyeratne YD, Tanck MW, Mizusawa Y, Batchvarov V, Barc J, Crotti L, et al.\nSCN5A mutation type and a genetic risk score associate variably with Brugada syn-\ndrome phenotype in SCN5A families. Circ Genom Precis Med 2020;13:e002911.\n171. Harper AR, Goel A, Grace C, Thomson KL, Petersen SE, Xu X, et al. Common gen-\netic variants and modiﬁable risk factors underpin hypertrophic cardiomyopathy\nsusceptibility and expressivity. Nat Genet 2021;53:135–142.\n172. Tadros R, Francis C, Xu X, Vermeer AMC, Harper AR, Huurman R, et al. Shared\ngenetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies\nwith opposite directions of effect. Nat Genet 2021;53:128–134.\n173. Tadros R, Tan HL, ESCAPE-NET Investigators, El Mathari S, Kors JA, Postema PG,\net al. Predicting cardiac electrical response to sodium-channel blockade and\nBrugada syndrome using polygenic risk scores. Eur Heart J 2019;40:3097–3107.\n174. Ware JS, Roberts AM, Cook SA. Next generation sequencing for clinical diagnostics\nand personalised medicine: implications for the next generation cardiologist. Heart\n2012;98:276–281.\n175. Ashar FN, Mitchell RN, Albert CM, Newton-Cheh C, Brody JA, Müller-Nurasyid M,\net al. A comprehensive evaluation of the genetic architecture of sudden cardiac ar-\nrest. Eur Heart J 2018;39:3961–3969.\n176. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guide-\nlines for the interpretation of sequence variants: a joint consensus recommenda-\ntion of the American College of Medical Genetics and Genomics and the\nAssociation for Molecular Pathology. Genet Med 2015;17:405–424.\n177. Ingles J, Lind JM, Phongsavan P, Semsarian C. Psychosocial impact of specialized car-\ndiac genetic clinics for hypertrophic cardiomyopathy. Genet Med 2008;10:117–120.\n178. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, et al. HRS/EHRA\nexpert consensus statement on the state of genetic testing for the channelopathies\nand cardiomyopathies: this document was developed as a partnership between the\nHeart Rhythm Society (HRS) and the European Heart Rhythm Association\n(EHRA). Europace 2011;13:1077–1109.\n179. Conte G, Wilde A, Behr ER, Scherr D, Lenarczyk R, Gandjbachkh E, et al.\nImportance of dedicated units for the management of patients with inherited ar-\nrhythmia syndromes. Circ Genom Precis Med 2021;14:e003313.\n180. Minier M, Probst V, Berthome P, Tixier R, Briand J, Geoffroy O, et al. Age at diag-\nnosis of Brugada syndrome: inﬂuence on clinical characteristics and risk of arrhyth-\nmia. Heart Rhythm 2020;17:743–749.\n181. Wong LCH, Roses-Noguer F, Till JA, Behr ER. Cardiac evaluation of pediatric re-\nlatives in sudden arrhythmic death syndrome: a 2-center experience. Circ\nArrhythm Electrophysiol 2014;7:800–806.\n182. Mellor GJ, Blom LJ, Groeneveld SA, Winkel BG, Ensam B, Bargehr J, et al. Familial\nevaluation in idiopathic ventricular ﬁbrillation: diagnostic yield and signiﬁcance of J\nWave Syndromes. Circ Arrhythm Electrophysiol 2021;14:e009089.\n183. Lahrouchi N, Raju H, Lodder EM, Papatheodorou E, Ware JS, Papadakis M, et al.\nUtility of post-mortem genetic testing in cases of sudden arrhythmic death syn-\ndrome. J Am Coll Cardiol 2017;69:2134–2145.\n184. Faber TS, Gradinger R, Treusch S, Morkel C, Brachmann J, Bode C, et al. Incidence\nof ventricular tachyarrhythmias during permanent pacemaker therapy in low-risk\npatients results from the German multicentre EVENTS study. Eur Heart J 2007;\n28:2238–2242.\n185. Middlekauff HR, Stevenson WG, Stevenson LW, Saxon LA. Syncope in advanced\nheart failure: high risk of sudden death regardless of origin of syncope. J Am Coll\nCardiol 1993;21:110–116.\n186. Noda T, Shimizu W, Taguchi A, Aiba T, Satomi K, Suyama K, et al. Malignant entity\nof idiopathic ventricular ﬁbrillation and polymorphic ventricular tachycardia in-\nitiated by premature extrasystoles originating from the right ventricular outﬂow\ntract. J Am Coll Cardiol 2005;46:1288–1294.\n187. Belhassen B, Viskin S. Idiopathic ventricular tachycardia and ﬁbrillation. J Cardiovasc\nElectrophysiol 1993;4:356–368.\n188. Zareba W, Platonov P. ECG patterns related to arrhythmias and sudden death:\nchannelopathies, early repolarization, and pre-excitation. ESC CardioMed. 3rd\ned. Oxford University Press; 2022, p382–389.\n189. Voigt J-U. Left ventricular function, heart failure, and resynchronization therapy.\nESC CardioMed. 3rd ed. Oxford University Press; 2022, p450–454.\n190. Edvardsen T. Cardiomyopathies, myocarditis, and the transplanted heart. ESC\nCardioMed. 3rd ed. Oxford University Press; 2022, p456–460.\n191. Cygankiewicz I. Ambulatory ECG monitoring. ESC CardioMed. 3rd ed. Oxford\nUniversity Press; 2022, p393–400.\n192. Gray B, Kirby A, Kabunga P, Freedman SB, Yeates L, Kanthan A, et al. Twelve-lead\nambulatory electrocardiographic monitoring in Brugada syndrome: potential diag-\nnostic and prognostic implications. Heart Rhythm 2017;14:866–874.\n193. Karogiannis N, Senior R. Stress echocardiography. ESC CardioMed. 3rd ed. Oxford\nUniversity Press; 2022, p431–434.\n194. Nucifora G, Muser D, Masci PG, Barison A, Rebellato L, Piccoli G, et al. Prevalence\nand prognostic value of concealed structural abnormalities in patients with appar-\nently idiopathic ventricular arrhythmias of left versus right ventricular origin: a mag-\nnetic resonance imaging study. Circ Arrhythm Electrophysiol 2014;7:456–462.\n195. Muser D, Nucifora G, Muser D, Nucifora G, Pieroni M, Castro SA, et al. Prognostic\nvalue of nonischemic ringlike left ventricular scar in patients with apparently idio-\npathic nonsustained ventricular arrhythmias. Circulation 2021;143:1359–1373.\n196. Josephson ME, Callans DJ. Using the twelve-lead electrocardiogram to localize the\nsite of origin of ventricular tachycardia. Heart Rhythm 2005;2:443–446.\n197. Corrado D, Basso C, Leoni L, Tokajuk B, Bauce B, Frigo G, et al. Three-dimensional\nelectroanatomic voltage mapping increases accuracy of diagnosing arrhythmogenic\nright ventricular cardiomyopathy/dysplasia. Circulation 2005;111:3042–3050.\n198. Casella M, Dello Russo A, Bergonti M, Catto V, Conte E, Sommariva E, et al.\nDiagnostic yield of electroanatomic voltage mapping in guiding endomyocardial bi-\nopsies. Circulation 2020;142:1249–1260.\n199. Haanschoten DM, Adiyaman A, ‘t Hart NA, Jager PL, Elvan A. Value of 3D mapping-\nguided endomyocardial biopsy in cardiac sarcoidosis: case series and narrative re-\nview on the value of electro-anatomic mapping-guided endomyocardial biopsies.\nEur J Clin Invest 2021;51:e13497.\n200. Tung R, Bauer B, Schelbert H, Lynch JP, Auerbach M, Gupta P, et al. Incidence of\nabnormal positron emission tomography in patients with unexplained cardiomyop-\nathy and ventricular arrhythmias: the potential role of occult inﬂammation in ar-\nrhythmogenesis. Heart Rhythm 2015;12:2488–2498.\n201. Palmisano A, Vignale D, Peretto G, Busnardo E, Calcagno C, Campochiaro C, et al.\nHybrid FDG-PET/MR or FDG-PET/CT to detect disease activity in patients with\npersisting arrhythmias after myocarditis. JACC Cardiovasc Imaging 2021;14:\n288–292.\n202. Venlet J, Piers SRD, Jongbloed JDH, Androulakis AFA, Naruse Y, den Uijl DW, et al.\nIsolated subepicardial right ventricular outﬂow tract scar in athletes with ventricu-\nlar tachycardia. J Am Coll Cardiol 2017;69:497–507.\n203. Geri G, Dumas F, Bougouin W, Varenne O, Daviaud F, Pène F, et al. Immediate per-\ncutaneous coronary intervention is associated with improved short- and long-term\nsurvival after out-of-hospital cardiac arrest. Circ Cardiovasc Interv 2015;8:e002303.\n204. Vyas A, Chan PS, Cram P, Nallamothu BK, McNally B, Girotra S. Early coronary\nangiography and survival after out-of-hospital cardiac arrest. Circ Cardiovasc Interv\n2015;8:e002321.\n205. Kalarus Z, Svendsen JH, Capodanno D, Dan G-A, De Maria E, Gorenek B, et al.\nCardiac arrhythmias in the emergency settings of acute coronary syndrome and re-\nvascularization: an European Heart Rhythm Association (EHRA) consensus docu-\nment, endorsed by the European Association of Percutaneous Cardiovascular\nInterventions (EAPCI), and European Acute Cardiovascular Care Association\n(ACCA). Europace 2019;21:1603–1604.\n206. Noc M, Fajadet J, Lassen JF, Kala P, MacCarthy P, Olivecrona GK, et al. Invasive cor-\nonary treatment strategies for out-of-hospital cardiac arrest: a consensus state-\nment\nfrom\nthe\nEuropean\nassociation\nfor\npercutaneous\ncardiovascular\ninterventions (EAPCI)/stent for life (SFL) groups. EuroIntervention 2014;10:31–37.\n207. Verma BR, Sharma V, Shekhar S, Kaur M, Khubber S, Bansal A, et al. Coronary angi-\nography in patients with out-of-hospital cardiac arrest without ST-segment eleva-\ntion: a systematic review and meta-analysis. JACC Cardiovasc Interv 2020;13:\n2193–2205.\n208. Barbarawi M, Zayed Y, Kheiri B, Barbarawi O, Al-Abdouh A, Dhillon H, et al.\nOptimal timing of coronary intervention in patients resuscitated from cardiac ar-\nrest without ST-segment elevation myocardial infarction (NSTEMI): a systematic\nreview and meta-analysis. Resuscitation 2019;144:137–144.\n209. Meng-Chang Y, Meng-Jun W, Xiao-Yan X, Peng KL, Peng YG, RuRong W.\nCoronary angiography or not after cardiac arrest without ST segment elevation:\na systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e22197.\n210. Khan MS, Shah SMM, Mubashir A, Khan AR, Fatima K, Schenone AL, et al. Early cor-\nonary angiography in patients resuscitated from out of hospital cardiac arrest\nESC Guidelines\n4105\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nwithout ST-segment elevation: a systematic review and meta-analysis. Resuscitation\n2017;121:127–134.\n211. Welsford M, Bossard M, Shortt C, Pritchard J, Natarajan MK, Belley-Côté EP. Does\nearly coronary angiography improve survival after out-of-hospital cardiac arrest? A\nsystematic review with meta-analysis. Can J Cardiol 2018;34:180–194.\n212. Chelly J, Mongardon N, Dumas F, Varenne O, Spaulding C, Vignaux O, et al. Beneﬁt\nof an early and systematic imaging procedure after cardiac arrest: insights from the\nPROCAT (Parisian Region Out of Hospital Cardiac Arrest) registry. Resuscitation\n2012;83:1444–1450.\n213. Stiles MK, Wilde AAM, Abrams DJ, Ackerman MJ, Albert CM, Behr ER, et al. 2020\nAPHRS/HRS expert consensus statement on the investigation of decedents with\nsudden unexplained death and patients with sudden cardiac arrest, and of their\nfamilies. Heart Rhythm 2021;18:e1–e50.\n214. Tseng ZH, Olgin JE, Vittinghoff E, Ursell PC, Kim AS, Sporer K, et al. Prospective\ncountywide surveillance and autopsy characterization of sudden cardiac death:\nPOST SCD study. Circulation 2018;137:2689–2700.\n215. Fellmann F, van El CG, Charron P, Michaud K, Howard HC, Boers SN, et al.\nEuropean recommendations integrating genetic testing into multidisciplinary man-\nagement of sudden cardiac death. Eur J Hum Genet 2019;27:1763–1773.\n216. Yamamoto T, Takayama M, Sato N, Yodogawa K, Iwasaki Y-K, Kato K, et al.\nInappropriate analyses of automated external deﬁbrillators used during in-hospital\nventricular ﬁbrillation. Circ J 2008;72:679–681.\n217. Sweeney MO, Ruetz LL, Belk P, Mullen TJ, Johnson JW, Sheldon T. Bradycardia\npacing-induced short-long-short sequences at the onset of ventricular tachyar-\nrhythmias: a possible mechanism of proarrhythmia? J Am Coll Cardiol 2007;50:\n614–622.\n218. Tseng ZH, Hayward RM, Clark NM, Mulvanny CG, Colburn BJ, Ursell PC, et al.\nSudden death in patients with cardiac implantable electronic devices. JAMA Intern\nMed 2015;175:1342–1350.\n219. Lacour P, Buschmann C, Storm C, Nee J, Parwani AS, Huemer M, et al. Cardiac im-\nplantable electronic device interrogation at forensic autopsy: an underestimated re-\nsource? Circulation 2018;137:2730–2740.\n220. Curcio A, Mazzanti A, Bloise R, Monteforte N, IndolﬁC, Priori SG, et al. Clinical\npresentation and outcome of Brugada syndrome diagnosed with the new 2013 cri-\nteria. J Cardiovasc Electrophysiol 2016;27:937–943.\n221. Haïssaguerre M, Shah DC, Jaïs P, Shoda M, Kautzner J, Arentz T, et al. Role of\nPurkinje conducting system in triggering of idiopathic ventricular ﬁbrillation.\nLancet 2002;359:677–678.\n222. Krahn AD, Healey JS, Chauhan V, Birnie DH, Simpson CS, Champagne J, et al.\nSystematic assessment of patients with unexplained cardiac arrest: cardiac arrest\nsurvivors with preserved ejection fraction registry (CASPER). Circulation 2009;\n120:278–285.\n223. van der Werf C, Hofman N, Tan HL, van Dessel PF, Alders M, van der Wal AC, et al.\nDiagnostic yield in sudden unexplained death and aborted cardiac arrest in the\nyoung: the experience of a tertiary referral center in The Netherlands. Heart\nRhythm 2010;7:1383–1389.\n224. Eckart RE, Scoville SL, Campbell CL, Shry EA, Stajduhar KC, Potter RN, et al.\nSudden death in young adults: a 25-year review of autopsies in military recruits.\nAnn Intern Med 2004;141:829–834.\n225. Kunadian V, Chieffo A, Camici PG, Berry C, Escaned J, Maas AHEM, et al. An EAPCI\nexpert consensus document on ischaemia with non-obstructive coronary arteries\nin collaboration with European Society of Cardiology Working Group on\nCoronary\nPathophysiology\n&\nMicrocirculation\nEndorsed\nby\nCoronary\nVasomotor Disorders International Study Group. Eur Heart J 2020;41:3504–3520.\n226. Rodrigues P, Joshi A, Williams H, Westwood M, Petersen SE, Zemrak F, et al.\nDiagnosis and prognosis in sudden cardiac arrest survivors without coronary artery\ndisease: utility of a clinical approach using cardiac magnetic resonance imaging. Circ\nCardiovasc Imaging 2017;10:e006709.\n227. White JA, Fine NM, Gula L, Yee R, Skanes A, Klein G, et al. Utility of cardiovascular\nmagnetic resonance in identifying substrate for malignant ventricular arrhythmias.\nCirc Cardiovasc Imaging 2012;5:12–20.\n228. Basso C, Perazzolo Marra M, Rizzo S, De Lazzari M, Giorgi B, Cipriani A, et al.\nArrhythmic mitral valve prolapse and sudden cardiac death. Circulation 2015;132:\n556–566.\n229. Obeyesekere MN, Klein GJ, Modi S, Leong-Sit P, Gula LJ, Yee R, et al. How to per-\nform and interpret provocative testing for the diagnosis of Brugada syndrome,\nlong-QT syndrome, and catecholaminergic polymorphic ventricular tachycardia.\nCirc Arrhythm Electrophysiol 2011;4:958–964.\n230. Cheung CC, Mellor G, Deyell MW, Ensam B, Batchvarov V, Papadakis M, et al.\nComparison of ajmaline and procainamide provocation tests in the diagnosis of\nBrugada syndrome. JACC Clin Electrophysiol 2019;5:504–512.\n231. Antzelevitch C, Yan G-X, Ackerman MJ, Borggrefe M, Corrado D, Guo J, et al.\nJ-Wave syndromes expert consensus conference report: emerging concepts and\ngaps in knowledge. Europace 2017;19:665–694.\n232. Adler A, van der Werf C, Postema PG, Rosso R, Bhuiyan ZA, Kalman JM, et al. The\nphenomenon of ‘QT stunning’: the abnormal QT prolongation provoked by stand-\ning persists even as the heart rate returns to normal in patients with long QT syn-\ndrome. Heart Rhythm 2012;9:901–908.\n233. Dionne A, Fournier A, Dahdah N, Abrams D, Khairy P, Abadir S. Dynamic QT\ninterval changes from supine to standing in healthy children. Can J Cardiol 2018;\n34:66–72.\n234. Foo FS, Stiles MK, Heaven D. Unmasking latent preexcitation of a right-sided acces-\nsory pathway with intravenous adenosine after unexplained sudden cardiac arrest. J\nArrhythm 2020;36:939–941.\n235. Marjamaa A, Hiippala A, Arrhenius B, Lahtinen AM, Kontula K, Toivonen L, et al.\nIntravenous epinephrine infusion test in diagnosis of catecholaminergic polymorph-\nic ventricular tachycardia. J Cardiovasc Electrophysiol 2012;23:194–199.\n236. Ackerman MJ, Khositseth A, Tester DJ, Hejlik JB, Shen W-K, Porter CJ.\nEpinephrine-induced QT interval prolongation: a gene-speciﬁc paradoxical re-\nsponse in congenital long QT syndrome. Mayo Clin Proc 2002;77:413–421.\n237. Shimizu W, Noda T, Takaki H, Nagaya N, Satomi K, Kurita T, et al. Diagnostic value\nof epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congenital\nlong QT syndrome. Heart Rhythm 2004;1:276–283.\n238. Magnano AR, Talathoti N, Hallur R, Bloomﬁeld DM, Garan H. Sympathomimetic\ninfusion and cardiac repolarization: the normative effects of epinephrine and iso-\nproterenol in healthy subjects. J Cardiovasc Electrophysiol 2006;17:983–989.\n239. Vyas H, Hejlik J, Ackerman MJ. Epinephrine QT stress testing in the evaluation of\ncongenital long-QT syndrome: diagnostic accuracy of the paradoxical QT re-\nsponse. Circulation 2006;113:1385–1392.\n240. Waldmann V, Bougouin W, Karam N, Narayanan K, Sharifzadehgan A, Spaulding C,\net al. Coronary vasospasm-related sudden cardiac arrest in the community. J Am\nColl Cardiol 2018;72:814–815.\n241. Etienne P, Huchet F, Gaborit N, Barc J, Thollet A, Kyndt F, et al. Mental stress test: a\nrapid, simple, and efﬁcient test to unmask long QT syndrome. Europace 2018;20:\n2014–2020.\n242. Kop WJ, Krantz DS, Nearing BD, Gottdiener JS, Quigley JF, O’Callahan M, et al.\nEffects of acute mental stress and exercise on T-wave alternans in patients with im-\nplantable cardioverter deﬁbrillators and controls. Circulation 2004;109:1864–1869.\n243. Schwartz PJ, Lia C. QTc behavior during exercise and genetic testing for the\nlong-QT syndrome. Circulation 2011;124:2181–2184.\n244. Wang YS, Scheinman MM, Chien WW, Cohen TJ, Lesh MD, Grifﬁn JC. Patients\nwith supraventricular tachycardia presenting with aborted sudden death: incidence,\nmechanism and long-term follow-up. J Am Coll Cardiol 1991;18:1711–1719.\n245. Roberts JD, Gollob MH, Young C, Connors SP, Gray C, Wilton SB, et al. Bundle\nbranch re-entrant ventricular tachycardia: novel genetic mechanisms in a life-\nthreatening arrhythmia. JACC Clin Electrophysiol 2017;3:276–288.\n246. Santangeli P, Hamilton-Craig C, Dello Russo A, Pieroni M, Casella M, Pelargonio G,\net al. Imaging of scar in patients with ventricular arrhythmias of right ventricular ori-\ngin: cardiac magnetic resonance versus electroanatomic mapping. J Cardiovasc\nElectrophysiol 2011;22:1359–1366.\n247. Haïssaguerre M, Duchateau J, Dubois R, Hocini M, Cheniti G, Sacher F, et al.\nIdiopathic ventricular ﬁbrillation: role of Purkinje system and microstructural myo-\ncardial abnormalities. JACC Clin Electrophysiol 2020;6:591–608.\n248. Haïssaguerre M, Hocini M, Cheniti G, Duchateau J, Sacher F, Puyo S, et al. Localized\nstructural alterations underlying a subset of unexplained sudden cardiac death. Circ\nArrhythm Electrophysiol 2018;11:e006120.\n249. Mellor G, Laksman ZWM, Tadros R, Roberts JD, Gerull B, Simpson CS, et al.\nGenetic testing in the evaluation of unexplained cardiac arrest: from the\nCASPER (Cardiac Arrest Survivors With Preserved Ejection Fraction Registry).\nCirc Cardiovasc Genet 2017;10:e001686.\n250. Burns C, Bagnall RD, Lam L, Semsarian C, Ingles J. Multiple gene variants in hyper-\ntrophic cardiomyopathy in the era of next-generation sequencing. Circ Cardiovasc\nGenet 2017;10:e001666.\n251. Karam N, Jabre P, Narayanan K, Sharifzadehgan A, Perier M-C, Tennenbaum J, et al.\nPsychological support and medical screening of ﬁrst-degree relatives of sudden car-\ndiac arrest victims. JACC Clin Electrophysiol 2020;6:586–587.\n252. Behr E, Wood DA, Wright M, Syrris P, Sheppard MN, Casey A, et al. Cardiological\nassessment of ﬁrst-degree relatives in sudden arrhythmic death syndrome. Lancet\n2003;362:1457–1459.\n253. Tan HL, Hofman N, van Langen IM, van der Wal AC, Wilde AAM. Sudden unex-\nplained death: heritability and diagnostic yield of cardiological and genetic examin-\nation in surviving relatives. Circulation 2005;112:207–213.\n254. Lemkes JS, Janssens GN, van der Hoeven NW, Jewbali LSD, Dubois EA, Meuwissen\nM, et al. Coronary angiography after cardiac arrest without ST-segment elevation.\nN Engl J Med 2019;380:1397–1407.\n255. Kern KB, Radsel P, Jentzer JC, Seder DB, Lee KS, Lotun K, et al. Randomized pilot\nclinical trial of early coronary angiography versus no early coronary angiography\nafter cardiac arrest without ST-segment elevation: the PEARL study. Circulation\n2020;142:2002–2012.\n4106\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n256. Desch S, Freund A, Akin I, Behnes M, Preusch MR, Zelniker TA, et al. Angiography\nafter out-of-hospital cardiac arrest without ST-segment elevation. N Engl J Med\n2021;385:2544–2553.\n257. Arnaout M, Mongardon N, Deye N, Legriel S, Dumas F, Sauneuf B, et al.\nOut-of-hospital cardiac arrest from brain cause: epidemiology, clinical features,\nand outcome in a multicenter cohort. Crit Care Med 2015;43:453–460.\n258. Horner JM, Horner MM, Ackerman MJ. The diagnostic utility of recovery phase\nQTc during treadmill exercise stress testing in the evaluation of long QT syndrome.\nHeart Rhythm 2011;8:1698–1704.\n259. Perrin MJ, Angaran P, Laksman Z, Zhang H, Porepa LF, Rutberg J, et al. Exercise test-\ning in asymptomatic gene carriers exposes a latent electrical substrate of arrhyth-\nmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2013;62:1772–1779.\n260. Waldmann V, Bougouin W, Karam N, Dumas F, Sharifzadehgan A, Gandjbakhch E,\net al. Characteristics and clinical assessment of unexplained sudden cardiac arrest in\nthe real-world setting: focus on idiopathic ventricular ﬁbrillation. Eur Heart J 2018;\n39:1981–1987.\n261. Nakao K, Ohgushi M, Yoshimura M, Morooka K, Okumura K, Ogawa H, et al.\nHyperventilation as a speciﬁc test for diagnosis of coronary artery spasm. Am J\nCardiol 1997;80:545–549.\n262. Behr ER, Casey A, Sheppard M, Wright M, Bowker TJ, Davies MJ, et al. Sudden ar-\nrhythmic death syndrome: a national survey of sudden unexplained cardiac death.\nHeart 2007;93:601–605.\n263. Basso C, Aguilera B, Banner J, Cohle S, d’Amati G, de Gouveia RH, et al. Guidelines\nfor autopsy investigation of sudden cardiac death: 2017 update from the\nAssociation for European Cardiovascular Pathology. Virchows Arch 2017;471:\n691–705.\n264. de Noronha SV, Behr ER, Papadakis M, Ohta-Ogo K, Banya W, Wells J, et al. The\nimportance of specialist cardiac histopathological examination in the investigation\nof young sudden cardiac deaths. Europace 2014;16:899–907.\n265. Gulino SP, Burns K, Gunther WM, MacLeod H. Improving forensic pathologic in-\nvestigation of sudden death in the young. Acad Forensic Pathol 2018;8:347–391.\n266. Hansen BL, Jacobsen EM, Kjerrumgaard A, Tfelt-Hansen J, Winkel BG, Bundgaard\nH, et al. Diagnostic yield in victims of sudden cardiac death and their relatives.\nEuropace 2020;22:964–971.\n267. Bjune T, Risgaard B, Kruckow L, Glinge C, Ingemann-Hansen O, Leth PM, et al.\nPost-mortem toxicology in young sudden cardiac death victims: a nationwide co-\nhort study. Europace 2018;20:614–621.\n268. Allan KS, Morrison LJ, Pinter A, Tu JV, Dorian P, Rescu Epistry Investigators.\n‘Presumed cardiac’ arrest in children and young adults: a misnomer? Resuscitation\n2017;117:73–79.\n269. Lahrouchi N, Raju H, Lodder EM, Papatheodorou S, Miles C, Ware JS, et al. The\nyield of postmortem genetic testing in sudden death cases with structural ﬁndings\nat autopsy. Eur J Hum Genet 2020;28:17–22.\n270. Tester DJ, Medeiros-Domingo A, Will ML, Haglund CM, Ackerman MJ. Cardiac\nchannel molecular autopsy: insights from 173 consecutive cases of autopsy-\nnegative sudden unexplained death referred for postmortem genetic testing.\nMayo Clin Proc 2012;87:524–539.\n271. Papadakis M, Raju H, Behr ER, De Noronha SV, Spath N, Kouloubinis A, et al.\nSudden cardiac death with autopsy ﬁndings of uncertain signiﬁcance: potential\nfor erroneous interpretation. Circ Arrhythm Electrophysiol 2013;6:588–596.\n272. Jacobsen EM, Hansen BL, Kjerrumgaard A, Tfelt-Hansen J, Hassager C, Kjaergaard J,\net al. Diagnostic yield and long-term outcome of nonischemic sudden cardiac arrest\nsurvivors and their relatives: results from a tertiary referral center. Heart Rhythm\n2020;17:1679–1686.\n273. Kjerrumgaard A, Jacobsen EM, Hansen BL, Tfelt-Hansen J, Winkel BG, Christensen\nAH, et al. Diagnostic ﬁndings and follow-up outcomes in relatives to young non-\nautopsied sudden death victims. Int J Cardiol 2020;318:61–66.\n274. Shanks GW, Tester DJ, Ackerman JP, Simpson MA, Behr ER, White SM, et al.\nImportance of variant interpretation in whole-exome molecular autopsy:\npopulation-based case series. Circulation 2018;137:2705–2715.\n275. Narula N, Tester DJ, Paulmichl A, Maleszewski JJ, Ackerman MJ. Post-mortem\nWhole exome sequencing with gene-speciﬁc analysis for autopsy-negative sudden\nunexplained death in the young: a case series. Pediatr Cardiol 2015;36:768–778.\n276. Miles CJ, Behr ER. The role of genetic testing in unexplained sudden death. Transl\nRes 2016;168:59–73.\n277. Behr ER, Dalageorgou C, Christiansen M, Syrris P, Hughes S, Tome Esteban MT,\net al. Sudden arrhythmic death syndrome: familial evaluation identiﬁes inheritable\nheart disease in the majority of families. Eur Heart J 2008;29:1670–1680.\n278. Kumar S, Peters S, Thompson T, Morgan N, Maccicoca I, Trainer A, et al. Familial\ncardiological and targeted genetic evaluation: low yield in sudden unexplained death\nand high yield in unexplained cardiac arrest syndromes. Heart Rhythm 2013;10:\n1653–1660.\n279. McGorrian C, Constant O, Harper N, O’Donnell C, Codd M, Keelan E, et al.\nFamily-based cardiac screening in relatives of victims of sudden arrhythmic death\nsyndrome. Europace 2013;15:1050–1058.\n280. Mellor G, Raju H, de Noronha SV, Papadakis M, Sharma S, Behr ER, et al. Clinical\ncharacteristics and circumstances of death in the sudden arrhythmic death syn-\ndrome. Circ Arrhythm Electrophysiol 2014;7:1078–1083.\n281. Papadakis M, Papatheodorou E, Mellor G, Raju H, Bastiaenen R, Wijeyeratne Y,\net al. The diagnostic yield of Brugada syndrome after sudden death with normal aut-\nopsy. J Am Coll Cardiol 2018;71:1204–1214.\n282. Mellor G, Nelson CP, Robb C, Raju H, Wijeyeratne Y, Hengstenberg C, et al. The\nprevalence and signiﬁcance of the early repolarization pattern in sudden arrhythmic\ndeath syndrome families. Circ Arrhythm Electrophysiol 2016;9:e003960.\n283. Nunn LM, Lopes LR, Syrris P, Murphy C, Plagnol V, Firman E, et al. Diagnostic yield\nof molecular autopsy in patients with sudden arrhythmic death syndrome using tar-\ngeted exome sequencing. Europace 2016;18:888–896.\n284. van der Werf C, Stiekema L, Tan HL, Hofman N, Alders M, van der Wal AC, et al.\nLow rate of cardiac events in ﬁrst-degree relatives of diagnosis-negative young sud-\nden unexplained death syndrome victims during follow-up. Heart Rhythm 2014;11:\n1728–1732.\n285. Madhavan M, Friedman PA, Lennon RJ, Prasad A, White RD, Sriram CS, et al.\nImplantable cardioverter-deﬁbrillator therapy in patients with ventricular ﬁbrilla-\ntion out of hospital cardiac arrest secondary to acute coronary syndrome. J Am\nHeart Assoc 2015;4:e001255.\n286. Wyse DG, Friedman PL, Brodsky MA, Beckman KJ, Carlson MD, Curtis AB, et al.\nLife-threatening ventricular arrhythmias due to transient or correctable causes:\nhigh risk for death in follow-up. J Am Coll Cardiol 2001;38:1718–1724.\n287. Goyal A, Spertus JA, Gosch K, Venkitachalam L, Jones PG, Van den Berghe G, et al.\nSerum potassium levels and mortality in acute myocardial infarction. JAMA 2012;\n307:157–164.\n288. Hoppe LK, Muhlack DC, Koenig W, Carr PR, Brenner H, Schöttker B. Association\nof abnormal serum potassium levels with arrhythmias and cardiovascular mortality:\na systematic review and meta-analysis of observational studies. Cardiovasc Drugs\nTher 2018;32:197–212.\n289. Ravn Jacobsen M, Jabbari R, Glinge C, Kjær Stampe N, Butt JH, Blanche P, et al.\nPotassium disturbances and risk of ventricular ﬁbrillation among patients with\nST-segment-elevation myocardial infarction. J Am Heart Assoc 2020;9:e014160.\n290. Ahmed W, Flynn MA, Alpert MA. Cardiovascular complications of weight reduc-\ntion diets. Am J Med Sci 2001;321:280–284.\n291. Stephenson V. In pharmacy nursing—a dynamic new ﬁeld. Nurs RSA 1988;3:51–53.\n292. Dumas F, Cariou A, Manzo-Silberman S, Grimaldi D, Vivien B, Rosencher J, et al.\nImmediate percutaneous coronary intervention is associated with better survival\nafter out-of-hospital cardiac arrest: insights from the PROCAT (Parisian Region\nOut of hospital Cardiac ArresT) registry. Circ Cardiovasc Interv 2010;3:200–207.\n293. Gibbs C, Thalamus J, Heldal K, Holla ØL, Haugaa KH, Hysing J. Predictors of mor-\ntality in high-risk patients with QT prolongation in a community hospital. Europace\n2018;20:f99–f107.\n294. Simpson TF, Salazar JW, Vittinghoff E, Probert J, Iwahashi A, Olgin JE, et al.\nAssociation of QT-prolonging medications with risk of autopsy-deﬁned causes of\nsudden death. JAMA Intern Med 2020;180:698–706.\n295. Tzivoni D, Banai S, Schuger C, Benhorin J, Keren A, Gottlieb S, et al. Treatment of\ntorsade de pointes with magnesium sulfate. Circulation 1988;77:392–397.\n296. Ladejobi A, Pasupula DK, Adhikari S, Javed A, Durrani AF, Patil S, et al. Implantable\ndeﬁbrillator therapy in cardiac arrest survivors with a reversible cause. Circ Arrhythm\nElectrophysiol 2018;11:e005940.\n297. Postema PG, Wolpert C, Amin AS, Probst V, Borggrefe M, Roden DM, et al. Drugs\nand Brugada syndrome patients: review of the literature, recommendations, and an\nup-to-date website (www.brugadadrugs.org). Heart Rhythm 2009;6:1335–1341.\n298. Schupp T, Behnes M, von Zworowsky M, Kim S-H, Weidner K, Rusnak J, et al.\nHypokalemia but not hyperkalemia is associated with recurrences of ventricular ta-\nchyarrhythmias in ICD recipients. Clin Lab 2020;66.\n299. Gupta A, Pasupula DK, Bhonsale A, Kancharla K, Wang NC, Adelstein E, et al.\nImplantable cardioverter-deﬁbrillator therapy in device recipients who survived a\ncardiac arrest associated with a reversible cause. J Cardiovasc Electrophysiol 2018;\n29:1413–1417.\n300. Marill KA, Wolfram S, Desouza IS, Nishijima DK, Kay D, Setnik GS, et al. Adenosine\nfor wide-complex tachycardia: efﬁcacy and safety. Crit Care Med 2009;37:\n2512–2518.\n301. Lerman BB, Belardinelli L, West GA, Berne RM, DiMarco JP. Adenosine-sensitive\nventricular tachycardia: evidence suggesting cyclic AMP-mediated triggered activity.\nCirculation 1986;74:270–280.\n302. Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomström-Lundqvist C, et al.\n2019 ESC Guidelines for the management of patients with supraventricular\ntachycardiaThe task force for the management of patients with supraventricular\ntachycardia of the European Society of Cardiology (ESC). Eur Heart J 2020;41:\n655–720.\n303. Ortiz M, Martín A, Arribas F, Coll-Vinent B, Del Arco C, Peinado R, et al.\nRandomized comparison of intravenous procainamide vs. intravenous amiodarone\nESC Guidelines\n4107\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nfor the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study.\nEur Heart J 2017;38:1329–1335.\n304. Gill JS, Mehta D, Ward DE, Camm AJ. Efﬁcacy of ﬂecainide, sotalol, and verapamil in\nthe treatment of right ventricular tachycardia in patients without overt cardiac ab-\nnormality. Br Heart J 1992;68:392–397.\n305. Manz M, Mletzko R, Jung W, Lüderitz B. Electrophysiological and haemodynamic\neffects of lidocaine and ajmaline in the management of sustained ventricular tachy-\ncardia. Eur Heart J 1992;13:1123–1128.\n306. Buxton AE, Marchlinski FE, Doherty JU, Cassidy DM, Vassallo JA, Flores BT, et al.\nRepetitive, monomorphic ventricular tachycardia: clinical and electrophysiologic\ncharacteristics in patients with and patients without organic heart disease. Am J\nCardiol 1984;54:997–1002.\n307. Grifﬁth MJ, Garratt CJ, Rowland E, Ward DE, Camm AJ. Effects of intravenous ad-\nenosine on verapamil-sensitive ‘idiopathic’ ventricular tachycardia. Am J Cardiol\n1994;73:759–764.\n308. Buxton AE, Marchlinski FE, Doherty JU, Flores B, Josephson ME. Hazards of intra-\nvenous verapamil for sustained ventricular tachycardia. Am J Cardiol 1987;59:\n1107–1110.\n309. Rankin AC, Rae AP, Cobbe SM. Misuse of intravenous verapamil in patients with\nventricular tachycardia. Lancet 1987;2:472–474.\n310. Pedersen CT, Kay GN, Kalman J, Borggrefe M, Della-Bella P, Dickfeld T, et al.\nEHRA/HRS/APHRS expert consensus on ventricular arrhythmias. Europace 2014;\n16:1257–1283.\n311. Cronin EM, Bogun FM, Maury P, Peichl P, Chen M, Namboodiri N, et al. 2019 HRS/\nEHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ven-\ntricular arrhythmias. Europace 2019;21:1143–1144.\n312. Kowlgi GN, Cha Y-M. Management of ventricular electrical storm: a contemporary\nappraisal. Europace 2020;22:1768–1780.\n313. Guerra F, Shkoza M, Scappini L, Flori M, Capucci A. Role of electrical storm as a\nmortality and morbidity risk factor and its clinical predictors: a meta-analysis.\nEuropace 2014;16:347–353.\n314. Noda T, Kurita T, Nitta T, Chiba Y, Furushima H, Matsumoto N, et al. Signiﬁcant\nimpact of electrical storm on mortality in patients with structural heart disease\nand an implantable cardiac deﬁbrillator. Int J Cardiol 2018;255:85–91.\n315. Soar J, Maconochie I, Wyckoff MH, Olasveengen TM, Singletary EM, Greif R, et al.\n2019 International consensus on cardiopulmonary resuscitation and emergency\ncardiovascular care science with treatment recommendations: summary from\nthe basic life support; advanced life support; pediatric life support; neonatal life sup-\nport; education, implementation, and teams; and ﬁrst aid task forces. Circulation\n2019;140:e826–e880.\n316. Eiﬂing M, Razavi M, Massumi A. The evaluation and management of electrical storm.\nTex Heart Inst J 2011;38:111–121.\n317. Chatzidou S, Kontogiannis C, Tsilimigras DI, Georgiopoulos G, Kosmopoulos M,\nPapadopoulou E, et al. Propranolol versus metoprolol for treatment of electrical\nstorm in patients with implantable cardioverter-deﬁbrillator. J Am Coll Cardiol\n2018;71:1897–1906.\n318. Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, et al. Comparison of\nbeta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks\nfrom implantable cardioverter deﬁbrillators: the OPTIC Study: a randomized trial.\nJAMA 2006;295:165–171.\n319. Shiga T, Ikeda T, Shimizu W, Kinugawa K, Sakamoto A, Nagai R, et al. Efﬁcacy and\nsafety of landiolol in patients with ventricular tachyarrhythmias with or without re-\nnal impairment – subanalysis of the J-Land II study. Circ Rep 2020;2:440–445.\n320. Kanamori K, Aoyagi T, Mikamo T, Tsutsui K, Kunishima T, Inaba H, et al. Successful\ntreatment of refractory electrical storm with landiolol after more than 100 electric-\nal deﬁbrillations. Int Heart J 2015;56:555–557.\n321. Gorgels AP, van den Dool A, Hofs A, Mulleneers R, Smeets JL, Vos MA, et al.\nComparison of procainamide and lidocaine in terminating sustained monomorphic\nventricular tachycardia. Am J Cardiol 1996;78:43–46.\n322. Martí-Carvajal AJ, Simancas-Racines D, Anand V, Bangdiwala S. Prophylactic lido-\ncaine for myocardial infarction. Cochrane Database Syst Rev 2015;2015:CD008553.\n323. Viskin S, Chorin E, Viskin D, Hochstadt A, Halkin A, Tovia-Brodie O, et al.\nQuinidine-responsive polymorphic ventricular tachycardia in patients with coron-\nary heart disease. Circulation 2019;139:2304–2314.\n324. Viskin S, Hochstadt A, Chorin E, Viskin D, Havakuk O, Khoury S, et al.\nQuinidine-responsive out-of-hospital polymorphic ventricular tachycardia in pa-\ntients with coronary heart disease. Europace 2020;22:265–273.\n325. Martins RP, Urien J-M, Barbarot N, Rieul G, Sellal J-M, Borella L, et al. Effectiveness\nof deep sedation for patients with intractable electrical storm refractory to antiar-\nrhythmic drugs. Circulation 2020;142:1599–1601.\n326. Fudim M, Boortz-Marx R, Ganesh A, Waldron NH, Qadri YJ, Patel CB, et al. Stellate\nganglion blockade for the treatment of refractory ventricular arrhythmias: a sys-\ntematic review and meta-analysis. J Cardiovasc Electrophysiol 2017;28:1460–1467.\n327. Do DH, Bradﬁeld J, Ajijola OA, Vaseghi M, Le J, Rahman S, et al. Thoracic epidural\nanesthesia can be effective for the short-term management of ventricular tachycar-\ndia storm. J Am Heart Assoc 2017;6:e007080.\n328. Vaseghi M, Barwad P, Malavassi Corrales FJ, Tandri H, Mathuria N, Shah R, et al.\nCardiac sympathetic denervation for refractory ventricular arrhythmias. J Am Coll\nCardiol 2017;69:3070–3080.\n329. Gatzoulis KA, Andrikopoulos GK, Apostolopoulos T, Sotiropoulos E, Zervopoulos\nG, Antoniou J, et al. Electrical storm is an independent predictor of adverse long-\nterm outcome in the era of implantable deﬁbrillator therapy. Europace 2005;7:\n184–192.\n330. Carbucicchio C, Santamaria M, Trevisi N, Maccabelli G, Giraldi F, Fassini G, et al.\nCatheter ablation for the treatment of electrical storm in patients with implantable\ncardioverter-deﬁbrillators: short- and long-term outcomes in a prospective single-\ncenter study. Circulation 2008;117:462–469.\n331. Vergara P, Tung R, Vaseghi M, Brombin C, Frankel DS, Di Biase L, et al. Successful\nventricular tachycardia ablation in patients with electrical storm reduces recur-\nrences and improves survival. Heart Rhythm 2018;15:48–55.\n332. Komatsu Y, Hocini M, Nogami A, Maury P, Peichl P, Iwasaki Y, et al. Catheter ab-\nlation of refractory ventricular ﬁbrillation storm after myocardial infarction: a multi-\ncenter study. Circulation 2019;139:2315–2325.\n333. Knecht S, Sacher F, Wright M, Hocini M, Nogami A, Arentz T, et al. Long-term\nfollow-up of idiopathic ventricular ﬁbrillation ablation: a multicenter study. J Am\nColl Cardiol 2009;54:522–528.\n334. Peichl P, Cihák R, Kozeluhová M, Wichterle D, Vancura V, Kautzner J. Catheter ab-\nlation of arrhythmic storm triggered by monomorphic ectopic beats in patients\nwith coronary artery disease. J Interv Card Electrophysiol 2010;27:51–59.\n335. Le Pennec-Prigent S, Flecher E, Auffret V, Leurent G, Daubert J-C, Leclercq C, et al.\nEffectiveness of extracorporeal life support for patients with cardiogenic shock due\nto intractable arrhythmic storm. Crit Care Med 2017;45:e281–e289.\n336. Mariani S, Napp LC, Lo Coco V, Delnoij TSR, Luermans JGLM, Ter Bekke RMA,\net al. Mechanical circulatory support for life-threatening arrhythmia: a systematic\nreview. Int J Cardiol 2020;308:42–49.\n337. Muser D, Liang JJ, Castro SA, Hayashi T, Enriquez A, Troutman GS, et al. Outcomes\nwith prophylactic use of percutaneous left ventricular assist devices in high-risk pa-\ntients undergoing catheter ablation of scar-related ventricular tachycardia: a\npropensity-score matched analysis. Heart Rhythm 2018;15:1500–1506.\n338. Mathuria N, Wu G, Rojas-Delgado F, Shuraih M, Razavi M, Civitello A, et al.\nOutcomes of pre-emptive and rescue use of percutaneous left ventricular assist de-\nvice in patients with structural heart disease undergoing catheter ablation of ven-\ntricular tachycardia. J Interv Card Electrophysiol 2017;48:27–34.\n339. Patel KK, Spertus JA, Khariton Y, Tang Y, Curtis LH, Chan PS, et al. Association be-\ntween prompt deﬁbrillation and epinephrine treatment with long-term survival\nafter in-hospital cardiac arrest. Circulation 2018;137:2041–2051.\n340. Vaseghi M, Gima J, Kanaan C, Ajijola OA, Marmureanu A, Mahajan A, et al. Cardiac\nsympathetic denervation in patients with refractory ventricular arrhythmias or\nelectrical storm: Intermediate and long-term follow-up. Heart Rhythm 2014;11:\n360–366.\n341. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016\nESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:\nthe task force for the diagnosis and treatment of acute and chronic heart failure of\nthe European Society of Cardiology (ESC) Developed with the special contribution\nof the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129–2200.\n342. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021\nESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.\nEur Heart J 2021;42:3599–3726.\n343. AlJaroudi WA, Refaat MM, Habib RH, Al-Shaar L, Singh M, Gutmann R, et al. Effect\nof angiotensin-converting enzyme inhibitors and receptor blockers on appropriate\nimplantable cardiac deﬁbrillator shock in patients with severe systolic heart failure\n(from the GRADE Multicenter Study). Am J Cardiol 2015;115:924–931.\n344. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a\nselective aldosterone blocker, in patients with left ventricular dysfunction after\nmyocardial infarction. N Engl J Med 2003;348:1309–1321.\n345. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.\nAngiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med\n2014;371:993–1004.\n346. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al.\nCardiovascular and renal outcomes with empagliﬂozin in heart failure. N Engl J\nMed 2020;383:1413–1424.\n347. Desai AS, McMurray JJV, Packer M, Swedberg K, Rouleau JL, Chen F, et al. Effect of\nthe angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on\nmode of death in heart failure patients. Eur Heart J 2015;36:1990–1997.\n348. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al.\n2020 ESC Guidelines for the diagnosis and management of atrial ﬁbrillation devel-\noped in collaboration with the European Association for Cardio-Thoracic Surgery\n(EACTS): The task force for the diagnosis and management of atrial ﬁbrillation of\n4108\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nthe European Society of Cardiology (ESC) Developed with the special contribution\nof the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;\n42:373–498.\n349. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian im-\nplantable deﬁbrillator study (CIDS): a randomized trial of the implantable cardio-\nverter deﬁbrillator against amiodarone. Circulation 2000;101:1297–1302.\n350. Antiarrhythmics versus Implantable Deﬁbrillators (AVID) Investigators. A compari-\nson of antiarrhythmic-drug therapy with implantable deﬁbrillators in patients resus-\ncitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576–1583.\n351. Kuck KH, Cappato R, Siebels J, Rüppel R. Randomized comparison of antiarrhyth-\nmic drug therapy with implantable deﬁbrillators in patients resuscitated from car-\ndiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000;102:\n748–754.\n352. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al.\nMeta-analysis of the implantable cardioverter deﬁbrillator secondary prevention\ntrials.\nAVID,\nCASH\nand\nCIDS\nstudies.\nAntiarrhythmics\nvs\nImplantable\nDeﬁbrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable\nDeﬁbrillator Study. Eur Heart J 2000;21:2071–2078.\n353. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved sur-\nvival with an implanted deﬁbrillator in patients with coronary disease at high risk for\nventricular arrhythmia. N Engl J Med 1996;335:1933–1940.\n354. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic\nimplantation of a deﬁbrillator in patients with myocardial infarction and reduced\nejection fraction. N Engl J Med 2002;346:877–883.\n355. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Haﬂey G. A rando-\nmized study of the prevention of sudden death in patients with coronary artery dis-\nease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;\n341:1882–1890.\n356. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or\nan implantable cardioverter-deﬁbrillator for congestive heart failure. N Engl J Med\n2005;352:225–237.\n357. Zabel M, Willems R, Lubinski A, Bauer A, Brugada J, Conen D, et al. Clinical effect-\niveness of primary prevention implantable cardioverter-deﬁbrillators: results of the\nEU-CERT-ICD controlled multicentre cohort study. Eur Heart J 2020;41:\n3437–3447.\n358. Schrage B, Uijl A, Benson L, Westermann D, Ståhlberg M, Stolfo D, et al.\nAssociation between use of primary-prevention implantable cardioverter-\ndeﬁbrillators and mortality in patients with heart failure: a prospective propensity\nscore-matched analysis from the Swedish Heart Failure Registry. Circulation 2019;\n140:1530–1539.\n359. Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. Deﬁbrillator im-\nplantation in patients with nonischemic systolic heart failure. N Engl J Med 2016;\n375:1221–1230.\n360. Jukema JW, Timal RJ, Rotmans JI, Hensen LCR, Buiten MS, de Bie MK, et al.\nProphylactic use of implantable cardioverter-deﬁbrillators in the prevention of sud-\nden cardiac death in dialysis patients. Circulation 2019;139:2628–2638.\n361. Sticherling C, Arendacka B, Svendsen JH, Wijers S, Friede T, Stockinger J, et al. Sex\ndifferences in outcomes of primary prevention implantable cardioverter-\ndeﬁbrillator therapy: combined registry data from eleven European countries.\nEuropace 2018;20:963–970.\n362. Junttila MJ, Pelli A, Kenttä TV, Friede T, Willems R, Bergau L, et al. Appropriate\nshocks and mortality in patients with versus without diabetes with prophylactic im-\nplantable cardioverter deﬁbrillators. Diabetes Care 2020;43:196–200.\n363. Koller MT, Schaer B, Wolbers M, Sticherling C, Bucher HC, Osswald S. Death with-\nout prior appropriate implantable cardioverter-deﬁbrillator therapy: a competing\nrisk study. Circulation 2008;117:1918–1926.\n364. Cleland JGF, Halliday BP, Prasad SK. Selecting patients with nonischemic dilated car-\ndiomyopathy for ICDs: myocardial function, ﬁbrosis, and what’s attached? J Am Coll\nCardiol 2017;70:1228–1231.\n365. Younis A, Goldberger JJ, Kutyifa V, Zareba W, Polonsky B, Klein H, et al. Predicted\nbeneﬁt of an implantable cardioverter-deﬁbrillator: the MADIT-ICD beneﬁt score.\nEur Heart J 2021;42:1676–1684.\n366. Knops RE, Olde Nordkamp LRA, Delnoy P-PHM, Boersma LVA, Kuschyk J,\nEl-Chami MF, et al. Subcutaneous or transvenous deﬁbrillator therapy. N Engl J\nMed 2020;383:526–536.\n367. Cleland JGF, Daubert J-C, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al.\nThe effect of cardiac resynchronization on morbidity and mortality in heart failure.\nN Engl J Med 2005;352:1539–1549.\n368. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al.\nCardiac-resynchronization therapy with or without an implantable deﬁbrillator in\nadvanced chronic heart failure. N Engl J Med 2004;350:2140–2150.\n369. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al.\nCardiac-resynchronization therapy for the prevention of heart-failure events. N\nEngl J Med 2009;361:1329–1338.\n370. Masri A, Altibi AM, Erqou S, Zmaili MA, Saleh A, Al-Adham R, et al. Wearable\ncardioverter-deﬁbrillator therapy for the prevention of sudden cardiac death: a sys-\ntematic review and meta-analysis. JACC Clin Electrophysiol 2019;5:152–161.\n371. Garcia R, Combes N, Defaye P, Narayanan K, Guedon-Moreau L, Boveda S, et al.\nWearable cardioverter-deﬁbrillator in patients with a transient risk of sudden car-\ndiac death: the WEARIT-France cohort study. Europace 2021;23:73–81.\n372. Olgin JE, Pletcher MJ, Vittinghoff E, Wranicz J, Malik R, Morin DP, et al. Wearable\ncardioverter-deﬁbrillator after myocardial infarction. N Engl J Med 2018;379:\n1205–1215.\n373. Scott PA, Silberbauer J, McDonagh TA, Murgatroyd FD. Impact of prolonged im-\nplantable cardioverter-deﬁbrillator arrhythmia detection times on outcomes: a\nmeta-analysis. Heart Rhythm 2014;11:828–835.\n374. Tan VH, Wilton SB, Kuriachan V, Sumner GL, Exner DV. Impact of programming\nstrategies aimed at reducing nonessential implantable cardioverter deﬁbrillator\ntherapies on mortality: a systematic review and meta-analysis. Circ Arrhythm\nElectrophysiol 2014;7:164–170.\n375. Saeed M, Hanna I, Robotis D, Styperek R, Polosajian L, Khan A, et al. Programming\nimplantable cardioverter-deﬁbrillators in patients with primary prevention indica-\ntion to prolong time to ﬁrst shock: results from the PROVIDE study. J Cardiovasc\nElectrophysiol 2014;25:52–59.\n376. Wilkoff BL, Fauchier L, Stiles MK, Morillo CA, Al-Khatib SM, Almendral J, et al. 2015\nHRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implanta-\nble cardioverter-deﬁbrillator programming and testing. Europace 2016;18:\n159–183.\n377. Stiles MK, Fauchier L, Morillo CA, Wilkoff BL, ESC Scientiﬁc Document Group.\n2019 HRS/EHRA/APHRS/LAHRS focused update to 2015 expert consensus state-\nment on optimal implantable cardioverter-deﬁbrillator programming and testing.\nEuropace 2019;21:1442–1443.\n378. Barsheshet A, Moss AJ, McNitt S, Jons C, Glikson M, Klein HU, et al. Long-term im-\nplications of cumulative right ventricular pacing among patients with an implantable\ncardioverter-deﬁbrillator. Heart Rhythm 2011;8:212–218.\n379. Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, et al.\nDual-chamber pacing or ventricular backup pacing in patients with an implantable\ndeﬁbrillator: the Dual Chamber and VVI Implantable Deﬁbrillator (DAVID) Trial.\nJAMA 2002;288:3115–3123.\n380. Olshansky B, Day JD, Moore S, Gering L, Rosenbaum M, McGuire M, et al. Is dual-\nchamber programming inferior to single-chamber programming in an implantable\ncardioverter-deﬁbrillator?\nResults\nof\nthe\nINTRINSIC\nRV\n(Inhibition\nof\nUnnecessary RV Pacing With AVSH in ICDs) study. Circulation 2007;115:9–16.\n381. Hindricks G, Kühl M, Dagres N. The implantable cardioverter deﬁbrillator, conclu-\nsions on sudden cardiac death, and future perspective. ESC CardioMed. 3rd ed.\nOxford University Press; 2022, p2370–2376.\n382. Gasparini M, Proclemer A, Klersy C, Kloppe A, Ferrer JBM, Hersi A, et al. Effect of\nlong-detection interval vs standard-detection interval for implantable cardioverter-\ndeﬁbrillators on antitachycardia pacing and shock delivery: the ADVANCE III ran-\ndomized clinical trial. JAMA 2013;309:1903–1911.\n383. Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, et al.\nReduction in inappropriate therapy and mortality through ICD programming. N\nEngl J Med 2012;367:2275–2283.\n384. Wilkoff BL, Ousdigian KT, Sterns LD, Wang ZJ, Wilson RD, Morgan JM, et al. A\ncomparison of empiric to physician-tailored programming of implantable\ncardioverter-deﬁbrillators: results from the prospective randomized multicenter\nEMPIRIC trial. J Am Coll Cardiol 2006;48:330–339.\n385. Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lu F, Lee SW, et al. Strategic pro-\ngramming of detection and therapy parameters in implantable cardioverter-\ndeﬁbrillators reduces shocks in primary prevention patients: results from the\nPREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol\n2008;52:541–550.\n386. Gilliam FR, Hayes DL, Boehmer JP, Day J, Heidenreich PA, Seth M, et al. Real world\nevaluation of dual-zone ICD and CRT-D programming compared to single-zone\nprogramming: the ALTITUDE REDUCES study. J Cardiovasc Electrophysiol 2011;\n22:1023–1029.\n387. Hernandez-Ojeda J, Arbelo E, Borras R, Berne P, Tolosana JM, Gomez-Juanatey A,\net al. Patients with Brugada syndrome and implanted cardioverter-deﬁbrillators:\nlong-term follow-up. J Am Coll Cardiol 2017;70:1991–2002.\n388. Gold MR, Weiss R, Theuns DAMJ, Smith W, Leon A, Knight BP, et al. Use of a dis-\ncrimination algorithm to reduce inappropriate shocks with a subcutaneous implan-\ntable cardioverter-deﬁbrillator. Heart Rhythm 2014;11:1352–1358.\n389. Mesquita J, Cavaco D, Ferreira A, Lopes N, Santos PG, Carvalho MS, et al.\nEffectiveness of subcutaneous implantable cardioverter-deﬁbrillators and determi-\nnants of inappropriate shock delivery. Int J Cardiol 2017;232:176–180.\n390. Gold MR, Lambiase PD, El-Chami MF, Knops RE, Aasbo JD, Bongiorni MG, et al.\nPrimary results from the understanding outcomes with the S-ICD in primary pre-\nvention patients with low ejection fraction (UNTOUCHED) trial. Circulation 2021;\n143:7–17.\nESC Guidelines\n4109\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n391. Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO,\net al. Prospective randomized multicenter trial of empirical antitachycardia pacing\nversus shocks for spontaneous rapid ventricular tachycardia in patients with im-\nplantable cardioverter-deﬁbrillators: Pacing Fast Ventricular Tachycardia Reduces\nShock Therapies (PainFREE Rx II) trial results. Circulation 2004;110:2591–2596.\n392. Gulizia MM, Piraino L, Scherillo M, Puntrello C, Vasco C, Scianaro MC, et al. A ran-\ndomized study to compare ramp versus burst antitachycardia pacing therapies to\ntreat fast ventricular tachyarrhythmias in patients with implantable cardioverter de-\nﬁbrillators: the PITAGORA ICD trial. Circ Arrhythm Electrophysiol 2009;2:146–153.\n393. Saxon LA, Hayes DL, Gilliam FR, Heidenreich PA, Day J, Seth M, et al. Long-term\noutcome after ICD and CRT implantation and inﬂuence of remote device follow-\nup: the ALTITUDE survival study. Circulation 2010;122:2359–2367.\n394. Varma N, Piccini JP, Snell J, Fischer A, Dalal N, Mittal S. The relationship between\nlevel of adherence to automatic wireless remote monitoring and survival in pace-\nmaker and deﬁbrillator patients. J Am Coll Cardiol 2015;65:2601–2610.\n395. Guédon-Moreau L, Kouakam C, Klug D, Marquié C, Brigadeau F, Boulé S, et al.\nDecreased delivery of inappropriate shocks achieved by remote monitoring of\nICD: a substudy of the ECOST trial. J Cardiovasc Electrophysiol 2014;25:763–770.\n396. Varma N, Michalski J, Epstein AE, Schweikert R. Automatic remote monitoring of\nimplantable cardioverter-deﬁbrillator lead and generator performance: the\nLumos-T Safely RedUceS RouTine Ofﬁce Device Follow-Up (TRUST) trial. Circ\nArrhythm Electrophysiol 2010;3:428–436.\n397. Ploux S, Swerdlow CD, Strik M, Welte N, Klotz N, Ritter P, et al. Towards eradi-\ncation of inappropriate therapies for ICD lead failure by combining comprehensive\nremote monitoring and lead noise alerts. J Cardiovasc Electrophysiol 2018;29:\n1125–1134.\n398. Ellenbogen KA, Gunderson BD, Stromberg KD, Swerdlow CD. Performance of\nLead Integrity Alert to assist in the clinical diagnosis of implantable cardioverter de-\nﬁbrillator lead failures: analysis of different implantable cardioverter deﬁbrillator\nleads. Circ Arrhythm Electrophysiol 2013;6:1169–1177.\n399. Swerdlow CD, Gunderson BD, Ousdigian KT, Abeyratne A, Sachanandani H,\nEllenbogen KA. Downloadable software algorithm reduces inappropriate shocks\ncaused by implantable cardioverter-deﬁbrillator lead fractures: a prospective study.\nCirculation 2010;122:1449–1455.\n400. Ruwald MH, Abu-Zeitone A, Jons C, Ruwald A-C, McNitt S, Kutyifa V, et al. Impact\nof\ncarvedilol\nand\nmetoprolol on\ninappropriate implantable\ncardioverter-\ndeﬁbrillator therapy: the MADIT-CRT trial (Multicenter Automatic Deﬁbrillator\nImplantation With Cardiac Resynchronization Therapy). J Am Coll Cardiol 2013;\n62:1343–1350.\n401. Miyazaki S, Taniguchi H, Kusa S, Komatsu Y, Ichihara N, Takagi T, et al. Catheter\nablation of atrial tachyarrhythmias causing inappropriate implantable cardioverter-\ndeﬁbrillator shocks. Europace 2015;17:289–294.\n402. Mainigi SK, Almuti K, Figueredo VM, Guttenplan NA, Aouthmany A, Smukler J, et al.\nUsefulness of radiofrequency ablation of supraventricular tachycardia to decrease\ninappropriate shocks from implantable cardioverter-deﬁbrillators. Am J Cardiol\n2012;109:231–237.\n403. Kosiuk J, Nedios S, Darma A, Rolf S, Richter S, Arya A, et al. Impact of single atrial\nﬁbrillation catheter ablation on implantable cardioverter deﬁbrillator therapies in\npatients with ischaemic and non-ischaemic cardiomyopathies. Europace 2014;16:\n1322–1326.\n404. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early rhythm-\ncontrol therapy in patients with atrial ﬁbrillation. N Engl J Med 2020;383:\n1305–1316.\n405. Gasparini M, Kloppe A, Lunati M, Anselme F, Landolina M, Martinez-Ferrer JB, et al.\nAtrioventricular junction ablation in patients with atrial ﬁbrillation treated with car-\ndiac resynchronization therapy: positive impact on ventricular arrhythmias, implan-\ntable cardioverter-deﬁbrillator therapies and hospitalizations: atrioventricular\njunction ablation in CRT patients with AF. Eur J Heart Fail 2018;20:1472–1481.\n406. Gasparini M, Galimberti P. Rate control: ablation and device therapy (ablate and\npace). ESC CardioMed. 3rd ed. Oxford University Press; 2022, p2159–2162.\n407. Kitamura T, Fukamizu S, Kawamura I, Hojo R, Aoyama Y, Komiyama K, et al.\nLong-term efﬁcacy of catheter ablation for paroxysmal atrial ﬁbrillation in patients\nwith Brugada syndrome and an implantable cardioverter-deﬁbrillator to prevent in-\nappropriate shock therapy. Heart Rhythm 2016;13:1455–1459.\n408. Magyar-Russell G, Thombs BD, Cai JX, Baveja T, Kuhl EA, Singh PP, et al. The preva-\nlence of anxiety and depression in adults with implantable cardioverter deﬁbrilla-\ntors: a systematic review. J Psychosom Res 2011;71:223–231.\n409. Tzeis S, Kolb C, Baumert J, Reents T, Zrenner B, Deisenhofer I, et al. Effect of de-\npression on mortality in implantable cardioverter deﬁbrillator recipients—ﬁndings\nfrom the prospective LICAD study. Pacing Clin Electrophysiol 2011;34:991–997.\n410. Andersen CM, Theuns DAMJ, Johansen JB, Pedersen SS. Anxiety, depression, ven-\ntricular arrhythmias and mortality in patients with an implantable cardioverter de-\nﬁbrillator: 7 years’ follow-up of the MIDAS cohort. Gen Hosp Psychiatry 2020;66:\n154–160.\n411. Berg SK, Thygesen LC, Svendsen JH, Christensen AV, Zwisler A-D. Anxiety pre-\ndicts mortality in ICD patients: results from the cross-sectional national\nCopenHeartICD survey with register follow-up. Pacing Clin Electrophysiol 2014;\n37:1641–1650.\n412. Thylén I, Moser DK, Strömberg A, Dekker RA, Chung ML. Concerns about implan-\ntable cardioverter-deﬁbrillator shocks mediate the relationship between actual\nshocks and psychological distress. Europace 2016;18:828–835.\n413. Pedersen SS, van Domburg RT, Theuns DAMJ, Jordaens L, Erdman RAM. Concerns\nabout the implantable cardioverter deﬁbrillator: a determinant of anxiety and de-\npressive symptoms independent of experienced shocks. Am Heart J 2005;149:\n664–669.\n414. Frizelle DJ, Lewin B, Kaye G, Moniz-Cook ED. Development of a measure of the\nconcerns held by people with implanted cardioverter deﬁbrillators: the ICDC. Br\nJ Health Psychol 2006;11:293–301.\n415. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr\nScand 1983;67:361–370.\n416. Frydensberg VS, Johansen JB, Möller S, Riahi S, Wehberg S, Haarbo J, et al. Anxiety\nand depression symptoms in Danish patients with an implantable cardioverter-\ndeﬁbrillator: prevalence and association with indication and sex up to 2 years of\nfollow-up (data from the national DEFIB-WOMEN study). Europace 2020;22:\n1830–1840.\n417. Hoogwegt MT, Kupper N, Theuns DAMJ, Zijlstra WP, Jordaens L, Pedersen SS.\nUndertreatment of anxiety and depression in patients with an implantable\ncardioverter-deﬁbrillator: impact on health status. Health Psychol 2012;31:\n745–753.\n418. Lane DA, Aguinaga L, Blomström-Lundqvist C, Boriani G, Dan G-A, Hills MT, et al.\nCardiac tachyarrhythmias and patient values and preferences for their manage-\nment: the European Heart Rhythm Association (EHRA) consensus document en-\ndorsed by the Heart Rhythm Society (HRS), Asia Paciﬁc Heart Rhythm Society\n(APHRS),\nand\nSociedad\nLatinoamericana\nde\nEstimulación\nCardíaca\ny\nElectroﬁsiología (SOLEACE). Europace 2015;17:1747–1769.\n419. Dunbar SB, Dougherty CM, Sears SF, Carroll DL, Goldstein NE, Mark DB, et al.\nEducational and psychological interventions to improve outcomes for recipients\nof implantable cardioverter deﬁbrillators and their families: a scientiﬁc statement\nfrom the American Heart Association. Circulation 2012;126:2146–2172.\n420. Sears SF, Sowell LDV, Kuhl EA, Kovacs AH, Serber ER, Handberg E, et al. The ICD\nshock and stress management program: a randomized trial of psychosocial treat-\nment to optimize quality of life in ICD patients. Pacing Clin Electrophysiol 2007;\n30:858–864.\n421. Berg SK, Rasmussen TB, Herning M, Svendsen JH, Christensen AV, Thygesen LC.\nCognitive behavioural therapy signiﬁcantly reduces anxiety in patients with im-\nplanted cardioverter deﬁbrillator compared with usual care: ﬁndings from the\nScreen-ICD randomised controlled trial. Eur J Prev Cardiol 2020;27:258–268.\n422. Schulz SM, Ritter O, Zniva R, Nordbeck P, Wacker C, Jack M, et al. Efﬁcacy of a\nweb-based intervention for improving psychosocial well-being in patients with im-\nplantable cardioverter-deﬁbrillators: the randomized controlled ICD-FORUM trial.\nEur Heart J 2020;41:1203–1211.\n423. van den Broek KC, Tekle FB, Habibović M, Alings M, van der Voort PH, Denollet J.\nEmotional distress, positive affect, and mortality in patients with an implantable car-\ndioverter deﬁbrillator. Int J Cardiol 2013;165:327–332.\n424. Hauptman PJ, Chibnall JT, Guild C, Armbrecht ES. Patient perceptions, physician\ncommunication, and the implantable cardioverter-deﬁbrillator. JAMA Intern Med\n2013;173:571–577.\n425. Cikes M, Jakus N, Claggett B, Brugts JJ, Timmermans P, Pouleur A-C, et al. Cardiac\nimplantable electronic devices with a deﬁbrillator component and all-cause mortal-\nity in left ventricular assist device carriers: results from the PCHF-VAD registry. Eur\nJ Heart Fail 2019;21:1129–1141.\n426. Galand V, Flécher E, Auffret V, Boulé S, Vincentelli A, Dambrin C, et al. Predictors\nand clinical impact of late ventricular arrhythmias in patients with continuous-ﬂow\nleft ventricular assist devices. JACC Clin Electrophysiol 2018;4:1166–1175.\n427. Nakahara S, Chien C, Gelow J, Dalouk K, Henrikson CA, Mudd J, et al. Ventricular\narrhythmias after left ventricular assist device. Circ Arrhythm Electrophysiol 2013;6:\n648–654.\n428. Clerkin KJ, Topkara VK, Demmer RT, Dizon JM, Yuzefpolskaya M, Fried JA, et al.\nImplantable cardioverter-deﬁbrillators in patients with a continuous-ﬂow left ven-\ntricular assist device: an analysis of the INTERMACS registry. JACC Heart Fail 2017;\n5:916–926.\n429. Oz MC, Rose EA, Slater J, Kuiper JJ, Catanese KA, Levin HR. Malignant ventricular\narrhythmias are well tolerated in patients receiving long-term left ventricular assist\ndevices. J Am Coll Cardiol 1994;24:1688–1691.\n430. Potapov EV, Antonides C, Crespo-Leiro MG, Combes A, Färber G, Hannan MM,\net al. 2019 EACTS Expert Consensus on long-term mechanical circulatory support.\nEur J Cardiothorac Surg 56:230–270.\n4110\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n431. Makki N, Mesubi O, Steyers C, Olshansky B, Abraham WT. Meta-analysis of the\nrelation of ventricular arrhythmias to all-cause mortality after implantation of a\nleft ventricular assist device. Am J Cardiol 2015;116:1385–1390.\n432. Yoruk A, Sherazi S, Massey HT, Kutyifa V, McNitt S, Hallinan W, et al. Predictors\nand clinical relevance of ventricular tachyarrhythmias in ambulatory patients with\na continuous ﬂow left ventricular assist device. Heart Rhythm 2016;13:1052–1056.\n433. Bedi M, Kormos R, Winowich S, McNamara DM, Mathier MA, Murali S. Ventricular\narrhythmias during left ventricular assist device support. Am J Cardiol 2007;99:\n1151–1153.\n434. Brenyo A, Rao M, Koneru S, Hallinan W, Shah S, Massey HT, et al. Risk of mortality\nfor ventricular arrhythmia in ambulatory LVAD patients. J Cardiovasc Electrophysiol\n2012;23:515–520.\n435. Vakil K, Kazmirczak F, Sathnur N, Adabag S, Cantillon DJ, Kiehl EL, et al. Implantable\ncardioverter-deﬁbrillator use in patients with left ventricular assist devices: a sys-\ntematic review and meta-analysis. JACC Heart Fail 2016;4:772–779.\n436. Refaat MM, Tanaka T, Kormos RL, McNamara D, Teuteberg J, Winowich S, et al.\nSurvival beneﬁt of implantable cardioverter-deﬁbrillators in left ventricular assist\ndevice-supported heart failure patients. J Card Fail 2012;18:140–145.\n437. Cantillon DJ, Tarakji KG, Kumbhani DJ, Smedira NG, Starling RC, Wilkoff BL.\nImproved survival among ventricular assist device recipients with a concomitant im-\nplantable cardioverter-deﬁbrillator. Heart Rhythm 2010;7:466–471.\n438. Joyce E, Starling RC. HFrEF other treatment: ventricular assist devices. ESC\nCardioMed. 3rd ed. Oxford University Press; 2022, p1884–1889.\n439. Younes A, Al-Kindi SG, Alajaji W, Mackall JA, Oliveira GH. Presence of implantable\ncardioverter-deﬁbrillators and wait-list mortality of patients supported with left\nventricular assist devices as bridge to heart transplantation. Int J Cardiol 2017;\n231:211–215.\n440. Agrawal S, Garg L, Nanda S, Sharma A, Bhatia N, Manda Y, et al. The role of implan-\ntable cardioverter-deﬁbrillators in patients with continuous ﬂow left ventricular as-\nsist devices – a meta-analysis. Int J Cardiol 2016;222:379–384.\n441. Blomström-Lundqvist C, Traykov V, Erba PA, Burri H, Nielsen JC, Bongiorni MG,\net al. European Heart Rhythm Association (EHRA) international consensus docu-\nment on how to prevent, diagnose, and treat cardiac implantable electronic device\ninfections-endorsed by the Heart Rhythm Society (HRS), the Asia Paciﬁc Heart\nRhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS),\nInternational Society for Cardiovascular Infectious Diseases (ISCVID) and the\nEuropean Society of Clinical Microbiology and Infectious Diseases (ESCMID) in col-\nlaboration with the European Association for Cardio-Thoracic Surgery (EACTS).\nEuropace 2020;22:515–549.\n442. Burri H, Starck C, Auricchio A, BifﬁM, Burri M, D’Avila A, et al. EHRA expert con-\nsensus statement and practical guide on optimal implantation technique for con-\nventional pacemakers and implantable cardioverter-deﬁbrillators: endorsed by\nthe Heart Rhythm Society (HRS), the Asia Paciﬁc Heart Rhythm Society\n(APHRS), and the Latin-American Heart Rhythm Society (LAHRS). Europace\n2021;23:983–1008.\n443. Tarakji KG, Mittal S, Kennergren C, Corey R, Poole JE, Schloss E, et al. Antibacterial\nenvelope to prevent cardiac implantable device infection. N Engl J Med 2019;380:\n1895–1905.\n444. Atti V, Turagam MK, Garg J, Koerber S, Angirekula A, Gopinathannair R, et al.\nSubclavian and axillary vein access versus cephalic vein cutdown for cardiac implan-\ntable electronic device implantation: a meta-analysis. JACC Clin Electrophysiol 2020;6:\n661–671.\n445. Benz AP, Vamos M, Erath JW, Hohnloser SH. Cephalic vs. subclavian lead implant-\nation in cardiac implantable electronic devices: a systematic review and\nmeta-analysis. Europace 2019;21:121–129.\n446. Chan N-Y, Kwong N-P, Cheong A-P. Venous access and long-term pacemaker lead\nfailure: comparing contrast-guided axillary vein puncture with subclavian puncture\nand cephalic cutdown. Europace 2017;19:1193–1197.\n447. Defaye P, Boveda S, Klug D, Beganton F, Piot O, Narayanan K, et al. Dual- vs. single-\nchamber deﬁbrillators for primary prevention of sudden cardiac death: long-term\nfollow-up of the Déﬁbrillateur Automatique Implantable-Prévention Primaire\nregistry. Europace 2017;19:1478–1484.\n448. Dewland TA, Pellegrini CN, Wang Y, Marcus GM, Keung E, Varosy PD.\nDual-chamber implantable cardioverter-deﬁbrillator selection is associated with in-\ncreased complication rates and mortality among patients enrolled in the NCDR im-\nplantable cardioverter-deﬁbrillator registry. J Am Coll Cardiol 2011;58:1007–1013.\n449. Friedman PA, Bradley D, Koestler C, Slusser J, Hodge D, Bailey K, et al. A prospect-\nive randomized trial of single- or dual-chamber implantable cardioverter-\ndeﬁbrillators to minimize inappropriate shock risk in primary sudden cardiac death\nprevention. Europace 2014;16:1460–1468.\n450. Chen B-W, Liu Q, Wang X, Dang A-M. Are dual-chamber implantable\ncardioverter-deﬁbrillators really better than single-chamber ones? A systematic re-\nview and meta-analysis. J Interv Card Electrophysiol 2014;39:273–280.\n451. Epstein LM, Love CJ, Wilkoff BL, Chung MK, Hackler JW, Bongiorni MG, et al.\nSuperior vena cava deﬁbrillator coils make transvenous lead extraction more chal-\nlenging and riskier. J Am Coll Cardiol 2013;61:987–989.\n452. Larsen JM, Hjortshøj SP, Nielsen JC, Johansen JB, Petersen HH, Haarbo J, et al.\nSingle-coil and dual-coil deﬁbrillator leads and association with clinical outcomes\nin a complete Danish nationwide ICD cohort. Heart Rhythm 2016;13:706–712.\n453. Kumar KR, Mandleywala SN, Madias C, Weinstock J, Rowin EJ, Maron BJ, et al.\nSingle coil implantable cardioverter deﬁbrillator leads in patients with hypertrophic\ncardiomyopathy. Am J Cardiol 2020;125:1896–1900.\n454. Friedman PA, Rasmussen MJ, Grice S, Trusty J, Glikson M, Stanton MS. Deﬁbrillation\nthresholds are increased by right-sided implantation of totally transvenous implan-\ntable cardioverter deﬁbrillators. Pacing Clin Electrophysiol 1999;22:1186–1192.\n455. Stoevelaar R, Brinkman-Stoppelenburg A, Bhagwandien RE, van Bruchem-Visser\nRL, Theuns DA, van der Heide A, et al. The incidence and impact of implantable\ncardioverter deﬁbrillator shocks in the last phase of life: an integrated review.\nEur J Cardiovasc Nurs 2018;17:477–485.\n456. Kapa S, Mueller PS, Hayes DL, Asirvatham SJ. Perspectives on withdrawing pace-\nmaker and implantable cardioverter-deﬁbrillator therapies at end of life: results\nof a survey of medical and legal professionals and patients. Mayo Clin Proc 2010;\n85:981–990.\n457. Padeletti L, Arnar DO, Boncinelli L, Brachman J, Camm JA, Daubert JC, et al. EHRA\nExpert Consensus Statement on the management of cardiovascular implantable\nelectronic devices in patients nearing end of life or requesting withdrawal of ther-\napy. Europace 2010;12:1480–1489.\n458. Stoevelaar R, Brinkman-Stoppelenburg A, van Driel AG, Theuns DA, Bhagwandien\nRE, van Bruchem-Visser RL, et al. Trends in time in the management of the implan-\ntable cardioverter deﬁbrillator in the last phase of life: a retrospective study of med-\nical records. Eur J Cardiovasc Nurs 2019;18:449–457.\n459. Kirkpatrick JN, Gottlieb M, Sehgal P, Patel R, Verdino RJ. Deactivation of implanta-\nble cardioverter deﬁbrillators in terminal illness and end of life care. Am J Cardiol\n2012;109:91–94.\n460. Stevenson WG, Khan H, Sager P, Saxon LA, Middlekauff HR, Natterson PD, et al.\nIdentiﬁcation of reentry circuit sites during catheter mapping and radiofrequency\nablation of ventricular tachycardia late after myocardial infarction. Circulation\n1993;88:1647–1670.\n461. de Bakker JM, van Capelle FJ, Janse MJ, Tasseron S, Vermeulen JT, de Jonge N, et al.\nSlow conduction in the infarcted human heart. “Zigzag” course of activation.\nCirculation 1993;88:915–926.\n462. de Chillou C, Lacroix D, Klug D, Magnin-Poull I, Marquié C, Messier M, et al. Isthmus\ncharacteristics of reentrant ventricular tachycardia after myocardial infarction.\nCirculation 2002;105:726–731.\n463. Hsia HH, Callans DJ, Marchlinski FE. Characterization of endocardial electrophysio-\nlogical substrate in patients with nonischemic cardiomyopathy and monomorphic\nventricular tachycardia. Circulation 2003;108:704–710.\n464. Soejima K, Stevenson WG, Sapp JL, Selwyn AP, Couper G, Epstein LM. Endocardial\nand epicardial radiofrequency ablation of ventricular tachycardia associated with di-\nlated cardiomyopathy. J Am Coll Cardiol 2004;43:1834–1842.\n465. Miljoen H, State S, Dechillou C, Magninpoull I, Dotto P, Andronache M, et al.\nElectroanatomic mapping characteristics of ventricular tachycardia in patients\nwith arrhythmogenic right ventricular cardiomyopathy/dysplasia. Europace 2005;\n7:516–524.\n466. Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al.\n2015 ESC Guidelines for the management of patients with ventricular arrhythmias\nand the prevention of sudden cardiac death: The task force for the Management of\nPatients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death\nof the European Society of Cardiology (ESC). Endorsed by: Association for\nEuropean Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36:\n2793–2867.\n467. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al.\n2017 AHA/ACC/HRS Guideline for management of patients with ventricular ar-\nrhythmias and the prevention of sudden cardiac death: executive summary. J Am\nColl Cardiol 2018;72:1677–1749.\n468. Towbin JA, McKenna WJ, Abrams DJ, Ackerman MJ, Calkins H, Darrieux FCC, et al.\n2019 HRS expert consensus statement on evaluation, risk stratiﬁcation, and man-\nagement of arrhythmogenic cardiomyopathy: executive summary. Heart Rhythm\n2019;16:e373–e407.\n469. Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown MW, et al. Long-term\nclinical course of patients after termination of ventricular tachyarrhythmia by an im-\nplanted deﬁbrillator. Circulation 2004;110:3760–3765.\n470. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, et al.\nPrognostic importance of deﬁbrillator shocks in patients with heart failure. N\nEngl J Med 2008;359:1009–1017.\n471. Sapp JL, Wells GA, Parkash R, Stevenson WG, Blier L, Sarrazin J-F, et al. Ventricular\ntachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med 2016;\n375:111–121.\nESC Guidelines\n4111\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n472. Piccini JP, Berger JS, O’Connor CM. Amiodarone for the prevention of sudden car-\ndiac death: a meta-analysis of randomized controlled trials. Eur Heart J 2009;30:\n1245–1253.\n473. Palaniswamy C, Kolte D, Harikrishnan P, Khera S, Aronow WS, Mujib M, et al.\nCatheter ablation of postinfarction ventricular tachycardia: ten-year trends in util-\nization, in-hospital complications, and in-hospital mortality in the United States.\nHeart Rhythm 2014;11:2056–2063.\n474. Caceres J, Jazayeri M, McKinnie J, Avitall B, Denker ST, Tchou P, et al. Sustained bun-\ndle branch reentry as a mechanism of clinical tachycardia. Circulation 1989;79:\n256–270.\n475. Blanck Z, Dhala A, Deshpande S, Sra J, Jazayeri M, Akhtar M. Bundle branch re-\nentrant ventricular tachycardia: cumulative experience in 48 patients. J Cardiovasc\nElectrophysiol 1993;4:253–262.\n476. Chen H, Shi L, Yang B, Ju W, Zhang F, Yang G, et al. Electrophysiological character-\nistics of bundle branch reentry ventricular tachycardia in patients without structural\nheart disease. Circ Arrhythm Electrophysiol 2018;11:e006049.\n477. Pathak RK, Fahed J, Santangeli P, Hyman MC, Liang JJ, Kubala M, et al. Long-term\noutcome of catheter ablation for treatment of bundle branch re-entrant tachycar-\ndia. JACC Clin Electrophysiol 2018;4:331–338.\n478. Stevenson WG, Wilber DJ, Natale A, Jackman WM, Marchlinski FE, Talbert T, et al.\nIrrigated radiofrequency catheter ablation guided by electroanatomic mapping for\nrecurrent ventricular tachycardia after myocardial infarction: the multicenter ther-\nmocool ventricular tachycardia ablation trial. Circulation 2008;118:2773–2782.\n479. Della Bella P, Baratto F, Tsiachris D, Trevisi N, Vergara P, Bisceglia C, et al.\nManagement of ventricular tachycardia in the setting of a dedicated unit for the\ntreatment of complex ventricular arrhythmias: long-term outcome after ablation.\nCirculation 2013;127:1359–1368.\n480. Maury P, Baratto F, Zeppenfeld K, Klein G, Delacretaz E, Sacher F, et al.\nRadio-frequency ablation as primary management of well-tolerated sustained\nmonomorphic ventricular tachycardia in patients with structural heart disease\nand left ventricular ejection fraction over 30%. Eur Heart J 2014;35:1479–1485.\n481. Tung R, Vaseghi M, Frankel DS, Vergara P, Di Biase L, Nagashima K, et al. Freedom\nfrom recurrent ventricular tachycardia after catheter ablation is associated with im-\nproved survival in patients with structural heart disease: an International VT\nAblation Center Collaborative Group study. Heart Rhythm 2015;12:1997–2007.\n482. Santangeli P, Zado ES, Supple GE, Haqqani HM, Garcia FC, Tschabrunn CM, et al.\nLong-term outcome with catheter ablation of ventricular tachycardia in patients\nwith\narrhythmogenic\nright\nventricular\ncardiomyopathy.\nCirc\nArrhythm\nElectrophysiol 2015;8:1413–1421.\n483. Marchlinski FE, Haffajee CI, Beshai JF, Dickfeld T-ML, Gonzalez MD, Hsia HH, et al.\nLong-term success of irrigated radiofrequency catheter ablation of sustained ven-\ntricular tachycardia. J Am Coll Cardiol 2016;67:674–683.\n484. Reddy VY, Reynolds MR, Neuzil P, Richardson AW, Taborsky M, Jongnarangsin K,\net al. Prophylactic catheter ablation for the prevention of deﬁbrillator therapy. N\nEngl J Med 2007;357:2657–2665.\n485. Kuck K-H, Schaumann A, Eckardt L, Willems S, Ventura R, Delacrétaz E, et al.\nCatheter ablation of stable ventricular tachycardia before deﬁbrillator implantation\nin patients with coronary heart disease (VTACH): a multicentre randomised con-\ntrolled trial. Lancet 2010;375:31–40.\n486. Anter E, Kleber AG, Rottmann M, Leshem E, Barkagan M, Tschabrunn CM, et al.\nInfarct-related ventricular tachycardia. JACC Clin Electrophysiol 2018;4:1033–1048.\n487. Marchlinski FE, Callans DJ, Gottlieb CD, Zado E. Linear ablation lesions for control\nof unmappable ventricular tachycardia in patients with ischemic and nonischemic\ncardiomyopathy. Circulation 2000;101:1288–1296.\n488. de Chillou C, Groben L, Magnin-Poull I, Andronache M, Abbas MM, Zhang N, et al.\nLocalizing the critical isthmus of postinfarct ventricular tachycardia: the value of\npace-mapping during sinus rhythm. Heart Rhythm 2014;11:175–181.\n489. Jaïs P, Maury P, Khairy P, Sacher F, Nault I, Komatsu Y, et al. Elimination of local ab-\nnormal ventricular activities: a new end point for substrate modiﬁcation in patients\nwith scar-related ventricular tachycardia. Circulation 2012;125:2184–2196.\n490. Berruezo A, Fernandez-Armenta J. Lines, circles, channels, and clouds: looking for\nthe best design for substrate-guided ablation of ventricular tachycardia. Europace\n2014;16:943–945.\n491. Di Biase L, Burkhardt JD, Lakkireddy D, Carbucicchio C, Mohanty S, Mohanty P,\net al. Ablation of stable VTs versus substrate ablation in ischemic cardiomyopathy.\nJ Am Coll Cardiol 2015;66:2872–2882.\n492. Berruezo A, Fernández-Armenta J, Andreu D, Penela D, Herczku C, Evertz R, et al.\nScar dechanneling: new method for scar-related left ventricular tachycardia sub-\nstrate ablation. Circ Arrhythm Electrophysiol 2015;8:326–336.\n493. Haïssaguerre M, Shoda M, Jaïs P, Nogami A, Shah DC, Kautzner J, et al. Mapping and\nablation of idiopathic ventricular ﬁbrillation. Circulation 2002;106:962–967.\n494. Shirai Y, Liang JJ, Santangeli P, Arkles JS, Schaller RD, Supple GE, et al. Comparison\nof the ventricular tachycardia circuit between patients with ischemic and nonis-\nchemic cardiomyopathies: detailed characterization by entrainment. Circ Arrhythm\nElectrophysiol 2019;12:e007249.\n495. Bhaskaran A, Tung R, Stevenson WG, Kumar S. Catheter ablation of VT in non-\nischaemic cardiomyopathies: endocardial, epicardial and intramural approaches.\nHeart Lung Circ 2019;28:84–101.\n496. Tung R, Raiman M, Liao H, Zhan X, Chung FP, Nagel R, et al. Simultaneous endo-\ncardial and epicardial delineation of 3D reentrant ventricular tachycardia. J Am Coll\nCardiol 2020;75:884–897.\n497. Dinov B, Fiedler L, Schönbauer R, Bollmann A, Rolf S, Piorkowski C, et al.\nOutcomes in catheter ablation of ventricular tachycardia in dilated nonischemic\ncardiomyopathy compared with ischemic cardiomyopathy: results from the\nProspective Heart Centre of Leipzig VT (HELP-VT) Study. Circulation 2014;129:\n728–736.\n498. Proietti R, Essebag V, Beardsall J, Hache P, Pantano A, Wulffhart Z, et al.\nSubstrate-guided ablation of haemodynamically tolerated and untolerated ven-\ntricular tachycardia in patients with structural heart disease: effect of cardiomyop-\nathy type and acute success on long-term outcome. Europace 2015;17:461–467.\n499. Ebert M, Richter S, Dinov B, Zeppenfeld K, Hindricks G. Evaluation and manage-\nment of ventricular tachycardia in patients with dilated cardiomyopathy. Heart\nRhythm 2019;16:624–631.\n500. Proietti R, Lichelli L, Lellouche N, Dhanjal T. The challenge of optimising ablation\nlesions in catheter ablation of ventricular tachycardia. J Arrhythmia 2021;37:\n140–147.\n501. Tokuda M, Sobieszczyk P, Eisenhauer AC, Kojodjojo P, Inada K, Koplan BA, et al.\nTranscoronary ethanol ablation for recurrent ventricular tachycardia after failed\ncatheter ablation: an update. Circ Arrhythm Electrophysiol 2011;4:889–896.\n502. Kreidieh B, Rodríguez-Mañero M, Schurmann P, Ibarra-Cortez SH, Dave AS,\nValderrábano M. Retrograde coronary venous ethanol infusion for ablation of re-\nfractory ventricular tachycardia. Circ Arrhythm Electrophysiol 2016;9:e004352.\n503. Nguyen DT, Tzou WS, Sandhu A, Gianni C, Anter E, Tung R, et al. Prospective mul-\nticenter experience with cooled radiofrequency ablation using high impedance ir-\nrigant to target deep myocardial substrate refractory to standard ablation. JACC Clin\nElectrophysiol 2018;4:1176–1185.\n504. Stevenson WG, Tedrow UB, Reddy V, AbdelWahab A, Dukkipati S, John RM, et al.\nInfusion needle radiofrequency ablation for treatment of refractory ventricular ar-\nrhythmias. J Am Coll Cardiol 2019;73:1413–1425.\n505. Igarashi M, Nogami A, Fukamizu S, Sekiguchi Y, Nitta J, Sakamoto N, et al. Acute and\nlong-term results of bipolar radiofrequency catheter ablation of refractory ven-\ntricular arrhythmias of deep intramural origin. Heart Rhythm 2020;17:1500–1507.\n506. Della Bella P, Peretto G, Paglino G, Bisceglia C, Radinovic A, Sala S, et al. Bipolar\nradiofrequency ablation for ventricular tachycardias originating from the interven-\ntricular septum: safety and efﬁcacy in a pilot cohort study. Heart Rhythm 2020;17:\n2111–2118.\n507. Cuculich PS, Schill MR, Kashani R, Mutic S, Lang A, Cooper D, et al. Noninvasive\ncardiac radiation for ablation of ventricular tachycardia. N Engl J Med 2017;377:\n2325–2336.\n508. Robinson CG, Samson PP, Moore KMS, Hugo GD, Knutson N, Mutic S, et al. Phase\nI/II trial of electrophysiology-guided noninvasive cardiac radioablation for ventricu-\nlar tachycardia. Circulation 2019;139:313–321.\n509. Anter E, Hutchinson MD, Deo R, Haqqani HM, Callans DJ, Gerstenfeld EP, et al.\nSurgical ablation of refractory ventricular tachycardia in patients with nonischemic\ncardiomyopathy. Circ Arrhythm Electrophysiol 2011;4:494–500.\n510. Fernández-Armenta J, Berruezo A, Andreu D, Camara O, Silva E, Serra L, et al.\nThree-dimensional architecture of scar and conducting channels based on high\nresolution ce-CMR: insights for ventricular tachycardia ablation. Circ Arrhythm\nElectrophysiol 2013;6:528–537.\n511. Mahida S, Sacher F, Dubois R, Sermesant M, Bogun F, Haïssaguerre M, et al. Cardiac\nimaging in patients with ventricular tachycardia. Circulation 2017;136:2491–2507.\n512. Andreu D, Penela D, Acosta J, Fernández-Armenta J, Perea RJ, Soto-Iglesias D, et al.\nCardiac magnetic resonance–aided scar dechanneling: inﬂuence on acute and long-\nterm outcomes. Heart Rhythm 2017;14:1121–1128.\n513. Kuo L, Liang JJ, Nazarian S, Marchlinski FE. Multimodality imaging to guide ventricu-\nlar tachycardia ablation in patients with non-ischaemic cardiomyopathy. Arrhythm\nElectrophysiol Rev 2020;8:255–264.\n514. Roca-Luque I, Van Breukelen A, Alarcon F, Garre P, Tolosana JM, Borras R, et al.\nVentricular scar channel entrances identiﬁed by new wideband cardiac magnetic\nresonance sequence to guide ventricular tachycardia ablation in patients with car-\ndiac deﬁbrillators. Europace 2020;22:598–606.\n515. Betensky BP, Marchlinski FE. Outcomes of catheter ablation of ventricular tachy-\ncardia in the setting of structural heart disease. Curr Cardiol Rep 2016;18:68.\n516. Dukkipati SR, Koruth JS, Choudry S, Miller MA, Whang W, Reddy VY. Catheter ab-\nlation of ventricular tachycardia in structural heart disease. J Am Coll Cardiol 2017;\n70:2924–2941.\n517. Zeppenfeld K. Ventricular tachycardia ablation in nonischemic cardiomyopathy.\nJACC Clin Electrophysiol 2018;4:1123–1140.\n518. Guandalini GS, Liang JJ, Marchlinski FE. Ventricular tachycardia ablation. JACC Clin\nElectrophysiol 2019;5:1363–1383.\n4112\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n519. Peichl P, Wichterle D, Pavlu L, Cihak R, Aldhoon B, Kautzner J. Complications of\ncatheter ablation of ventricular tachycardia: a single-center experience. Circ\nArrhythm Electrophysiol 2014;7:684–690.\n520. Katz DF, Turakhia MP, Sauer WH, Tzou WS, Heath RR, Zipse MM, et al. Safety of\nventricular tachycardia ablation in clinical practice: ﬁndings from 9699 hospital dis-\ncharge records. Circ Arrhythm Electrophysiol 2015;8:362–370.\n521. Cheung JW, Yeo I, Ip JE, Thomas G, Liu CF, Markowitz SM, et al. Outcomes, costs,\nand 30-day readmissions after catheter ablation of myocardial infarct–associated\nventricular tachycardia in the real world: nationwide readmissions database 2010\nto 2015. Circ Arrhythm Electrophysiol 2018;11:e006754.\n522. Hendriks AA, Akca F, Dabiri Abkenari L, Khan M, Bhagwandien R, Yap S-C, et al.\nSafety and clinical outcome of catheter ablation of ventricular arrhythmias using\ncontact force sensing: consecutive case series. J Cardiovasc Electrophysiol 2015;26:\n1224–1229.\n523. Nogami A. Purkinje-related arrhythmias part I: monomorphic ventricular tachycar-\ndias. Pacing Clin Electrophysiol 2011;34:624–650.\n524. Lerman BB. Mechanism, diagnosis, and treatment of outﬂow tract tachycardia. Nat\nRev Cardiol 2015;12:597–608.\n525. Kobayashi Y. Idiopathic ventricular premature contraction and ventricular tachy-\ncardia: distribution of the origin, diagnostic algorithm, and catheter ablation. J\nNippon Med Sch 2018;85:87–94.\n526. Tada H, Ito S, Naito S, Kurosaki K, Kubota S, Sugiyasu A, et al. Idiopathic ventricular\narrhythmia arising from the mitral annulus: a distinct subgroup of idiopathic ven-\ntricular arrhythmias. J Am Coll Cardiol 2005;45:877–886.\n527. Wasmer K, Köbe J, Dechering DG, Bittner A, Pott C, Mönnig G, et al. Ventricular\narrhythmias from the mitral annulus: patient characteristics, electrophysiological\nﬁndings, ablation, and prognosis. Heart Rhythm 2013;10:783–788.\n528. Tada H, Tadokoro K, Ito S, Naito S, Hashimoto T, Kaseno K, et al. Idiopathic ven-\ntricular arrhythmias originating from the tricuspid annulus: prevalence, electrocar-\ndiographic characteristics, and results of radiofrequency catheter ablation. Heart\nRhythm 2007;4:7–16.\n529. Yamada T, Doppalapudi H, McElderry HT, Okada T, Murakami Y, Inden Y, et al.\nElectrocardiographic and electrophysiological characteristics in idiopathic ventricu-\nlar arrhythmias originating from the papillary muscles in the left ventricle: relevance\nfor catheter ablation. Circ Arrhythm Electrophysiol 2010;3:324–331.\n530. Macias C, Nakamura K, Tung R, Boyle NG, Kalyanam S, Bradﬁeld JS. Importance of\ndelayed enhanced cardiac MRI in idiopathic RVOT-VT: differentiating mimics in-\ncluding early stage ARVC and cardiac sarcoidosis. J Atr Fibrillation 2014;7:1097.\n531. Heeger C-H, Hayashi K, Kuck K-H, Ouyang F. Catheter ablation of idiopathic ven-\ntricular arrhythmias arising from the cardiac outﬂow tracts—recent insights and\ntechniques for the successful treatment of common and challenging cases. Circ J\n2016;80:1073–1086.\n532. Pathak RK, Ariyarathna N, Garcia FC, Sanders P, Marchlinski FE. Catheter ablation\nof idiopathic ventricular arrhythmias. Heart Lung Circ 2019;28:102–109.\n533. Yamada T, McElderry HT, Doppalapudi H, Murakami Y, Yoshida Y, Yoshida N, et al.\nIdiopathic ventricular arrhythmias originating from the aortic root prevalence, elec-\ntrocardiographic and electrophysiologic characteristics, and results of radiofre-\nquency catheter ablation. J Am Coll Cardiol 2008;52:139–147.\n534. Van Herendael H, Garcia F, Lin D, Riley M, Bala R, Cooper J, et al. Idiopathic right\nventricular arrhythmias not arising from the outﬂow tract: prevalence, electrocar-\ndiographic characteristics, and outcome of catheter ablation. Heart Rhythm 2011;8:\n511–518.\n535. Latchamsetty R, Yokokawa M, Morady F, Kim HM, Mathew S, Tilz R, et al.\nMulticenter outcomes for catheter ablation of idiopathic premature ventricular\ncomplexes. JACC Clin Electrophysiol 2015;1:116–123.\n536. Liu Y, Fang Z, Yang B, Kojodjojo P, Chen H, Ju W, et al. Catheter ablation of fasci-\ncular ventricular tachycardia: long-term clinical outcomes and mechanisms of re-\ncurrence. Circ Arrhythm Electrophysiol 2015;8:1443–1451.\n537. Hayashi T, Liang JJ, Shirai Y, Kuo L, Muser D, Kubala M, et al. Trends in successful\nablation sites and outcomes of ablation for idiopathic outﬂow tract ventricular ar-\nrhythmias. JACC Clin Electrophysiol 2020;6:221–230.\n538. Farré J, Wellens HJ. Philippe Coumel: a founding father of modern arrhythmology.\nEuropace 2004;6:464–465.\n539. Neira V, Enriquez A, Simpson C, Baranchuk A. Update on long QT syndrome. J\nCardiovasc Electrophysiol 2019;30:3068–3078.\n540. Winbo A, Paterson DJ. The brain-heart connection in sympathetically triggered in-\nherited arrhythmia syndromes. Heart Lung Circ 2020;29:529–537.\n541. Schwartz PJ, Priori SG, Cerrone M, Spazzolini C, Odero A, Napolitano C, et al. Left\ncardiac sympathetic denervation in the management of high-risk patients affected\nby the long-QT syndrome. Circulation 2004;109:1826–1833.\n542. Surman TL, Stuklis RG, Chan JC. Thoracoscopic sympathectomy for long QT syn-\ndrome. Literature review and case study. Heart Lung Circ 2019;28:486–494.\n543. Orvin K, Eisen A, Goldenberg I, Gottlieb S, Kornowski R, Matetzky S, et al.\nOutcome of contemporary acute coronary syndrome complicated by ventricular\ntachyarrhythmias. Europace 2016;18:219–226.\n544. Demirel F, Rasoul S, Elvan A, Ottervanger JP, Dambrink J-HE, Gosselink ATM, et al.\nImpact of out-of-hospital cardiac arrest due to ventricular ﬁbrillation in patients\nwith ST-elevation myocardial infarction admitted for primary percutaneous coron-\nary intervention: Impact of ventricular ﬁbrillation in STEMI patients. Eur Heart J\nAcute Cardiovasc Care 2015;4:16–23.\n545. Mehta RH, Starr AZ, Lopes RD, Hochman JS, Widimsky P, Pieper KS, et al.\nIncidence of and outcomes associated with ventricular tachycardia or ﬁbrillation\nin patients undergoing primary percutaneous coronary intervention. JAMA 2009;\n301:1779–1789.\n546. Demidova MM, Carlson J, Erlinge D, Platonov PG. Predictors of ventricular ﬁbrilla-\ntion at reperfusion in patients with acute ST-elevation myocardial infarction treated\nby primary percutaneous coronary intervention. Am J Cardiol 2015;115:417–422.\n547. Cheng Y-J, Li Z-Y, Yao F-J, Xu X-J, Ji C-C, Chen X-M, et al. Early repolarization is\nassociated with a signiﬁcantly increased risk of ventricular arrhythmias and sudden\ncardiac death in patients with structural heart diseases. Heart Rhythm 2017;14:\n1157–1164.\n548. Dumas F, Bougouin W, Geri G, Lamhaut L, Rosencher J, Pène F, et al. Emergency\npercutaneous coronary intervention in post-cardiac arrest patients without\nST-segment elevation pattern: insights from the PROCAT II registry. JACC\nCardiovasc Interv 2016;9:1011–1018.\n549. Chatterjee S, Chaudhuri D, Vedanthan R, Fuster V, Ibanez B, Bangalore S, et al. Early\nintravenous\nbeta-blockers\nin\npatients\nwith\nacute\ncoronary\nsyndrome–a\nmeta-analysis of randomized trials. Int J Cardiol 2013;168:915–921.\n550. Roolvink V, Ibáñez B, Ottervanger JP, Pizarro G, van Royen N, Mateos A, et al. Early\nintravenous beta-blockers in patients with ST-segment elevation myocardial infarc-\ntion before primary percutaneous coronary intervention. J Am Coll Cardiol 2016;67:\n2705–2715.\n551. Piccini JP, Hranitzky PM, Kilaru R, Rouleau J-L, White HD, Aylward PE, et al.\nRelation of mortality to failure to prescribe beta blockers acutely in patients with\nsustained ventricular tachycardia and ventricular ﬁbrillation following acute myo-\ncardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial\n[VALIANT] Registry). Am J Cardiol 2008;102:1427–1432.\n552. Nademanee K, Taylor R, Bailey WE, Rieders DE, Kosar EM. Treating electrical\nstorm: sympathetic blockade versus advanced cardiac life support-guided therapy.\nCirculation 2000;102:742–747.\n553. Bundgaard JS, Jacobsen PK, Grand J, Lindholm MG, Hassager C, Pehrson S, et al.\nDeep sedation as temporary bridge to deﬁnitive treatment of ventricular arrhyth-\nmia storm. Eur Heart J Acute Cardiovasc Care 2020;9:657–664.\n554. Piccini JP, Schulte PJ, Pieper KS, Mehta RH, White HD, Van de Werf F, et al.\nAntiarrhythmic drug therapy for sustained ventricular arrhythmias complicating\nacute myocardial infarction. Crit Care Med 2011;39:78–83.\n555. Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone as\ncompared with lidocaine for shock-resistant ventricular ﬁbrillation. N Engl J Med\n2002;346:884–890.\n556. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al.\nMortality and morbidity in patients receiving encainide, ﬂecainide, or placebo.\nThe Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781–788.\n557. Baudry G, Sonneville R, Waintraub X, Lebreton G, Deguillard C, Mertens E, et al.\nExtracorporeal membrane oxygenation to support life-threatening drug-refractory\nelectrical storm. Crit Care Med 2020;48:e856–e863.\n558. Demidova MM, Smith JG, Höijer C-J, Holmqvist F, Erlinge D, Platonov PG.\nPrognostic impact of early ventricular ﬁbrillation in patients with ST-elevation myo-\ncardial infarction treated with primary PCI. Eur Heart J Acute Cardiovasc Care 2012;\n1:302–311.\n559. Podolecki T, Lenarczyk R, Kowalczyk J, Jedrzejczyk-Patej E, Chodor P, Mazurek M,\net al. Prognostic signiﬁcance of complex ventricular arrhythmias complicating\nST-segment elevation myocardial infarction. Am J Cardiol 2018;121:805–809.\n560. Bougouin W, Marijon E, Puymirat E, Defaye P, Celermajer DS, Le Heuzey J-Y, et al.\nIncidence of sudden cardiac death after ventricular ﬁbrillation complicating acute\nmyocardial infarction: a 5-year cause-of-death analysis of the FAST-MI 2005 regis-\ntry. Eur Heart J 2014;35:116–122.\n561. Liang JJ, Hodge DO, Mehta RA, Russo AM, Prasad A, Cha Y-M. Outcomes in pa-\ntients with sustained ventricular tachyarrhythmias occurring within 48 h of acute\nmyocardial infarction: when is ICD appropriate? Europace 2014;16:1759–1766.\n562. Ahn J-M, Lee KH, Yoo S-Y, Cho Y-R, Suh J, Shin E-S, et al. Prognosis of variant angina\nmanifesting as aborted sudden cardiac death. J Am Coll Cardiol 2016;68:137–145.\n563. Sueda S, Kohno H. Optimal medications and appropriate implantable cardioverter-\ndeﬁbrillator shocks in aborted sudden cardiac death due to coronary spasm. Intern\nMed 2018;57:1361–1369.\n564. Rodríguez-Mañero M, Oloriz T, le Polain de Waroux J-B, Burri H, Kreidieh B, de\nAsmundis C, et al. Long-term prognosis of patients with life-threatening ventricular\narrhythmias induced by coronary artery spasm. Europace 2018;20:851–858.\n565. Solomon SD, Zelenkofske S, McMurray JJV, Finn PV, Velazquez E, Ertl G, et al.\nSudden death in patients with myocardial infarction and left ventricular dysfunction,\nheart failure, or both. N Engl J Med 2005;352:2581–2588.\nESC Guidelines\n4113\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n566. Busk M, Maeng M, Kristensen SD, Thuesen L, Krusell LR, Mortensen LS, et al.\nTiming, causes, and predictors of death after three years’ follow-up in the\nDanish Multicenter Randomized Study of Fibrinolysis versus Primary Angioplasty\nin Acute Myocardial Infarction (DANAMI-2) trial. Am J Cardiol 2009;104:210–215.\n567. St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moyé LA, Dagenais GR, et al.\nQuantitative two-dimensional echocardiographic measurements are major predic-\ntors of adverse cardiovascular events after acute myocardial infarction. The pro-\ntective effects of captopril. Circulation 1994;89:68–75.\n568. Søholm H, Lønborg J, Andersen MJ, Vejlstrup N, Engstrøm T, Møller JE, et al.\nRepeated echocardiography after ﬁrst ever ST-segment elevation myocardial in-\nfarction treated with primary percutaneous coronary intervention–is it necessary?\nEur Heart J Acute Cardiovasc Care 2015;4:528–536.\n569. Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D,\net al. Deﬁbrillator implantation early after myocardial infarction. N Engl J Med\n2009;361:1427–1436.\n570. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al.\nProphylactic use of an implantable cardioverter-deﬁbrillator after acute myocardial\ninfarction. N Engl J Med 2004;351:2481–2488.\n571. Exner DV, Kavanagh KM, Slawnych MP, Mitchell LB, Ramadan D, Aggarwal SG, et al.\nNoninvasive risk assessment early after a myocardial infarction the REFINE study. J\nAm Coll Cardiol 2007;50:2275–2284.\n572. Zaman S, Narayan A, Thiagalingam A, Sivagangabalan G, Thomas S, Ross DL, et al.\nLong-term arrhythmia-free survival in patients with severe left ventricular dysfunc-\ntion and no inducible ventricular tachycardia after myocardial infarction. Circulation\n2014;129:848–854.\n573. Daubert MA, White JA, Al-Khalidi HR, Velazquez EJ, Rao SV, Crowley AL, et al.\nCardiac remodeling after large ST-elevation myocardial infarction in the current\ntherapeutic era. Am Heart J 2020;223:87–97.\n574. Chew DS, Heikki H, Schmidt G, Kavanagh KM, Dommasch M, Bloch Thomsen PE,\net al. Change in left ventricular ejection fraction following ﬁrst myocardial infarction\nand outcome. JACC Clin Electrophysiol 2018;4:672–682.\n575. Bänsch D, Oyang F, Antz M, Arentz T, Weber R, Val-Mejias JE, et al. Successful cath-\neter ablation of electrical storm after myocardial infarction. Circulation 2003;108:\n3011–3016.\n576. Altmann DR, Mutschelknauss M, Ehl N, Koller M, Schaer B, Jörg L, et al. Prevalence\nof severely impaired left ventricular ejection fraction after reperfused ST-elevation\nmyocardial infarction. Swiss Med Wkly 2013;143:w13869.\n577. Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, et al. Declining risk\nof sudden death in heart failure. N Engl J Med 2017;377:41–51.\n578. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myo-\ncardial infarction in patients with frequent or repetitive ventricular premature de-\npolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia\nTrial Investigators. Lancet 1997;349:675–682.\n579. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, et al. Randomised\ntrial of effect of amiodarone on mortality in patients with left-ventricular dysfunc-\ntion after recent myocardial infarction: EMIAT. European Myocardial Infarct\nAmiodarone Trial Investigators. Lancet 1997;349:667–674.\n580. Clemens M, Peichl P, Wichterle D, Pavlů L, Čihák R, Aldhoon B, et al. Catheter ab-\nlation of ventricular tachycardia as the ﬁrst-line therapy in patients with coronary\nartery disease and preserved left ventricular systolic function: long-term results:\nVT ablation in patients with preserved LV function. J Cardiovasc Electrophysiol\n2015;26:1105–1110.\n581. Paciﬁco A, Hohnloser SH, Williams JH, Tao B, Saksena S, Henry PD, et al.\nPrevention of implantable-deﬁbrillator shocks by treatment with sotalol.\nD,\nL-Sotalol Implantable Cardioverter-Deﬁbrillator Study Group. N Engl J Med 1999;\n340:1855–1862.\n582. Willems S, Tilz RR, Steven D, Kääb S, Wegscheider K, Gellér L, et al. Preventive or\ndeferred ablation of ventricular tachycardia in patients with ischemic cardiomyop-\nathy and implantable deﬁbrillator (BERLIN VT): a multicenter randomized trial.\nCirculation 2020;141:1057–1067.\n583. Kuck K-H, Tilz RR, Deneke T, Hoffmann BA, Ventura R, Hansen PS, et al. Impact of\nsubstrate modiﬁcation by catheter ablation on implantable cardioverter–deﬁbrilla-\ntor interventions in patients with unstable ventricular arrhythmias and coronary ar-\ntery disease: results from the multicenter randomized controlled SMS (substrate\nmodiﬁcation study). Circ Arrhythm Electrophysiol 2017;10:e004422.\n584. Olshansky B, Hahn EA, Hartz VL, Prater SP, Mason JW. Clinical signiﬁcance of syn-\ncope in the electrophysiologic study versus electrocardiographic monitoring\n(ESVEM) trial. The ESVEM Investigators. Am Heart J 1999;137:878–886.\n585. Molossi S, Agrawal H, Mery CM, Krishnamurthy R, Masand P, Sexson Tejtel SK,\net al. Outcomes in anomalous aortic origin of a coronary artery following a pro-\nspective standardized approach. Circ Cardiovasc Interv 2020;13:e008445.\n586. Krasuski RA, Magyar D, Hart S, Kalahasti V, Lorber R, Hobbs R, et al. Long-term\noutcome and impact of surgery on adults with coronary arteries originating from\nthe opposite coronary cusp. Circulation 2011;123:154–162.\n587. Jegatheeswaran A, Devlin PJ, McCrindle BW, Williams WG, Jacobs ML, Blackstone\nEH, et al. Features associated with myocardial ischemia in anomalous aortic origin\nof a coronary artery: a congenital heart surgeons’ society study. J Thorac Cardiovasc\nSurg 2019;158:822–834.\n588. Jegatheeswaran A, Devlin PJ, Williams WG, Brothers JA, Jacobs ML, DeCampli\nWM, et al. Outcomes after anomalous aortic origin of a coronary artery repair:\na congenital heart surgeons’ society study. J Thorac Cardiovasc Surg 2020;160:\n757–771.\n589. Hoffmayer KS, Bhave PD, Marcus GM, James CA, Tichnell C, Chopra N, et al. An\nelectrocardiographic scoring system for distinguishing right ventricular outﬂow\ntract arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy\nfrom idiopathic ventricular tachycardia. Heart Rhythm 2013;10:477–482.\n590. Yokokawa M, Siontis KC, Kim HM, Stojanovska J, Latchamsetty R, Crawford T, et al.\nValue of cardiac magnetic resonance imaging and programmed ventricular stimula-\ntion in patients with frequent premature ventricular complexes undergoing radio-\nfrequency ablation. Heart Rhythm 2017;14:1695–1701.\n591. Muser D, Santangeli P, Castro SA, Casado Arroyo R, Maeda S, Benhayon DA, et al.\nRisk stratiﬁcation of patients with apparently idiopathic premature ventricular con-\ntractions: a multicenter international CMR registry. JACC Clin Electrophysiol 2020;6:\n722–735.\n592. Kjekshus J, Bathen J, Orning OM, Storstein L. A double-blind, crossover comparison\nof ﬂecainide acetate and disopyramide phosphate in the treatment of ventricular\npremature complexes. Am J Cardiol 1984;53:72B–78B.\n593. Hamon D, Swid MA, Rajendran PS, Liu A, Boyle NG, Shivkumar K, et al. Premature\nventricular contraction diurnal proﬁles predict distinct clinical characteristics and\nbeta-blocker responses. J Cardiovasc Electrophysiol 2019;30:836–843.\n594. Primeau R, Agha A, Giorgi C, Shenasa M, Nadeau R. Long term efﬁcacy and toxicity\nof amiodarone in the treatment of refractory cardiac arrhythmias. Can J Cardiol\n1989;5:98–104.\n595. Ling Z, Liu Z, Su L, Zipunnikov V, Wu J, Du H, et al. Radiofrequency ablation versus\nantiarrhythmic medication for treatment of ventricular premature beats from the\nright ventricular outﬂow tract: prospective randomized study. Circ Arrhythm\nElectrophysiol 2014;7:237–243.\n596. Baksiene D, Sileikiene R, Sileikis V, Kazakevicius T, Zabiela V, Zebiene M, et al.\nIdiopathic ventricular tachycardia in children: curative therapy with radiofrequency\nablation. Medicina (Kaunas) 2007;43:803–807.\n597. Blaufox AD, Felix GL, Saul JP, Pediatric Catheter Ablation Registry. Radiofrequency\ncatheter ablation in infants ,/=18 months old: when is it done and how do they\nfare?: Short-term data from the pediatric ablation registry. Circulation 2001;104:\n2803–2808.\n598. Lapage MJ, Bradley DJ, Dick M. Verapamil in infants: an exaggerated fear? Pediatr\nCardiol 2013;34:1532–1534.\n599. Lee AKY, Andrade J, Hawkins NM, Alexander G, Bennett MT, Chakrabarti S, et al.\nOutcomes of untreated frequent premature ventricular complexes with normal\nleft ventricular function. Heart 2019;105:1408–1413.\n600. Baman TS, Lange DC, Ilg KJ, Gupta SK, Liu T-Y, Alguire C, et al. Relationship be-\ntween burden of premature ventricular complexes and left ventricular function.\nHeart Rhythm 2010;7:865–869.\n601. van Huls van Taxis CFB, Piers SRD, de Riva Silva M, Dekkers OM, Pijnappels DA,\nSchalij MJ, et al. Fatigue as presenting symptom and a high burden of premature ven-\ntricular contractions are independently associated with increased ventricular wall\nstress\nin\npatients\nwith\nnormal\nleft\nventricular\nfunction.\nCirc\nArrhythm\nElectrophysiol 2015;8:1452–1459.\n602. Sharma N, Cortez D, Imundo JR. High burden of premature ventricular contrac-\ntions in structurally normal hearts: to worry or not in pediatric patients? Ann\nNoninvasive Electrocardiol 2019;24:e12663.\n603. Niwano S, Wakisaka Y, Niwano H, Fukaya H, Kurokawa S, Kiryu M, et al. Prognostic\nsigniﬁcance of frequent premature ventricular contractions originating from the\nventricular outﬂow tract in patients with normal left ventricular function. Heart\n2009;95:1230–1237.\n604. Krittayaphong R, Sriratanasathavorn C, Dumavibhat C, Pumprueg S, Boonyapisit\nW, Pooranawattanakul S, et al. Electrocardiographic predictors of long-term out-\ncomes after radiofrequency ablation in patients with right-ventricular outﬂow tract\ntachycardia. Europace 2006;8:601–606.\n605. Komatsu Y, Nogami A, Kurosaki K, Morishima I, Masuda K, Ozawa T, et al.\nFascicular ventricular tachycardia originating from papillary muscles: Purkinje net-\nwork involvement in the reentrant circuit. Circ Arrhythm Electrophysiol 2017;10:\ne004549.\n606. Kirk CR, Gibbs JL, Thomas R, Radley-Smith R, Qureshi SA. Cardiovascular collapse\nafter verapamil in supraventricular tachycardia. Arch Dis Child 1987;62:1265–1266.\n607. Duffee DF, Shen WK, Smith HC. Suppression of frequent premature ventricular\ncontractions and improvement of left ventricular function in patients with pre-\nsumed idiopathic dilated cardiomyopathy. Mayo Clin Proc 1998;73:430–433.\n4114\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n608. Chugh SS, Shen WK, Luria DM, Smith HC. First evidence of premature ventricular\ncomplex-induced cardiomyopathy: a potentially reversible cause of heart failure. J\nCardiovasc Electrophysiol 2000;11:328–329.\n609. Penela D, Van Huls Van Taxis C, Van Huls Vans Taxis C, Aguinaga L,\nFernández-Armenta J, Mont L, et al. Neurohormonal, structural, and functional re-\ncovery pattern after premature ventricular complex ablation is independent of\nstructural heart disease status in patients with depressed left ventricular ejection\nfraction: a prospective multicenter study. J Am Coll Cardiol 2013;62:1195–1202.\n610. Penela D, Acosta J, Aguinaga L, Tercedor L, Ordoñez A, Fernández-Armenta J, et al.\nAblation of frequent PVC in patients meeting criteria for primary prevention ICD\nimplant: safety of withholding the implant. Heart Rhythm 2015;12:2434–2442.\n611. Voskoboinik A, Hadjis A, Alhede C, Im SI, Park H, Moss J, et al. Predictors of adverse\noutcome in patients with frequent premature ventricular complexes: the ABC-VT\nrisk score. Heart Rhythm 2020;17:1066–1074.\n612. Lee A, Denman R, Haqqani HM. Ventricular ectopy in the context of left ventricular\nsystolic dysfunction: risk factors and outcomes following catheter ablation. Heart\nLung Circ 2019;28:379–388.\n613. Sadron Blaye-Felice M, Hamon D, Sacher F, Pascale P, Rollin A, Duparc A, et al.\nPremature ventricular contraction-induced cardiomyopathy: related clinical and\nelectrophysiologic parameters. Heart Rhythm 2016;13:103–110.\n614. Penela D, Fernández-Armenta J, Aguinaga L, Tercedor L, Ordoñez A, Bisbal F, et al.\nClinical recognition of pure premature ventricular complex-induced cardiomyop-\nathy at presentation. Heart Rhythm 2017;14:1864–1870.\n615. Aquaro GD, Pingitore A, Strata E, Di Bella G, Molinaro S, Lombardi M. Cardiac\nmagnetic resonance predicts outcome in patients with premature ventricular com-\nplexes of left bundle branch block morphology. J Am Coll Cardiol 2010;56:\n1235–1243.\n616. Oebel S, Dinov B, Arya A, Hilbert S, Sommer P, Bollmann A, et al. ECG morphology\nof premature ventricular contractions predicts the presence of myocardial ﬁbrotic\nsubstrate on cardiac magnetic resonance imaging in patients undergoing ablation. J\nCardiovasc Electrophysiol 2017;28:1316–1323.\n617. Mountantonakis SE, Frankel DS, Gerstenfeld EP, Dixit S, Lin D, Hutchinson MD,\net al. Reversal of outﬂow tract ventricular premature depolarization–induced car-\ndiomyopathy with ablation: effect of residual arrhythmia burden and preexisting\ncardiomyopathy on outcome. Heart Rhythm 2011;8:1608–1614.\n618. Zang M, Zhang T, Mao J, Zhou S, He B. Beneﬁcial effects of catheter ablation of fre-\nquent premature ventricular complexes on left ventricular function. Heart 2014;\n100:787–793.\n619. Wijnmaalen AP, Delgado V, Schalij MJ, van Huls van Taxis CFB, Holman ER, Bax JJ,\net al. Beneﬁcial effects of catheter ablation on left ventricular and right ventricular\nfunction in patients with frequent premature ventricular contractions and pre-\nserved ejection fraction. Heart 2010;96:1275–1280.\n620. Bogun F, Crawford T, Reich S, Koelling TM, Armstrong W, Good E, et al.\nRadiofrequency ablation of frequent, idiopathic premature ventricular complexes:\ncomparison with a control group without intervention. Heart Rhythm 2007;4:\n863–867.\n621. Sarrazin J-F, Labounty T, Kuhne M, Crawford T, Armstrong WF, Desjardins B, et al.\nImpact of radiofrequency ablation of frequent post-infarction premature ventricu-\nlar complexes on left ventricular ejection fraction. Heart Rhythm 2009;6:\n1543–1549.\n622. El Kadri M, Yokokawa M, Labounty T, Mueller G, Crawford T, Good E, et al. Effect\nof ablation of frequent premature ventricular complexes on left ventricular func-\ntion in patients with nonischemic cardiomyopathy. Heart Rhythm 2015;12:\n706–713.\n623. Lakkireddy D, Di Biase L, Ryschon K, Biria M, Swarup V, Reddy YM, et al.\nRadiofrequency ablation of premature ventricular ectopy improves the efﬁcacy\nof cardiac resynchronization therapy in nonresponders. J Am Coll Cardiol 2012;\n60:1531–1539.\n624. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, et al.\nAmiodarone in patients with congestive heart failure and asymptomatic ventricular\narrhythmia. Survival trial of antiarrhythmic therapy in congestive heart failure. N\nEngl J Med 1995;333:77–82.\n625. Zhong L, Lee Y-H, Huang X-M, Asirvatham SJ, Shen W-K, Friedman PA, et al.\nRelative efﬁcacy of catheter ablation vs antiarrhythmic drugs in treating premature\nventricular contractions: a single-center retrospective study. Heart Rhythm 2014;\n11:187–193.\n626. Hyman MC, Mustin D, Supple G, Schaller RD, Santangeli P, Arkles J, et al. Class IC\nantiarrhythmic drugs for suspected premature ventricular contraction-induced car-\ndiomyopathy. Heart Rhythm 2018;15:159–163.\n627. Laurent G, Saal S, Amarouch MY, Béziau DM, Marsman RFJ, Faivre L, et al. Multifocal\nectopic Purkinje-related premature contractions: a new SCN5A-related cardiac\nchannelopathy. J Am Coll Cardiol 2012;60:144–156.\n628. Calloe K, Broendberg AK, Christensen AH, Pedersen LN, Olesen MS, de Los\nAngeles Tejada M, et al. Multifocal atrial and ventricular premature contractions\nwith an increased risk of dilated cardiomyopathy caused by a Nav1.5\ngain-of-function mutation (G213D). Int J Cardiol 2018;257:160–167.\n629. Mann SA, Castro ML, Ohanian M, Guo G, Zodgekar P, Sheu A, et al. R222Q\nSCN5A mutation is associated with reversible ventricular ectopy and dilated car-\ndiomyopathy. J Am Coll Cardiol 2012;60:1566–1573.\n630. Beckermann TM, McLeod K, Murday V, Potet F, George AL. Novel SCN5A muta-\ntion in amiodarone-responsive multifocal ventricular ectopy-associated cardiomy-\nopathy. Heart Rhythm 2014;11:1446–1453.\n631. Doisne N, Waldmann V, Redheuil A, Waintraub X, Fressart V, Ader F, et al. A novel\ngain-of-function\nmutation\nin\nSCN5A\nresponsible\nfor\nmultifocal\nectopic\nPurkinje-related premature contractions. Hum Mutat 2020;41:850–859.\n632. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al.\nClassiﬁcation of the cardiomyopathies: a position statement from the European\nSociety Of Cardiology Working Group on Myocardial and Pericardial Diseases.\nEur Heart J 2008;29:270–276.\n633. Codd MB, Sugrue DD, Gersh BJ, Melton LJ. Epidemiology of idiopathic dilated and\nhypertrophic cardiomyopathy. A population-based study in Olmsted County,\nMinnesota, 1975–1984. Circulation 1989;80:564–572.\n634. Weintraub RG, Semsarian C, Macdonald P. Dilated cardiomyopathy. Lancet 2017;\n390:400–414.\n635. Beggs SAS, Jhund PS, Jackson CE, McMurray JJV, Gardner RS. Non-ischaemic car-\ndiomyopathy, sudden death and implantable deﬁbrillators: a review and\nmeta-analysis. Heart 2018;104:144–150.\n636. Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, et al. Incidence,\ncauses, and outcomes of dilated cardiomyopathy in children. JAMA 2006;296:\n1867–1876.\n637. Pahl E, Sleeper LA, Canter CE, Hsu DT, Lu M, Webber SA, et al. Incidence of and\nrisk factors for sudden cardiac death in children with dilated cardiomyopathy: a re-\nport from the Pediatric Cardiomyopathy Registry. J Am Coll Cardiol 2012;59:\n607–615.\n638. Bharucha T, Lee KJ, Daubeney PEF, Nugent AW, Turner C, Sholler GF, et al.\nSudden death in childhood cardiomyopathy: results from a long-term national\npopulation-based study. J Am Coll Cardiol 2015;65:2302–2310.\n639. Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Böhm M, et al. Proposal\nfor a revised deﬁnition of dilated cardiomyopathy, hypokinetic non-dilated cardio-\nmyopathy, and its implications for clinical practice: a position statement of the ESC\nworking group on myocardial and pericardial diseases. Eur Heart J 2016;37:\n1850–1858.\n640. Asselbergs FW, Sammani A, Elliott P, Gimeno JR, Tavazzi L, Tendera M, et al.\nDifferences between familial and sporadic dilated cardiomyopathy: ESC EORP\nCardiomyopathy & Myocarditis registry. ESC Heart Fail 2021;8:95–105.\n641. Ader F, De Groote P, Réant P, Rooryck-Thambo C, Dupin-Deguine D, Rambaud C,\net al. FLNC pathogenic variants in patients with cardiomyopathies: prevalence and\ngenotype-phenotype correlations. Clin Genet 2019;96:317–329.\n642. Kayvanpour E, Sedaghat-Hamedani F, Amr A, Lai A, Haas J, Holzer DB, et al.\nGenotype-phenotype associations in dilated cardiomyopathy: meta-analysis on\nmore than 8000 individuals. Clin Res Cardiol 2017;106:127–139.\n643. Ortiz-Genga MF, Cuenca S, Dal Ferro M, Zorio E, Salgado-Aranda R, Climent V,\net al. Truncating FLNC mutations are associated with high-risk dilated and arrhyth-\nmogenic cardiomyopathies. J Am Coll Cardiol 2016;68:2440–2451.\n644. van den Hoogenhof MMG, Beqqali A, Amin AS, van der Made I, Auﬁero S, Khan\nMAF, et al. RBM20 mutations induce an arrhythmogenic dilated cardiomyopathy\nrelated to disturbed calcium handling. Circulation 2018;138:1330–1342.\n645. Gigli M, Merlo M, Graw SL, Barbati G, Rowland TJ, Slavov DB, et al. Genetic risk of\narrhythmic phenotypes in patients with dilated cardiomyopathy. J Am Coll Cardiol\n2019;74:1480–1490.\n646. Heliö T, Elliott P, Koskenvuo JW, Gimeno JR, Tavazzi L, Tendera M, et al. ESC EORP\ncardiomyopathy registry: real-life practice of genetic counselling and testing in adult\ncardiomyopathy patients. ESC Heart Fail 2020;7:3013–3021.\n647. Elming MB, Nielsen JC, Haarbo J, Videbæk L, Korup E, Signorovitch J, et al. Age and\noutcomes of primary prevention implantable cardioverter-deﬁbrillators in patients\nwith nonischemic systolic heart failure. Circulation 2017;136:1772–1780.\n648. Kristensen SL, Levy WC, Shadman R, Nielsen JC, Haarbo J, Videbæk L, et al. Risk\nmodels for prediction of implantable cardioverter-deﬁbrillator beneﬁt. JACC\nHeart Fail 2019;7:717–724.\n649. Wolff G, Lin Y, Karathanos A, Brockmeyer M, Wolters S, Nowak B, et al.\nImplantable cardioverter/deﬁbrillators for primary prevention in dilated cardiomy-\nopathy post-DANISH: an updated meta-analysis and systematic review of rando-\nmized controlled trials. Clin Res Cardiol 2017;106:501–513.\n650. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NAM, Anderson KP, et al.\nProphylactic deﬁbrillator implantation in patients with nonischemic dilated cardio-\nmyopathy. N Engl J Med 2004;350:2151–2158.\n651. Klem I, Klein M, Khan M, Yang EY, Nabi F, Ivanov A, et al. Relationship of LVEF and\nmyocardial scar to long-term mortality risk and mode of death in patients with non-\nischemic cardiomyopathy. Circulation 2021;143:1343–1358.\nESC Guidelines\n4115\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "surgery",
        "arb",
        "references",
        "ct"
      ]
    }
  ]
}